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Abstract 
 
Chiral Alkaloid Derivatives: Synthesis and medicinal chemistry applications 
 
Daniel Canning 
 
The preparation of a selection of novel opioid alkaloids based on alteration at the 1, 3 
and 6 positions of codeine and morphine has been achieved. Herein we present the 
synthetic methodology, structural characterisation and biological evaluation of these 
novel opioid species.   
 
A range of opioid derivatives with modification at the 6 position to form linked bis-
opioid species were successfully synthesised. The derived compounds contain both 
ester and ether linked moieties. A selection of derivatives with modification at the 1 
position of codeine were also generated through Heck, Stille and Suzuki palladium 
catalysed carbon-carbon coupling. A combination of both synthetic approaches has led 
to a variety of opioid species with modification at both the 1 and 6 positions. 
 
A selection of the opioid species generated were analysed for their binding affinity to 
the mu opioid receptor through radioligand binding techniques. Binding affinities of a 
variety of the opioid species to a selection of metals were also assessed by metal picrate 
extraction studies. 
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Chapter 1 
 
Literature Survey 
 
1.1 Introduction 
 
The opium alkaloids derived from the seed pods of the opium poppy, Papaver 
somniferum have become some of the most commonly prescribed drugs in medicine. The 
principle components from the opium poppy, morphine (1) and its 3-O-methylated form, 
codeine (2) have been employed to treat ailments as diverse as diabetes, asthma, diarrhea, 
ulcers and alcohol dependence. The vast majority of literature on the opium alkaloids 
however, understandably focuses on their role as powerful analgesic compounds.1-4 The 
activity exhibited by morphine and its derivatives has been shown to be highly dependent 
on the structural composition of the compound.5, 6 The potency and efficacy can be 
controlled efficiently and effectively by alterations of the parent molecular scaffold. 
 
The specific set of structural features common to the opioid family of alkaloids can be 
defined within a few parameters, namely,  
• A tertiary nitrogen with a small alkyl substituent,  
• A quaternary carbon,  
• A phenyl group or its isosteric equivalent directly attached to the quaternary 
carbon 
• And a two carbon spacer between the quaternary carbon and the tertiary 
nitrogen. 
Any of the derivates of morphine which possess these basic structural components 
structure can act as either an agonist or antagonist of the opioid receptor. 
 
The opioid receptors belong to the G-protein-coupled receptors (GPCR) and are therefore 
related structurally to the receptors for many neurotransmitters and other agents acting to 
modulate the activity of nerve cells. The opioid receptors can be separated into three 
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2 
main groups divided historically on their binding affinity to certain structural 
compounds.7-9 
 
 
Fig 1.1 Structure of morphine (1) and codeine (2)  
 
The three main receptor subtypes are, mu, µ (referring to binding to the morphine 
structure), kappa, κ (the ketocyclazocine structure) and delta, δ (the 
endorphin/enkephalin structure). It has been demonstrated experimentally that the GPCR 
opioid receptors can also form homodimer10-12 (µ-µ, κ-κ, δ-δ) and heterodimer13-15 (µ-δ, µ-
κ) species with different combinations of interacting GPCRs having distinct 
pharmacological properties. Thus the distinct binding of opioid ligands to the receptor 
site is dependant on the interaction with receptor subtypes (µ, κ, δ) along with the various 
combinations of homodimer (µ-µ) and heterodimer species (µ-δ).  
 
 
Fig 1.2 Interaction of Morphine with the Mu Opioid Receptor Site 
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Studies into the binding of the opium alkaloids, in particular morphine, show that 
morphine’s interaction is mainly the result of the mu, (µ) receptor. 15, 16 An examination 
of the mu receptor (Fig 1.2) shows that there is an anionic site (8 by 6.5 Å) that binds to 
the charged nitrogen molecule of morphine, a cavity, which accommodates the piperidine 
ring, and a flat surface for binding the aromatic portion of the molecule. McFadyen et al17 
have investigated the pharmacophore of mu opioid ligands which provides more 
information on drug receptor interations (Fig 1.3).  All active agonists and antagonists 
must fit these receptor models to some degree.  
 
 
Fig 1.3 Pharmacophore for mu opioid ligands17 
 
The opium alkaloids, in particular morphine, are a very useful and potent analgesic 
family of drugs, however, it should be noted that the opium alkaloids have potentially 
severe side effects.18, 19 Morphine is a highly addictive compound with the onset of 
physical and psychological dependence developing very rapidly with administration. Its 
powerful analgesic effects are accompanied by euphoria, decreased gastrointestinal 
motility, physical dependence and respiratory depression. Respiratory depression is the 
main cause of death upon morphine overdose.20 The numerous damaging side effects of 
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4 
morphine, in particular its potent addiction, provides much of the impetus for the 
research of new derivatives.  
 
1.2 Binding Properties of Modified Opioids 
 
Due to the outstanding benefits of morphine aligned with its potent side effects there 
are continuous efforts to discover and develop new analgesic compounds. Two types of 
approaches have been used to design and synthesise new opioid drugs. The first 
approach is modification of previously known morphine analogues. Development of 
new opioid analgesics based on the morphine, has focused on modifications of the 
opioid scaffold including addition, replacement and deletion of various ring systems 
and functional groups. A broad variety of useful classes of analgesic compounds have 
been developed including the morphinans21 (3), benzomorphans22 (4), 
phenylpiperidines23 (5) and methadone-type24 (6) compounds (Fig 1.4). As well as 
providing novel analgesic ligands these compounds also provide a suitable reference for 
structure activity relationships for further opioid derivatives.   
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Fig 1.4 Classes of morphine based derivatives (3-6) and endogenous opioids (7-8) 
 
The second approach to create novel opioid drugs is the modification of endogenous 
ligands such as enkephalin25 (7) and endomorphin26 (8) (Fig 1.4). The endogenous 
Literature Survey 
——————————————————————————————————————— 
 
 
——————————————————————————————————————— 
 
5 
opioid ligands are a series of compounds which are produced naturally within the body 
by the hypothalamus and pituitary gland. Structurally they consist of a short sequence 
of amino acids linked by peptide bonds. They are similar to the morphine based opioid 
ligands in their ability to produce analgesic effects through interaction with the opioid 
receptors. As with the morphine based ligands a series of peptide based opioid 
derivatives have been developed with the aim of producing potent and selective 
agonists at the receptor site without the inherent side effects. Thus there is a huge 
volume of literature on structural modifications of opioid compounds with the 
corresponding interactions with the opioid receptor sites. Of particular interest for this 
project is the morphine derivatives based on modification of the molecule at the phenol, 
secondary alcohol and nitrogen positions, 3, 6 and 17 respectively (Fig 1.5).  
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Fig 1.5 Modification of morphine (1) at the 3, 6 and 17 positions and formation of “linked” opioids (9)  
 
Information in relation to modification of the A-ring of the morphine scaffold along 
with the formation of “linked” morphine based ligands (9, see section 1.2.5) is also 
highly relevant. For this reason further discussion of opioid ligands-receptor 
interactions will focus on an in depth analysis of the structural derivatives related to 
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morphine, modified at these sites in the opiate scaffold. The information provided in 
this chapter can be utilised to predict the opioid receptor properties of the novel opioid 
derivatives synthesised as part of this project along with providing methods to 
selectively control or inhibit the binding affinity.   
 
Where available, data for the affinity of opioid compounds is presented as the 
equilibrium inhibition constant (Ki) for each sub receptor type (µ, κ, δ). Affinity to the 
receptor site is also presented as the median effective concentration (EC50) or the 
median inhibitory concentration (IC50). The lower the Ki, EC50 or IC50 value the higher 
affinity to the receptor. The median effective dose (ED50) which relates to the analgesic 
activity is also included where available. As noted in the literature15, 16 the interaction of 
morphine with the opioid receptor is mainly through the mu subtype. Thus the data for 
morphine and its structural derivatives mainly focuses on this subtype. Also important 
to note is that a high affinity to the opioid receptor site does not imply that the 
compound will be a potent analgesic. Some compounds which bind strongly to the 
opioid receptors may be antagonists and thus exhibit no analgesic effect.  
 
1.2.1 Nitrogen Modification 
 
The tertiary nitrogen in the morphine skeleton has proven to be a very important feature 
required for analgesic activity. In fact it should be noted that a tertiary nitrogen will be 
found in every potent analgesic compound. Modification of the tertiary nitrogen portion 
of the morphine skeleton has been shown to drastically effect the analgesic action (Fig 
1.6).5 Formation of the quaternary nitrogen has a significant effect on the analgesic 
properties.27 Both N-methylmorphine chloride (11) and N-methylcodeine chloride (12) 
exhibit much lower analgesic activity than the corresponding tertiary nitrogen opioids, 
morphine and codeine.  
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Fig 1.6 Structures of N-modified opioids  
 
An examination of modified morphine derivatives shows that N-substitution and 
analgesic activity are dependent strongly on the functional group attached. In general 
substitution of the nitrogen atom lowers the analgesic activity. Conversion of the methyl 
group on the nitrogen atom to other alkyl groups has been shown to dramatically reduce 
or completely inhibit analgesia. Portoghese28 has investigated some of the derivatives of 
morphine with the N-substituent of the molecule altered from the methyl functionality 
(Fig 1.6). Results from the studies show that substitution of the nitrogen atom (ie 
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8 
replacing the CH3 group) with n-propyl (14), n-butyl (15) or allyl (16) functionalities 
results in compounds which have significantly lower analgesia (Table 1.1).  
 
The analgesic activity of compounds 17 and 19 is also lowered by substitution with an 
aromatic ring. However the presence of the aromatic ring with a two carbon spacer 
between the nitrogen atom and the aromatic ring in compound 18 results in increased 
analgesic activity. Compound 18 has a six fold increase in analgesic activity relative to 
morphine.28, 29 The combination of the two carbon spacer and the aromatic ring aids the 
analgesic effect. If the carbon spacer is only one carbon (17) or three carbons (19) the 
same increase in analgesia is not observed.  
 
Compound Analgesic Activity* 
Morphine, 1 1 
13 < 0.1 
14 0 
15 < 0.1 
16 < 0.1 
17 < 0.1 
18 6 
19 < 0.1 
Table 1.1 Relative analgesic activity of N-substituted morphine derivatives (*Analgesic activity is relative 
to morphine (1), a value of 10 signifies the compound is 10 times more potent than morphine (1)) 
 
Substitution of a cyclopropylmethyl functional group on the nitrogen is shown to increase 
the affinity.30 Compound 20 exhibits an IC50 value of 2.16 ± 0.14 nM which is over thirty 
times higher than the calculated value for morphine (1) at 68.2 ± 15.0 nM (Table 1.2).    
 
Compound IC50 (nM) 
Morphine, 1 68.2 ± 15.0 
20 2.16 ± 0.14 
Table 1.2 IC50 values for morphine and 20 
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Compound EC50 (nM)  
(µ) 
Morphine, 1 4.4 
21 37 
Codeine, 2 2,500 
22 1,500 
Table 1.3 EC50 values for morphine (1), codeine (2) and their corresponding N-demethylated derivatives, 
21 and 22  
 
Removal of the methyl substitution on the nitrogen also exhibits an effect on the affinity 
of opioid derivatives at the opioid receptor site (Table 1.3).31, 32 For morphine (1) there is 
a considerable reduction in the affinity with N-dealkylation to compound 21. The 
calculated EC50 value for the normorphine derivative (21) is over eight times higher than 
morphine. However there is a much smaller effect for codeine (2) and its N-dealkylated 
derivative (22). Removal of the methyl group on the nitrogen results in a small increase 
in the EC50 value for the codeine derivative 22. A widely used N-substituted compound is 
N-allylnormorphine (16). N-allylnormorphine acts as an antagonist at the mu opioid 
receptor site and is used to counter act the respiratory depressant properties of 
morphine.33  
 
1.2.2 Hydroxyl Modification  
 
Modification of the phenolic hydroxyl at position 3 or the secondary hydroxyl at the 
position 6 has an important effect on the affinity and analgesic activity of morphine 
derivatives (Fig 1.7). In general alteration of the phenolic hydroxyl has been shown to 
greatly affect the activity while adjustment at the secondary hydroxyl has a much lower 
effect.  
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Fig 1.7 Structures of hydroxyl modified opioids 
 
Modification of the phenolic hydroxyl has been shown to significantly lower the 
analgesic activity of morphine derivatives (Table 1.4).34 Alteration of the phenolic 
hydroxyl at the 3 position in morphine (1) to the methoxy derivative (codeine, 2) lowers 
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11 
the analgesic activity by 5 times with ED50 values of 0.26-0.83 and 1.21-3.91 mg/kg 
respectively. If the bulkier t-butyl group is substituted at this position as in 23 then the 
activity is reduced by almost 60 times with an ED50 value of 13.40-53.60 mg/kg. 
Binding affinities (IC50) to the opioid receptor for codeine (2) and 23 are also reduced 
by 370 and 740 times respectively. 
 
Mignat and co-workers35 have investigated the binding affinity of a selection of 
morphine-3-esters to the opioid receptor site (Table 1.5). As expected it was found that 
modification of the phenolic hydroxyl lowered the affinity for the mu opioid site. As the 
steric “bulk” of the substituent is increased from compounds 24, 25 and 26 the affinity 
to the mu opioid receptor is decreased by 16, 178 and 1444 times respectively. 
 
Compound IC50 (nM) ED50 (mg/kg) 
Morphine, 1 27 0.26 – 0.83 
Codeine, 2 10,000 1.21 – 3.91 
23 20,000 13.40 - 53.60 
Table 1.4 IC50 and ED50 values for morphine (1), codeine (2) and 23  
 
As expected morphine exhibits the highest affinity to the mu opioid receptor site with a 
Ki value of 1.8 ± 0.2 nM. Affinity to the other two opioid subtype receptors, kappa and 
delta is reduced by over 32 and 88 times respectively. Compound 24 exhibits much 
higher binding to the mu receptor site than codeine (2). The affinity of codeine (2) is 
over 370 times lower than morphine (1) but the affinity of compound 24 is only 16 
times lower. It would be expected that the greater steric “bulk” of the aromatic ring 
present in 24 would lower the affinity more than the methyl substitution in codeine (2). 
The higher affinity displayed by 24 can be explained by analysis of the pharmacophore 
of the mu opioid site. Affinity to the mu opioid receptor site is increased by providing a 
relatively planar electron rich region at this position of the drug scaffold. Therefore, 
while the aromatic ring in 17 provides undesired steric bulk, the extra electron rich 
aromatic ring aids binding to the mu opioid receptor site. 
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Compound Ki (nM) 
 µ κ δ 
Morphine, 1 1.8 ± 0.2 58 ± 8 160 ± 50 
24 29 ± 7 1,000 ± 100 2,500 ± 300 
25 320 ± 30 20,000 ± 1,100 530 ± 40 
26 2,600 ± 300 70,000 ± 3,500 39,000 ± 7,500 
Table 1.5 Ki values for morphine (1) and morphine-3-esters, 24-26. 
 
Modification at the secondary hydroxyl 6 position has a much lower effect on binding 
to the opioid receptor site relative to modification at the phenolic hydroxyl.36, 37 
Substitution at the 6 position with a methyl group for morphine and codeine has a very 
small effect on affinity to the mu receptor (Table 1.6).36 Compound 27 which has a 
methoxy functional group at the 6 position exhibits slightly higher affinity to the mu 
opioid receptor site than morphine (1) with Ki values of 1.1 ± 0.5 and 1.7 ± 0.5 nM 
respectively. In comparison the same modification of morphine at the phenolic 
hydroxyl results in codeine (2) which has a binding affinity to the mu opioid receptor of 
approximately 370 times lower. The same trend is noted for the codeine derivative (28), 
substitution with a methoxy group at the 6 hydroxy position only has a minor effect on 
mu receptor affinity. 
 
Compound Ki (nM) 
 µ κ δ 
Morphine, 1 1.7 ± 0.5 65.5 ± 22.6 104.57 ± 27.18 
27 1.1 ± 0.5 22.8 ± 11.0 65.8 ± 17.2 
Codeine, 2 727 ± 128 25,411 ± 10,015 52,207 ± 25,421 
28 1,910 ± 930 5,430 ± 2,290 4,410 ± 1,500 
Table 1.6 Ki values for morphine (1), codeine (2), 27 and 28  
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Compound Ki (nM) 
 µ κ δ 
Morphine, 1 6.22 ± 0.86 84.7 ± 4.01 218.0 ± 41.2 
29 1.73 ± 0.26 157.0 ± 12.6 22.2 ± 3.4 
30 17.7 ± 2.8 149.9 ± 12.2 84.9 ± 8.4 
31 28.4 ± 5.2 832.9 ± 24.1 205.0 ± 10.2 
32 30.1 ± 1.4 >10,000 68 ± 4.6 
Table 1.7 Ki values for morphine (1) and morphine-6-esters, 29-32 
 
Marples and co-workers have synthesized a variety of morphine-6-esters along with 
examining their binding affinities to the opioid receptor (Table 1.7).37 As expected 
modification at the 6 position has a much lower effect on the affinity relative to the 
phenolic hydroxyl. Compound 32 displayed the lowest affinity at 30.1 ± 1.4 nM which is 
almost 5 times lower than morphine at 6.22 ± 0.86 nM. It is interesting to note that a 
hydroxyl functional group on the aromatic ring at the para position (29) results in a 
compound with an affinity to the mu opioid receptor site of 1.73 ± 0.26 nM, over 3 times 
higher than the calculated value for morphine (1).  Removal of the hydroxyl functional 
groups at the 3 and 6 positions of the morphine scaffold also has an effect on binding to 
the opioid receptor.36, 38 There is a much greater effect upon removal of the phenolic 
hydroxyl relative to the secondary hydroxyl group. Removal of the phenolic hydroxyl at 
the 3 position for 33 lowers the ED50 over 2.5 times and the binding affinity by over 30 
(Table 1.8).38       
 
Compound EC50 (nmol) ED50 (µmol/kg) 
Morphine, 1 3.0 2.4 – 4.4 
33 100 6.7 – 11.2 
Table 1.8 EC50 and ED50 values for morphine (1) and 33 
 
In contrast removal of the secondary hydroxyl group at the 6 position has a much lower 
effect on the efficacy of the opioid derivatives.36 Removal of the hydroxyl group at the 
6 position for the morphine derivative 34 only has a minor effect on its affinity to the 
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mu opioid receptor with Ki values for morphine (1) and 34 of 1.7 ± 0.5 and 2.9 ± 1.1 
nM respectively. In contrast there is a slight increase in affinity for the mu receptor for 
the codeine derivative, 35 with a Ki value of 305 ± 79 nM in comparison to codeine (2) 
at 727 ± 128 nM (Table 1.9).  
 
Compound Ki (nM) 
 µ κ δ 
Morphine, 1 1.7 ± 0.5 65.5 ± 22.6 104.57 ± 27.18 
34 2.9 ± 1.1 45.5 ± 3.1 11.8 ± 3.1 
Codeine, 2 727 ± 128 25,411 ± 10,015 52,207 ± 25,421 
35 305 ± 79 3090 ± 150 4,520 ± 710 
 Table 1.9 Ki values for morphine (1), codeine (2), 34 and 35. 
 
Removal of the the allylic double bond has only a small effect on binding to the mu 
receptor site (Table 1.10).32 If the allylic double bond is removed from morphine for the 
dihydromorphine derivative (36) there is almost no change on the binding affinity to the 
mu opioid receptor site, with EC50 values of 194 ± 34 and 190 ± 35 nM respectively. 
For codeine (2) and its corresponding derivative, dihydrocodeine (38), the affinity is 
lowered by approximately half with EC50 values of 10,640 ± 840 and 20,350 ± 2,990 
nM respectively.   
 
Compound EC50 (nM)  
(µ) 
Morphine, 1 194 ± 34 
36 190 ± 35 
37 51 ± 3 
Codeine, 2 10,640 ± 840 
38 20,350 ± 2,990 
39 2,230 ± 280 
Table 1.10 EC50 values for morphine (1), codeine (2), 36-39 
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Removal of the allylic double bond combined with
 
formation of the ketone functional 
group results in a significant increase in the binding affinity to the mu receptor (Table 
1.10)
.
32
 Formation of the ketone functionality along with removal of the allylic double 
bond increases the affinity of the hydromorphone derivative (37) by almost four times. 
The EC50 value for morphine (1) is calculated at 194 ± 34 nM with the corresponding 
ketone derivative (37) at 51 ± 3 nM. A similar result is observed with the hydrocodone 
derivative (39), the affinity increases four fold.  
 
Removal of the hydroxyl group at the 6 position combined with the removal of the 
allylic double bond has a significant effect on the analgesic activity and affinity of the 
opioid derivatives (Table 1.11).34 Removal of these two functionalities from the opioid 
scaffold significantly increases the analgesic effects and affinity of the opioid 
derivatives. For the morphine derivative 40, the ED50 is increased by almost 5 times 
while the IC50 increases by almost 7. A similar trend is noted for the codeine derivative 
41, with the ED50 increasing by almost 4 times and affinity by 5 times. Compounds 40, 
41 and 42 also display the expected trend vide supra, increasing steric “bulk” at the 
phenolic hydroxyl 3 postion leads to lower affinity to the receptor site.
 
 
Compound IC50 (nM) ED50 (mg/kg) 
Morphine, 1 27 0.26 – 0.83 
Codeine, 2 10,000 1.21 – 3.91 
23 20,000 13.40 - 53.60 
40 4 0.06 – 0.18 
41 2,000 0.34 – 1.22 
42 3,000 3.13 – 8.00 
Table 1.11 IC50 and ED50 values for morphine (1), codeine (2), 23 and 40-42 
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1.2.3 Amine Derivatives at the Hydroxyl Positions  
 
Replacement of the oxygen atom by a nitrogen leads to a variety of novel opioid 
derivatives. Modifications of the opioid skeleton have been achieved at both the 3 
phenolic and 6 hydroxyl positions (Fig 1.8). An examination of some modified 
morphine derivatives by Wentland and co-workers39 have investigated if the NH2 group 
is a suitable bioisoteric replacement of the phenolic functional group (Table 1.12). 
 
 
Fig 1.8 Structures of amine modified opioids at the phenolic 3 position 
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Replacement of the phenolic hydroxyl group by the NH2 moiety lowered the affinity for 
the mu receptor from 0.88 ± 0.14 nM (morphine, 1) to 53 ± 3 nM (43) corresponding to 
a lower affinity of approximately 60 times. If an aromatic ring is connected to the 
nitrogen this increases the affinity. The mu affinity of 44 at 63 ± 15 nM is almost 
doubled if the methyl group is replaced by an aromatic ring as in compound 47 at 33 ± 
5.1 nM. This would be expected as a similar pattern is noted for codeine (1) and the 
closely related aromatic derivative (24).    
 
Compound Ki (nM) 
 µ κ δ 
Morphine, 1 0.88 ± 0.14 24 ± 2.3 140 ± 18 
43 53 ± 3 740 ± 75 2,400 ± 190 
44 63 ± 15 2,800 ± 420 5,700 ± 1,100 
45 240 ± 16 290 ± 8.1 1,600 ± 110 
46 59 ± 3.7 240 ± 23 1,500 ± 100 
47 33 ± 5.1 3,400 ± 540 5,500 ± 190 
Table 1.12 Ki values for morphine (1) and 43-47 
 
A selection of further amine modified opioid derivatives at the 3 phenolic position were 
synthesised and analysed by Decker and co-workers.40 Decker studied amine modified 
opioids based on levorphanol (48), cyclorphan (49) and butorphan (50). Levorphanol 
(48) is a structural derivative of morphine in which the oxygen bridge from the D ring 
is removed along with the hydroxyl at the 6 position. Levorphanol (48) cylorphan (49) 
and butorphan (50) have potent affinities to the mu opioid receptor site with Ki values 
of 0.21 ± 0.2 nM, 0.062 ± 0.003 nM and 0.23 ± 0.01 nM  respectively (Table 1.13).41  
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Compound Ki (nM) 
 µ κ δ 
Morphine, 1 0.88 ± 0.14 24 ± 2.3 140 ± 18 
Levorphanol, 48 0.21 ± 0.2 2.3 ± 0.3 4.2 ± 2.3 
49 0.062 ± 0.003 0.034 ± 0.002 1.9 ± 0.1 
50 0.23 ± 0.01 0.079 ± 0.003 5.9 ± 0.6 
Table 1.13 Ki values for, morphine (1) and 48-50 
 
Compound Ki (nM) 
 µ κ δ 
Cyclorphan, 49 0.062 ± 0.003 0.034 ± 0.002 1.9 ± 0.1 
51 0.26 ± 0.012 0.34 ± 0.031 29 ± 4.4 
52 0.080 ± 0.005 0.047 ± 0.0035 5.4 ± 0.11 
53 3.9 ± 0.28 1.6 ± 0.15 16 ± 1.5 
Butorphan, 50 0.23 ± 0.01 0.079 ± 0.003 5.9 ± 0.6 
54 1.7 ± 0.24 1.5 ± 0.17 39 ± 3.5 
55 1.7 ± 0.053 2.8 ± 0.33 130 ± 11 
Table 1.14 Ki values for compounds 49-55 
 
Cyclorphan (49) exhibits a much higher affinity to the mu receptor due to the 
cyclopropylmethyl functional group on the nitrogen. This correlates with the results 
observed for compound 20. Decker and co-workers observed a similar result to 
Wentland, that replacement of the phenolic hydroxyl at the 3 position by a selection of 
amine functional groups resulted in lower affinity to the mu receptor site (Table 1.14). 
The calculated Ki values for the mu receptor for cyclorphan (49) and its related amine 
derivatives 51, 52 and 53 are 0.062 ± 0.003, 0.26 ± 0.012, 0.080 ± 0.005 and 3.9 ± 0.28 
nM respectively.  
 
Amine modification at the hydroxyl 6 position of the opioid skeleton has focused 
primarily on the β-naltrexamine opioid derivatives (Fig 1.9). Along with modification 
of the hydroxyl at the 6 position the naltrexamine derivatives also have the allylic 
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double bond reduced and a new hydroxyl group substituted at the 14 position. 
Reduction of the allylic double bond has shown to have little effect on the binding 
affinity of opioids to the receptor site (Table 1.10).32  
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Fig 1.9 Structures of amide opioids  
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Substitution of a hydroxyl at the 14 position also has a small effect on the analgesic 
activity (Table 1.15).6, 42 Substitution of a hydroxyl group at the 14 position almost 
doubles the analgesic activity with respect to compounds 37 and oxymorphone (56) 
with ED50 values of 0.3 and 0.17 mg/kg respectively. 
 
Compound ED50 (mg/kg) 
Morphine, 1 2.1 
37 0.3 
Oxymorphone, 56 0.17 
Table 1.15 ED50 value for morphine (1), 37 and 56 
 
Bostros and co-workers synthesised and analysed a variety of amide derivatives based 
on β-naltrexamine (Table 1.16).43 Formation of the amide bond at the 6 position results 
in opioid derivatives with significant binding to the receptor site. It is also significant to 
note that the cis derivative (59) results in a lower IC50 value than the corresponding 
trans derivatives (58) at values of 39 ± 22 and 130 ± 60 nM respectively.     
 
Compound IC50 (nM) ED50 (µmol/kg) 
57 144 ± 94 9.6 - 10.0 
58 130 ± 60 ND 
59 39 ± 22 3.0 – 31.8 
60 31 ± 10 < 20 
Table 1.16 IC50 and ED50 values for 57-60, (ND, not determined) 
 
Further amide derivatives also exhibit relatively high binding to the mu opioid receptor 
site (Table 1.17).44 Relatively high affinity to the receptor site is noted for compounds 
with the aromatic ring present on the amide functional group. However it should be noted 
that further substitution on the aromatic ring has a detrimental effect on potency of the 
opioid compound. For the unmodified aromatic ring derivative (61) the Ki value is 
calculated at 0.07 nM. If a chlorine atom is substituted into the aromatic ring (62) the 
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affinity is lowered to 0.1 nM, while inserting a methyl group (63) lowers the affinity to 
0.23 nM.     
 
Compound Ki (nM) 
 µ κ δ 
61 0.07 0.2 3.1 
62 0.1 0.2 5.0 
63 0.23 0.6 9.6 
65 0.2 0.8 5.1 
Table 1.17 Ki values for 61-63 and 65. 
 
Ghirmai and co-workers have investigated further amide derivatives (Table 1.18).45 As 
expected formation of the amide functional group at the 6 hydroxyl position only 
results in a slight effect on the binding affinity to the mu opioid receptor. Relative to 
naltrexone (64) at a Ki value of 0.30 ± 0 nM the amide functionalized opioids 62, 66, 67 
and 68 exhibit Ki values of 0.61 ± 0.09, 0.88 ± 0.10, 0.82 ± 0.10 and 1.09 ± 0.20 nM 
respectively. As noted by Derrick and co-workers44 increasing modification of the 
aromatic ring results in lower affinity. The t-butyl derivative (68) exhibits the lowest 
affinity at 1.09 ± 0.20 nM.  
 
Compound Ki (nM) 
 µ κ δ 
Naltrexone, 64 0.30 ± 0 0.81 ± 0.02 16.31 ± 1.10 
62 0.61 ± 0.09 0.23 ± 0.03 2.6 ± 0.3 
66 0.88 ± 0.10 0.29 ± 0.04 2.2 ± 0.3 
67 0.82 ± 0.10 0.37 ± 0.05 1.4 ± 0.2 
68 1.09 ± 0.20 0.37 ± 0.06 1.4 ± 0.1 
Table 1.18 Ki values for, 62, 64 and 66-68 
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Fig 1.10 Structures of hydrazone based opioids  
 
Another approach for modification of the secondary hydroxyl at the 6 position is the 
formation of hydrazone derivatives (Fig 1.10).46, 47 Hahn and co-workers have 
synthesised a selection of hydrazone derivatives based on modification of naloxone 
(69) and oxymorphone (56).47 Formation of the hydrazone functional group at the 6 
hydroxy position does not have a significant effect on binding to the receptor site for 
the naloxone based compounds (Table 1.19). For naloxone (69) and 70 the IC50 values 
are almost identical at 3.1 ± 1.5 and 3.0 ± 1.1 nM respectively. The highest affinity is 
observed for 71 at 1.1 ± 0.5 nM while the lowest is observed 74 at 8.0 ± 1.7 nM.       
 
Compound IC50 (nM)  
(µ) 
Naloxone, 69 3.1 ± 1.5 
70 3.0 ± 1.1 
71 1.1 ± 0.5 
72 1.8 ± 0.2 
73 7.5 ± 2.5 
74 8.0 ± 1.7 
Table 1.19 IC50 values for naloxone (69) and 70-74 
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1.2.4 A-Ring Modification 
 
Research has shown that substitution of the aromatic A-ring on the opioid scaffold at the 
1 and 2 positions results in a marked decrease affinity to the opioid receptor (Fig 1.11).5, 6 
The bromocodeine (75) and chlorocodeine (76) derivatives exhibit only about half the 
analgesic activity of the parent codeine (2) molecule. The presence of an acetyl group at 
the 1 position for acetocodeine (77) also results in a significant decrease in analgesic 
action. Lousberg and co-workers48 also investigated the effect of a fluorine atom at the 1 
position of the codeine scaffold (78). The resulting ED50 values for fluorocodeine (78) at 
7.9 mg/kg and codeine (2) at 7.5 mg/kg suggest that the decrease in analgesic potency 
from substitution of the aromatic A-ring is strongly influenced by the steric bulk of the 
functional group attached (Table 1.20).  
 
Compound ED50 (mg/kg) 
Codeine, 2 7.5 
78 7.9 
Table 1.20 ED50 values for codeine (2) and 78 
 
Substitution at the 2 position for the levorphanol type derivatives (79, 80) also show a 
significant decrease in analgesic activity. The placement of a methyl group at the 2 
position of levorphanol (48) results in an increase in the ED50 value of over 18 times 
with values of 0.5 mg/kg and 9.1 mg/kg for levorphanol (48) and 80 respectively (Table 
1.21).6 The calculated ED50 value for 80 is over 20 times higher than levorphanol (48) 
at 2.9 - 5.0 mg/kg and 0.06 - 0.22 mg/kg respectively (Table 1.22).49  
 
Compound ED50 (mg/kg) 
Morphine, 1 2.1 
Codeine, 2 14.2 
Levorphanol, 48 0.5 
79 9.1 
Table 1.21 ED50 values for morphine (1), codeine (2), 48 and 79 
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Fig 1.11 Structures of A-ring modified opioids  
 
The binding affinity to the mu opioid receptor is also much lower for 80 with respect to 
levorphanol (48) at IC50 values of 13,000 nM and 4 nM respectively. However it should 
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be noted that compound 80 also lacks the phenolic hydroxyl at the 3 position which has 
been shown previously (Table 1.8, 33) to be important in binding to the receptor site. 
 
Compound IC50 (nM)  
(µ) 
ED50 (mg/kg) 
Morphine, 1 27 0.26 – 0.83 
Codeine, 2 10,000 1.40 – 4.45 
Levorphanol, 48 4 0.06 – 0.22 
80 13,000 2.9 – 5.0 
Table 1.22 IC50 and ED50 values for morphine (1), codeine (2), 48 and 80 
 
The aminothiazole type morphinans (81-83) also provide additional information on the 
effect A-ring substitution has on drug receptor interactions.41, 50 The formation of an 
aminothiazole at 2/3 position of the aromatic A-ring (81) results in the affinity for the 
mu receptor decreasing by over 5 times with respect to levorphanol (48). The calculated 
Ki values for 81 and levorphanol (48) are 1.1 ± 0.1 and 0.21 ± 0.02 nM respectively 
(Table 1.23).41  
 
Compound Ki (nM) 
 µ κ δ 
Morphine, (1) 0.88 ± 0.14 24 ± 2 140 ± 18 
Levorphanol, (48) 0.21 ± 0.02 2.3 ± 0.3 4.2 ± 2.3 
81 1.1 ± 0.1 6.4 ± 0.5 190 ± 10 
82 130 ± 6 29 ± 1 1100 ± 30 
Table 1.23 Ki values for morphine (1), 48, 81 and 82 
 
However, if the aminothiazole ring is in the 1/2 position on the aromatic ring (82) the 
affinity for the mu receptor is decreased by over 600 times with respect to levorphanol 
(48). Modification of the fused aminothiazole ring system to compounds 84 and 85 
results in lower affinity to the receptor site with respect to 83 (Table 1.24).50 The 
affinities to the mu opioid recptor site for 83, 84 and 85 were calculated at 1.5 ± 0.1, 
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150 ± 5.1 and 160 ± 21 nM respectively. The affinities for the kappa receptor for 83, 84 
and 85 were calculated at 0.049 ± 0.005, 52 ± 1.0 and 47 ± 1.6 nM respectively. 
 
Compound Ki (nM) 
 µ κ δ 
Cyclorphan, 49 0.062 ± 0.003 0.034 ± 0.002 1.9 ± 0.072 
83 1.5 ± 0.2 0.049 ± 0.005 29 ± 2 
84 150 ± 5.1 52 ± 1.0 ND 
85 160 ± 21 47 ± 1.6 ND 
Table 1.24 Ki values 49 and 83-85 (ND, not determined) 
 
Decker and co-workers have synthesized and analysed a variety of butorphan (50) 
based opioids with modifications at the 2 position of the aromatic A-ring (Table 1.25). 
Depending on the functional group attached to the A-ring the affinity to the mu opioid 
receptor site is reduced by between 1,500 times (87) and over 16 times (90) with 
respect to butorphan (50). The affinity to the kappa receptor is also reduced with 
calculated Ki values for butorphan (50), 87 and 88 of 0.079 ± 0.003, 86 ± 2.2 and 72 ± 
3.1 nM respectively.  
 
Compound Ki (nM) 
 µ κ δ 
Butorphan, 50 0.23 ± 0.01 0.079 ± 0.003 5.9 ± 0.55 
86 15 ± 1.5 40 ± 4.2 1,400 ± 121 
87 360 ± 27 86 ± 2.2 >10, 000 
88 180 ± 21 72 ± 3.1 >10,000 
89 330 ± 55 350 ± 20 >10,000 
90 3.8 ± 0.46 0.62 ± 0.058 180 ± 11 
Table 1.25 Ki values 50 and 86-90 
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1.2.5 Bivalent Opioid Derivatives 
 
The formation of bivalent opioid ligands is an important aspect of modern opioid drug 
research.51-53 The presence of two pharmacophores within an opioid ligand, which can 
interact with more than one receptor site, dramatically enhances the therapeutic range 
of opioid drugs. As the opioid receptor contains three distinct subtypes (µ, κ, δ)7-9 along 
with homodimer10-12 (µ-µ, κ-κ, δ-δ) and heterodimer13-15 (µ-δ, µ-κ) sites, the interaction 
of bivalent opioids leads to unique benefits over the corresponding monovalent 
equivalents. The presence of a second opioid pharmacophore with a distinct binding 
profile can lead to opioid drugs with improved analgesia, reduced side effects and a 
decrease in opioid analgesic tolerance.54 The variety of bivalent opioid drugs includes 
peptide derivatives (91)55, morphine type derivatives (9)52 and mixed type ligands (92) 
(Fig 1.12).53, 56  
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Fig 1.12 Structures of bivalent opioids 9, 91 and 92 with two pharmacophores 
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An in depth discussion of the biological interaction of bivalent ligands with the opioid 
receptor is beyond the scope of this review. However it is relevant to examine the 
binding affinities and analgesic effects from a structure activity relationship aspect. Of 
particular interest for this research project is the bivalent opioid compounds based on 
the morphine scaffold which are linked through the 3 and 6 positions.  
 
A series of bivalent opioid compounds, based on modification at the 3 position of 
cyclorphan (49) and butorphan (50) have been synthesized and evaluated for their 
binding affinity to the µ, κ and δ opioid receptors.57 Neumeyer and co-workers have 
investigated a variety of bivalent opioid compounds (Fig 1.13) based on butorphan (50) 
and linked via ester and ether spacers (Table 1.26).58 The length of the spacer group has 
an effect on binding to the receptor site. The affinity for the mu opioid receptor of 93 is 
over two times higher than 95 at Ki values of 29 ± 1.2 and 66 ± 4.3 nM respectively. 
The affinity for the kappa receptor is over six times higher when the carbon chain 
spacer is shortened from ten carbons (95) to four carbons (93). The same result is 
observed with the ester linked compounds 94 and 96 with Ki values at the mu opioid 
receptor site of 0.16 ± 0.01 and 0.090 ± 0.004 nM respectively. The ester linked 
compounds 94 and 96 also exhibit much higher affinities to the opioid receptor than the 
corresponding ether linked ligands 93 and 95.  
 
Compound Ki (nM) 
 µ κ δ 
Butorphan, 50 0.23 ± 0.01 0.079 ± 0.003 5.9 ± 0.55 
93 29 ± 1.2 18 ± 1.3 730 ± 29 
94 0.16 ± 0.01 0.076 ± 0.002 9.4 ± 0.44 
95 66 ± 4.3 120 ± 8.2 2,500 ± 91 
96 0.090 ± 0.004 0.049 ± 0.001 4.2 ± 0.44 
97 0.23 ± 0.22 0.070 ± 0.03 44 ± 6.8 
98 4.7 ± 0.64 4.2 ± 0.81 400 ± 46 
99 3.3 ± 0.26 3.4 ± 0.08 920 ± 95 
Table 1.26 Ki values for 50 and 93-99 
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Fig 1.13 Structures of bivalent opioids based on butorphan linked through the 3 positions   
 
The Ki value at the mu receptor for the ether linked compound 93 is over 180 times 
lower than the corresponding ester derivative 94. Compound 94 also exhibits a higher 
affinity to the mu opioid receptor than the non-linked butorphan (50). The non-linked 
derivative 97 displays a binding affinity to the mu receptor of 0.23 ± 0.22 nM which is 
identical to butorphan (50) at 0.23 ± 0.01 nM. Therefore the presence of a second 
pharmacophore introduced by the bivalent ligand 94 has an effect on the affinity to the 
mu opioid receptor. Introduction of an aromatic ring in the spacer moiety lowers that 
affinity for the mu opioid receptor with respect to 94. The calculated Ki values for the 
mu receptor for 94, 98 and 99 are 0.16 ± 0.01, 4.7 ± 0.64 and 3.3 ± 0.26 nM. 
 
Fulton and co-workers have investigated further varieties of bivalent opioids (Fig 1.14) 
linked through the 3 position of the aromatic ring (Table 1.27).59 If the length of the 
carbon spacer is reduced, as in 100, the affinity to the mu opioid receptor is increased 
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with respect to the butyl linked compound (93).  Introduction of a hydroxyl functional 
group within the spacer unit also increases the affinity to the mu receptor.  
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Fig 1.14 Structures of bivalent opioids linked through the 3 position  
 
Compound 100 exhibits a Ki value of 7.1 ± 0.19 nM, however when a hydroxyl group is 
introduced into the spacer unit the affinity is increased over seven times, as in 101 at 
0.95 ± 0.16 nM. The bivalent opioid (102) has a greater affinity to the mu opioid 
receptor than the equivalent monovalent ligand (103) at Ki values of 2.4 ± 0.43 and 7.4 
± 0.26 nM respectively.      
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Compound Ki (nM) 
 µ κ δ 
Butorphan, 50 0.23 ± 0.01 0.079 ± 0.003 5.9 ± 0.55 
100 7.1 ± 0.19 6.2 ± 0.53 180 ± 3.3 
101 0.95 ± 0.16 0.99 ± 0.022 37 ± 3.3 
102 2.4 ± 0.43 120 ± 8.2 27 ± 1.9 
103 7.4 ± 0.26 8.3 ± 0.68 52 ± 2.8 
Table 1.27 Ki values for 50 and 100-103 
 
Substitution of methyl groups into the carbon spacer moiety for the ester linked bivalent 
opioids (Fig 1.14) lowers the affinity to the mu opioid receptor (Table 1.28).60 The 
calculated Ki values for the mu receptor for 96 and 104 are 0.090 ± 0.004 and 0.95 ± 
0.057 nM respectively corresponding to over 10 times lower affinity with substitution 
of a methyl group in the spacer region. 
 
Compound Ki (nM) 
 µ κ ∆ 
Butorphan, 50 0.23 ± 0.01 0.079 ± 0.003 5.9 ± 0.55 
96 0.090 ± 0.004 0.049 ± 0.001 4.2 ± 0.44 
104 0.95 ± 0.057 0.62 ± 0.071 37 ± 1.8 
105 0.46 ± 0.024 0.42 ± 0.0081 20 ± 0.074 
106 0.47 ± 0.027 0.47 ± 0.046 15 ± 0.86 
Table 1.28 Ki values for 50, 96 and 104-106 
 
Peng and co-workers have examined some bivalent opioid ligands (Fig 1.14) linked by 
amide bonds (Table 1.29).61 Affinity to the mu opioid receptor site is lowered if the 
ester bonds linker are replaced with amides. 107 has a Ki value of 3.3 ± 0.3 nM which 
is over 20 times higher than the ester analogue 94 at 0.16 ± 0.01 nM. The same trend is 
noted when the spacer length is increased as in compounds 96 and 108.      
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Compound Ki (nM) 
 µ κ ∆ 
Butorphan, 50 0.23 ± 0.01 0.079 ± 0.003 5.9 ± 0.55 
94 0.16 ± 0.01 0.076 ± 0.002 9.4 ± 0.44 
96 0.090 ± 0.004 0.049 ± 0.001 4.2 ± 0.44 
107 3.3 ± 0.3 3.8 ± 0.4 ND 
108 5.7 ± 0.1 7.5 ± 1.0 38 ± 3.7 
Table 1.29 Ki values 50, 94, 96, 107 and 108 (ND, not determined) 
 
Formation of bivalent opioids at the 6 position of the morphine scaffold has focused on 
naltrexamine and oxymorphamine derivatives.62, 63 Portoghese and co-workers have 
synthesised a selection of bivalent opioid ligands (Fig 1.15) and investigated the 
binding affinity to the µ, κ and δ opioid receptors (Table 1.30).64  
 
Compound Ki (nM) 
 µ κ ∆ 
9 14 ± 3 460 ± 78 50 ± 2 
109 50 ± 10 500 ± 45 100 ± 45 
110 44 ± 7 590 ± 118 110 ± 10 
111 180 ± 41 6,400 ± 262 480 ± 32 
113 34 ± 3 1,000 ± 128 26 ± 4 
Table 1.30 Ki values for 9, 109-111 and 113 
 
Compound 9 exhibits the highest affinity for the mu receptor at 14 ± 3 nM. If the spacer 
length is increased (113) or decreased (110) the affinity for the mu receptor is lower, 
with values for 113 and 110 of 34 ± 3 and 44 ± 7 nM respectively. The affinity for the 
mu receptor for the bivalent opioid, 9 is 12 times higher than the related monomer 
derivative (111).   
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Fig 1.15 Structures of bivalent opioids linked through the 6 position 
 
Another selection of bivalent opioids have been generated based on opioid azine linked 
derivatives (Fig 1.15).65, 66 Hahn and co-workers have synthesised a variety of 
oxymorphone based bivalent opioid ligands and analysed the binding affinity to the µ, κ 
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and δ opioid receptors (Table 1.31).66 The binding affinity to the opioid receptors for 
the azine linked bivalent ligands are identical to the parent opioid compounds. The 
highest affinity to the mu receptor was noted for 115 at 1.4 ± 0.2 nM while the lowest 
was 112 at 1.8 ± 0.6 nM. No difference was observed in the binding affinities for the 
bivalent ligands (114, 115) and the related monomers (116, 117)    
 
Compound IC50 (nM) 
 µ κ ∆ 
Oxymorphone, 56 1.8 ± 0.6 1.0 ± 0.4 4.9 ± 2.7 
112 1.8 ± 0.6 1.2 ± 0.6 2.9 ± 1.2 
114 1.6 ± 0.4 2.4 ± 0.6 21.6 ± 17 
115 1.4 ± 0.2 2.0 ± 0.4 3.9 ± 0.2 
116 1.6 ± 0.6 0.7 ± 0.6  7.4 ± 3.0 
117 1.4 ± 0.2 1.8 ± 0.1 9.7 ± 1.2 
Table 1.31 Ki values for 56, 112 and 114-117 
 
1.3 Conclusion 
 
The morphine based opioid alkaloids are hugely important to modern medicine due to 
their potent analgesic effects. However the powerful analgesic effects are coupled with 
possible severe side effects including decreased gastrointestinal motility, physical 
dependence and respiratory depression. Therefore a major research initiative has been 
undertaken to develop a variety of opioid analogues which will retain the potent 
analgesic properties without the detrimental side effects. As such there is a substantial 
volume of literature in relation to SAR (structure activity relationship) analysis of the 
opioid scaffold. Of particular interest for this project is the morphine derivatives based 
on modification at the phenol, secondary alcohol and nitrogen positions (3, 6 and 17 
respectively). Information in relation to modification of the A-ring of the morphine 
scaffold along with the formation of “linked” morphine based bivalent ligands is also 
highly relevant. 
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The tertiary nitrogen present within morphine is vital for analgesic activity. In general 
modification at the 17 position of the morphine scaffold has been shown to lower the 
potency of the parent compound however substitution with a cyclopropylmethyl group 
(20) has been shown to enhance the activity. Modification at the phenol hydroxyl group 
has a major effect on the receptor affinity while the secondary alcohol has only a minor 
influence. Substitution at the aromatic ring lowers the affinity to the receptor site 
especially substitution at the 1 position of the opioid scaffold. Formation of “linked” 
opioid compounds can lead to bivalent opioid ligands which contain two 
pharmacophores linked by a spacer unit. The affinity of the bivalent opioids is 
dependant on the distance between the two pharmacophores as well as the functional 
groups present along the spacer unit.  
 
The following chapters outline the synthesis of a series of novel opioid derivatives 
along with analysis of their mu opioid receptor and metal binding affinities. The 
information provided by this chapter can be utilised to assist the prediction of the 
opioid receptor properties of these novel opioid derivatives along with methods to 
selectively control the binding affinity.   
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Chapter 2 
 
Synthesis and Structural Characterisation of Ester and Ether Linked 
Codeine Derivatives  
 
2.1 Introduction 
 
This chapter details the synthesis of a series of novel opioid derivatives based on 
structural modification of codeine (2) to form linked di-codeine derivatives. Both ester 
and ether linked derivatives are included along with their structural characterisation. 
Previous studies on opioid derivatives37, 67, 68 have shown that it is possible to convert 
the secondary alcohol bond at the 6 position (Fig 2.1) to an ester or ether moiety.  
 
 
Fig 2.1 Structure of morphine (1) and codeine (2) 
 
If we take this process further it should be possible to use a diacid chloride (118) which 
will react with two codeine molecules. Therefore, the diacid chloride species will act as 
a bridge linking the two codeine molecules through ester bonds (Scheme 2.1). In 
addition the formation and structural characterisation of ether linked opioid derivatives 
is included (Scheme 2.2). Modification at this position of the molecule has been shown 
to affect the binding affinity to the opioid receptors (Chapter 1, 1.2.2) thus formation of 
these bivalent opioid derivatives could have uses as potential novel analgesic 
therapeutics (Chapter 4).  
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Scheme 2.1 General reaction scheme for the formation of di-codeine derivative 119 
 
Due to the presence of the numerous oxygen donor atoms in the “cavity site” formed 
within the molecule there is potential for interactions between metal cationic species 
(Chapter 5). Thus it could be envisioned that metal complexes may form with the 
linked opioid derivatives which may lead to sensor applications.  
 
 
Scheme 2.2 General reaction scheme for the formation of di-codeine derivative 121 
 
2.2 Synthesis of Ester Linked Codeine Derivatives 
 
Preliminary work on the generation of the ester linked compounds was investigated 
using NEt3 as the base and DCM as the solvent, as previous work within the research 
group had shown this to be a suitable method for esterification of similar systems. 
However, the conversions to the desired linked compound (119) were poor when using 
terephthaloyl dichloride (118), with only trace amounts of product formed (Scheme 
2.3). By replacing NEt3 with K2CO3 the conversion was increased to 62%. 
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Scheme 2.3 Reaction scheme for the formation of 119 using NEt3 
   
Compound Diacid Chloride 
Conversion 
(from 1H NMR) 
119 
 
62% 
126 
 
50% 
127 
ClCl
OO
123
 
69% 
128 
 
Trace 
Table 2.1 Conversions to desired linked compounds using K2CO3  
 
However, when K2CO3 was employed for other diacid chlorides, the conversions to the 
desired linked compounds in general were still lower than desired (Table 2.1). Some of 
the reaction parameters were explored further with the aim of developing a suitable 
method that would result in good conversions to the desired linked compounds 
regardless of the diacid chloride. The main parameters investigated were base, solvent 
and temperature. An examination of some of the reaction conditions investigated for the 
formation of 119 are outlined in (Table 2.2). The mono addition product was not 
observed by 1H NMR of the crude or isolated from column chromatography. 
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Solvent Temp Base (2 Eq) Conversion  
(from 1H NMR) 
DCM RT NEt3 Trace 
DCM RT K2CO3 62% 
DCM 40 °C K2CO3 59% 
DCM RT Na2CO3 17% 
DCM RT KOH 26% 
DCM RT NaOH 19% 
DCM RT NaH 50% 
DCM RT DMAP 82% 
DCM 40 °C DMAP 83% 
THF RT K2CO3 Trace 
THF 66 °C K2CO3 Trace 
THF RT Na2CO3 Trace 
THF RT NaH 41% 
Pyridine RT Solvent (pyridine) 21% 
Pyridine 115 °C Solvent (pyridine) 22% 
Table 2.2 Analysis of reaction parameters on formation of 119 
 
The preferred base was either K2CO3 or DMAP with conversions of 62% and 82% 
respectively. Conversions were also satisfactory (50%) when using NaH however 
numerous by products were seen in the crude 1H NMR. When the solvent was changed 
from DCM to THF the % conversions lowered significantly, employing THF with 
either K2CO3 or Na2CO3 resulted in almost no product. When pyridine was used as the 
solvent the % conversion was very low at 21%. Increasing the temperature for DCM, 
THF or pyridine with a range of bases (Table 2.2) showed no affect on product 
formation. As DMAP was found to be the most suitable base for generation of 119 it 
was investigated using other diacid chloride compounds (Table 2.3). When potassium 
carbonate is replaced with DMAP the percentage conversion went from 50% to 92 %, 
69% to 95% and trace amounts to 67% for compounds 126, 127 and 128 respectively. 
Therefore, employing DMAP resulted in increased conversions for all the tested diacid 
Ester and Ether Linked Codeine 
——————————————————————————————————————— 
 
 
——————————————————————————————————————— 
 
40 
chlorides. DMAP is a well known activating agent for acid chlorides and it has been 
reported previously in the formation of ester bonds at the 6 hydroxyl position.37 
Reducing the equivalents of DMAP used in the reaction to 1.1 Eq resulted in no 
discernible reduction in formation of the product. 
 
Compound Base Conversion (from 1H NMR) 
126 K2CO3 50% 
126 DMAP 92% 
127 K2CO3 69% 
127 DMAP 95% 
128 K2CO3 Trace 
128 DMAP 67% 
Table 2.3 Comparison of product formation from K2CO3 and DMAP 
 
 
Scheme 2.4 Reaction scheme for the formation of 125 
 
When this reaction condition was utilised for the benzoyl product (125) (Scheme 2.4), it 
resulted in almost 100% conversion to the desired product, isolated yield of 92%. The 
variance in formation of the linked compounds was most likely due to the relative 
reactivity’s of the acid dichlorides employed and steric effects. Using the reaction 
conditions outlined (Scheme 2.5) a selection of eight ester linked opioid products were 
synthesised in isolated yields of 39% - 82% (Fig 2.2). These isolated yields could be 
improved by further development of the reaction conditions and improved purification 
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of the resulting crude mixtures. However the aim was not to develop a high isolated 
yield process but to synthesise the compounds for further analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig 2.2 Ester linked codeine derivatives with isolated yields 
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Scheme 2.5 Reaction scheme for the formation of 119 using DMAP 
 
Purification of the ester compounds was achieved through column chromatography 
followed by recrystallisation. The mobile phase employed for these compounds was a 
DCM methanol mixture with small amounts of ammonia solution added to the mobile 
phase to prevent tailing (SiO2 10% MeOH/DCM, 1% NH4OH). The acidic nature of the 
silica column results in some sites to which the basic nitrogen moieties present in the 
structures can interact. This causes the target compound to drag giving a broad Rf 
value. When column chromatography is performed on the linked products using silica it 
was noted that there was some degradation of the ester bonds, resulting in the linked 
products degrading to the codeine starting material. While no significant percentage of 
the ester bonds degraded the amount of time spent on the silica column is an important 
factor to consider. Recrystallisations were performed via slow cooling technique for 
single solvent recrystallisations (acetone) and solvent diffusion for two solvent 
recrystallisations (CHCl3:Hexane). 
 
2.3 Synthesis of Ether Linked Codeine Derivatives  
 
2.3.1 Method Development 
 
Formation of ether linked opioid derivatives has previously been presented by Frensch 
and Voegtle (1979) (Fig 2.3).69 The method involves refluxing 1,2-bis(2-
chloroethoxy)ethane or 1-chloro-2-(2-(2-(2-chloroethoxy)ethoxy)ethoxy)ethane with 
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morphine in butanol in the presence of sodium hydroxide. Compound 133 was isolated 
in 8% yield while 134 was only isolated in 10% yield. However attempts to join the two 
morphine units with 2,6-bis(bromomethyl)pyridine to form the ether linked derivative 
proved unsuccessful with only 135 isolated as the major product in 10% yield. While 
this work illustrates that it is possible to form ether linked opioid compounds the low 
yield is undesirable. Frensch and co-workers have not published further studies in this 
area since 1979. 
  
 
Fig 2.3 Ether linked morphine derivatives, 133, 134 and 135  
 
Previous studies within the research group investigating the formation of ether linked 
opiate compounds based on modification of morphine have previously been 
undertaken.70 After extensive investigation suitable methods were developed to form a 
variety of ether linked morphine opioids in 64% - 94% yield.  
 
 
Scheme 2.6 Reaction scheme for the formation of 136 
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If the reaction is carried out in methanol under reflux with the addition of sodium 
methoxide the para linked morphine ether, 136 can be formed in 68% yield (Scheme 
2.6). Of curent interest for this research project is the reaction conditions required for 
the formation of ether linked compounds at the 6 position. Formation of ether linkers at 
the 6 position has previously been undertaken in the research group as part of an 
investigation to form macrocyclic opiate derivatives (Scheme 2.7). The optimum 
conditions for the formation of the linked ether compound 138 involve refluxing 137 in 
THF with the addition of the dichloride, KOH and KI.   
 
 
Scheme 2.7 Reaction scheme for the formation of 138 
 
2.3.2 Synthesis of Novel Ether Linked Codeine Compounds 
 
The previously developed reaction conditions were utilised to form the ether linked 
codeine compounds. Both the para (121) and meta (139) linked ether derivatives were 
synthesised using the same method (Scheme 2.8) in modest yields of 55% and 59% 
respectively (Fig 2.4). The reaction was performed using both the 1,4-
bis(bromomethyl)benzene (Scheme 2.8) and 1,4-bis(chloromethyl)benzene (Scheme 
2.9) with the bromo-derivative resulting in better yields. 
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Scheme 2.8 Reaction scheme for the formation of 121 using 1,4-bis(bromomethyl)benzene 
 
 
Scheme 2.9 Reaction scheme for the formation of 121 using 1,4-bis(chloromethyl)benzene 
 
 
 
 
 
Fig 2.4 Codeine derivatives 121 (from Scheme 2.8) and 139 (using 1,3-bis(bromomethyl)benzene under 
same reaction conditions) with isolated yields  
 
Purification of the ether compounds was achieved through column chromatography 
followed by recrystallisation. The mobile phase employed was a DCM methanol 
mixture with small amounts of ammonia solution added to the mobile phase to prevent 
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tailing (SiO2 10% MeOH/DCM, 1% NH4OH). Recrystallisations for both compounds 
were performed via solvent diffusion using a CHCl3:Hexane mixture. 
 
2.4 NMR Study of Ester and Ether Linked Compounds 
 
2.4.1 NMR Study of Compound 119 
 
A study of 119 was performed by analysis of 1H, 13C, 13C DEPT, COSY, HMQC and 
HMBC NMR spectra. The structure of compound 119 is outlined below in Fig 2.5. In 
total 119 contains C44H44N2O8 corresponding to a molecular mass of 728.8288. The 
molecule contains two codeine structural units resulting in a symmetrical compound, ie 
H14 and H14’ are identical under NMR analysis. Compound 119 has been fully labeled 
in Fig 2.5, however for clarity in further discussions H14 will refer to both H14 and 
H14’, C1 will refer to both C1 and C1’ etc.  The majority of the peaks in the 1H proton 
spectrum for 119 can be assigned based on their relative δ values and splitting patterns. 
Most peaks in the 1H proton NMR for 119 are broadly similar to the codeine starting 
material (Figs 2.6–2.7). 
 
 
Fig 2.5 Structure of codeine (2) and 119 with labelled atoms 
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Fig 2.6 1H Proton NMR of Codeine (2) 
 
Analysis of the 1H NMR spectrum of 119 (Fig 2.7) shows protons H21 in the aromatic 
linker moiety appear as the expected singlet at δ 8.07. The aromatic peaks 
corresponding to H2 and H1 appear as doublets with J values of 8.0 Hz (consistent with 
vincinal coupling constants for protons in an aromatic ring system) and chemical shifts 
of δ 6.59 and δ 6.50 respectively. Proton H7 at δ 5.74-5.70 couples with H8, H6, and 
H14, however accurate J coupling can not be calculated due to peak overlap. The 
strongest coupling for H7 can be calculated roughly at 10.0 Hz which would 
correspond to coupling with H8 (consistent with vicinal coupling constants on alkenes). 
Weak coupling is also observed with H6 and H14 however J values cannot be 
accurately determined due to peak overlap. Proton H8 (δ 5.48-5.44) has a similar 
pattern to H7, strong coupling with H7 (J value 10.0 Hz) and weak coupling to H6 and 
H14. Proton H5 appears as a doublet with a J value of 6.8 Hz at δ 5.14 while the methyl 
protons corresponding to H18 and H17 appear as singlets at δ 3.64 and δ 2.39 
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respectively. The multiplets at δ 3.33-3.31 and δ 2.77-2.74 relate to protons H9 and 
H14 respectively.  
 
The methylene protons H10, H16 and H15 all have two different δ values for each 
proton as they are diastereotopic hydrogens. Proton H10A, at δ 2.99 appears as a 
doublet with a J value of 18.4 Hz due to geminal coupling. Proton H10B at δ 2.35-2.23 
appears as a doublet of doublets due to geminal and H9 coupling. However due to peak 
overlap J values can not be accurately determined. Proton H16 at δ 2.54 appears as a 
doublet of doublets due to geminal and weak H15 coupling with J values of 12.0 and 
4.0 Hz. Proton H16 at δ 2.35-2.23 appears as a multiplet due to peak overlap. Proton 
H15 at δ 2.02 appears as a doublet of doublet of doublets due to geminal and strong 
H16 coupling with J values of 12.4, 12.4 and 4.8 Hz. Proton H15 at δ 1.83 appears as a 
doublet of doublets due to geminal and weak H16 coupling with J values of 12.8 and 
2.0 Hz.        
 
 
Fig 2.7 1H Proton NMR of 119 
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The most significant peak in the spectrum corresponds to H6. It is expected that 
conversion from the secondary alcohol (codeine, 2) to the ester (119) at the 6 position 
of the molecule should have a large effect on the chemical shift. As expected the proton 
at this position is downfield shifted from δ 4.09 to δ 5.40-5.36 (Fig 2.6 and Fig 2.7). As 
a result this peak can be used to calculate to a good estimation the percentage formation 
of product from the crude reaction mixture. 
 
While most peaks can be assigned based on the 1H proton spectrum the COSY 
spectrum provides additional and complementary information (Figs 2.8-2.10).  
 
 
Fig 2.8 COSY spectrum of 119 
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Fig 2.9 COSY spectrum of 119 showing cross peak correlations between δ 5.0-7.0 
 
Examining the δ region of 5.0-7.0 (Fig 2.9) displays the strong coupling between H2 
and H1 (10.0 Hz). H1 also shows weak coupling to H10 while H2 exhibits very weak 
coupling with H18. As expected there is strong coupling observed between protons H5 
and H6 via three bond coupling. Proton H5 also couples very weakly with H7 and H8. 
Protons H7 and H8 display strong coupling with each other (10.0 Hz), while, weaker 
coupling to protons H14 and H6 is observed.  
 
Ester and Ether Linked Codeine 
——————————————————————————————————————— 
 
 
——————————————————————————————————————— 
 
51 
 
Fig 2.10 COSY spectrum of 119 showing peak correlations between δ 1.5-3.5 
 
Analysis of the δ region of 1.5-3.5 (Fig 2.10) displays the remaining correlations in 
119. Proton H9 couples to H14 and H10B, while proton H10B also couples with H10A 
through geminal coupling. Protons H16 and H15 couple with each other as well as 
displaying the expected geminal coupling for diastereotopic hydrogens. Overall 
analysis of 119 by COSY NMR illustrates that the coupling patterns assigned based on 
the 1H NMR analysis are correct. A summary of the proton proton coupling for 119 is 
provided in Table 2.4. 
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Proton No. Couples with 
21 21 
2 2, 1, 18* 
1 1, 2, 10* 
7 7, 8, 14, 6*, 5* 
8 8, 7, 14, 6*, 5* 
6 6, 5, 14, 7*, 8* 
5 5, 6, 7*, 8* 
18 18, 2* 
9 9, 14, 10 
10 10, 9 
14 14, 7, 8, 6, 9 
16 16, 15 
17 17 
15 15, 16 
Table 2.4 Proton proton correlations from COSY spectrum of 119, *denotes weak coupling.  
 
An examination of the 13C, 13C DEPT, HMQC and HMBC allows the carbon atoms of 
119 to be accurately assigned. The majority of the peaks for 119 can be assigned based 
on their relative δ values in the 13C spectrum (Fig 2.11) with most peaks again similar 
to the codeine starting material. Further analysis by 13C DEPT, HMQC and HMBC 
provides additional information.  
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 Fig 2.11 13C spectrum of 119 
 
Fig 2.12 13C DEPT spectrum of 119 
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As expected the carbonyl carbon C19 has the highest δ value at 165.34 with C20 and 
C21 appearing at the expected δ values for aromatic carbons at 133.89 and 129.77 
respectively. From 13C DEPT analysis it is clear which carbons correspond to the 
quaternary and methylene carbons (Fig 2.12). In total 119 contains 7 quaternary 
carbons corresponding to C19, C4, C3, C20, C12, C11 and C13 at δ values of 165.34, 
146.61, 142.21, 133.89, 130.71, 126.95 and 42.60 respectively. The three methylene 
carbons for C16, C15 and C10 have δ values of 46.76, 35.36 and 20.34 respectively. 
Some of the carbon peaks appear at very similar δ values and accurate peak assignment 
is not possible from 13C and 13C DEPT alone. Accurate confirmation about assigning 
the carbon peaks is aided by HMQC (Fig 2.13-2.16) and HMBC (Fig 2.17, 2.18) NMR 
analysis. A summary of the carbon proton coupling is provided in Table 2.5. 
 
δ Value (ppm) 
Assigned Peak No. 
Carbon Proton 
8 129.87 5.48-5.44 
21 129.77 8.07 
7 128.28 5.74-5.70 
1 119.34 6.50 
2 114.30 6.59 
5 87.80 5.14 
6 68.84 5.40-5.36 
9 59.14 3.33-3.31 
18 56.76 3.64 
16 46.76 2.54, 2.35-2.23 
17 43.11 2.39 
14 40.66 2.77-2.74 
15 35.36 2.02, 1.83 
10 20.34 2.99, 2.35-2.23 
Table 2.5 Carbon proton correlations from HMQC of 119  
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Fig 2.13 HMQC spectrum of 119 
 
Fig 2.14 HMQC spectrum of 119 showing peak correlations between δ 5.0-8.5 
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Fig 2.15 HMQC spectrum of 119 showing peak correlations between δ 5.5-8.2 for C8, C21 and C7 
 
Fig 2.16 HMQC spectrum of 119 showing peak correlations between δ 1.5-5.5 
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For full peak assignment of the carbon spectrum it is also helpful to examine the 
HMBC of 119 which provides important structural information about the correlation 
between protons and the quaternary carbons (Figs 2.17-2.18). As expected proton H21 
shows coupling with carbons C19, C20 and C21. Proton H2 displays coupling with 
carbons C4, C3 and C11, while proton H1 exhibits coupling with C3 and C12. Proton 
H5 displays coupling with carbons C4, C12 and C7.  
 
Fig 2.17 HMBC spectrum of 119 
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Fig 2.18 HMBC spectrum of 119 showing peak correlations between δ 5.0-8.5  
 
2.4.2 NMR Study of Compound 121 
 
The same approach was employed to fully assign the proton and carbon spectra for the 
ether linked para derivative 121 (Fig 2.19). In total 121 contains C44H48N2O6 
corresponding to a molecular mass of 700.8617. Compound 121 contains much of the 
same skeleton as 119 and as such the 1H, 13C, 13C DEPT, COSY, HMQC and HMBC 
spectra will appear very similar. As per 119, compound 121 the molecule contains two 
codeine structural units resulting in a symmetrical compound, ie H14 and H14’ are 
identical under NMR analysis. Compound 121 has been fully labeled in Fig 2.19, 
however for clarity in further discussions H19 will refer to both H19 and H19’, C21 
will refer to both C21 and C21’ etc. 
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Fig 2.19 Structure of 121 with labeled atoms 
 
Analysis of the 1H NMR spectrum of 121 (Fig 2.20) shows that the protons 
corresponding to the opiate scaffold are similar to 119. As expected the main 
differences are due to the modification of the linker species from the ester to the ether.  
 
Fig 2.20 1H spectrum of 121 
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In comparison with 119 the most significant peaks in the spectrum correspond to H21, 
H6 and H19 (Table 2.6). Proton H21 for 119 is at a δ value of 8.07 while proton H21 
for 121 is shifted upfield at δ 7.34.  Proton H6 for 121 is at the expected δ value of 
3.90-3.87 while it is downfield shifted to δ 5.40-5.36 when attached to the carbonyl in 
119. Protons H19 at δ 4.77 and 4.57 correspond to the expected AB splitting pattern 
with J values of 12.0 Hz. 
 
δ Value (ppm) 
Proton 
119 121 
1 6.50 6.43 
2 6.59 6.55 
5 5.14 4.91 
6 5.40-5.36 3.90-3.87 
7 5.74-5.70 5.69-5.66 
8 5.46 5.23 
21 8.07 7.34 
Table 2.6 Comparison of selected δ values for 119 and 121 from 1H NMR 
 
The COSY spectrum for 121 provides additional information in relation to peak 
assigments (Figs 2.21-2.23). Again the coupling pattern for 121 as expected, is similar 
to 119 with the main difference corresponding to H19 at δ 4.77 and 4.57. A summary of 
the proton proton coupling for 121 is provided in Table 2.7. 
 
 
 
 
 
 
 
 
 
Ester and Ether Linked Codeine 
——————————————————————————————————————— 
 
 
——————————————————————————————————————— 
 
61 
 
Proton No. Couples with 
21 21 
2 2, 1 
1 1, 2, 10* 
7 7, 8, 14, 6*, 5* 
8 8, 7, 14, 6*, 5* 
5 5, 6, 7*, 8* 
19 19, 
6 6, 5, 14, 7*, 8* 
18 18 
9 9, 14, 10 
10 10, 9 
14 14, 7, 8, 6, 9 
16 16, 15 
17 17 
15 15, 16 
Table 2.7 Proton proton correlations from COSY spectrum of 121, *denotes weak coupling. 
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Fig 2.21 COSY spectrum of 121 
 
Fig 2.22 COSY spectrum of 121 showing cross peak correlations between δ 4.0-6.8 
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Fig 2.23 COSY spectrum of 121 showing cross peak correlations between δ 1.6-4.0 
 
An examination of the 13C, 13C DEPT, HMQC and HMBC allows the carbon atoms of 
121 to be accurately assigned. The majority of the peaks for 121 can be assigned based 
on their relative δ values in the 13C spectrum (Fig 2.24) with most peaks again similar 
to 119 (Table 2.8). Further analysis by 13C DEPT, HMQC and HMBC provides 
additional information. The most significant difference between 119 and 121 from 13C 
analysis corresponds to C19. As expected the absence of the carbonyl group at the C19 
position results in C19 at a δ value of 70.44 for 121, compared to a δ value of 165.34 
for 119.  
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Fig 2.24 13C spectrum of 121 
 
Fig 2.25 13C DEPT spectrum of 121 
Ester and Ether Linked Codeine 
——————————————————————————————————————— 
 
 
——————————————————————————————————————— 
 
65 
 
δ Value (ppm) 
Carbon 
119 121 
1 119.34 118.82 
2 114.30 113.48 
5 87.80 89.59 
6 68.84 72.99 
7 128.28 130.94 
8 129.87 128.71 
19 165.34 70.44 
20 133.89 137.65 
21 129.77 127.96 
Table 2.8 Comparison of selected δ values for 119 and 121 from 13C NMR 
 
From 13C DEPT it is clear which carbons correspond to the quaternary and methylene 
carbons (Fig 2.25). In total 121 contains 6 quaternary carbons corresponding to C4, C3, 
C20, C12, C11 and C13 at δ values of 147.46, 142.16, 137.65, 130.84, 126.94 and 
43.34 respectively. The four methylene carbons for C19, C16, C15 and C10 have δ 
values of 70.44, 46.55, 35.89 and 20.50 respectively.  
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Analysis by HMQC NMR provides proton carbon coupling for 121 (Figs 2.26-2.28). 
The main difference between 119 and 121 is the proton H19 and carbon C19 coupling 
(Fig 2.28). A summary of the carbon proton coupling for 121 is provided in Table 2.9.  
 
δ Value (ppm) 
Assigned Peak No. 
Carbon Proton 
7 130.94 5.69-5.66 
8 128.71 5.23 
21 127.96 7.34 
1 118.82 6.44 
2 113.48 6.56 
5 89.59 4.91 
6 72.99 3.90-3.87 
19 70.44 4.77, 4.57 
9 58.96 3.27-3.25 
18 56.55 3.76 
16 46.55 2.49, 2.36-2.29 
17 43.12 2.36 
14 41.00 2.56-2.55 
15 35.89 1.94, 1.80 
10 20.50 2.94, 2.22 
Table 2.9 Carbon proton correlations from HMQC of 121  
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Fig 2.26 HMQC spectrum of 121 
 
Fig 2.27 HMQC spectrum of 121 showing peak correlations between δ 5.1-7.6 
Ester and Ether Linked Codeine 
——————————————————————————————————————— 
 
 
——————————————————————————————————————— 
 
68 
 
Fig 2.28 HMQC spectrum of 121 showing peak correlations between δ 1.5-5.0 
 
For full peak assignment of the carbon spectrum it is also helpful to examine the 
HMBC of 121 (Figs 2.29-2.30). As expected proton H21 shows coupling with carbons 
C19, C20, and C21. Proton H2 exhibits coupling with carbons C4, C3 and C11, while 
proton H1 exhibits coupling with C3 and C12. Proton H5 displays coupling with 
carbons C4, and C12, while proton H19, shows coupling with C20, and C21’.  
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Fig 2.29 HMBC spectrum of 121 
 
Fig 2.30 HMBC spectrum of 121 showing peak correlations at δ 4.5-7.5 
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2.5 X-ray Crystallography Studies of Ester Linked Codeine Derivatives 
 
An understanding of the crystal structure of the linked opioid derivatives can provide 
valuable information in relation to the drug-receptor interaction at the receptor binding 
sites (Chapter 4). This may aid in the understanding of the mode of action of these 
therapeutic agents. Also analysis of the crystal structure can provide important 
information on the potential of these compounds to interact with metal cationic species 
(Chapter 5). From the x-ray crystallographic analysis the structural data of the linked 
opioid compounds 126 and 127 was estimated using Mercury 2.3 software. This data is 
based on solid state and it must be emphasised that the opioid compounds may undergo 
significant conformational changes when interacting with the opioid receptor site 
(Chapter 4) or metal cation species (Chapter 5). 
 
2.5.1 X-ray Crystallography Study of 126 
 
Crystals suitable for single crystal X-ray determination of 126 were grown by slow 
evaporation from CHCl3:hexane (1:4), yielding colourless block shaped crystals. 
Compound 126 crystallises in the space group P21 with selected bond distances, bond 
angles and torsion angles given in Table 2.10. As expected ring conformations for each 
codeine structural unit are similar to previously reported opioid derivatives which each 
codeine unit adopting the classic T-shaped configuration.71, 72 
  
 
Fig 2.31 Structure of 126 and codeine (2) with ring labels and atom labels 
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Fig 2.32 X-ray crystal structure of 126 
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Fig 2.33 ORTEP diagram of 126 with atom labels 
 
The bond length for C6-O3 is 1.445(2) Å while C6’-O3’ is slightly longer at 1.455(2) 
Å. The bond length for C5-C6 is 1.544(2) Å with the corresponding bond C5’-C6’, in 
the other codeine moiety again slightly longer at 1.564(2) Å. The bond lengths for O3-
C19 and O3’-C26 are identical at 1.346(2) Å and 1.347(2) Å respectively. The bond 
angle for C5-C6-O3 is 112.3(1)° while C5’-C6’-O3’ is calculated at 110.1(1)°. The 
bond angles for C7-C6-O3 and C7’-C6’-O3’ are comparable at 106.6(1)° and 106.8(1)° 
respectively. The most noticeable differences in 126 are the variations in relative 
torsion angles for each codeine moiety. There are minimal differences in the torsion 
angles between each codeine unit for the A and B rings. The torsion angle for C1-C2-
C3-C4 is 0.7(2) while the value for C1’-C2’-C3’-C4’ is 3.5(2). The torsion angle for 
C10-C11-C12-C13 is 7.0(2) while the value for C10’-C11’-C12’-C13’is 3.8(2). As 
expected the major differences between each codeine scaffold correspond to the C-ring 
and the linker section of the molecule. The torsion angle for C5-C6-C7-C8 is 42.7(2) 
while the related torsion angle for C5’-C6’-C7’-C8’ on the other codeine unit is 
24.8(2). Likewise the calculated torsion angles for C7-C8-C14-C13 and C7’-C8’-C14’-
C13’ are -40.9(2) and -27.7(2) respectively. For O2-C5-C6-O3 the torsion angle was 
calculated at -34.3(2)° however the corresponding torsion angle of O2’-C5’-C6’-O3’ 
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was calculated at -11.5(2)°. A similar result is displayed with C19-O3-C6-C5 and C26-
O3’-C6’-C5’ with torsion angles of -76.8(2)° and -66.8(2)° respectively. For more 
details on the X-ray crystal data for 126 see Appendix A, A.1.   
 
Bond Lengths (Å) 
C6-O3 1.445(2) C6’-O3’ 1.455(2) 
C5-C6 1.544(2) C5’-C6’ 1.564(2) 
O3-C19 1.346(2) 
 
O3’-C26 1.347(2) 
Bond Angles (°) 
C5-C6-O3 112.3(1) C5’-C6’-O3’ 110.1(1) 
C7-C6-O3 106.6(1) C7’-C6’-O3’ 106.8(1) 
C6-O3-C19 116.5(1) C6’-O3’-C26 
 
114.1(1) 
Torsion Angles (°) 
A Ring 
C11-C1-C2-C3 -3.9(3) C11’-C1’-C2’-C3’ -0.8(3) 
C1-C2-C3-C4 0.7(2) C1’-C2’-C3’-C4’ 3.5(2) 
B Ring 
C14-C9-C10-C11 31.9(2) C14’-C9’-C10’-C11’ 37.6(2) 
C10-C11-C12-C13 7.0(2) C10’-C11’-C12’-C13’ 3.8(2) 
C Ring 
C5-C6-C7-C8 42.7(2) C5’-C6’-C7’-C8’ 24.8(2) 
C6-C7-C8-C14 -3.2 (2) C6’-C7’-C8’-C14’ -6.5 (3) 
C13-C5-C6-C7 -31.8 (2) C13’-C5’-C6’-C7’ -6.3 (2) 
C7-C8-C14-C13 -40.9 (2) C7’-C8’-C14’-C13’ -27.7 (2) 
Linker Section 
O2-C5 –C6-O3 -34.3 (2)  O2’-C5’-C6’-O3’ -11.5 (2) 
C19-O3-C6-C5 -76.8 (2) C26-O3’-C6’-C5’ -66.8 (2) 
Table 2.10 Selected bond distances and bond angles and torsion angles for 126 with estimated standard 
deviations in parenthesis 
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Fig 2.34 X-ray crystal packing of 126 
 
2.5.2 X-ray Crystallography Study of 127 
 
Crystals suitable for single crystal X-ray determination of 127 (Fig 2.35) were grown 
by slow evaporation from chloroform:hexane (1:4), yielding colourless block shaped 
crystals. Compound 127 crystallises in the space group P212121 with selected bond 
distances, bond angles and torsion angles given in Table 2.11. As noted with 126 each 
codeine unit adopts the T-shaped configuration of classic opioid compounds.  
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Fig 2.35 Structure of 127 with atom labels 
 
 
 
Fig 2.36 X-ray crystal structure of 127 
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Fig 2.37 ORTEP diagram of 127 with atom labels 
 
The bond length for C6-O3 is 1.450(2) Å while C6’-O3’ is almost identical at 1.455(2) 
Å. The bond length for C5-C6 is 1.537(2) Å with the corresponding bond C5’-C6’, in 
the other codeine moiety identical at 1.536(2) Å. The bond lengths for O3-C19 and 
O3’-C26 are also identical at 1.340(2) Å and 1.344(2) Å respectively. The bond angle 
for C5-C6-O3 is 114.1(1)° which is identical to C5’-C6’-O3’ at 114.0(1)°. The bond 
angles for C7-C6-O3 and C7’-C6’-O3’ are similar at 106.1(1)° and 106.9(1)° 
respectively. The most noticeable differences in 127 are the variations in relative 
torsion angles for each codeine structural unit however there is much less variation than 
was noted for 126. As expected there is only minimal difference between the torsion 
angles for the A and B rings. The most noticeable differences are in the C ring and the 
linker section. The torsion angle for C5-C6-C7-C8 is 44.0(2) while the related torsion 
angle for C5’-C6’-C7’-C8’ on the other codeine unit is 49.5(2). Likewise the calculated 
torsion angles for C7-C8-C14-C13 and C7’-C8’-C14’-C13’ are -40.0(2) and -41.4(2) 
respectively. For O2-C5-C6-O3 the torsion angle was calculated at -35.5(2)° with the 
corresponding torsion angle of O2’-C5’-C6’-O3’ calculated at -42.1(2)°. The torsion 
angles for C19-O3-C6-C5 and C26-O3’-C6’-C5’ were calculated at -77.4(2)° and -
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75.1(2)° respectively. Compound 127 is not symmetrical in the solid state. For more 
details on the X-ray crystal data for 127 see Appendix A, A.2.   
 
Bond Lengths (Å) 
C6-O3 1.450(2) C6’-O3’ 1.455(2) 
C5-C6 1.537(2) C5’-C6’ 1.536(2) 
O3-C19 1.340(2) O3’-C26 1.344(2) 
 
Bond Angles (°) 
C5-C6-O3 114.1(1) C5’-C6’-O3’ 114.0(1) 
C7-C6-O3 106.1(1) C7’-C6’-O3’ 106.9(1) 
C6-O3-C19 117.8(1) C6’-O3’-C26 
 
116.7(2) 
Torsion Angles (°) 
A Ring 
C11-C1-C2-C3 -4.1(3) C11’-C1’-C2’-C3’ -4.1(3) 
C1-C2-C3-C4 0.6(3) C1’-C2’-C3’-C4’ 0.9(3) 
B Ring 
C14-C9-C10-C11 31.9(2) C14’-C9’-C10’-C11’ 31.2(2) 
C10-C11-C12-C13 3.0(3) C10’-C11’-C12’-C13’ 1.9(3) 
C Ring 
C5-C6-C7-C8 44.0(2) C5’-C6’-C7’-C8’ 49.5(2) 
C6-C7-C8-C14 -4.6(3) C6’-C7’-C8’-C14’ -6.3(3) 
C13-C5-C6-C7 -32.2(2) C13’-C5’-C6’-C7’ -37.6(2) 
C7-C8-C14-C13 -40.0(2) C7’-C8’-C14’-C13’ -41.4(2) 
Linker Section 
O2-C5 -C6-O3 -35.5(2)  O2’-C5’-C6’-O3’ -42.1(2) 
C19-O3-C6-C5 -77.4(2) C26-O3’-C6’-C5’ -75.1(2) 
Table 2.11 Selected bond distances and bond angles and torsion angles for 127 with estimated standard 
deviations in parenthesis 
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Fig 2.38 X-ray crystal packing of 127 
 
2.6 Conclusion 
 
The synthesis and structural characterisation of ester and ether “linked” codeine 
derivatives has been achieved. A selection of eight novel ester linked codeine 
derivatives (119, 126-132) were successfully synthesised in modest to good isolated 
yields of 39% - 82%. Initial synthesis of the ester linked codeine derivatives via NEt3 in 
DCM under N2 resulted in minimal conversion to the desired compounds. An 
investigation into improved reaction conditions was performed with the choice of base 
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(NEt3, K2CO3, Na2CO3, NaH, KOH, NaOH, DMAP), solvent (DCM, THF, pyridine) 
and temperature analysed. After analysis it was found that the ester linked codeine 
compounds can be generated in modest to good yields via the reaction of codeine with 
the appropriate acid chloride species in the presence of DMAP in DCM under N2. 
Increasing the temperature of the reaction had no discernable affects on product 
formation. Purification was achieved by a combination of column chromatography and 
recrystallisation. Full characterisation was performed by m.p., IR, [α]D, HRMS, 1H 
NMR, 13C NMR, DEPT, COSY, HMQC and HMBC. An in depth NMR analysis of one 
of the ester linked compounds (119) was also performed with full peak assignments. An 
examination of the X-ray crystal structures of two of the ester linked codeine 
derivatives was also performed (126, 127).  
 
Successful generation of two ether linked compounds (121, 139) was also achieved in 
isolated yields of 55% and 59%. Based on previous experiments within the research 
group the compounds were synthesised via the reaction of codeine with the appropriate 
ether linker in the presence of KOH, KI in THF at 66 °C. Purification was similar to the 
ester derivatives via combination of column chromatography and recrystallisation. The 
1,4-bis(bromomethyl)benzene species resulted in a higher yield than the 1,4-
bis(chloromethyl)benzene species. Full characterisation was performed by m.p., IR, 
[α]D, HRMS, 1H NMR, 13C NMR, DEPT, COSY, HMQC and HMBC. An in depth 
NMR analysis of an ether linked compound (121) was also performed with full peak 
assignments.  
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Chapter 3 
 
Synthesis and Structural Characterisation of A-Ring Modified 
Codeine Derivatives  
 
3.1 Introduction 
 
This chapter details the synthesis of a series on novel opioid compounds based on 
structural modification at the 1 and 6 positions of the codeine (2) scaffold. Previous 
studies on opioid derivatives have shown that modification at the 1 position of the 
aromatic ring is possible through halogenation73 (75) and palladium coupling74 (140) 
(Fig 3.1). By combining the palladium coupling techniques with the formation of linked 
codeine derivatives (Chapter 2) a series of novel opioid derivatives can be generated 
(Scheme 3.1). 
 
Fig 3.1 Codeine (2) and A-ring modified codeine derivatives, 75 (halogenated derivative) and 140 
(palladium catalysed carbon-carbon coupled derivative).  
 
Palladium coupling chemistry has received a lot of interest over recent years with much 
of the work involving Heck75, Stille76, and Suzuki77 coupling. Heck coupling involves the 
reaction of an unsaturated halide with an alkene in the presence of a base such as 
triethylamine and a palladium catalyst, most commonly palladium acetate. The halide 
species is usually an aryl, benzyl or vinyl compound with the alkene often electron-
deficient, such as an acrylate ester. Normally a phosphine ligand is also used for the 
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reaction, usually triphenylphosphine. For the purposes of this research the opioid 
derivatives are acting as the halide species. 
 
Stille coupling is a versatile method for the formation of carbon-carbon bonds which 
employs the reactions between halides and stannanes. The main benefit of this method is 
that there are very few limitations on the halide group which is an important factor that 
has to be considered when the opioids are acting as the halide species. However, it must 
also be noted that many of the tin compounds have high toxicity78 and trace amounts of 
tin impurities can often be difficult to remove successfully during purification. The other 
important general coupling method employed is Suzuki coupling. The reaction proceeds 
via the reaction of an aryl or vinyl boronic acid species with an aryl or vinyl halide 
compound again catalysed by palladium. 
 
 
Scheme 3.1 Formation of para ester linked codeine compound (141) with A-ring modification 
 
Modification of the A-ring of opioids has been shown to lower the binding affinity to 
the mu opioid receptor (Chapter 1, 1.2.4) thus formation of these compounds could 
have important applications in relation to analgesic therapeutics (Chapter 4). A-ring 
modification on the linked codeine species (Scheme 3.1) could also affect metal 
binding thus expanding the scope for sensor applications.  
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3.2 Synthesis of A-ring Modified Codeine Derivatives 
 
3.2.1 Halogenated Codeine Derivatives 
 
The first step in the formation of A-ring modified opioids is the generation of the 
halogenated codeine structures, bromocodeine (75), iodocodeine (142) and 
chlorocodeine (76). Wilson et al have previously shown that halogenation at the 1 
position is possible using the appropriate halogenated N-succinimide in an acidic 
environment.73    Halogenation was only observed at the aromatic 1 position of the ring 
(Fig 3.2).  
 
 
Fig 3.2 Structure of codeine (2) and bromocodeine (75) showing halogenation at the 1 position 
 
No halogenation of the carbon-carbon double bond (positions 7 and 8) was observed or 
at the 2 position of the aromatic ring. Halogenation of the aromatic ring preferentially 
favours the 1 position due to the strong para-directing moiety of the ring fusion ether at 
the 4 position. Synthesis of these compounds was performed using the appropriate 
halogenated N-succinimide in TFA (Scheme 3.2). Isolated yields for the halogenated 
compounds (75, 76, 142) were between 62-89% (Fig 3.3). The highest isolated yield 
was achieved for the iodine derivative (142) at 89% while the chlorine derivative (76) 
resulted in the lowest isolated yield at 62%. To achieve chlorination at the 1 position of 
the aromatic ring it was necessary to increase the reaction temperature to 90°C. When 
the reaction with N-chlorosuccinimide was performed at RT no product was observed, 
with only codeine starting material recovered. The reactivity of the N-halosuccinimide 
compounds are in agreement with the literature.73,79  
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Scheme 3.2 Reaction scheme for the formation of bromocodeine (75) 
 
 
  
   
Fig 3.3 Halogenated derivatives of codeine with isolated yields using N-halosuccinimides 
 
3.2.2 Halogenated Ester Linked Codeine Derivatives  
 
As esterification has previously been demonstrated at the secondary alcohol sites 
(Chapter 2, 2.2.1) to form the linked opioid derivatives we decided to generate the 
halogenated analogues of the linked species. There are two routes to synthesise the 
desired esterified halogenation species (Scheme 3.3). Generation of the ester linked 
compound (7) followed by halogenation (route A) or halogenation of the aromatic ring 
followed by esterification (route B). Of note is the possible susceptibility of the ester 
bonds to hydrolysis especially in the presence of an acid or base. 
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Scheme 3.3 Two possible routes to the formation of ester linked halogenated codeine derivative (143) 
 
Synthesis of the halogenated species is via the acid catalysed reaction of the appropriate 
opioid with N-halogenated succinimide.73 The ester bonds would be highly prone to 
hydrolysis under these conditions and would degrade to the corresponding alcohol. 
Thus route A (Scheme 3.3) would not be a suitable path to approach the generation of 
the desired halogenated ester compounds. For this reason route B, initial halogenation 
of the aromatic A-ring followed by esterification was chosen.  
 
 
Scheme 3.4 Reaction scheme for the formation of 143 
 
A selection of linked bromocodeine (143-148) and iodocodeine (149, 150) derivatives 
were synthesised with alteration dependent on the diacid chloride employed in the 
reaction. The halogenated codeine derivatives were synthesised according to Wilson et 
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al.73 The same method, catalytic DMAP as the base, was employed for the generation 
of all the brominated ester linked compounds (Scheme 3.4). The isolated yields for the 
six brominated ester compounds (143-148) were between 39% and 89%, (Fig 3.4).   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig 3.4 Ester linked bromocodeine (143-148) and iodocodeine (149, 150) derivatives with isolated yields 
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As noted for the codeine linked esters the isolated yields could be improved through 
futher development of reaction conditions and purification if necessary. Purification on 
the brominated species was performed as per the codeine linked esters, via column 
chromatography and recrystallisation. As observed in the reactions of the acid chlorides 
with codeine the conversions from bromocodeine to the ester linked structures varied 
depending on the diacid chloride (Chapter 2, 2.2.1). As expected the conversions for 
bromocodeine to the desired linked species are similar to that of codeine. Again lower 
conversions were seen when using diglycolyl dichloride or 2,6-pyridinedicarbonyl 
dichloride. Esterification was also attempted using iodocodeine as the halogenated 
derivative (149, 150) (Fig 3.4). As expected these reactions exhibited similar results to 
the bromocodeine derivatives. 
 
 
 
 
 
 
 
 
 
 
Fig 3.5 Ether linked bromocodeine (151, 152) and iodocodeine (153, 154) derivatives with isolated 
yields  
 
Synthesis of the halogenated versions of the ether linked compounds was also 
undertaken (151-154). The same route as the ester linked products was employed, 
initial formation of the halogenated codeine species followed by completion of the 
ether linked compound.  In total four halogenated compounds were synthesized using 
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both the bromocodeine (75) and iodocodeine (142) derivatives with the α,α’-dibromo-
p-xylene and α,α’-dibromo-m-xylene linker units. Isolated yields for the halogenated 
derivatives (151-154) were comparable to the non halogenated compounds (121, 139) 
in the range of 45% - 59% (Fig 3.5). Purification of the ether derivatives was achieved 
through a combination of recrystallisation and column chromatography. The mobile 
phase employed for these compounds was similar to the ester derivatives, a DCM 
methanol mixture with small amounts of ammonia solution added to the mobile phase 
to prevent tailing.  
 
3.2.3 Palladium Coupling of the Halogenated Codeine 
 
With the formation of a variety of halogenated opioid derivatives proving successful 
(143-154) further modification of the aromatic A-ring via palladium coupling 
techniques was undertaken. Previous studies into carbon-carbon coupling have shown 
that the chlorine atom is less reactive than bromine and iodine. As the chlorine 
derivative (76) was also isolated in significantly lower yields the bromocodeine (75) 
and iodocodeine (142) compounds were used for palladium coupling.  
 
Davies et al74 had previously shown that palladium coupling was possible on 
bromocodeine resulting in a variety of A-ring modified opiates in high yields (Fig 3.6). 
Four opioid derivatives (140, 155-157) previously reported by Davies and co-workers74 
were synthesised as these would be important intermediates in the future synthesis of 
A-ring modified linked opioids (141, Scheme 3.1). An examination of the halogenated 
opiate structure reveals that there may be some side reactions possible due to the 
presence of the allylic ether moiety which has been shown to react under palladium 
catalysis to the corresponding vinyl ether.74, 80 In addition there could be some 
competition from intermolecular Heck reactions.  
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Fig 3.6 A-ring modified codeine derivatives previously reported  
 
The allylic alcohol at the 6 position was protected as a t-butyldimethylsilyl ether 
(Scheme 3.5). The bromocodeine (158) and iodocodeine (159) derivative were 
protected in yields of 89% and 86% respectively. This is comparable to the isolated 
yield observed for the protection of codeine to form 160 (Fig 3.7). Following the 
palladium coupling step, facile deprotection by TBAF in THF resulting in high 
conversions to the desired compounds is expected. 
 
 
Scheme 3.5 Reaction conditions for protection of the secondary alcohol 
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Fig 3.7 TBDMS protected opioid derivatives, 158-160 with isolated yields 
 
Generation of compounds 140 and 155 (Scheme 3.6) was initially undertaken with the 
bromocodeine derivative (158) using 2 mol% of palladium acetate, leading to moderate 
yields of 53% and 43 % for 140 and 155 respectively. The mol% of palladium acetate 
was increased to 5 mol% resulting in increased yields of 54% and 50% for 140 and 155 
respectively. However when the percentage of palladium acetate was increased to 10 
mol% and 20 mol% no further improvement on the isolated yields was observed. 
Employing the iodocodeine derivative (159) instead of the bromocodeine (158) resulted 
in increased yields for 140 and 155 of 63% and 62% respectively (Scheme 3.6).  
 
 
Scheme 3.6 Reaction scheme for the formation of 140 and 155 
 
Analysis of the crude 1H NMR spectra for both compounds did not reveal the presence 
of any side reactions taking place. The carbon-carbon double bond for both derivatives 
was assigned as the trans conformer due to the J coupling value of 16.0 Hz, 
corresponding to an (E)-geometry. Examination of the crude 1H NMR spectra also 
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showed that the protecting group was stable to the palladium coupling reaction 
conditions. Confirmation of the stability of the protecting group was provided by 
isolation of 161 (Scheme 3.7) The isolated yield for 161 was 85%, comparable to the 
reported value.74 Thus a significant portion of the product is being lost through the 
deprotection step via the reaction workup and purification.  
 
 
Scheme 3.7 Reaction scheme for the formation of 161 
 
The two further opioid derivatives (156, 157) were synthesized via Stille and Suzuki 
palladium coupling methodologies. The iodocodeine derivative (159) was utilised in the 
synthesis as this had previously resulted in improved yields relative to the 
bromocodeine derivative (158). Compound 156 was generated using 
tributyl(phenylethynyl)tin in an isolated yield of 48% after TBDMS deprotection 
(Scheme 3.8). Evidence from the crude 1H NMR spectra showed that the secondary 
alcohol was still protected after the palladium coupling step which is in agreement with 
the protected methyl acrylate (161) isolated previously. 
 
Davies et al74 also reported the formation of 157 using phenyltributyltin however it was 
decided to explore an alternative method for the formation of this derivative. One of the 
main drawbacks of Stille coupling is the potential toxicity of the tin complexes 
employed in the reaction.78 Compound 157 could also be formed through Suzuki 
coupling by utilizing phenylboronic acid (Scheme 3.9). Suzuki coupling proved 
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successful for the formation of 157 with the isolated yield of 80% after deprotection 
comparable to the other palladium coupled derivatives. 
 
O
MeO
TBDMSO
NMe
I
O
MeO
HO
NMe
156
Reaction Conditions; (i) Pd(OAc)2 (5 mol%), tributyl-
(phenylethynyl)-tin (1.2 Eq), PPh3 (20 mol%), NEt3,
DMF, 100°C (ii) TBAF (2 Eq), THF, RT
159
(i), (ii)
48 % HH
 
Scheme 3.8 Reaction conditions for the formation of 156 
 
 
Scheme 3.9 Reaction conditions for the formation of 157 
 
Two novel pyridine derivatives, 162 and 163 were also successfully synthesised using 
the same Heck coupling methodology in isolated yields of 79% and 64% respectively, 
after deprotection (Scheme 3.10). The TBDMS protected derivatives 164 and 165 were 
also isolated for these compounds in yields of 92% and 81% (Fig 3.9) again illustrating 
that Heck palladium catalysed coupling proceeds successfully for these opioid 
derivatives. Isolated yields for the formation of A-ring modified opioid compounds are 
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presented in Fig 3.8 and Fig 3.9. Isolated yields based on the work of Davies et al74 are 
presented in Fig 3.8 while novel A-ring modified codeine derivatives are presented in 
Fig 3.9.   
 
 
Scheme 3.10 Reaction scheme for the formation of 162 and 163 
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Fig 3.8 Isolated yields for compounds, 140, 155-157 and 161 based on the work of Davies et al74, 
a(isolated yields after palladium coupling step), b(isolated yields after both coupling and deprotection 
step)  
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Fig 3.9 Novel palladium coupled opioid derivatives (162-165) with isolated yields, a(isolated yields after 
palladium coupling step), b(isolated yields after both coupling and deprotection step)  
 
3.2.4 Palladium Coupling of the Linked Codeine Compounds 
 
With the successful generation of a series of palladium catalysed carbon-carbon 
coupled codeine derivatives (Fig 3.8 and Fig 3.9) the next process was to combine the 
palladium coupling methods developed with the methods for formation of the linked 
derivatives (Chapter 2, 2.2). Thus, it should be possible to synthesise linked codeine 
derivatives at the 6 position with A-ring modification. Analysis of the desired 
compounds illustrated that there was two synthetic avenues of approach (Scheme 3.11). 
Either we first perform the palladium coupling of the aromatic ring and then 
esterification (route A) or first generate the ester linked compounds and then perform 
the palladium coupling (route B). Again it is important to take into consideration the 
susceptibility of the ester bonds to hydrolysis especially in the presence of an acid or 
base. 
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Scheme 3.11 Possible routes to the formation of ester linked A-ring modified codeine derivative (141)    
 
It was decided to examine both routes to generate the desired compounds. While the 
ester bond may be susceptible to degradation under the palladium coupling conditions 
this route could potentially be more beneficial because it would involve less synthetic 
steps. As the secondary alcohol for the ester linked derivatives is already “blocked” 
there is no need for the protection and deprotection steps. Overall from the starting 
material of iodocodeine (142), route B (Scheme 3.13) would take only two synthetic 
steps in comparison to four steps for route A (Scheme 3.12). 
 
Initially synthesis of the A-ring modified linked codeine compounds was investigated 
using route A to avoid any potential complications from the ester bond degradation. 
Once the compounds had successfully been generated then investigation of route B 
would be undertaken and compared. The compounds were generated based on 
terephthaloyl dichloride as previous analysis (Chapter 2 and Chapter 3) had illustrated 
that the para linked ester derivatives (119, 143, 149) can be isolated in good yields.  
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Scheme 3.12 Possible synthetic route for the formation of 141, via route A 
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Scheme 3.13 Possible synthetic route for the formation of 141, via route B  
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Scheme 3.14 Reaction conditions for the formation of 167 via synthetic route A 
 
Using the synthetic methods developed in Chapter 2 it was possible to generate six A-
ring modified opioid derivatives (141, 166-170) with the para ester linker (Scheme 
3.14) in isolated yields of 49% - 65% (Fig 3.10) following route A. The meta ester 
linked derivative (171) was also synthesised via route A. Purification of these 
compounds was achieved through a combination of recrystallisations and column 
chromatography. Route B as an alternative synthetic method for the generation of three 
A-ring modified opioid derivatives (166-168) also proved successful (Scheme 3.15). 
Isolated yields for the para ester linked derivatives (166-168) of 42% - 63% were 
achieved for route B.  
 
Scheme 3.15 Reaction conditions for the formation of 167 via synthetic route B 
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Fig 3.10 Isolated yields for 141, 166-171 for the final synthetic step, a(route A) or b(route B)  
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As the linked iodinated derivative (149) contains two active sites for palladium 
coupling the relative mol% for palladium acetate was doubled along with the 
equivalents of the other reactants. The most significant aspect of these reactions was the 
stability of the ester bonds. From analysis of the crude 1H NMR spectra no product 
degradation at the 6 position was observed, thus, the ester bonds are stable to the 
palladium coupling reaction conditions. 
 
Route A results in higher yields for the final synthetic step of the reaction (Fig 3.10), 
however, route A contains four synthetic steps in comparison to only two for route B. If 
we examine the overall yield for the final product taking the isolated yields from each 
step then route B is comparable to route A for compounds 166-168 (Table 3.1). A 
schematic representation for the synthesis of 167 from iodocodeine (142) for route A 
and route B is provided in Schemes 3.16 and 3.17. The overall yield of 167 from the 
starting material (iodocodeine, 142) for route A is 39% while from route B the overall 
yield is 37%. As the final isolated yields for each route are comparable route B is more 
practical as it contains less synthetic steps.  
 
Compound Overall % yield from iodocodeine (142) 
 Route A Route B 
166 30% 32% 
167 39% 37% 
168 27% 33% 
Table 3.1 Comparison of overall % yields for 166-168 from iodocodeine (142) for synthetic route A and 
route B  
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H HH
HH
 
Scheme 3.16 Synthetic route A for the formation of 167 with isolated yields  
 
 
Scheme 3.17 Synthetic route B for the formation of 167 with isolated yields  
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3.3 NMR Study of Compound 141  
 
An NMR study of 141 was performed via analysis of 1H, 13C, 13C DEPT, COSY, 
HMQC and HMBC NMR experiments. The structure of compound 141 is outlined 
below in Fig 3.11. In total 141 contains C52H52N2O12 corresponding to a molecular 
mass of 896.3520. Compound 141 contains much of the same skeleton as 119 (Chapter 
2) and as such the NMR spectra will appear very similar. The molecule contains two 
codeine structural units with the protons and carbons from each structural unit being the 
same. Thus the molecule contains H14 and H14’ both of which are identical under 
NMR analysis. Compound 141 has been fully labelled in Fig 3.11, however for clarity 
in further discussions H19 will refer to both H19 and H19’, C21 will refer to both C21 
and C21’ etc. 
 
Fig 3.11 Structure of codeine (2) and compound 141 
 
Analysis of the 1H NMR spectrum of 141 (Fig 3.12) shows that the protons 
corresponding to the opiate scaffold are similar. As expected the main differences 
between 141 and 119 are due to the modification of the A-ring from the methyl acrylate 
functional group. In comparison with 119 the most significant peaks in the 1H NMR 
spectrum correspond to H2, H22, H23 and H25 (Table 3.2). Proton H2 for 119 appears 
as a doublet at δ 6.59 while it appears as a singlet (due to the absence of coupling with 
H1) for 141 at δ 6.91.  Protons H22 and H23 appear as doublets at δ 7.76 and δ 6.18 
respectively with J values of 16.0 Hz. A coupling constant of 16.0 Hz corresponds to 
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the trans isomer, therefore 141 adopts an (E)-geometry. The methyl proton 
corresponding to H25 appears as singlet at δ 3.73.  
 
Fig 3.12 1H Proton NMR of 141 
 
δ Value (ppm) 
Proton 
119 141 
1 6.50 N/A 
2 6.59 6.91 
5 5.14 5.20 
6 5.40-5.36 5.41-5.38 
7 5.74-5.70 5.75-5.72 
8 5.48-5.44 5.48-5.44 
18 3.64 3.67 
25 N/A 3.73 
Table 3.2 Comparison of selected δ values for 119 and 141 from 1H NMR 
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Analysis of the COSY spectrum for 141 provides additional and complementary 
information in relation to peak assigments (Figs 3.13-3.15). The coupling pattern for 
141 is similar to 119 with the main difference corresponding to H2, H22, H23 and H25. 
As expected protons H22 and H23 exhibit strong coupling with each other. A summary 
of the proton proton coupling for 141 is provided in Table 3.3 
 
Fig 3.13 COSY spectrum of 141 
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Fig 3.14 COSY spectrum of 141 showing cross peak correlations between δ 5.0-8.0 
 
Fig 3.15 COSY spectrum of 141 showing peak correlations between δ 1.6-4.0  
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Proton No. Couples with 
21 21 
22 22,23 
2 2, 
23 23, 22 
7 7, 8, 14, 6*, 5* 
8 8, 14, 6*, 5* 
6 6, 5, 14, 7*, 8* 
5 5, 6, 7*, 8* 
25 25 
18 18 
9 9, 14, 10, 
10 10, 9, 
14 14, 7, 8, 6, 9 
16 16, 15 
17 17 
15 15, 16 
Table 3.3 Proton proton correlations from COSY spectrum of 141, *denotes weak coupling.  
 
Analysis of the 13C, 13C DEPT, HMQC and HMBC allows the carbon atoms of 141 to 
be accurately assigned. The majority of the peaks for 141 can be assigned based on 
their relative δ values in the 13C spectrum (Fig 3.16) with most peaks again broadly 
similar to 119 (Table 3.4). Further analysis by 13C DEPT, HMQC and HMBC provides 
additional information. The most significant difference between 119 and 141 from 13C 
analysis corresponds to C1 and C2. C1 for 119 appears at δ value of 119.34 but it is 
downfield shifted for 141 at a δ value of 125.01. From 13C DEPT analysis it is clear 
which carbons correspond to the quaternary and methylene carbons (Fig 3.17). In total 
141 contains 9 quaternary carbons corresponding to C24, C19, C4, C3, C20, C12, C11, 
C1 and C13 at δ values of 167.84, 165.21, 149.14, 142.77, 133.80, 131.29, 127.69, 
125.04 and 42.67 respectively.     
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Fig 3.16 13C spectrum of 141 
 
Fig 3.17 13C DEPT spectrum of 141 
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δ Value (ppm) 
Carbon 
119 141 
1 119.34 125.04 
2 114.30 111.87 
5 87.80 88.55 
6 68.84 68.73 
7 128.28 128.44 
8 129.87 129.80 
18 56.76 56.53 
25 N/A 51.68 
Table 3.4 Comparison of selected δ values for 119 and 141 from 13C NMR 
 
As expected C1 now corresponds to a quaternary carbon due to A-ring modification. 
The three methylene carbons for C16, C15 and C10 have δ values of 46.47, 35.30 and 
19.16 respectively. Analysis by HMQC NMR provides proton carbon coupling for 141 
(Figs 3.18-3.20). 
  
Fig 3.18 HMQC spectrum of 141 
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Fig 3.19 HMQC spectrum of 141 showing peak correlations between δ 5.0-8.5 
 
Fig 3.20 HMQC spectrum of 141 showing peak correlations between δ 1.0-5.8 
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The main difference between 119 and 141 is the proton carbon coupling observed for 
protons H22, H23 and H25 and their corresponding carbons. A summary of the carbon 
proton coupling for 141 is provided in Table 3.5. For full peak assignment of the carbon 
spectrum it is also helpful to examine the HMBC of 141 (Figs 3.21-3.22). As expected 
proton H22 shows coupling with carbons C2, C23 (weak coupling), C11 and C24. 
Proton H23 exhibits coupling with carbons C1 and C24. Definitive assignment of H18 
and H25 is provided by HMBC with H25 coupling with the expected C24 and H18 
coupling with C3. 
 
δ Value (ppm) 
Assigned Peak No. 
Carbon Proton 
22 140.82 7.76 
8 129.80 5.48-5.44 
21 129.78 8.07 
7 128.44 5.75-5.72 
23 115.73 6.18 
2 111.87 6.91 
5 88.55 5.20 
6 68.73 5.41-5.38 
9 58.78 3.42-3.40 
18 56.53 3.67 
25 51.68 3.73 
16 46.47 2.56, 2.35-2.23 
17 43.14 2.41 
14 40.23 2.78 
15 35.30 2.04, 1.82 
10 19.16 3.10, 2.35-2.23 
Table 3.5 Carbon proton correlations from HMQC of 141  
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Fig 3.21 HMBC spectrum of 141 
 
Fig 3.22 HMBC spectrum of 141 showing peak correlations between δ 5.0-8.5  
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3.4 X-ray Crystallography Study of 162 
 
Crystals suitable for single crystal X-ray determination of 162 were grown by slow 
evaporation from chloroform:hexane (1:4), yielding colourless block shaped crystals. 
Compound 162 crystallises in the space group P 21 with selected bond distances, bond 
angles and torsion angles given in Table 3.6. As expected the ring conformations for 
the codeine scaffold are similar to previously reported opioid derivatives with the 
compound adopting the classic T-shaped configuration.71, 72  
 
 
Fig 3.23 Structure of compound 162 and codeine (2) with ring labels and atom labels 
 
The aromatic A-ring and the pyridine ring adopt a planar confirmation while the E ring 
adopts the chair confirmation.  As expected the A-ring exhibits some deviation from 
planarity with torsion angles for C11-C1-C2-C3 and C1-C2-C3-C4 of -1.4(2) and 
2.3(2) respectively. From the x-ray crystal structure it is clear that the molecule adopts 
the (E) geometry for the alkene double bond at carbons C19-C20. Formation of the (E) 
geometry is in agreement with 1H NMR analysis with the J coupling constant for 
protons H19 and H20 calculated at 16.0 Hz. For more details on the X-ray crystal data 
for 162 see Appendix A, A.3.    
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Fig 3.24 X-ray crystal structure of 162 
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Bond Lengths (Å) 
C1-C19 1.465(2) C20-C21 1.463(2) 
C1-C2 1.412(2) C11-C1 1.415(2) 
C5-C6 
 
1.538(2) C6-O3 1.419(2) 
Bond Angles (°) 
C1-C19-C20 127.9(1) C21-C20-C19 125.6(1) 
C11-C1-C2 119.5(1) C22-C21-C24 115. 6(1) 
C5-C6-O3 
 
110.4(1) C7-C6-O3 113.0(1) 
Torsion Angles (°) 
A-ring 
C11-C1-C2-C3 -1.4(2) C1-C2-C3-C4 2.3(2) 
B Ring 
C14-C9-C10-C11 32.8(2) C10-C11-C12-C13 4.6(2) 
C Ring 
C5-C6-C7-C8 40.1(2) C6-C7-C8-C14 -5.4(2) 
Pyridine Ring 
C20-C21-C22-C23 178.5(2) C20-C21-C24-C25 -178.2(2) 
C21-C22-C23-N2 0.4(3) C1-C19-C20-C21 175.8(1) 
Table 3.6 Selected bond distances and bond angles and torsion angles for 162 with estimated standard 
deviations in parenthesis 
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Fig 3.25 ORTEP diagram of 162 with atom labels 
 
 
Fig 3.26 X-ray crystal packing of 162 
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3.5 Conclusion  
 
The synthesis and structural characterisation of a variety of ester and ether “linked” 
codeine derivatives with modification at the 1 position of the aromatic ring has been 
achieved. 
 
A selection of twelve novel ester (143-150) and ether (151-154) linked codeine 
derivatives with halogenation at the 1 position of the aromatic ring were successfully 
synthesised in modest to good isolated yields of 39% - 89%. Synthesis of the ester and 
ether linked codeine derivatives was achieved by initially forming the appropriate halo-
codeine derivatives (75, 142) followed by formation of the “linked” compounds 
(methodology from chapter 2). Halogenation at the 1 position of codeine was achieved 
by using the appropriate halogenated N-succinimide in an acidic environment. 
Purification was achieved by a combination of column chromatography and 
recrystallisation. Full characterisation was performed by m.p., IR, [α]D, HRMS, 1H 
NMR, 13C NMR, DEPT, COSY, HMQC and HMBC.  
 
A selection of five previously reported74 palladium coupled codeine derivatives (140, 
155-157, 161) and four novel palladium coupled codeine derivatives (162-165) were 
successfully synthesised in modest to good isolated yields of 39% - 89%. Synthesis of 
the palladium coupled codeine derivatives involved the use of Heck, Stille and Suzuki 
coupling methods. The palladium coupled codeine derivatives were further utilised in 
the synthesis of a selection of seven (141, 166-171) novel linked codeine derivatives 
with modification at the 1 position of the aromatic ring. Purification of the opioid 
derivatives was achieved by a combination of column chromatography and 
recrystallisation. Full characterisation was performed by m.p., IR, [α]D, HRMS, 1H 
NMR, 13C NMR, DEPT, COSY, HMQC and HMBC. An in depth NMR analysis of one 
of the palladium modified ester linked compounds (141) was performed with full peak 
assignments. An examination of the X-ray crystal structure of one of the palladium 
modified codeine derivatives (162) was also performed. 
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Chapter 4 
 
Mu Opioid Receptor Binding Studies 
 
4.1 Introduction 
 
This chapter outlines the binding affinity of a selection of opioid derivatives for the mu 
opioid receptor. Experimental analysis was performed via radioligand competitive 
binding techniques resulting in calculation of the Ki and IC50 values of a series of novel 
opioid derivatives. 
 
Radioligand receptor binding studies are a widely used technique to determine the 
affinity of drugs for specific receptor sites. Thus they can be used to determine if a drug 
is likely to have therapeutic or adverse affects at different receptors. They can often 
provide vital information in relation to receptor subtypes and be used to chart the 
distribution of receptors throughout the body or tissue sample. The basis of receptor 
binding techniques is the formation of a receptor-ligand (drug) complex which contains 
a radiolabelled ligand. Once the receptor-ligand complex is formed then its 
radioactivity can be measured. Based on the radioactivity (Ci/mmol) of the sample the 
relative percentage of ligand bound can be deduced and thus the binding affinity (1/Kd) 
for the receptor site can be calculated.  The two basic types of receptor binding 
experiments are saturation and competition binding experiments. 
 
4.1.1 Saturation Binding Experiment 
 
Saturation binding experiments are used to directly determine the affinity (1/Kd) of a 
radiolabelled ligand for a receptor site. In this case the ligand (drug) being analysed is a 
radiolabelled species (often with 3H or 125I) which is incubated at increasing 
concentrations with the receptor (Fig 4.1).81 As the concentration of radioligand 
increases, more of the receptor-ligand complex will form. The dissociation constant 
(Kd, concentration at which 50% of the receptor sites are occupied) can then be directly 
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calculated from the resulting graph (Fig 4.2). As the concentration of radioactive ligand 
increases, a point is reached where no more receptor-ligand complex is formed. This 
value is known as Bmax and it refers to the amount of radioactive ligand required to 
saturate the receptor sites. Bmax can also be used as a measure of the number of receptor 
sites present in a tissue sample. The main drawback of saturation binding experiments 
is the requirement that the ligand (drug) being analysed must be radiolabelled. This is 
often an impractical and costly procedure to undertake especially if numerous ligand 
species need to be analysed. 
  
 
 
Fig 4.1 Radiolabelled opioid, morphine-[N-methyl-14C]-6-glucuronide (172)  
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Fig 4.2 Saturation Binding Experiment with calculated Bmax and Kd values 
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4.1.2 Competition Binding Experiment 
 
Competition binding experiments on the other hand can be used to determine the 
affinity of unlabelled ligand species. The affinity of an unlabelled ligand for a receptor 
can be measured indirectly by analysing its ability to compete with and inhibit the 
binding of a known radioactive ligand to the same receptor site. In competition binding 
experiments, the unlabelled ligand is incubated at various concentrations with the 
receptor in the presence of a fixed concentration of radiolabeled ligand species. As the 
concentration of the unlabelled ligand increases, the amount of radioligand bound to the 
receptor site decreases. As the formation of the receptor-radioligand complex decreases 
then so too does the measured radioactivity in the tissue sample (Fig 4.3). The affinity 
of the unlabelled ligand for the receptor site can thus be calculated based on the 
inhibition of the formation of the radioligand-receptor complex. The dissociation 
constants for the unlabelled ligands from competitive binding experiments are often 
referred to as Ki (instead of Kd) due to the fact that they are calculated based on the 
inhibition of a radioligand and not the direct ligand-receptor complex formation (as in 
saturation binding experiments). The Ki value for an unlabelled drug should be the 
same as the Kd obtained for the same drug in radiolabelled form. 
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Fig 4.3 Competition Binding Experiment with calculated Ki value 
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4.2 Results and Discussion 
  
4.2.1 Method Development 
 
The opioid receptors belong to the G-protein-coupled family of receptors with three 
main subtypes, mu (µ), kappa (κ) and delta (δ), (for further information on opioid 
receptors please see chapter 1). Studies into the binding of the opium alkaloids, in 
particular morphine, show that morphine’s binding to brain tissue is mainly the result of 
a single receptor, called the mu (µ) receptor.16 Therefore as the novel compounds 
synthesised in this project are analogues of morphine analysis is based on the affinity to 
the mu opioid receptor site. As the opioid derivatives contain no radioactive labelled 
atoms it was necessary to analyse them via competition binding experiments. It was 
decided to use 3H DAMGO (173) as the radioligand species because it displays high 
affinity and specificity for the mu opioid receptor site (Fig 4.4).82-84 Although our 
collaborator Dr. David Finn (Dept. of Pharmacology and Therapeutics, NUIG and 
Centre for Pain Research) is an expert in cannabinoid analgesia, no previous 
investigation of competitive binding experiments had been performed on opioid 
derivatives in their research labs. As the affinities (1/Ki) of the unlabelled opioid 
compounds are based on their ability to compete with the radiolabeled ligand, it was 
necessary to investigate the experimental parameters of 3H DAMGO binding to the 
receptor site. Thus prior to the analysis of the affinity (1/Ki) of the novel opioid 
compounds, a robust and reliable method had to be developed      
 
 
Fig 4.4 Structure of DAMGO (173) 
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Prior to development of an experimental method for a competitive binding experiment 
the tissue samples expressing the mu opioid receptor were prepared according to 
standard methods85, 86 as outlined in the experimental (4.4.1). The samples were 
prepared from the brain tissue of male Lister-hooded rats as the highest expression of 
mu opioid receptors is found in the brain tissue. An important part of the receptor tissue 
preparation is the removal of endogenous opioids from the receptor sites. The rat brain 
tissue will contain endogenous opioid species and it is important to remove these 
ligands from the tissue samples to avoid interference with the radioligand binding 
assay. The samples were homogenised and stored at -80°C in 1 mL aliquots until 
required for experimental analysis.  
 
For each experimental analysis, tissue samples were removed from the -80°C freezer 
and allowed to thaw. Once the samples had thawed they were combined and vortexed / 
sonicated to ensure a homogenous sample. For each thawed homogenous sample it was 
necessary to analyse the protein concentration via the Bradford-dye binding 
procedure.87 This was to ensure that for each experiment, the exact same amount of 
protein was being added. Each brain tissue membrane homogenate would contain slight 
differences in protein concentrations and thus different concentrations of receptor sites. 
Therefore by analysing the protein concentration of each thawed tissue sample the same 
amount of receptor-expressing tissue (400 µg) could be employed in every experiment.     
 
Before any analysis is performed, it is important to discuss the role of specific and non-
specific binding (NSB) for radioligand binding techniques. Specific binding refers to 
the binding of the radioactive ligand to the particular receptor site being analysed. 
However, it is usually possible for radioligands to bind to more than one site. These 
extra binding sites are referred to as the non-specific binding sites. Non-specific 
binding sites can be receptors in the same family or other receptor families which 
recognise the radiolabelled ligand. There may also be non-specific binding to non-
receptor portions of the tissue sample or sites on the test-tubes or glass filter paper. In 
order to distinguish binding to specific sites from non-specific binding a set of 
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incubations can be run alongside the tested sample in which an unlabelled ligand is 
added in an excess concentration which blocks the radioligand binding to the specific 
receptor site, but not the non-specific sites. It is important to choose a non-labelled 
inhibitor which displays high binding to the receptor site in question but low affinity for 
the non-specific sites. Thus the specific sites will be essentially “blocked” and only the 
non-specific sites will interact with the radioactive ligand species. Therefore, from 
analysis of the radioactivity of the resulting samples, the non-specific binding of the 
radiolabelled compound can be estimated. When the experiment is performed in the 
absence of the unlabelled ligand, the binding can be referred to as the total binding. 
Thus the specific binding of the radioactive ligand can be calculated by the difference 
between the total and non-specific binding.    
 
• Total Binding – Non-Specific Binding = Specific Binding 
  
A suitable unlabelled ligand for the mu opioid receptor is naloxone (69) (Fig 4.5).83 
Naloxone has a very high affinity for the mu opioid receptor and acts as a competitive 
antagonist. Thus it can be used to block the specific binding site of 3H DAMGO to the 
mu opioid receptor. 
 
 
Fig 4.5 Structure of Naloxone (69) 
 
The experimental design first focused on the association kinetics of 3H DAMGO to the 
tissue receptor site. The kinetics study was performed to calculate the time at which 
equilibrium conditions are met for 3H DAMGO binding to the mu receptor in the tissue 
homogenate. A fixed concentration of 3H DAMGO was incubated with the tissue 
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membrane sample and analysed at different time intervals (Fig 4.6). Once the 
radioactive ligand (3H DAMGO) is added to the tissue membrane it will begin to bind 
to or associate with the receptor site. As more 3H DAMGO binds to the receptor site, 
the radioactivity of the analysed sample will increase. After a certain period of time the 
receptor and ligand will have reached equilibrium also known as steady state 
conditions. For each experiment duplicate samples were assayed for each time point 
with the mean taken for the total binding value. Non-specific binding was calculated 
using naloxone. After approximately sixty minutes, 3H DAMGO had reached steady 
state conditions with the receptor site. Therefore the required incubation time for the 
competitive binding experiments was sixty minutes.     
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Fig 4.6 Association kinetics for 3H DAMGO to receptor site 
 
Once the incubation time for 3H DAMGO to the tissue membrane sample had been 
calculated, it was necessary to accurately calculate the equilibrium dissociation constant 
(Kd) for same. Knowledge of the exact dissociation constant for 3H DAMGO to the 
tissue samples was necessary in order to develop an accurate and reliable experiment 
for the determination of the novel opioid compounds. Generally for competition 
binding experiments the concentration of radioligand is 80% of the Kd value. If the 
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radioactive ligand is used in too high a concentration then excessively high 
concentrations of the unlabelled drug will be necessary to inhibit binding to the receptor 
site. However, if the concentration of radioactive ligand used is too low then the 
resulting radioactive counts of the tissue samples may be too low for accurate results. 
Therefore a saturation binding experiment was performed for 3H DAMGO binding to 
the tissue membrane samples to calculate its Kd value (Fig 4.7).    
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Fig 4.7 Kd determination for 3H DAMGO 
 
3H DAMGO was analysed over a range of six concentrations from 2 – 20 nM. For each 
experiment duplicate samples were made for each concentration with the mean taken 
for the total binding value. Non-specific binding was calculated using naloxone. The 
experiment was performed in triplicate with the average of the three values used to 
calculate the Kd value for 3H DAMGO to the tissue membrane. The average value for 
the Kd of 3H DAMGO was calculated at 2.484 nM. Therefore the concentration used 
for the competitive binding experiments was 2.000 nM (approximately 80%).   
 
Once the incubation time and Kd value for the radiolabelled ligand, (3H DAMGO) in 
the rat tissue membrane homogenate had been calculated, the experimental analysis of 
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the novel compounds could be investigated. The experimental procedure involves 
addition of a fixed amount of radioligand (3H DAMGO) 2.000 nM, to each sample vial, 
followed by the addition of the unlabelled drugs at a range of 10 different 
concentrations. A fixed amount of tissue membrane (corresponding to 400 µg protein) 
sample was then added to each vial followed by incubation at 20°C for 60 minutes.  
Sigmoidal Competition Binding Curve
-9 -8 -7 -6 -5 -4 -3
0
25
50
75
100
125
log M [Unlabelled Drug]
B
o
u
n
d 
(fm
o
l/m
g 
Pr
o
t.)
B
o
u
n
d 
(fm
o
l/m
g 
Pr
o
t.)
B
o
u
n
d 
(fm
o
l/m
g 
Pr
o
t.)
B
o
u
n
d 
(fm
o
l/m
g 
Pr
o
t.)
 
Fig 4.8 Sigmoidal competition binding curve 
 
It should be noted that different drug compounds will have higher or lower affinity for 
the receptor site therefore the concentration range used for each unlabelled drug 
(ligand) could be different. An initial stock solution of opioid compound in the aqueous 
buffer solution is made up and then diluted to the desired concentration range. If a drug 
has low affinity for the receptor site then the concentration range will need to be 
increased to allow it to compete with the radioactive ligand (3H DAMGO). Conversely 
if the drug compound has a very high affinity for the receptor site then the 
concentration range will need to be lowered, otherwise very little of the radioactive 
ligand may bind to the receptor site, resulting in low radioactive readings from the 
tissue sample. Ideally, the resulting sigmoidal competition binding curve should appear 
as outlined in Fig 4.8.  
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4.2.2 Results and Analysis 
 
Once a method had been successfully developed, the mu opioid receptor affinity of a 
selection of opioid derivatives with modification at the 1, 3 and 6 positions were 
analysed. In total 24 compounds were analysed (1, 2, 75, 76, 119, 126-128 142, 144, 
145, 160, 161, {174-176, 181}88, {137, 138, 177-180, 182}70) with the results presented 
in Tables 4.1–4.7. For each experiment duplicate samples were run for each 
concentration with the mean taken for the total binding value. Non-specific binding was 
calculated using naloxone. Each compound was analysed in triplicate with the results 
presented as the mean and errors reported as SEM (Standard Error of the Mean). Each 
compound was analysed as the free base except for morphine (1) which was analysed 
as the hydrochloride trihydrate derivative. 
 
Opioid IC50 (nM) Ki (nM) 
O
HO
NMe
HO
1
H
 
19.7 ± 0.3 10.9 ± 0.2 
O
HO
NMe
MeO
2
H
 
4,500 ± 1,010 2,500 ± 559 
Table 4.1 IC50 and Ki values for opioid standards, morphine (1) and codeine (2) 
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Opioid IC50 (nM) Ki (nM) 
O
HO
NMe
MeO Cl
76
H
 
6,180 ± 266* 3,420 ± 181* 
O
HO
NMe
MeO Br
75
H
 
18,000 ± 2,290* 9,990 ± 1,550* 
 
O
HO
NMe
MeO I
142
H
 
16,800 ± 1,480* 9,290 ± 1,000* 
                 
O
TBDMSO
NMe
MeO
160
H
 
17,900 ± 2,540  9,920 ± 1,410 
                  
107,000 ± 21,600 59,100 ± 12,000 
Table 4.2 IC50 and Ki values for A-ring modified codeine compounds, *samples analysed in duplicate 
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Opioid IC50 (nM) Ki (nM) 
     
17,800 ± 4,810 9,750 ± 2,680 
   
39,400 ± 7,380 21,800 ± 4,090 
       
10,500 ± 1,140 5,860 ± 654 
   
876 ± 110 486 ± 61 
   
25,700 ± 3,410 14,300 ± 1890 
       
15,600 ± 1,960 8,650 ± 1,080 
Table 4.3 IC50 and Ki values for linked codeine ester compounds 
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Opioid IC50 (nM) Ki (nM) 
 
159 ± 32 87.9 ± 18 
      
74.3 ± 4 41.2 ± 2 
    
133 ± 34 73.9 ± 19 
Table 4.4 IC50 and Ki values for linked morphine ester compounds 
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Opioid IC50 (nM) Ki (nM) 
   
226 ± 27 125 ± 15 
 
230 ± 28 128 ± 15 
 
1,090 ± 158 603 ± 87 
 
1,930 ± 424 1070 ± 235 
Table 4.5 IC50 and Ki values for linked morphine ether compounds 
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Opioid IC50 (nM) Ki (nM) 
 
316 ± 28 175 ± 15 
 
557 ± 73 309 ± 41 
Table 4.6 IC50 and Ki values for morphine macrocyclic compounds 
 
Model 
System 
IC50 (nM) Ki (nM) 
 
164,000 ± 
69,900 
90,800 ± 
38,700 
 
56,100 ± 
9,470 
31,100 ± 
5,240 
Table 4.7 IC50 and Ki values for macrocyclic diol model systems 
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Initial experimental analysis was performed on morphine and codeine as they could be 
used as standards for the experiment. These results could be used to validate the method 
and also for comparisons to the novel opioid compounds. The calculated Ki of both the 
morphine (1) and codeine (2) standards (10.9 ± 0.2 nM and 2,500 ± 559 respectively) 
compare favourably with other similar investigations found in the literature.31, 34, 35, 37, 89 
Depending on the tissue sample analysed the Ki values of codeine are usually found to 
be between 200-600 times greater than that of morphine (Table 4.8).  
 
Tissue Sample Morphine (nM) Codeine (nM) 
Rat Brain Tissue (Ki)89 1.2 ± 0.32 248 ± 101.1 
Rat Brain Tissue (IC50)34 27 10,000 
Mouse Brain Tissue (Ki)37 6.22 ± 0.86 ND 
Guinea Pig Brain Tissue (Ki)35 1.8 ± 0.6 350 ± 110 
Monkey Brain Tissue (EC50)31 4.4 2,500 
Table 4.8 Comparison of literature values for mu opioid receptor affinities for morphine (1) and codeine 
(2) in brain tissue (ND, not determined) 
 
Morphine (1) and codeine (2) with Ki values of 10.9 ± 0.2 nM and 2,500 ± 559 nM 
respectively corresponds to codeine having a Ki value approximately 230 times higher 
(i.e. lower affinity) than morphine. Accurate analysis of the opioid standards validates 
the method used to test the compounds as well as providing a reference point for the 
analysis of the unknown opioids. Sigmoidal competition binding curves for codeine and 
morphine opioid standards with reported Ki and IC50 values are shown in Fig 4.9 
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Codeine 2nd Sample
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Morphine 3rd Sample
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Fig 4.9 Sigmoidal competition binding curves for morphine (1) and codeine (2) with calculated IC50 and 
Ki values (performed in triplicate) 
 
It should be noted that the concentration ranges used for the competitive binding 
experiments for morphine are much lower than for codeine, as can be seen in the 
sigmoidal dose response curves (Fig 4.9). As morphine has a much higher affinity for 
the mu opioid receptor site it inhibits 3H DAMGO at much lower concentrations. An 
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examination of the pharmacophore of mu opioid ligands17 (Fig 4.10) illustrates the 
structural components which have a significant impact on the affinity of the drug for 
the opioid receptor site. 
 
 
Fig 4.10 Pharmacophore for mu opioid ligands 
 
Previous studies have shown that halogen substitution of the aromatic ring lowers the 
binding affinity for the receptor site.5 For all the tested A-ring modified codeine 
derivatives (76, 75, 142, 161) there was a higher Ki value, corresponding to lower 
affinity for the receptor site (Table 4.2). The most notable increase was the Ki value for 
161, at 59,100 ± 12,000 nM (Graph 4.1). The Ki value for 161 is almost 24 times 
greater than codeine (2) at 2,500 ± 559 nM. This is most likely due to the increased 
steric bulk of the methyl acrylate moiety. Therefore modification at this position of the 
aromatic ring of codeine has a significant affect on the binding affinities for the mu 
opioid receptor site. Modification of the secondary alcohol at the six position of 160 
increased the Ki value to 9,920 ± 1,410 nM. 
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Graph 4.1 Comparison of Ki values for codeine (2) and A-ring modified derivatives (76, 75, 142, 160, 
161) 
 
For the experimental analysis of the linked opioid species (Tables 4.3 - 4.6) 0.1% 
TWEEN 80 was added to the stock solutions of the opioid compounds to aid solubility 
in the aqueous solution. Many of the linked opioid derivatives are only sparingly 
soluble in water and the addition of TWEEN 80 allowed the opioid compounds to 
solubilise into the aqueous incubation media at the desired concentrations. Before 
analysis of the linked opioid compounds was undertaken it was decided to investigate if 
TWEEN 80 would affect the resulting radioligand binding assay which had previously 
been developed. To analyse the affect of TWEEN 80 on the radioligand binding assay 
an experiment was performed on codeine (2) as the results could be directly compared 
with the previous data. The experiment was performed in duplicate and it was observed 
that the addition of 0.1% TWEEN 80 to the stock solution of codeine for the 
experiment had a minimal effect on the binding data. The resulting Ki from the 
TWEEN 80 experiments was calculated at 3,940 ± 637 nM (Fig 4.11) which is 
comparable to the results obtained when no TWEEN 80 is employed in formation of 
the opioid stock solutions for codeine (2) at 2,500 ± 559 nM (Fig 4.9).     
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Fig 4.11 Sigmoidal competition binding curves for codeine with the addition of 0.1% TWEEN 80 to the 
stock solution  
 
The calculated Ki values for the codeine ester compounds (Table 4.3) were between 2 
(127, 5,860 ± 654 nM) and almost 9 (126, 21,800 ± 4090 nM) times greater than 
codeine (4, 2,500 ± 559 nM) (Graph 4.2). It is interesting to examine the different 
binding affinities for the brominated (144, 145) and non-brominated (126, 127) ester 
linked compounds (Graph 4.3). For 127 the calculated Ki value of 5,860 ± 654 nM is 
lower than bromocodeine (75), at 9,990 ± 1,550 nM. Therefore when the A-ring of 127 
is brominated as in 145 the Ki value increases to 8,650 ± 1,080 nM. This would be 
expected as bromination of the A ring has been shown to lower the binding affinity of 
opioids for the mu receptor site.5 
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Graph 4.2 Comparison of Ki values for codeine (2) and ester linked derivatives (119, 126-128, 144, 145) 
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Thus it could be concluded that for compound 145 it is the bromination of the A-ring 
which is the limiting factor in relation to binding to the mu receptor site, as opposed to 
the ortho linked ester modification. For compound 126 the calculated Ki value of 
21,800 ± 4,090 nM is already much higher than bromocodeine (7) at 9,990 ± 1,550 nM. 
For the brominated derivative, 144, the calculated Ki value is 14,300 ± 1890 nM. 
Therefore it could be concluded that for compound 144 it is the meta linked ester 
modification which exerts a bigger influence on binding to the mu receptor.  The most 
interesting result from the ester linked codeine derivatives was noted for the compound 
128. Its Ki value at 486 ± 61 nM was calculated at 5 times lower than codeine (2, 2,500 
± 559 nM), therefore 128 has a higher affinity for the mu opioid receptor than codeine.  
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Graph 4.3 Comparison of Ki values for codeine (2) and bromocodeine (75) with brominated (144, 145) 
and non-brominated (126, 127) ester linked codeine derivatives. 
 
A selection of nine morphine derivatives (137, 138, 174-180) were also investigated for 
their affinities for the mu opioid receptor (Tables 4.4-4.6). The morphine derivatives 
tested included both ester (174-176) and ether (137, 177-179) linked morphine 
compounds as well as ether linked opiate macrocycles (138, 180). The three ester 
linked morphine structures (Table 4.4) investigated resulted in Ki values between 4 
(175, 41.2 ± 2 nM) and 8 (174, 87.9 ± 18 nM) times greater than morphine (5, 10.9 ± 
0.2 nM) (Graph 4.4). The ester linked morphine derivatives (174-176) exhibited the 
highest affinity to the mu opioid receptor site for the tested “linked” compounds. 
Compound 175 displayed the highest affinity of the linked opioid derivatives at 41.2 ± 
2 nM. 
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Graph 4.4 Comparison of Ki values for morphine (1) and ester linked morphine derivatives (174-176) 
 
The calculated Ki values for the morphine ether derivatives were between 11 (177, 125 
± 15 nM) and almost 100 (179, 1070 ± 235 nM) times greater than that of morphine (1, 
10.9 ± 0.2 nM) (Graph 4.5). The most noticeable increase in the Ki value was noted for 
the “open” linked morphine compound with the macrocyclic moiety in the linker 
species, 179, at 1070 ± 235 nM. This is probably due to steric effects with the bulky 
crown ether moiety in the linker species lowering the formation of the receptor ligand 
complex at the mu opioid receptor site 
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Graph 4.5 Comparison of Ki values for morphine (1) and ether linked morphine derivatives (137, 138, 
177-180)  
 
The “open” linked ether compounds 177, 178 and 137 exhibited Ki values of 125 ± 15 
nM, 128 ± 15 nM and 603 ± 87 nM respectively. A comparison of the “open” linked 
ether (137) and the closed macrocyclic derivatives (138 and 180) shows that closing the 
morphine scaffold increases the affinity for the receptor site (Graph 4.6). The calculated 
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Ki value for the “open” linked derivative, 137 was 603 ± 87 nM while the macrocyclic 
derivatives 138 and 180 were 309 ± 41 nM and 175 ± 15 nM respectively. 
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Graph 4.6 Comparison of Ki values for morphine (1) and ether linked morphine derivatives (137, 138 
and 180)  
 
As expected, the diol model system macrocyclic structures displayed negligable affinity 
for the mu opioid receptor site (Table 4.7). The calculated Ki values for 181 and 182 
were 90,800 ± 38,700 nM and 31,100 ± 5,240 nM respectively.   
 
4.2.3 Discussion 
 
The linked opioid compounds analysed as part of this project can be classed as “dual” 
or “twin” drugs due to the presence of two pharmacophoric groups covalently bonded 
to each other (Fig 4.12). They can be further classified as “identical twin drugs” or 
homodimer derivatives as the two pharmacophoric groups are identical. There is 
increasing interest in the potential benefits of twin and multiple ligand type drugs.90-92 
The administration of twin drugs can have favorable effects compared to the addition of 
the two separate drugs as the new twin drug will have its own distinct pharmacokinetic 
properties (absorption, distribution metabolism excretion and toxicity, ADMET). 
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Fig 4.12 Compound 175 highlighting the two morphine pharmacophores 
 
Previous studies on linked opioid compounds have lead to a variety of bivalent opioid 
derivatives64, 65, 58, 59, 93 (for further information on bivalent opioid compounds see 
Chapter 1). Portoghese and co-workers have synthesised a variety of opioid bivalent 
ligands and analysed their opioid receptor affinities (Fig 4.13).64  
 
 
Fig 4.13 Structures of opioid compounds 9 and 111 
 
They have found that simultaneous interaction of both pharmacophores of the drug 
molecule is possible at the mu opioid receptor site. As the affinity of the bivalent ligand 
(9) is greater than double the affinity of the corresponding monovalent ligand (111) 
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(Table 4.9) then it can be concluded that the bivalent ligand must be interacting with 
more than one receptor site. By analogy it can be concluded that the novel linked opioid 
compounds analysed as part of this project may also interact with more than one mu 
receptor site. 
 
Compound Ki nM 
9 14 ± 3 
111 180 ± 41 
Table 4.9 Ki values for compounds 9 and 111 to the mu opioid receptor 
 
Before discussing the interactions of the novel linked opioids with the mu opioid 
receptor site we should discuss possible enzymatic degradation. An important aspect to 
consider for all drugs, but especially “twin” drugs is the role of enzymatic degradation 
in both in vitro and in vivo studies. It is known that both codeine and heroin exhibit 
their analgesic effects after being converted to morphine by enzymatic degradation. 
Codeine is O-demethylated to morphine in humans by cytochrome P450-2D6 (CYP-
2D6).32 By analogy it could be envisioned that the novel “linked” opioid compounds 
may also exhibit analgesic effects due to degradation to morphine. Both the ester (119, 
126-128, 144, 145, 174-176) and ether (137, 138, 177-180) linked novel compounds 
would be susceptible to metabolism in vivo, via plasma esterases and enzymatic 
cytochrome P450. If the analgesic effect of the novel linked derivatives is dependent on 
conversion to morphine, the rate of conversion in vivo to morphine could potentially 
lead to slow-release type analgesics. It would be expected that the ester linked codeine 
(119, 126-128, 144, 145) and morphine (174-176) derivatives would be more 
susceptible to in vivo degradation (via enzymatic hydrolysis) than the corresponding 
ether compounds. Mignat and co-workers have investigated the binding affinity and 
rate of hydrolysis of a selection of morphine-3-esters (Fig 4.14) (Table 4.10).35 
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Fig 4.14 Structures of morphine-3-esters 
 
  
Hydrolysed % (Tris-Buffer 50 
mM) 37 °C 
Human 
Plasma 37 °C 
Compound Ki (nM) 60 (min) 24 (h) t1/2 (h) 
Morphine, 1 1.8    
24 29 3 35 0.62 
183 160 0.6 9 0.94 
184 8,200 0 0 >300 
185 360 0 0 >300 
186 52 1.1 4 8.3 
Table 4.10 Ki values and hydrolysis data for morphine (1) and morphine-3-esters 24, 183-186 
 
The rate of hydrolysis of the morphine-3-esters gives an indication of the stability of 
the ester bond which can be compared with the novel ester linked compounds analysed 
in this project. An examination of the stability of the ester bond in both buffer solution 
(Tris-Buffer 50 mM) and in human plasma (to measure plasma catalysed hydrolysis) 
was undertaken. In general the ester bond is stable to the aqueous buffer solution over 
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the experimental incubation time frame of 60 minutes. The highest percentage of 
hydrolysis to morphine was noted for compound 24 at only 3% after 60 minutes. If the 
compounds are incubated with the aqueous buffer solution for 24 hours there is an 
increase in hydrolysis with the highest corresponding to 24 at 35%.  
 
In the presence of human plasma there is a much higher rate of hydrolysis for the ester 
bonds. Compound 24 is hydrolysed by 50% after 0.62 hours while compound 183 is 
hydrolysed by 50% after 0.94 hours. The experimental data also highlight that there is a 
large variance in hydrolysis rates depending on the particular ester formed. Thus choice 
of the ester functional group has a major effect on the rate of hydrolysis. It should also 
be noted that some of the morphine-3-esters exhibited no hydrolysis even after 
relatively harsh conditions. Compounds 184 and 185 displayed no degradation to 
morphine after incubation at 37 °C after 300 hours in the human plasma.   
 
It can be concluded from the relatively low hydrolysis in the buffer solution compared 
to the much higher rate in the human plasma sample that most of the ester hydrolysis is 
due to enzymatic degradation. The rat brain tissue homogenate utilised in the 
experimental analysis of the linked opioid compounds in this project could be a source 
of enzymes for ester hydrolysis. Both the ester (119, 126-128, 144, 145, 174-176) and 
ether (137, 138, 177-180) linked opioid compounds could potentially be partly 
metabolised during the experimental in vitro analysis. It is important to note that 
enzymatic degradation of the linked opioid compounds would lead to 2 active units. If 
we consider compound 175, enzymatic hydrolysis would lead to two morphine (1) 
derivatives (Fig 4.15).  
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Fig 4.15 Hydrolysis of compound 175 would result in two morphine (1) units 
 
The calculated Ki for 175 was 41.2 ± 2 nM which is almost 4 times lower than 
morphine (5) at 10.9 ± 0.2 nM. The calculated value for 174 in comparison was 87.9 ± 
18 nM. It is important to note that the difference in Ki values for compounds 174 and 
175 could be due to their different rates of hydrolysis. If 175 is hydrolysed more rapidly 
then 174 then more “free” morphine will be present in the incubation tube resulting in a 
higher calculated affinity for compound 175. Therefore the rate of enzymatic 
degradation for the linked opioid compounds should be considered when analysing the 
calculated Ki values. The rate of enzymatic degradation is an important factor to 
consider as it has important implications for in vitro testing and the potential use of the 
novel linked opioids as prodrugs in slow-release analgesics.  
 
From the calculated Ki values, it is clear that we are not observing 100% enzymatic 
degradation to “free” morphine within the 60 minute incubation time frame. If there 
was 100% degradation to morphine the observed Ki values for 174 and 175 would be 
much lower than 41.2 ± 2 nM and 87.9 ± 18 nM respectively. Therefore, from the Ki 
values of the novel opioid derivatives we know that the linked opioid compounds are 
present in the incubation tube. If the linked opioid compounds are present within the 
incubation tube then by analogy with Portoghese and co-workers64 we know that it is 
possible for the linked opioid derivatives to interact with more than one mu receptor 
site.  
 
Mu Opioid Receptor Binding Studies 
——————————————————————————————————————— 
 
 
——————————————————————————————————————— 
 
143 
Further extensive studies would be required to examine the exact mechanism of 
interaction between the linked opioid compounds and the mu opioid receptor site; 
however we can deduce some factors from these preliminary studies. When discussing 
the possible structural factors which may influence multi-receptor binding to the mu 
opioid site, the rates of enzymatic degradation for the different linked opioids has been 
ignored. However as noted earlier, the in vitro rates of degradation may have an effect 
on the resulting Ki values    
 
The aromatic ether linked opioids 177 and 178 exhibit identical affinity to the mu 
opioid receptor site with Ki values of 125 ± 15 nM and 128 ± 15 nM respectively. 
When the spacer length is increased in compound 137 the affinity to the receptor site 
decreases with a Ki value of 603 ± 87 nM. When the glycol linker is “locked” into 
position by the formation of the macrocyclic opioids (138 and 180) we observe a 
relative increase in affinity. The calculated Ki value for the “open” linked derivative, 
137 was 603 ± 87 nM while the macrocyclic derivatives 138 and 180 were 175 ± 15 
nM and 309 ± 41 nM respectively. A possible reason for the increased affinity for the 
macrocyclic opioids (138, 180) relative to the “open” linked derivative (137) is 
formation of the macrocyclic opioid may “force” the two morphine pharmacophore 
units closer together (Fig 4.16). Therefore having the two morphine pharmacophores 
close together may aid binding to the mu opioid receptor site.   
 
 
Fig 4.16 Structures of opioid compounds 137 and 138 
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The most interesting compound from the ester linked codeine (119, 126-228, 144, 145) 
and morphine (174-176) derivatives was compound 128. The Ki value for 128 was 
calculated at 486 ± 61 nM, approximately 5 times lower than codeine (2, 2,500 ± 559 
nM). As the affinity of the linked bivalent ligand (128) is greater than codeine (2) then 
it can be concluded that the bivalent ligand (128) may be interacting with more than 
one receptor site. In comparison to the aromatic ester linked codeine derivatives, 119 
(9,750 ± 2,680 nM), 126 (21,800 ± 4,090 nM) and 127 (5,860 ± 654 nM), 128 exhibits 
a much higher affinity to the mu receptor. A possible reason for the increased affinity of 
128 relative to the aromatic linked esters (119, 126, 127) is the linker group. If we 
consider that interaction of both pharmacophores in the molecule leads to increased 
affinity to the mu receptor site then any conformational restrictions due to the linker 
group will affect the Ki value.  
 
The increased flexibility of 128 relative to the aromatic linked esters (119, 126, 127) 
may allow the compound to arrange both pharmacophoric units more favourably to the 
mu receptor. As noted for the ether linked morphine derivatives having the two opioid 
pharmacophores in close proximity may aid in binding to the mu opioid receptor. It is 
unclear at this stage if the increased binding is due to two separate and distinct mu 
opioid receptors or a single receptor and an accessory binding site. Further studies 
would be required to examine the exact interaction of the linked opioids and the mu 
receptor. It is also possible that the bivalent opioid compounds may be binding to mu 
opioid receptor homodimers. 
 
Based on the data from this project some novel linked opioid targets, which may have 
promising mu receptor binding, are outlined in Fig 4.17. Formation of the linked 
opioids via the phenolic hydroxyl position lowers the affinity relative to morphine, as 
observed in the ester (174-176) and ether (137, 138, 177-180) linked morphine based 
opioids. It would be interesting to examine some of the corresponding ether (187, 188) 
or ester linked morphine derivatives which are linked at the secondary alcohol instead 
of the phenolic position (177, 178). If the two morphine pharmacophoric units are 
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linked through the secondary alcohol position the affinity of the linked derivative for 
the mu opioid receptor site could potentially be greater than morphine. This is assuming 
both morphine pharmacophores can interact with the receptor site which is plausible 
based on the calculated Ki values for the ester linked codeine derivative, 128.  
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Fig 4.17 Possible targets for linked opioid derivatives  
 
Interaction of the aromatic ring in the linker group may also have an effect on both 
pharmacophores interacting with the receptor thus analysis of 189 would be desirable. 
By analogy with 128, which exhibits an affinity to the mu receptor over five times 
higher than codeine, compound 189 may display increased affinity for the mu opioid 
receptor site relative to morphine. From the preliminary data there is also some 
evidence that the close proximity of both opioid pharmacophores may improve binding 
to the mu receptor. Therefore it would be appropriate to analyse a linked opioid 
derivative such as 190 in which both morphine pharmacophores are closely bound to 
each other. Although the stability to hydrolysis is an important consideration and 190 
may rapidly degrade.  
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4.3 Conclusion 
 
The affinity (1/Ki) of 24 compounds (1, 2, 75, 76, 119, 126-128, 142, 144, 145, 160, 
161, {174-176, 181}88, {137, 138, 177-180, 182}70) for the mu opioid receptor was 
calculated by competitive radioligand binding techniques. Prior to the experimental 
analysis, a robust and reliable radioligand competitive binding method was developed. 
It was also shown that the addition of 0.1% TWEEN 80 to the stock solutions of opioid 
standards had no significant effect on the radioligand binding method. The general 
trend noted for the novel opioid compounds was that modification at the 1, 3 and 6 
positions of the parent opioid structure lowered the affinity for the mu opioid receptor 
site. A selection of A ring modified codeine derivatives (75, 76, 142, 161) were 
analysed along with ester linked codeine compounds (119, 126-128, 144, 145). Also 
studied were a variety of ester (174-176) and ether (137, 138, 177-180) linked 
morphine based compounds. 
 
For all the analysed A-ring modified codeine derivatives there was a higher Ki value, 
corresponding to lower affinity for the receptor site, relative to codeine. Thus, 
modification at the 1 position was shown to lower the affinity for the mu receptor. This 
is especially noticeable for 161 with a Ki value of 59,100 ± 12,000 nM compared to 
codeine (2) at 2,500 ± 559 nM. Therefore, via modification at this position of the opioid 
skeleton we can “block” binding to the receptor site if desired. This is especially 
important if we want to pursue the opioid derivatives in potential sensor applications 
(Chapter 5). If the opioid derivatives display potential uses as sensors then binding to 
the mu opioid receptor site would be an undesirable side effect. Thus through A ring 
modification we have a relatively simple process to nullify the analgesic activity.     
 
In general the ester linked codeine compounds displayed lower affinity for the mu 
receptor site. The most interesting result from the analysis of the ester linked codeine 
structures was noted for the diglycol linked compound 128. Compound 128 displayed a 
Ki value of 486 ± 61 nM, five times lower than codeine’s calculated value at 2,500 ± 
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559 nM. Therefore it has been shown that formation of a “linked” codeine derivative 
can increase the binding affinity of opioid compounds for the mu opioid receptor site.    
 
The ester and ether linked morphine derivatives in general displayed lower affinity than 
the parent morphine structure with the ester linked morphine derivatives (174-176) 
displaying higher affinity for the mu receptor site than the ether linked compounds 
(137, 138, 177-180). The calculated Ki values of the novel morphine derivatives ranged 
from 41.2 ± 2 nM (174) to 1070 ± 235 nM (179) in comparison to a Ki value for 
morphine (1) of 10.9 ± 0.2 nM. It should be noted that codeine (2) is a widely used 
opioid analgesic with an affinity of approximately 2,500 ± 559 nM.  
 
Thus, a selection of linked opioid derivatives have been analysed which display a much 
higher affinity for the mu opioid receptor site than codeine. Therefore it is possible that 
they may have the potential to act as analgesic prodrugs. It should be noted that the 
results for the opioid binding have been generated in vitro with its corresponding 
limitations. It would be desirable to investigate these compounds and other opioid 
derivatives with in vivo experiments and thus parameters such as bioavailabilty and 
pharmokinetics could be examined.  
 
4.4 Experimental 
 
4.4.1 Tissue Membrane Preparation for Receptor Binding Protocol 
 
Rats (Male Lister-hooded rats (250 g, Charles River UK) were killed by decapitation 
and the brain minus cerebellum rapidly removed.  The brain was weighed and 
suspended in 8v/w ice cold buffer (buffer 50 mM Tris-HCl pH 7.4, ie 8 mL/g tissue). 
Brain tissue was homogenised at 1000 rpm/min for 20-30 sec at 4 °C. The sample was 
centrifuged at 40000 g at 4 °C for 20 min. Supernatant was discarded and the pellet was 
re-suspended in fresh buffer (8 v/w) using sonicator and vortex. The suspension was 
incubated at 37 °C for 30 min with shaking (to dissociate endogenous opioids from 
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receptors). The sample was centrifuged at 40000 g at 4 °C for 20 min. Supernatant was 
discarded and the pellet was re-suspended in fresh buffer (8 v/w) using sonicator and 
vortex. The sample was centrifuged at 40000 g at 4 °C for 20 min. The supernatant was 
discarded and the pellet was re-suspended in 10 mL of buffer solution using sonicator 
and vortex. The tissue membrane samples were stored as 1 mL aliquots at -80 °C. 
 
4.4.2 Determination of Protein Concentration in Tissue Homogenate Protocol 
 
Protein assay based on the Bradford-dye binding procedure, (solution, buffer 50 mM 
Tris-HCl pH 7.4). Stock solution of bovine serum albumin (BSA) 2 mg/mL, was 
prepared in buffer solution. Protein standards were prepared from stock bovine serum 
albumin (BSA), in buffer solution, in 6 concentration ranges, 0 ug/mL (blank), 100 
µg/mL, 250 µg/mL, 500 µg/mL, 750 µg/mL, 1000 µg/mL to volumes of 200 µL. 
Tissue membrane samples were removed from -80 °C freezer and allowed to thaw. 1 
mL aliquots of tissue samples were combined and vortexed / sonicated to ensure tissue 
sample was homogenous. Volume of tissue homogenate was removed and diluted by 
1/10 in buffer (ie 15 µL in 135 µL buffer). Thawed tissue membrane homogenate was 
stored on ice. 25 µL of protein standards or unknown was added to analysis wells in 
triplicate. 1250 µL of Coomassie Blue reagent was added to each well and left for 10 
min at room temp. Absorbance was read at 570 nm. Data was analysed using excel and 
graphpad prism software.  
 
4.4.3 Dissociation Kinetics for 3H DAMGO in Tissue Membrane Protocol 
 
Membrane tissue homogenate prepared as outlined in membrane prep protocol. (Buffer 
solution, 50 mM Tris-HCl pH 7.4). 3H DAMGO stock standard (Perkin Elmer), 
[Specific Activity 56.8 Ci/mmol, Conc. 1 mCi/mL] was made to stock solution of 10 
nM in buffer solution to volume of 3 mL. Assays for total binding and non-specific 
binding over a range of incubation times were performed in duplicate and in LP3 tubes. 
For the analysis of total binding, to each vial was added, 100 µL of 3H DAMGO, tissue 
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homogenate (corresponding to 400 µg protein) and made to final volume, 1 mL with 
buffer solution. (The volume of tissue homogenate added to each LP3 tube is dependant 
on the protein concentration of the homogenous tissue sample used, which was 
calculated based on the Bradford-dye binding procedure). For the analysis of non-
specific binding, to each vial was added, 100 µL of 3H DAMGO, 100 µL of NSB (non-
specific binding) agent (naloxone, conc. 100 µM), 400 µg tissue homogenate and made 
to final volume, 1 mL with buffer solution. Assay vials were split into six groups with 
each group incubated for different times at 20 °C, 15 min, 30 min, 45 min, 60 min, 90 
min and 120 min.  
 
The reaction was terminated by the addition of 5 mL buffer solution to each assay tube. 
Tissue membrane samples were collected under vacuum using a Brandel Harvester. 
Tissue membrane samples were collected onto glass fibre filters (Whatman GF/B 
filters) which were pre-soaked in 0.2% polyethylenimine solution. Whatman GF/B 
filters were washed with 3 x 5 mL buffer solution to remove any unbound 3H DAMGO 
from the tissue samples. Filter papers were then placed in scintillation vials to which 5 
mL of scintillation cocktail was added to each (Ecoscint A). Vials were capped, 
vortexed for 30 sec. and left overnight. Vials were placed on scintillation counter and 
radioactivity was recorded. Data was analysed using graphpad prism software to 
calculate the time at which steady state binding has occurred. 
 
4.4.4 Determination of Kd and Bmax Values of 3H DAMGO in Tissue Membrane 
Homogenate Protocol, (Saturation Binding Experiment) 
 
Membrane tissue homogenate prepared as outlined in membrane prep protocol. (Buffer 
solution, 50 mM Tris-HCl pH 7.4). 3H DAMGO stock standard (Perkin Elmer), [ 
Specific Activity 56.8 Ci/mmol, Conc. 1 mCi/mL ] made to stock solution of 200 nM in 
buffer solution to 1 mL. Serial 0.4 dilutions of stock 3H DAMGO solution were made 
using buffer solution resulting in six concentrations, 200 nM, 80 nM, 32 nM, 12.8 nM 
(12.5 nM), 5.12 nM (5 nM), 2.048 nM (2 nM). Assays for total binding and non-
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specific binding were performed in duplicate in LP3 glass tubes. For the analysis for 
total binding to each vial was added, 100 µL of 3H DAMGO in 6 concentrations, 400 
µg of tissue homogenate, and made up to final volume of 1 mL in buffer solution. For 
the analysis for non-specific binding to each vial was added, 100 µL of 3H DAMGO in 
6 concentrations, 100 µL of NSB (non-specific binding) agent (naloxone, conc. 100 
µM), tissue homogenate (corresponding to 400 µg protein) and made to final volume, 1 
mL with buffer solution. (The volume of tissue homogenate added to each LP3 tube is 
dependant on the protein concentration of the homogenous tissue sample used, which 
was calculated based on the Bradford-dye binding procedure). The vials were 
incubated at room temperature (20 °C) for 60 min. (Incubation time is dependant on the 
association kinetics for the particular experiment. It is the time at which steady state 
binding has occurred. See association kinetics protocol for experimental method).  
 
Reaction was terminated by the addition of 5 mL buffer solution to each assay tube. 
Tissue membrane samples were collected under vacuum using a Brandel Harvester. 
Tissue membrane samples were collected onto glass fibre filters (Whatman GF/B 
filters) which were pre-soaked in 0.2% polyethylenimine solution. Whatman GF/B 
filters were washed with 3 x 5 mL buffer solution to remove any unbound 3H DAMGO 
from the tissue samples. Filter papers were then placed in scintillation vials to which 5 
mL of scintillation cocktail was added to each (Ecoscint A). Vials were capped, 
vortexed for 30 sec. and left overnight. Vials were placed on scintillation counter and 
radioactivity was recorded. Data was analysed using graphpad prism software to 
calculate the Ki and Bmax parameters of 3H DAMGO. 
 
4.4.5 Determination of the Ki Values of Opioid Compounds Protocol (Competitive 
Binding Experiment) 
 
Membrane tissue homogenate prepared as outlined in membrane prep protocol. (Buffer 
solution, 50 mM Tris-HCl pH 7.4). 3H DAMGO stock standard (Perkin Elmer), 
[Specific Activity 56.8 Ci/mmol, Conc. 1 mCi/mL] made to stock solution of 20 nM in 
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buffer solution to final volume of 2.5 mL. (The concentration of the competitive 
radioligand (3H DAMGO) used for the experiment is dependant on its affinity for the 
tissue membrane sample, ie it’s Kd value. For competitive binding experiments the 
concentration of radioligand used is usually 80% of its Kd. See determination of Kd and 
Bmax values of 3H DAMGO protocol for experimental method). An opioid stock solution 
was prepared in buffer solution to a concentration of 10,000 µM.  From the opioid 
stock standard solution a series of dilutions in buffer solution were performed resulting 
in a series of 10 opioid solutions in decreasing concentration, ie 3000 µM, 1000 µM, 
300 µM, 100 µM, 30 µM, 10 µM, 3 µM, 1 µM, 0.3 µM and 0.1 µM. (The 
concentration range used for the experiment is dependant on the affinity of the drug for 
the receptor site).  
 
The experimental assay was performed in 24 LP3 tubes. To the first 20 assay vials was 
added, 100 µL of the opioid stock solutions in each of the 10 concentrations, 100 µL 3H 
DAMGO solution, tissue homogenate (corresponding to 400 µg protein) and made to 
final volume, 1 mL with buffer solution. (The volume of tissue homogenate added to 
each LP3 tube is dependant on the protein concentration of the homogenous tissue 
sample used, which was calculated based on the Bradford-dye binding procedure). To 
the next 2 assay vials was added, 100 µL naloxone solution (conc. 100 µM), 100 µL 3H 
DAMGO, tissue homogenate (corresponding to 400 µg protein) and made to final 
volume, 1 mL with buffer solution. (These assay vials, ie naloxone, are run in order to 
calculate the non-specific binding for the experiment). To the final 2 assay vials was 
added, 100 µL buffer solution, 100 µL 3H DAMGO, 400 µg tissue homogenate and 
made up to the final volume of 1 mL with buffer solution. (These assay vials are run as 
the blank samples for the experiment). The vials were incubated at room temperature 
(20 °C) for 60 min. (Incubation time is dependant on the association kinetics for the 
particular experiment. It is the time at which steady state binding has occurred. See 
association kinetics protocol for experimental method).  
 
Mu Opioid Receptor Binding Studies 
——————————————————————————————————————— 
 
 
——————————————————————————————————————— 
 
152 
Reaction was terminated by the addition of 5 mL buffer solution to each assay tube. 
Tissue membrane samples were collected under vacuum using a Brandel Harvester. 
Tissue membrane samples were collected onto glass fibre filters (Whatman GF/B 
filters) which were pre-soaked in 0.2% polyethylenimine solution. Whatman GF/B 
filters were washed with 3 x 5 mL buffer solution to remove any unbound 3H DAMGO 
from the tissue samples. Filter papers were then placed in scintillation vials to which 5 
mL of scintillation cocktail was added to each (Ecoscint A). Vials were capped, 
vortexed for 30 sec and left overnight. Vials were placed on scintillation counter and 
radioactivity was recorded. Data was analysed using graphpad prism software to 
calculate the Ki parameters of the opioid compound. 
 
Metal Picrate Extraction Studies 
——————————————————————————————————————— 
 
 
153 
——————————————————————————————————————— 
 
Chapter 5 
 
Metal Picrate Extraction Studies 
 
5.1 Introduction 
 
This chapter outlines the metal picrate binding studies performed on a series of opioid 
compounds. The aim is to investigate which metal cationic species may bind to the 
cavity site of the novel opioid derivatives (Fig 5.1). It could be possible that 
interactions between the metal cation species and the oxygen donor atoms could 
provide the stability required to form these complexes. This data provides important 
information relating to the novel opioid derivatives tested in relation to; 
 
• Suitability of the novel opioid derivatives as potential pro-drugs (Chapter 4). If the 
compounds exhibit high binding to a variety of metal ion species this could inhibit 
their potential as novel opioid pro-drugs. High metal cation binding could lead to 
potential toxicity problems.   
• Potential uses of the novel opioid compounds as metal ion sensors if significant 
metal binding is observed. 
 
 
Fig 5.1 Metal cationic species binding to the opioid cavity for compound 126 
 
Metal picrate extraction studies are a well established technique performed to analyse 
the metal binding properties of a variety of host species.94-96 The method is based on 
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measuring the relative distribution of a coloured metal salt (ie the metal picrate species) 
between water and an immiscible organic solvent containing the desired host species 
(Fig 5.2). If the complexing host compound has a high affinity to the metal species then 
a high percentage of the metal picrate salt will be “extracted” from the aqueous layer 
resulting in lower UV absorption. Conversly if there is little or no affinity between the 
host species and the metal cation the metal picrate salt will remain in the aqueous layer 
resulting in higher UV absorption. As a result, UV analysis of the absorption of the 
resulting aqueous layer provides an accurate measurement of metal binding affinities. 
 
                     
Fig 5.2 Partitioning of opioid species (127) and sodium picrate (191) between chloroform and water  
 
An important factor to consider for the metal binding is the relationship between the 
diameter of the metal cation and the cavity size of the opioid species. The cation 
diameters of the metal compounds tested are outlined in Table 5.1.95 From X-ray crystal 
analysis (Chapter 2, 2.5) information about the cavity size and orientation can be 
deduced. However, it must be remembered that this analysis is on solid state material 
while in solution different spatial orientations can be adopted. 
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Group I Group II Group III Group IV 
Metal Diameter Metal Diameter Metal Diameter Metal Diameter 
 (Ǻ)  (Å)  (Ǻ)  (Ǻ) 
Li+ 0.78 Mg2+ 0.78 La3+ NA Pb2+ 1.18 
Na+ 0.98 Ca2+ 1.06     
K+ 1.33 Zn2+ 0.75     
  Co2+ 0.75     
  Cu2+ 0.73     
Table 5.1 Metal cation diameters from ionic radius95 
 
5.2 Results and Discussion 
 
The cation selectivity of a selection of opioid derivatives with modification of the linker 
moiety were analysed by metal picrate extraction studies. In total twelve opioid 
compounds were analysed with ten metal picrates with results presented in Tables 5.2-
5.14. Also included are the results of a blank extraction study, with no host opioid 
compounds present in the chloroform layer. Furthermore it was decided to investigate if 
the A-ring modification on the opioid species would have an effect on the metal 
binding properties of the host compound. To this end a selection of four A-ring 
modified opioid derivatives were analysed against three metal picrate species, Na+, 
Cu2+, La3+, presented in Tables 5.15-5.18.  
 
The metal picrate extraction studies were performed by using host solutions of the 
opioid species in chloroform and picrate salt solutions in deionised water (Fig 5.2) 
according to the method by Pedersen.94 The solutions were shaken for 15 min and the 
absorption of the resulting aqueous layer was measured at 356 nm. The absorbance of 
the aqueous layer for each particular metal picrate salt was then compared to calibration 
curves previously determined to calculate the concentration of the metal picrate in the 
aqueous layer (Fig 5.3).   
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 Na Picrate Calibration Curve 
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Fig 5.3 Calibration curve for sodium metal picrate 
 
A calibration curve was determined for each of the ten metal picrate salts with the 
coefficient of determination (R2 value) greater than 99% for each. Each host opioid 
species and metal picrate was analysed in triplicate with the average of the three results 
reported with standard deviation < 0.015   
 
Opioid Cation % Extraction  
Li+ -1.13 
Na+ 1.47 
K+ 0.84 
Ca2+ 1.80 
Mg2+ 1.56 
Zn2+ 1.67 
Co2+ 1.72 
Cu2+ 1.12 
Pb2+ 1.75 
BLANK 
La3+ -1.79 
Table 5.2 Extraction results with Blank 
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Opioid Cation % Extraction 
Li+ 0.71 
Na+ 2.10 
K+ 2.78 
Ca2+ 2.66 
Mg2+ 7.68 
Zn2+ 4.77 
Co2+ 7.43 
Cu2+ 12.44 
Pb2+ 5.75 
O
HO
HO
NMe
1
H
 
La3+ 7.21 
Table 5.3 Extraction results with morphine (1) 
 
Opioid Cation % Extraction 
Li+ 2.70 
Na+ 0.81 
K+ 1.46 
Ca2+ 7.81 
Mg2+ 3.99 
Zn2+ 9.41 
Co2+ 7.35 
Cu2+ 1.89 
Pb2+ 2.68 
O
MeO
HO
NMe
2
H
 
La3+ -0.20 
Table 5.4 Extraction results with codeine (2) 
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Opioid Cation % Extraction 
Li+ 0.11 
Na+ -1.73 
K+ 1.03 
Ca2+ 12.61 
Mg2+ 17.20 
Zn2+ 7.54 
Co2+ 10.29 
Cu2+ 27.46 
Pb2+ 0.10 
 
La3+ 12.42 
Table 5.5 Extraction results with 119 
 
Opioid Cation % Extraction 
Li+ -0.23 
Na+ 3.96 
K+ 2.36 
Ca2+ 8.49 
Mg2+ 10.17 
Zn2+ 9.61 
Co2+ 9.45 
Cu2+ 22.39 
Pb2+ -0.07 
 
La3+ 16.21 
Table 5.6 Extraction results with 126 
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Opioid Cation % Extraction 
Li+ -1.99 
Na+ 8.25 
K+ 5.17 
Ca2+ 8.21 
Mg2+ 10.95 
Zn2+ 10.14 
Co2+ 10.12 
Cu2+ 36.55 
Pb2+ 7.13 
 
La3+ 13.47 
Table 5.7 Extraction results with 127 
 
Opioid Cation % Extraction 
Li+ -0.94 
Na+ 1.60 
K+ 1.03 
Ca2+ 6.11 
Mg2+ 7.72 
Zn2+ 7.98 
Co2+ 5.50 
Cu2+ 1.37 
Pb2+ 3.14 
 
La3+ 17.29 
Table 5.8 Extraction results with 131 
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Opioid Cation % Extraction 
Li+ -0.53 
Na+ -1.17 
K+ 3.23 
Ca2+ 10.50 
Mg2+ 11.68 
Zn2+ 9.49 
Co2+ 12.19 
Cu2+ 2.83 
Pb2+ 4.04 
 
La3+ 20.33 
Table 5.9 Extraction results with 128 
 
Opioid Cation % Extraction 
Li+ -0.04 
Na+ 7.49 
K+ 2.29 
Ca2+ 10.08 
Mg2+ 10.11 
Zn2+ 7.48 
Co2+ 8.63 
Cu2+ 24.11 
Pb2+ -1.34 
 
La3+ 15.04 
Table 5.10 Extraction results with 130 
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Opioid Cation % Extraction 
Li+ 1.05 
Na+ 0.81 
K+ 3.17 
Ca2+ 11.61 
Mg2+ 10.94 
Zn2+ 6.57 
Co2+ 9.51 
Cu2+ 21.45 
Pb2+ 4.59 
 
La3+ 18.73 
Table 5.11 Extraction results with 129 
 
Opioid Cation % Extraction 
Li+ 0.30 
Na+ 4.00 
K+ -1.55 
Ca2+ 12.10 
Mg2+ 8.06 
Zn2+ 2.93 
Co2+ 1.65 
Cu2+ 14.59 
Pb2+ 0.81 
 
La3+ 11.81 
Table 5.12 Extraction results with 132 
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Opioid Cation % Extraction 
Li+ -1.05 
Na+ 6.08 
K+ -1.93 
Ca2+ 14.94 
Mg2+ 14.91 
Zn2+ 14.06 
Co2+ 15.72 
Cu2+ 20.85 
Pb2+ 13.21 
 
La3+ 20.64 
Table 5.13 Extraction results with 121 
 
Opioid Cation % Extraction 
Li+ 2.82 
Na+ -0.61 
K+ 11.46 
Ca2+ 12.30 
Mg2+ 17.19 
Zn2+ 9.59 
Co2+ 12.87 
Cu2+ 32.35 
Pb2+ 13.57 
 
La3+ 19.70 
Table 5.14 Extraction results with 139 
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Opioid Cation % Extraction 
  
  
Na+ 0.64 
  
Cu2+ 34.49 
  
La3+ 16.35 
  
  
 
  
Table 5.15 Extraction results with 149 
 
Opioid Cation % Extraction 
  
  
Na+ 3.11 
  
Cu2+ 28.66 
  
La3+ 17.95 
  
  
 
  
Table 5.16 Extraction results with 141
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Opioid Cation % Extraction 
  
  
Na+ 1.19 
  
Cu2+ 32.86 
  
La3+ 16.50 
  
  
 
  
Table 5.17 Extraction results with 170 
 
Opioid Cation % Extraction 
  
  
Na+ -1.49 
  
Cu2+ 27.80 
  
La3+ 14.26 
  
  
O
MeO
O
NMe
O
OMe
O
MeN
O O
N N
168
H H
 
  
Table 5.18 Extraction results with 168 
 
From an examination of the blank samples investigated it is clear that there is no 
extraction of the metal picrate salts into the chloroform without the host opioid species. 
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However there is a small amount of variance from the expected zero percent binding, 
corresponding to ± 2%. This ± 2% deviation must be taken into account when analysing 
the extraction affinities of the host opioid species. Morphine (1) and codeine (2) were 
also analysed for their metal binding affinities. The data from these samples can then be 
directly correlated to the “linked” derivatives. 
 
The extraction data showed that both morphine (1) and codeine (2), before any 
modification to form a “linked” derivative have binding to some of the metal picrates 
(Graph 5.1). The highest affinity for codeine was found for Zn2+ at 9.4 % while 
morphine showed the highest affinity for Cu2+ at 12.4%. Interestingly morphine showed 
a much higher affinity for Cu2+ than codeine which only resulted in an extraction of 
1.9%. The only modification from morphine to codeine is the methoxy group at the 3 
position which as a result must have some effect on the affinity of the opioid 
compounds to the metal picrate.  
 
K+ Mg2+ Ca2+ Co2+ Zn2+ Cu2+ La3+ Na+ Li+ Pb2+
Metal Cations
0
2
4
6
8
10
12
14
%
 
E
x
tr
a
ct
io
n
% Extraction Values
Morphine (1)
Codeine (2)
  
Graph 5.1 % Extraction values for morphine (1) and codeine (2) 
 
Of more interest is the effect that modification at the six position of the opioids to form 
the “linked” derivatives has on the binding affinity to various metal picrates. As 
outlined previously the linked opioid compounds contain a cavity site which may form 
a host guest complex with various metal cationic species. An examination of the 
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extraction affinities for 119 compared to codeine shows that the linked compounds do 
show higher affinities for various metal cations especially Cu2+ and La3+ (Graph 5.2). 
For codeine the highest extraction was Zn2+ at 9.4% but 119 showed highest affinity for 
Cu2+ at 27.5%. Codeine only showed an extraction for Cu2+ at 1.9% which is over 
fourteen times lower than 119. Therefore the presence of the cavity site in the “linked” 
opioid derivate appears to have an effect on the affinity of the opioid compounds to 
metal cations. Compound 119 also exhibited modest affinity to Mg2+, Ca2+ and La3+ 
with extraction % values of 17.2%, 12.6% and 12.4% respectively.  
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Graph 5.2 % Extraction values for codeine (2) and 119 
 
As the cavity site has been shown to have an effect on the affinity of various metal 
cations, especially Cu2+ and La3+, to the opioid species it is important to investigate 
how modification at this site would affect the binding parameters. A comparison of the 
percentage extraction of the aromatic para-ester (119) derivative to the meta (126) and 
ortho (127) species shows that they are broadly similar (Graph 5.3). 119, 126 and 127 
display modest binding affinity to to Ca2+ Mg2+, Co2+ and Zn2+ with generally higher 
binding to Cu2+ and La3+. Each of the three compounds show the greatest affinity for 
Cu2+ with percentage extraction values of 27.5%, 22.4% and 36.6% for 119, 126 and 
127 respectively. They also exhibit modest binding to La3+ with percentage extraction 
values of 12.4%, 16.2% and 13.5% for 119, 126 and 127 respectively. Analysis of the 
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other aromatic linked compounds tested, the furan (130) and pyridine (131) linked 
derivatives display similar results except (Graph 5.4) 131 which exhibits a percentage 
extraction of Cu2+ of 1.4%. The percentage extraction to La3+ for 130 and 131 was 
calculated at 15.0% and 17.3% % respectively.  
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Graph 5.3 % Extraction values for 119, 126 and 127 
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Graph 5.4 % Extraction values for 119, 130 and 131 
 
Analysis of the non aromatic linked ester compounds 128, 129 and 132 show generally 
similar results with modest binding affinities to Ca2+ Mg2+, Co2+ and Zn2+ with 
typically higher binding to Cu2+ and La3+ (Graph 5.5). The percentage extraction values 
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for La3+ to 128, 129 and 132 were calculated at 20.3%, 18.7% and 11.8% respectively. 
As in the case of the pyridine linked ester derivative (131), the percentage extraction 
value for Cu2+ of 128 was calculated at 2.8% which is significantly lower than the other 
derivatives. Due to the increased flexibility of the non aromatic linked compounds it 
could be envisioned that they are able to adopt a favourable conformation around the 
metal cation at least relative to the more structurally hindered aromatic linked 
derivatives. However, this increase flexibility could be offset by the loss of cation-pi 
interactions which may be taking place between the metal cation and the aromatic-pi 
electrons of the aromatic “bridging” moiety.     
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Graph 5.5 % Extraction values for 128, 129 and 132 
 
Also examined were two ether linked compounds, the para (121) and meta (139) 
derivatives. It is interesting to note how the binding affinity is affected with the loss of 
two carbonyl groups on the “bridging” moiety. As with the ester linked compounds 
relatively modest extraction values were calculated for Ca2+ Mg2+, Co2+ and Zn2+ with 
higher binding to Cu2+ and La3+ (Graph 5.6). The percentage extraction values for the 
ether linked compounds are comparable to the corresponding esters with binding to 
Cu2+ of 20.9% and 32.4% for 121 and 139 respectively. The percentage extraction for 
La3+ was calculated at 20.6% and 19.7% for 121 and 139 respectively. 
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Without the two donor atoms provided by the carbonyl groups in the ester linked 
derivatives it could be expected the there should be a significant decrease in the 
percentage extractions calculated. However, it must also be noted that the oxygen atom 
of the carbonyl group may interfere with binding to the cavity site through steric 
effects, thus removing them would vacate the cavity pocket. The ether linked 
derivatives exhibit significantly increased affinity for the Pb2+ cationic species. The 
percentage extractions for Pb2+ were calculated at 13.2% and 13.6% for 121 and 139 
respectively. While this value is only a modest factor it should be noted that the highest 
percentage extraction value for the ester compounds was only 7.1% (127) with most 
values approximating to 0%.  
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Graph 5.6 % Extraction values for 121 and 139 
 
The metal picrate binding data of the ether and ester linked codeine derivatives 
analysed as part of this project can be compared to some ether linked morphine 
derivatives that have been analysed previously within the research group (Tables 5.19-
5.22).70 In general the ether linked morphine compounds exhibited similar trends to the 
linked codeine compounds, with minimal binding to Li+ and Na+ and increased binding 
to Cu2+ and La3+ species. As with the ether linked codeine compounds the ether linked 
morphine derivatives showed increased binding to Pb2+ relative to the ester derivatives.  
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The most prominent comparison is for the macrocyclic opioid compounds 180 and 192. 
Both of these compounds display much higher binding affinities to a variety of metal 
species especially Pb2+, Cu2+ and La3+.  The percentage metal extraction values for 
compounds 180 and 192 towards Pb2+ were calculated at 78.0% and 48.2% respectively 
while Cu2+ exhibited 72.6% and 60.6% respectively. The percentage binding towards 
Zn2+ and Co2+ has also been shown to be much higher for 180 and 192 with values for 
Zn2+ of 41.8% and 23.5% respectively and for Co2+ 54.6% and 36.6% respectively. Due 
to the relatively high percentage binding of the morphine macrocycles they may be 
better targets for sensor applications. The relatively low binding of the linked codeine 
ester’s on the other hand would lead them more towards use as prodrug candidates.   
 
Opioid Cation % Extraction 
Li+ 0.0 
Na+ 0.2 
K+ 2.5 
Ca2+ 8.7 
Mg2+ 8.0 
Zn2+ 4.2 
Co2+ 8.1 
Cu2+ 8.9 
Pb2+ 24.7 
 
La3+ 17.6 
Table 5.19 Extraction results with 13670 
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Opioid Cation % Extraction 
Li+ 1.9 
Na+ 4.2 
K+ 21.6 
Ca2+ 20.4 
Mg2+ 4.5 
Zn2+ 12.2 
Co2+ 28.6 
Cu2+ 45.7 
Pb2+ 40.4 
 
La3+ 16.5 
Table 5.20 Extraction results with 13770 
 
Opioid Cation % Extraction 
Li+ 0.4 
Na+ 0.4 
K+ 4.4 
Ca2+ 5.2 
Mg2+ 0.5 
Zn2+ 23.5 
Co2+ 36.6 
Cu2+ 60.6 
Pb2+ 48.2 
 
La3+ 39.8 
Table 5.21 Extraction results with 19270 
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Opioid Cation % Extraction 
Li+ 3.1 
Na+ 11.9 
K+ 17.5 
Ca2+ 19.8 
Mg2+ 21.3 
Zn2+ 41.8 
Co2+ 54.6 
Cu2+ 72.6 
Pb2+ 78.0  
La3+ 43.2 
Table 5.22 Extraction results with 18070 
 
On average the highest affinity of the opioid codeine derivatives tested was towards the 
Cu2+ cation. This was especially pronounced for the aromatic linked opioids with 
percentage extraction values for Cu2+ of 27.5%, 36.6% and 32.4% for 119, 127 and 139 
respectively. However, vide supra the morphine based ether linked opioids previously 
analysed within the research group70 exhibit much higher binding affininty to Cu2+ 
(Graph 5.7) 
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Graph 5.7 % Comparison of extraction values for opioid compounds to Cu2+  
 
Four A ring modified compounds were analysed (141, 149, 168, 170) based on the 
para-ester linked derivative (119) against three metal picrates, Na+, Cu2+ and La3+ 
(Graph 5.8). These opioid derivatives were chosen as a direct connection could then be 
made between A-ring modification (or lack thereof, 119) and binding affinity. Previous 
analysis had shown that significant binding to 119 was calculated for Cu2+ and La3+ 
hence these metal picrates were chosen for analysis.  
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Graph 5.8 % Extraction values for 119, 141, 149, 168 and 170 to Cu2+, La3+ and Na+  
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The Na+ metal picrate had shown negligible binding to most opioid species and hence it 
was chosen as a minimal binding metal cation. The percentage extraction values 
calculated for the A-ring modified derivatives demonstrate that modification at the 1 
position has little or no effect on the metal cationic binding to the cavity site. The 
calculated percentage extraction for Na+ was minimal as expected while the values for 
Cu2+ were 28.7%, 34.5%, 27.8% and 32.9% for 141, 149, 168 and 170 respectively. 
The binding values for La3+ were, 18.0%, 16.4%, 14.3%  and 16.5% for for 141, 149, 
168 and 170 respectively. 
 
5.3 Conclusion 
 
The cation selectivity to ten metal picrates (Li+, Na+ K+, Pb2+, Ca2+, Mg2+, Zn2+, Co2+, 
Cu2+ and La3+) of fourteen (119, 121, 126-132, 139, 141, 149, 168, 170) novel opioid 
compounds were analysed by metal picrate extraction studies. Overall relatively low 
metal binding was exhibited by the codeine derivatives analysed. The general trend 
noted for the opioid compounds is that they showed minimal binding to Li+, Na+, K+ 
and Pb2+, modest binding to Ca2+, Mg2+, Zn2+ and Co2+ and highest binding to Cu2+ and 
La3+ cations. Investigation of the A-ring modified compounds (141, 149, 168, 170) 
showed that alteration at the one position of the aromatic ring to a variety of functional 
groups had minimal effect on binding of the metal cation to the cavity site. The 
relatively low metal binding of the codeine derivatives to a variety of metal species 
implies that their use in sensor applications may be limited. However as these 
compounds have already displayed the potential as prodrug analgesic candidates low 
metal binding is desirable. High metal cationic binding to prodrug candidates can often 
lead to detrimental toxic side effects hence relatively low metal affinity for most of the 
“linked” codeine compounds is beneficial.  
 
The most promising result in relation to their potential as sensors is the affinity for the 
Cu2+ cation. In general the highest binding for the codeine derivatives was noted for the 
Cu2+ metal cation. When the percentage extraction values of the linked compounds are 
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compared to morphine (1) and codeine (2) there is a general increase in binding to the 
Cu2+ metal cation. This would appear to suggest that formation of the cavity site in the 
linked opioid derivatives has an important role in the binding affinity of the Cu2+ 
cation. The highest percentage extraction value calculated for Cu2+ was for 127 at 
36.6% while in contrast codeine (2) only exhibited an extraction value of 1.9%. 
Therefore the “linked” codeine compounds could have potential uses in sensor 
applications especially if further synthetic opioid derivatives are developed with 
increased Cu2+ binding. 
 
It also has to be mentioned that for the purpose of this study the stoichiometric ratio of 
the complexes formed was assumed to be 1:1, complexing agent:metal picrate. 
However, it should be noted that other compounds may form containing 1:2 or 1:3 
complexes. Future work on the potential use of opioid derivatives as sensors would 
focus on the ether linked morphine compounds (136, 137, 180, 192) especially the 
macrocyclic derivatives (180, 192). Previous work within the research group70 has 
highlighted that the morphine macrocyclic compounds exhibit the highest affinity to a 
variety of metal cations especially especially Pb2+, Cu2+ and La3+. The binding affinity 
of the open chain linked codeine compounds analysed as part of this project were much 
lower in contrast and thus have more potential as potential analgesic pro-drug 
candidates (Chapter 4). 
 
5.4 Experimental 
 
5.4.1 General Method for Picrate Salt Synthesis 
 
Picric acid (0.77 g, 65% suspension in water) was suspended in 20 mL of deionised 
water and warmed to 70 °C to make a saturated solution. The metal carbonate was 
added slowly to the hot solution with stirring until evolution of CO2 gas ceased. The 
contents were allowed to cool slowly to RT and then further cooled to 0 °C until a 
yellow solid precipitated. The yellow solid picrate metal salt was isolated by gravity 
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filtration, washed with 5 mL of ice cold water and allowed to air dry. In consultation 
with the head of safety it was not permitted to completely dry the metal picrates and 
therefore accurate isolated yields products could not be recorded. The following ten 
metal picrate salts were synthesised according to the method outlined above, 
LiC6H2N3O7, NaC6H2N3O7, KC6H2N3O7,, Ca(C6H2N3O7)2, Mg(C6H2N3O7)2, 
Zn(C6H2N3O7)2, Co(C6H2N3O7)2,  Cu(C6H2N3O7)2, Pb(C6H2N3O7)2, and 
La(C6H2N3O7)3. 
 
5.4.2 Picrate Extraction Studies 
 
A sample of each picrate salt was dried in vacuo, weighed and made up to a 1000 mL, 7 
x 10-5 M solution in deionised water. The solutions of the extracting opioid complexes 
were made up to a concentration of 1.75 x 10-5 M in chloroform. 6 mL of both the 
picrate solution and the opioid solution were transferred into a glass vial and shaken on 
an automatic shaker for 15 minutes at 600 oscillations per minute. Phases were allowed 
to separate at RT for 30 minutes before the UV absorption spectrum of the aqueous 
layer for each picrate salt sample was measured at 356 nm. All metal picrate extraction 
experiments were performed in triplicate with their mean UV absorbance values used 
for the calculations (standard deviation < 0.015). 
 
For each metal picrate salt a calibration curve was generated by making up solutions in 
the range of 7 x 10-5 M to 4.6 x 10-5 M and recording their UV absorbance at 356 nm. 
The coefficient of determination (R2 value) for each calibration curve was greater than 
99%. The % extraction values for the metal cations were calculated using the following 
equation: 
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Where (M Picrate
 
)0 is the number of moles of metal picrate in the aqueous layer 
originally, (M Picrate
 
)e is the number of moles of the picrate salt in the aqueous layer 
after extraction and (M Binding Agent
 
)org is the number of moles of binding agent in 
the organic layer. 
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Chapter 6 
 
Experimental 
 
6.1 Experimental 
 
All chemicals were purchased from Sigma-Aldrich, and used without further 
purification with the exception of codeine which was purchased from Johnson Matthey 
MacFarlan Smith, Edinburgh. THF was distilled under an atmosphere of nitrogen from 
sodium-benzophenone. DCM was distilled from CaH2. All other solvents and reagents 
were used as supplied (Analytical or HPLC grade) without further purification. Thin 
layer chromatography (TLC) was performed on aluminium sheets coated with 60 F254 
silica. TLC plates were visualised by UV (254 nm), iodine or aqueous potassium 
permanganate solution. Flash chromatography was performed on Davisil 60Å silica gel. 
Recrystallisations were performed via slow cooling technique for single solvent 
recrystallisations (acetone) and solvent diffusion for two solvent recrystallisations 
(CHCl3:Hexane). Melting point determinations were carried out using a Stuart, SMP3 
melting point apparatus. Infrared spectra were recorded on a Perkin Elmer FT-IR 
system, with ATR attachment. Optical rotations were measured on a Perkin Elmer 343 
Polarimeter in HPLC grade chloroform. High Resolution Mass Spectrometry (HRMS) 
was carried out on a Waters Corp. Liquid Chromatography Time of flight mass 
spectrometer at the Microanalytical Laboratory, University College Dublin or a Waters 
Micromass LCT Premier mass spectrometer at ABCRF laboratory, University College 
Cork. NMR spectra were obtained on a Bruker AC 400 NMR spectrometer operating at 
400 MHz for 1H NMR and 100 MHz for 13C NMR or where stated, on a Bruker AC 
600 NMR spectrometer operating at 600 MHz for 1H NMR and 150 MHz for 13C 
NMR. The 1H and 13C NMR shifts (δ) are expressed in ppm relative to 
tetramethylsilane with coupling constants values (J) expressed in Hertz (Hz). Chemical-
shift assignments for 1H and 13C spectra were assisted with COSY, DEPT, HMQC and 
HMBC experiments. The splitting patterns for NMR spectra are designated as follows: 
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s (singlet), d (doublet), t, (triplet), q, (quartet), p, (pentet), dd (doublet of doublets), ddd 
(doublet of doublet of doublets) and m (multiplet). 
 
Compounds are named based on IUPAC nomenclature. Numbering for NMR 
assignment is based on molecular structures provided and as per NMR study, Chapter 
2, 2.3.2. 
 
6.2 Ester and Ether Linked Codeine Derivatives 
  
Representative Procedure 1 
A flask was charged with the appropriate opioid, anhydrous DCM and base and put 
under a nitrogen atmosphere. The acid dichloride was dissolved in anhydrous DCM and 
added dropwise to the reaction mixture. The reaction mixture was stired at RT under 
nitrogen for 18 h, washed with distilled water (3 x 10 mL), dried over anhydrous 
Na2SO4 and concentrated in vacuo before purification. 
 
Representative Procedure 2 
A flask was charged with the appropriate opioid, distilled THF, appropriate haloalkane, 
KI and KOH and heated under reflux for 18 h. After cooling THF was removed via 
rotary evaporation and contents re-dissolved in DCM. The resulting mixture was 
filtered through a thin layer of celite and the filtrate washed with distilled water (3 x 10 
mL). The organic layer was dried over Na2SO4 and concentrated in vacuo before 
purification.  
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1,4-bis(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl benzene-
1,4-dicarboxylate, (119); 
 
 
 
Following representative procedure 1, codeine (2) (0.291 g, 0.97 mmol), DMAP (0.131 
g, 1.07 mmol, 1.1 Eq), DCM (10 mL) and terephthaloyl dichloride, (0.098 g, 0.48 
mmol, 0.5 Eq) gave, after purification by column chromatography (SiO2 10% 
MeOH/DCM, 1% NH4OH), 119, as a white solid in 73% yield (0.254 g, 0.35 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ, 8.07 (s, 4H, (H21, H21’))  6.59 (d, J = 8.0 Hz, 2H, (H2, 
H2’)), 6.50 (d, J = 8.0 Hz, 2H, (H1, H1’)), 5.74-5.70 (m, 2H, (H7, H7’)), 5.48-5.44 (m, 
2H, (H8, H8’)), 5.40-5.36 (m, 2H, (H6, H6’)), 5.14 (d, J = 6.8  Hz, 2H, (H5, H5’)), 3.64 
(s, 6H, (H18, H18’)) 3.33-3.31 (m, 2H, (H9, H9’)), 2.99 (d, J = 18.4 Hz, 2H, (H10, 
H10’)), 2.77-2.74 (m, 2H, (H14, H14’)), 2.54 (dd, J = 12.0, 4.0 Hz, 2H, (H16, H16’)), 
2.39 (s, 6H, (H17, H17’)), 2.35-2.23 (m, 4H, H16, H16’, H10, H10’)), 2.02 (ddd, J = 
12.4, 12.4, 4.8 Hz, 2H, (H15, H15’)), 1.83 (dd, J = 12.8, 2.0 Hz 2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ, 165.34 (C19, C19’), 146.61 (C4, C4’), 142.21 (C3, 
C3’), 133.89 (C20, C20’), 130.71 (C12, C12’), 129.87 (C8, C8’) 129.77 (C21, C21’), 
128.28 (C7, C7’), 126.95 (C11, C11’), 119.34 (C1, C1’) 114.30 (C2, C2’), 87.80 (C5, 
C5’), 68.84 (C6, C6’), 59.14 (C9, C9’) 56.76 (C18, C18’), 46.76 (C16, C16’), 43.11 
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(C17, C17’), 42.60 (C13, C13’), 40.66 (C14, C14’), 35.36 (C15, C15’), 20.34 (C10, 
C10’) 
IR: υ (cm-1), 2909, 1710 (C=O), 1503 (C-C, Ar), 1451, 1253, 1250, 1199, 1127, 1100, 
1057, 1017 
HRMS (EI, 70eV) Calculated for [M+H]+, C44H45N2O8+, requires: 729.3176, found 
729.3176, 
m.p. = 247-249 °C, [α]D = -233° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
1,3-bis(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl benzene-
1,3-dicarboxylate, (126); 
 
 
 
Following representative procedure 1, codeine (2) (0.451 g, 1.51 mmol), DMAP (0.203 
g, 1.66 mmol, 1.1 Eq), DCM (15 mL) and isophthaloyl dichloride (0.153 g, 0.75 mmol, 
0.5 Eq) gave, after purification by column chromatography (SiO2 10% MeOH/DCM, 
1% NH4OH) followed by recrystallisation in acetone, 126 as white solid in 82% yield 
(0.449 g, 0.62 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ, 8.65-8.64 (m, 1H, (H23)), 8.22 (dd, J = 7.6, 1.6 Hz, 
2H, (H21, H21’)), 7.46 (t, J = 7.6 Hz, 1H, (H22)), 6.57 (d, J = 8.4 Hz, 2H, (H2, H2’)), 
6.48 (d, J = 8.4 Hz, 2H, (H1, H1’)), 5.74-5.71 (m, 2H, (H7, H7’)), 5.46-5.43 (m, 2H, 
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(H8, H8’)) 5.39-5.35 (m, 2H, (H6, H6’)), 5.14 (dd, J = 6.8, 0.4 Hz, 2H, (H5, H5’)), 3.61 
(s, 6H, (H18, H18’)) 3.33-3.30 (m, 2H, (H9, H9’)), 2.98 (d, J = 18.4 Hz, 2H, (H10, 
H10’)), 2.75-2.73 (m, 2H, (H14, H14’)), 2.53 (dd, J = 12.0, 3.6 Hz 2H, (H16, H16’)), 
2.38 (s, 6H, (H17, H17’)), 2.35-2.22 (m, 4H, (H16, H16’, H10, H10’)), 2.01 (ddd, J = 
12.4, 12.4, 4.8 Hz, 2H, (H15, H15’)), 1.82 (dd, J = 12.8, 1.6 Hz, 2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ, 165.23 (C19, C19’), 146.73 (C4, C4’), 142.23 (C3, 
C3’), 134.34 (C21, C21’), 131.29 (C23), 130.71 (C12, C12’), 130.41 (C20, C20’), 
129.74 (C8, C8’), 128.41 (C7, C7’), 128.40 (C22), 126.96 (C11, C11’), 119.29 (C1, 
C1’), 114.52 (C2, C2’), 87.84 (C5, C5’), 68.90 (C6, C6’), 59.16 (C9, C9’), 56.84 (C18, 
C18’), 46.78 (C16, C16’), 43.10 (C17, C17’), 42.64 (C13, C13’), 40.69 (C14, C14’), 
35.36 (C15, C15’), 20.39 (C10, C10’) 
IR: υ (cm-1), 2903, 1708 (C=O), 1505 (C-C, Ar), 1439, 1303, 1279, 1237, 1144, 1097, 
1077, 1051, 1012 
HRMS (EI, 70eV) Calculated for [M+H]+, C44H45N2O8+, requires: 729.3176, found 
729.3165, m.p. = 256-258 °C, [α]D = -189° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
1,2-bis(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl benzene-
1,2-dicarboxylate, (127); 
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Following representative procedure 1, codeine (2) (0.352 g, 1.18 mmol), DMAP (0.159 
g, 1.30 mmol, 1.1 Eq), DCM (10 mL) and phthaloyl dichloride (0.085 mL, 0.59 mmol, 
0.5 Eq) gave, after purification by column chromatography (SiO2 10% MeOH/DCM, 
1% NH4OH) followed by recrystallisation in CHCl3:Hexane, 127 as a white solid in 
72% yield (0.309 g, 0.42 mmol). 
 
1H NMR, (CDCl3, 600 MHz) δ, 7.89-7.87 (m, 2H, (C21, C21’)), 7.49-7.48 (m, 2H, 
(C22, C22’))  6.59 (d, J = 8.2 Hz, 2H, (H2, H2’)), 6.48 (d, J = 8.2 Hz, 2H, (H1, H1’)), 
5.72-5.71 (m, 2H, (H7, H7’)), 5.38-5.34 (m, 4H, (H8, H8’, H6, H6’)), 5.17 (d, J = 6.6 
Hz, 2H, (H5, H5’)), 3.70 (s, 6H, (H18, H18’)), 3.39 (s, 2H, (H9, H9’)), 2.99 (d, J = 18.6 
Hz, 2H, (H10, H10’)), 2.85 (s, 2H, (H14, H14’)), 2.63 (d, J = 9.0 Hz, 2H, (H16, H16’)), 
2.45-2.38 (m, 8H, (H17, H17’, H16, H16’)), 2.33 (dd, J = 18.6, 6.0 Hz 2H, (H10, 
H10’)), 2.11 (ddd, J = 12.6, 12.6, 3.6 Hz 2H, (H15, H15’)), 1.84 (d, J = 10.8 Hz, 2H, 
(H15, H15’)) 
13C NMR, (CDCl3, 150 MHz) δ, 165.79 (C19, C19’), 145.80 (C4, C4’), 141.30 (C3, 
C3’), 130.90 (C20, C20’), 130.02 (C22, C22’), 129.45 (C12, C12’), 128.50 (C21, 
C21’), 127.86 (C8, C8’), 127.77 (C7, C7’), 125.27 (C11, C11’), 118.28 (C1, C1’), 
113.40 (C2, C2’), 86.89 (C5, C5’), 68.19 (C6, C6’), 58.33 (C9, C9’), 55.76 (C18, 
C18’), 45.79 (C16, C16’), 41.81 (C17, C17’), 41.47 (C13, C13’), 39.06 (C14, C14’), 
33.90 (C15, C15’), 19.60 (C10, C10’) 
IR: υ (cm-1), 2906, 1725 (C=O), 1498 (C-C, Ar), 1442, 1288, 1269, 1255, 1242, 1205 
1137, 1122, 1034, 1015 
HRMS (EI, 70eV) Calculated for [M+H]+, C44H45N2O8+, requires: 729.3176, found 
729.3199, m.p. = 231-233 °C, [α]D = -185° c = (0.10, CHCl3, 589 nm, 20 °C) 
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(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl 2-(2-
{[(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl]oxy}-2-
oxoethoxy)acetate, (128); 
 
 
 
Following representative procedure 1, codeine (2) (0.331 g, 1.11 mmol), DMAP (0.149 
g, 1.22 mmol, 1.1 Eq), DCM (10 mL) and diglycolyl dichloride (0.067 mL, 0.56 mmol, 
0.5 Eq) gave, after purification by column chromatography (SiO2 10% MeOH/DCM, 
1% NH4OH) followed by recrystallisation in CHCl3:Hexane, 128 as a white solid in 
40% yield (0.155 g, 0.22 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ 6.57 (d, J = 8.4 Hz, 2H, (H2, H2’)), 6.47 (d, J = 8.4 Hz, 
2H, (H1, H1’)), 5.58-5.55 (m, 2H, (H7, H7’)), 5.40-5.36 (m, 2H, (H8, H8’)) 5.22-5.19 
(m, 2H, (H6, H6’)), 5.02 (d, J = 6.8 Hz, 2H, (H5, H5’)), 4.35 (d, J = 6.8 Hz, 4H, (H20, 
H20’)), 3.73 (s, 6H, (H18, H18’)) 3.29-3.27 (m, 2H, (H9, H9’)), 2.96 (d, J = 18.4 Hz, 
2H, (H10, H10’)), 2.68-2.67 (m, 2H, (H14, H14’)), 2.51 (dd, J = 12.0, 3.6 Hz 2H, (H16, 
H16’)), 2.36 (s, 6H, (H17, H17’)), 2.29 (ddd, J = 12.4, 12.4, 3.6 Hz, 2H, (H16, H16’)), 
2.21 (dd, J = 18.4, 6.0 Hz, 2H, (H10, H10’)) 1.97 (ddd, J = 12.4, 12.4, 4.8 Hz, 2H, 
(H15, H15’)), 1.78 (dd, J = 12.4, 1.2 Hz, 2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ, 169.64 (C19 C19’), 146.53 (C4, C4’), 142.22 (C3, 
C3’), 130.50 (C12, C12’), 129.87 (C8, C8’), 127.97 (C7, C7’), 126.90 (C11, C11’), 
119.27 (C1, C1’), 113.62 (C2, C2’), 87.60 (C5, C5’), 68.54 (C6, C6’), 68.06 (C20, 
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C20’), 59.08 (C9, C9’), 56.51 (C18, C18’), 46.69 (C16, C16’), 43.07 (C17, C17’), 
42.59 (C13, C13’), 40.62 (C14, C14’), 35.35 (C15, C15’), 20.29 (C10, C10’)  
IR: υ (cm-1), 2911, 1750 (C=O), 1500 (C-C, Ar), 1441, 1282, 1253, 1213, 1150, 1102, 
1050, 1021 
HRMS (EI, 70eV) Calculated for [M+H]+, C40H45N2O9+, requires: 697.3125, found 
697.3128, m.p. = 183-185 °C, [α]D = -175° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl 
benzoate, (125); 
 
 
 
Following representative procedure 1, codeine (2) (0.305 g, 1.02 mmol), DMAP (0.137 
g, 1.12 mmol, 1.1 Eq), DCM (10 mL) and benzoyl chloride (0.118 mL, 1.02 mmol, 1 
Eq) gave, after purification by column chromatography (SiO2 10% MeOH/DCM, 1% 
NH4OH), 125 as a white solid in 92% yield (0.379 g, 0.94 mmol).  
 
1H and 13C NMR data in agreement with literature37 
1H NMR, (CDCl3, 400 MHz) δ 8.01 (dd, J = 7.6, 0.8 Hz 2H, (H21)), 7.50-7.46 (m, 1H, 
(H23)), 7.35 (t, J = 7.6 Hz, 2H, (H22)) 6.58 (d, J = 8.0 Hz, 1H, (H2), 6.47 (d, J = 8.0 
Hz, 1H, (H1)), 5.71-5.68 (m, 1H, (H7)), 5.44-5.40 (m, 1H, (H8)) 5.40-5.34 (m, 1H, 
(H6)), 5.12 (dd, J = 6.8, 0.8 Hz, 1H, (H5)), 3.64 (s, 3H, (H18)) 3.32-3.30 (m, 1H, (H9)), 
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2.98 (d, J = 18.8 Hz, 1H, (H10)), 2.74-2.73 (m, 1H, (H14)), 2.52 (dd, J = 8.0 Hz 4.0 Hz 
1H, (H16)), 2.37 (s, 3H, (H17)), 2.36-2.22 (m, 2H, (H16, H10)), 2.01 (ddd, J = 12.4, 
12.4, 5.2 Hz, 1H, (H15)), 1.82 (dd, J = 12.8, 2.0 Hz, 1H, (H15)) 
13C NMR, (CDCl3, 100 MHz) δ, 166.08 (C19), 146.82 (C4), 142.15 (C3), 133.05 
(C23), 130.88 (C20), 130.01 (C12), 129.93 (C21), 129.70 (C8), 128.56 (C7), 128.27 
(C22), 127.09 (C11), 119.23 (C1), 114.59 (C2), 88.16 (C5), 68.62 (C6), 59.11 (C9), 
56.90 (C18), 46.71 (C16), 43.12 (C17), 42.74 (C13), 40.75 (C14), 35.43 (C15), 20.38 
(C10) 
 
Bis(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl 2,2-
dimethylpropanedioate, (129); 
 
 
 
Following representative procedure 1, codeine (2) (0.329 g, 1.10 mmol), DMAP (0.148 
g, 1.21 mmol, 1.1 Eq), DCM (10 mL) and dimethylmalonyl dichloride (0.073 mL, 0.55 
mmol, 0.5 Eq) gave, after purification by column chromatography (SiO2 10% 
MeOH/DCM, 1% NH4OH) followed by recrystallisation in CHCl3:Hexane, 129 as a 
white solid in 39% yield (0.149 g, 0.21 mmol).  
  
1H NMR, (CDCl3, 400 MHz) δ, 6.56 (d, J = 8.4 Hz, 2H, (H2, H2’)), 6.44 (J = 8.4 Hz, 
2H, (H1, H1’)), 5.47-5.43 (m, 2H, (H7, H7’)), 5.32-5.28 (m, 2H, (H8, H8’)), 5.09-5.06 
(m, 2H, (H6, H6’)), 5.03 (dd, J = 6.8, 0.8 Hz, 2H, (H5, H5’)) 3.72 (s, 6H, (H18, H18’)) 
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3.28-3.26 (m, 2H, (H9, H9’)), 2.95 (d, J = 18.8 Hz, 2H, (H10, H10’)), 2.67-2.65 (s, 2H, 
(H14, H14’)), 2.51 (dd, J = 12.4, 4.0 Hz, 2H, (H16, H16’)), 2.37 (s, 6H, (H17, H17’)), 
2.29 (ddd, J = 12.4, 12.4, 3.6 Hz, 2H, (H16, H16’)), 2.20 (dd, J = 18.4, 6.0 Hz  2H, 
(H10, H10’)) 1.97 (ddd, J = 12.4, 12.4, 4.8 Hz, 2H, (H15, H15’)), 1.77 (dd, J = 12.8, 
1.6 Hz 2H, (H15, H15’)), 1.53 (s, 6H, (H21, H21’)) 
 
13C NMR, (CDCl3, 100 MHz) δ, 172.18 (C19, C19’), 146.83 (C4, C4’), 142.27 (C3, 
C3’), 130.60 (C12, C12’), 129.37 (C8, C8’), 128.39 (C7, C7’), 126.80 (C11, C11’), 
119.04 (C1, C1’), 114.08 (C2, C2’), 87.80 (C5, C5’), 68.88 (C6, C6’), 59.10 (C9, C9’), 
56.70 (C18, C18’), 50.02 (C20), 46.66 (C16, C16’), 43.07 (C17, C17’), 42.66 (C13, 
C13’), 40.56 (C14, C14’), 35.39 (C15, C15’), 22.70 (C21, C21’), 20.30 (C10, C10’) 
IR: υ (cm-1), 2932, 1731 (C=O), 1497 (C-C, Ar), 1440, 1283, 1252, 1206, 1169, 1149, 
1129, 1100, 1052, 1035, 1018 
HRMS (EI, 70eV) Calculated for [M+H]+, C41H47N2O8+, requires: 695.3332, found 
695.3351, m.p. = 203-205 °C, [α]D = -131° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
2,5-bis(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl furan-2,5-
dicarboxylate, (130); 
 
 
 
Following representative procedure 1, codeine (2) (0.396 g, 1.32 mmol), DMAP (0.178 
g, 1.46 mmol, 1.1 Eq), DCM (10 mL) and 2,5 furan-dichloride (0.127 g, 0.66 mmol, 0.5 
Eq) gave, after purification by column chromatography (SiO2 10% MeOH/DCM, 1% 
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NH4OH) followed by recrystallisation in CHCl3:Hexane, 130 as a white solid in 51% 
yield (0.243 g, 0.34 mmol).  
 
1H NMR, (CDCl3, 600 MHz) δ 7.19 (s, 2H, (H21, H21’)) 6.60 (d, J = 7.8 Hz, 2H, (H2, 
H2’)), 6.50 (d, J = 7.8 Hz, 2H, (H1, H1’)), 5.72-5.70 (m, 2H, (H7, H7’)), 5.45-5.42 (m, 
2H, (H8, H8’)) 5.36-5.34 (m, 2H, (H6, H6’)), 5.12 (d, J = 7.2 Hz, 2H, (H5, H5’)), 3.69 
(s, 6H, (H18, H18’)) 3.40 (s, 2H, (H9, H9’)), 2.99 (d, J = 18.6 Hz, 2H, (H10, H10’)), 
2.84 (s, 2H, (H14, H14’)), 2.63-2.62 (m, 2H, (H16, H16’)), 2.44 (s, 6H, (H17, H17’)), 
2.41-2.31 (m, 4H, (H16, H16’, H10, H10’)), 2.11-2.07 (m, 2H, (H15, H15’)), 1.84 (d, J 
= 13.2 Hz, 2H, (H15, H15’)) 
13C NMR, (CDCl3, 150 MHz) δ, 157.32 (C19, C19’), 146.74 (C20, C20’), 146.67 (C4, 
C4’), 142.41 (C3, C3’) 130.42 (C12, C12’), 129.43 (C8, C8’), 128.31 (C7, C7’), 126.42 
(C11, C11’), 119.46 (C1, C1’), 119.01 (C21, C21’), 114.85 (C2, C2’), 87.49 (C5, C5’), 
68.99 (C6, C6’), 59.32 (C9, C9’), 56.98 (C18, C18’), 46.81 (C16, C16’), 42.92 (C17, 
C17’), 42.42 (C13, C13’), 40.19 (C14, C14’), 35.14 (C15, C15’), 20.81 (C10, C10’) 
IR: υ (cm-1), 2933, 1719, 1706 (C=O), 1505, 1496 (C-C, Ar), 1439, 1298, 1276, 1253, 
1167, 1157, 1139, 1047, 1008  
HRMS (EI, 70eV) Calculated for [M+H]+, C42H43N2O9+, requires: 719.2969, found 
719.2967, m.p. = 251-253 °C, [α]D = -175° c = (0.10, CHCl3, 589 nm, 20 °C) 
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2,6-bis(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl pyridine-
2,6-dicarboxylate, (131); 
 
 
 
Following representative procedure 1, codeine (2) (0.398 g, 1.33 mmol), DMAP (0.178 
g, 1.46 mmol, 1.1 Eq), DCM (8 mL) and 2,6-pyridinedicarbonyl dichloride (0.136 g, 
0.67 mmol, 0.5 Eq) gave, after purification by column chromatography (SiO2 10% 
MeOH/DCM, 1% NH4OH) followed by recrystallisation in CHCl3:Hexane, 131 as a 
white solid in 49% yield (0.238 g, 0.33 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ, 8.24 (d, J = 7.6 Hz, 2H, (H21, H21’)), 7.91 (t, J = 7.6 
Hz, 1H, (H22)), 6.58 (d, J = 8.0 Hz, 2H, (H2, H2’)), 6.48 (d, J = 8.0 Hz, 2H, (H1, 
H1’)), 5.77-5.74 (m, 2H, (H7, H7’)), 5.45-5.42 (m, 4H, (H8, H8’, H6, H6’)), 5.19 (d, J 
= 6.4 Hz, 2H, (H5, H5’)), 3.65 (s, 6H, (H18, H18’)) 3.35-3.33 (m, 2H, (H9, H9’)), 2.99 
(d, J = 18.8 Hz, 2H, (H10, H10’)), 2.78-2.76 (m, 2H, (H14, H14’)), 2.56 (dd, J = 12.0, 
4.0 Hz, 2H, (H16, H16’)), 2.40 (s, 6H, (H17, H17’)), 2.34 (ddd, J = 12.0, 12.0, 3.2 Hz, 
2H, (H16, H16’)), 2.27 (dd, J = 18.8, 6.4 Hz  2H, (H10, H10’)), 2.05 (ddd, J = 12.4, 
12.4, 4.8 Hz, 2H, (H15, H15’)), 1.83 (dd, J = 12.4, 1.6 Hz, 2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ, 163.62 (C19, C19’), 148.57 (C20, C20’), 146.73 (C4, 
C4’), 142.20 (C3, C3’), 137.92 (C22, C22’), 130.70 (C12, C12’), 129.68 (C8, C8’), 
128.23 (C7, C7’), 128.14 (C21, C21’), 126.96 (C11, C11’), 119.35 (C1, C1’), 114.58 
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(C2, C2’), 87.73 (C5, C5’), 69.56 (C6, C6’), 59.14 (C9, C9’), 56.94 (C18, C18’), 46.71 
(C16, C16’), 43.02 (C17, C17’), 42.65 (C13, C13’), 40.50 (C14, C14’), 35.26 (C15, 
C15’), 20.42 (C10, C10) 
IR: υ (cm-1), 2910, 1748 (C=O), 1501 (C-C, Ar), 1445, 1281, 1231, 1172, 1147, 1048, 
1020 
HRMS (EI, 70eV) Calculated for [M+H]+, C43H44N3O8+, requires: 730.3128, found 
730.3137, m.p. = 232-234 °C, [α]D = -229° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
Bis(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl 
heptanedioate, (132); 
  
 
 
Following representative procedure 1, codeine (2) (0.301 g, 1.01 mmol), DMAP (0.136 
g, 1.11 mmol, 1.1 Eq), DCM (8 mL) and heptanedioyl dichloride (0.083 mL, 0.51 
mmol, 0.5 Eq) gave, after purification by column chromatography (SiO2 10% 
MeOH/DCM, 1% NH4OH) followed by recrystallisation in CHCl3:Hexane, 132 as an 
off white solid in 63% yield (0.232 g, 0.32 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ 6.58 (d, J = 8.4 Hz, 2H, (H2, H2’)), 6.47 (d, J = 8.4 Hz, 
2H, (H1, H1’)), 5.57-5.40 (m, 2H, (H7, H7’)), 5.38-5.34 (m, 2H, (H8, H8’)) 5.12-5.09 
(m, 2H, (H6, H6’)), 5.01 (dd, J = 6.8, 0.8 Hz, 2H, (H5, H5’)), 3.76 (s, 6H, (H18, 
H18’)), 3.31-3.28 (m, 2H, (H9, H9’)), 2.97 (d, J = 18.4 Hz, 2H, (H10, H10’)), 2.69-
2.67 (m, 2H, (H14, H14’)), 2.52 (dd, J = 12.0, 4.0 Hz, 2H, (H16, H16’)), 2.42-2.20 (m, 
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8H, (H16, H16’, H10, H10’, H20, H20’)), 2.38 (s, 6H, (H17, H17’)), 1.98 (ddd, J = 
12.4, 12.4, 4.8 Hz, 2H, (H15, H15’)), 1.79 (dd, J = 12.4, 1.6 Hz, 2H, (H15, H15’)), 
1.70-1.62 (m, 4H, (H21, H21’)), 1.42-1.36 (m, 2H, (H22)) 
13C NMR, (CDCl3, 100 MHz) δ, 173.15 (C19 C19’), 146.75 (C4, C4’), 142.18 (C3, 
C3’), 130.59 (C12, C12’), 129.51 (C8, C8’), 128.59 (C7, C7’), 126.87 (C11, C11’), 
119.10 (C1, C1’), 113.66 (C2, C2’), 88.05 (C5, C5’), 68.11 (C6, C6’), 59.07 (C9, C9’), 
56.57 (C18, C18’), 46.69 (C16, C16’), 43.09 (C17, C17’), 42.74 (C13, C13’), 40.71 
(C14, C14’), 35.41 (C15, C15’), 33.94 (C20, C20’), 28.72 (C21, C21’) 24.60 (C22), 
20.33 (C10, C10’) 
IR: υ (cm-1), 2928, 1731 (C=O), 1504 (C-C, Ar), 1441, 1277, 1252, 1202, 1173, 1156, 
1138, 1101, 1052, 1022 
HRMS (EI, 70eV) Calculated for [M+H]+, C43H51N2O8+, requires: 723.3645, found 
723.3647, m.p. = 55-57 °C, [α]D = -233° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
(1S,5R,13R,14S,17R)-10-methoxy-14-{[4-({[(1S,5R,13R,14S,17R)-10-methoxy-4-
methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-
14-yl]oxy}methyl)phenyl]methoxy}-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraene, (121);  
 
 
 
Following representative procedure 2, codeine (2) (0.653 g, 2.18 mmol), KOH (1.468 g, 
26.16 mmol, 12 Eq), THF (10 mL), KI (0.073 g, 0.44 mmol, 0.2 Eq) and 1,4-
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bis(bromomethyl)benzene (0.191 g, 1.09 mmol, 0.5 Eq) gave, after purification by 
column chromatography (SiO2 10% MeOH/DCM, 1% NH4OH) followed by 
recrystallisation in CHCl3:Hexane, 121 as an off white solid in 55% yield (0.419 g, 0.60 
mmol). 
 
1H NMR, (CDCl3, 400 MHz) δ, 7.34 (s, 4H, (H21, H21’))  6.55 (d, J = 8.0 Hz, 2H, (H2, 
H2’)), 6.43 (d, J = 8.0 Hz, 2H, (H1, H1’)), 5.69-5.66 (m, J = 10.0 Hz, 2H, (H7, H7’)), 
5.25-5.22 (m, 2H, (H8, H8’)), 4.91 (dd, J = 6.0, 0.8 Hz, 2H, (H5, H5’)), 4.77 (d, J = 
12.0 Hz, 2H, (H19, H19’)), 4.57 (d, J = 12.0 Hz, 2H, (H19, H19’)), 3.90-3.87 (m, 2H, 
(H6, H6’)), 3.76 (s, 6H, (H18, H18’)) 3.27-3.25 (m, 2H, (H9, H9’)), 2.94 (d, J = 18.4 
Hz, 2H, (H10, H10’)), 2.56-2.55 (m, 2H, (H14, H14’)), 2.49 (dd, J = 12.0, 3.6 Hz, 2H, 
(H16, H16’)), 2.36-2.29 (m, 8H, (H17, H17’, H16, H16’)), 2.22 (dd, 18.4, 6.0 Hz, 2H, 
(H10, H10’)), 1.94 (ddd, J = 12.4, 12.4, 4.8 Hz, 2H, (H15, H15’)), 1.80 (dd, J = 12.4, 
1.6 Hz, 2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ, 147.46 (C4, C4’), 142.16 (C3, C3’), 137.65 (C20, 
C20’), 130.94 (C7, C7’), 130.84 ( C12, C12’) 128.71 (C8, C8’), 127.96 (C21, C21’), 
126.94 (C11, C11’), 118.82 (C1, C1’) 113.48 (C2, C2’), 89.59 (C5, C5’), 72.99 (C6, 
C6’) 70.44 (C19, C19’), 58.96 (C9, C9’) 56.56 (C18, C18’), 46.55 (C16, C16’), 43.34 
(C13, C13’), 43.12 (C17, C17’), 41.00 (C14, C14’), 35.89 (C15, C15’), 20.50 (C10, 
C10’) 
IR: υ (cm-1), 2907, 1499 (C-C, Ar), 1441, 1277, 1253, 1203, 1121, 1100, 1052, 1019  
HRMS (EI, 70eV) Calculated for [M+H]+, C44H49N2O6+, requires: 701.3591, found 
701.3571, m.p. = 179-181 °C, [α]D = -240° c = (0.10, CHCl3, 589 nm, 20 °C) 
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(1S,5R,13R,14S,17R)-10-methoxy-14-{[3-({[(1S,5R,13R,14S,17R)-10-methoxy-4-
methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-
14-yl]oxy}methyl)phenyl]methoxy}-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraene, (139);  
 
 
 
Following representative procedure 2, codeine (2) (0.667 g, 2.23 mmol), KOH (1.501 g, 
26.76 mmol, 12 Eq), THF (10 mL), KI (0.075 g, 0.45 mmol, 0.2 Eq) and 1,3-
bis(bromomethyl)benzene (0.196 g, 1.12 mmol, 0.5 Eq) gave, after purification by 
column chromatography (SiO2 10% MeOH/DCM, 1% NH4OH) followed by 
recrystallisation in CHCl3:Hexane, 139 as an off white solid in 59% yield (0.461 g, 0.66 
mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ, 7.38 (s, 1H, (H23)), 7.32-7.24 (m, 3H, (H22, H21, 
H21’)), 6.56 (d, J = 8.4 Hz, 2H, (H2, H2’)), 6.44 (d, J = 8.4 Hz, 2H, (H1, H1’)), 5.72-
5.68 (m, 2H, (H7, H7’)), 5.27-5.23 (m, 2H, (H8, H8’)), 4.93 (dd, J = 6.0, 1.2 Hz, 2H, 
(H5, H5’)), 4.80 (d, J = 12.0 Hz, 2H, (H19, H19’)), 4.59 (d, J = 12.0 Hz, 2H, (H19, 
H19’)), 3.92-3.89 (m, 2H, (H6, H6’)), 3.76 (s, 6H, (H18, H18’)) 3.27-3.24 (m, 2H, (H9, 
H9’)), 2.96 (d, J = 18.4 Hz, 2H, (H10, H10’)), 2.56-2.55 (m, 2H, (H14, H14’)), 2.49 
(dd, J = 12.4, 4.4 Hz, 2H, (H16, H16’)), 2.37-2.30 (m, 2H, (H16, H16’)), 2.35 (s, 6H, 
(H17, H17’)), 2.23 (dd, J = 18.4, 6.4 Hz, 2H, (H10, H10’)), 1.93 (ddd, J = 12.4, 12.4, 
4.8 Hz, 2H, (H15, H15’)), 1.81 (dd, J = 12.4, 2.0 Hz, 2H, (H15, H15’)) 
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13C NMR, (CDCl3, 100 MHz) δ, 146.43 (C4, C4’), 141.25 (C3, C3’), 137.25 (C20, 
C20’), 130.13 (C7, C7’), 129.51 (C12, C12’), 127.54 (C8, C8’), 127.18 (C22), 126.18 
(C21, C21’), 126.16 (C23), 125.26 (C11, C11’), 117.87 (C1, C1’), 112.62 (C2, C2’), 
88.41 (C5, C5’), 71.92 (C6, C6’), 69.58 (C19, C19’), 58.06 (C9, C9’) 55.53 (C18, 
C18’), 45.53 (C16, C16’), 42.08 (C13, C13’), 41.76 (C17, C17’), 39.42 (C14, C14’), 
34.34 (C15, C15’), 19.66 (C10, C10’) 
IR: υ (cm-1), 2928, 1500 (C-C, Ar), 1441, 1277, 1254, 1156, 1120, 1100, 1084, 1052, 
1019  
HRMS (EI, 70eV) Calculated for [M+H]+, C44H49N2O6+, requires: 701.3591, found 
701.3589, m.p. = 99-101 °C, [α]D = -172° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
6.3 Halogenated Codeine Derivatives 
 
Representative Procedure 3 
A flask was charged with the appropriate opioid, appropriate halogen succinimide, and 
0.1M TFA aqueous solution. Contents stirred at corresponding temperature for 24 h. 
The pH of the reaction solution was adjusted to pH 8 via the addition of 10% NaOH 
solution and the aqueous phase was extracted with DCM. The organic phase was dried 
over anhydrous Na2SO4, filtered and concentrated in vacuo before purification.  
 
(1S,5R,13R,14S,17R)-8-bromo-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-ol, [1-
bromocodeine], (75); 
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Following representative procedure 3 and stirring at RT, codeine (2) (1.244 g, 4.16 
mmol), NBS (0.815 g, 4.58 mmol, 1.1 Eq) and TFA (150 mL) gave, after purification 
by column chromatography (SiO2 10% MeOH/DCM, 1% NH4OH) followed by 
recrystallisation in CHCl3:Hexane, 75 as an off white solid in 83% yield (1.302 g, 3.45 
mmol).  
 
1H NMR data in agreement with literature 97 
1H NMR, (CDCl3, 400 MHz) δ, 6.79 (s, 1H, (H2)), 5.66-5.64 (m, 1H, (H7)), 5.23-5.20 
(m, 1H, (H8)), 4.83 (dd, J = 6.4, 0.8 Hz, 1H, (H5)), 4.13-4.10 (m, 1H, (H6)), 3.75 (s, 
3H, (H18)), 3.36-3.34 (m, 1H, (H9)), 2.84 (d, J = 19.2 Hz, 1H, (H10)), 2.61-2.60 (m, 
1H, (H14)), 2.54 (dd, J = 12.4, 4.0 Hz, 1H, (H16)), 2.39 (s, 3H, (H17)), 2.27 (ddd, J = 
12.2, 12.2, 3.6 Hz, 1H, (H16)), 2.11 (dd, J = 19.2, 6.0 Hz, 1H, (H10)), 2.00 (ddd, J = 
12.4, 12.4, 4.8 Hz, 1H, (H15)), 1.80 (dd, J = 12.4, 2.0 Hz, 1H, (H10)) 
13C NMR, (CDCl3, 100 MHz) δ, 145.85 (C4), 143.06 (C3), 133.62 (C12), 132.39 (C7), 
128.10 (C8), 126.60 (C11), 115.64 (C1), 112.95 (C2), 91.66 (C5), 66.35 (C6), 58.78 
(C9), 56.39 (C18), 46.19 (C16), 43.44 (C17), 43.11 (C13), 40.52 (C14), 35.71 (C15), 
22.02 (C10) 
 
(1S,5R,13R,14S,17R)-8-iodo-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-ol, [1-
iodocodeine], (142); 
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Following representative procedure 3 and stirring at RT, codeine (2) (1.238 g, 4.14 
mmol), NIS (1.024 g, 4.55 mmol, 1.1 Eq) and TFA (150 mL) gave, after purification by 
column chromatography (SiO2 10% MeOH/DCM, 1% NH4OH) followed by 
recrystallisation in CHCl3:Hexane, 142 as an orange solid in 89% yield (1.563 g, 3.68 
mmol). 
 
1H NMR data in agreement with literature 98, 99 
1H NMR, (CDCl3, 400 MHz) δ, 7.02 (s, 1H, (H2)), 5.71-5.68 (m, 1H, (H7)), 5.22-5.18 
(m, 1H, (H8)), 4.86 (d, J = 6.4 Hz, 1H, (H5)), 4.16-4.12 (m, 1H, (H6)), 3.77 (s, 3H, 
(H18)), 3.55-3.53 (m, 1H, (H9)), 2.86 (s, 1H, (H14)), 2.78-2.73 (m, 2H, (H10, H16)), 
2.52 (s, 3H, (H17)), 2.40 (ddd, J = 12.4, 12.4, 3.6 Hz, 1H, (H16)), 2.24-2.14 (m, 2H, 
(H10, H15)), 1.85 (d, J = 11.6 Hz, 1H, (H15)) 
13C NMR, (CDCl3, 100 MHz) δ, 146.93 (C4), 143.54 (C3), 134.00 (C12), 131.79 (C7), 
129.42 (C8), 127.43 (C11), 121.84 (C1), 91.28 (C2), 87.79 (C5), 66.23 (C6), 59.72 
(C9), 56.42 (C18), 46.42 (C16), 43.36 (C17), 42.99 (C13), 40.04 (C14), 35.19 (C15), 
26.78 (C10) 
 
(1S,5R,13R,14S,17R)-8-chloro-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-ol, [1-
chlorocodeine], (76); 
 
 
 
Following representative procedure 3 and stirring at 90°C, codeine (2) (0.585 g, 1.96 
mmol), NCS (0.540 g, 4.04 mmol, 2.1 Eq) and TFA (40 mL) gave, after purification by 
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column chromatography (SiO2 10% MeOH/DCM, 1% NH4OH) followed by 
recrystallisation in CHCl3:Hexane, 76 as an off white solid in 62% yield (0.405 g, 1.22 
mmol). 
 
1H NMR data in agreement with literature 100 
1H NMR, (CDCl3, 400 MHz) δ, 6.63 (s, 1H (H2)), 5.67-5.65 (m, 1H, (H7)), 5.22-5.19 
(m, 1H, (H8)), 4.85 (dd, J = 6.8, 1.2 Hz, 1H, (H5)), 4.14-4.10 (m, 1H, (H6)), 3.76 (s, 
3H, (H18)), 3.43-3.41 (m, 1H, (H9)), 2.90 (d, J = 19.2 Hz, 1H, (H10)), 2.72 (s, 1H, 
(H14)), 2.61 (dd, J = 12.8, 4.4 Hz, 1H, (H16)), 2.43 (s, 3H, (H17)), 2.34 (ddd, J = 12.8, 
12.8, 3.6 Hz 1H, (H16)), 2.22 (dd, J = 19.2 Hz, 6.4 Hz, 1H, (H10)), 2.08 (ddd, J = 12.8, 
12.8, 5.6 Hz 1H, (H15)), 1.82 (dd, J = 12.8 Hz, 2.0 Hz, 1H, (H15)) 
13C NMR, (CDCl3, 100 MHz) δ, 145.28 (C4), 142.88 (C3), 133.80 (C12), 131.99 (C7), 
127.62 (C8), 124.20 (C11), 123.91 (C1), 113.03 (C2), 91.59 (C5), 66.24 (C6), 58.71 
(C9), 56.42 (C18), 46.31 (C16), 43.11 (C17), 42.91 (C13), 40.11 (C14), 35.31 (C15), 
19.82 (C10) 
 
1,4-bis(1S,5R,13R,14S,17R)-8-bromo-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl benzene-
1,4-dicarboxylate, (143); 
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Following representative procedure 1, 1-bromocodeine (75) (0.200 g, 0.53 mmol) 
DMAP (0.071 g, 0.58 mmol, 1.1 Eq), DCM (8 mL) and terephthaloyl dichloride, (0.054 
g, 0.27 mmol, 0.5 Eq) gave, after purification by column chromatography (SiO2 10% 
MeOH/DCM, 1% NH4OH) followed by recrystallisation in acetone, 143 as a white 
solid in 72% yield (0.172 g, 0.19 mmol). 
 
1H NMR, (CDCl3, 400 MHz) δ, 8.05 (s, 4H, (H21, H21’))  6.80 (s, 2H, (H2, H2’)), 
5.76-5.73 (m, 2H, (H7, H7’)), 5.47-5.43 (m, 2H, (H8, H8’)), 5.40-5.37 (m, 2H, (H6, 
H6’)), 5.17 (d, J = 6.8 Hz, 2H, (H5, H5’)), 3.62 (s, 6H, (H18, H18’)) 3.48-3.47 (m, 2H, 
(H9, H9’)), 2.90-2.85 (m, 4H, (H10, H10’, H14, H14’)), 2.65 (dd, J = 12.0, 3.6 Hz, 2H, 
(H16, H16’)), 2.46 (s, 6H, (H17, H17’)), 2.32 (ddd, J = 12.0, 12.0, 3.2 Hz, 2H, (H16, 
H16’)), 2.23 (dd, J = 19.2, 6.0 Hz, 2H, (H10, H10’)) 2.11 (ddd, J = 12.4, 12.4, 4.8 Hz, 
2H, (H15, H15’)), 1.85 (d, J = 11.2 Hz, 2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ, 164.18 (C19, C19’), 145.10 (C4, C4’), 142.19 (C3, 
C3’), 132.78 (C20, C20’), 130.92 (C12, C12’), 128.73 (C21, C21’), 128.29 (C8, C8), 
127.60 (C7, C7’), 125.06 (C11, C11’), 116.04 (C2, C2’), 111.65 (C1, C1’) 86.88 (C5, 
C5’), 67.40 (C6, C6’), 58.12 (C9, C9’), 55.73 (C18, C18’), 45.52 (C16, C16’), 41.89 
(C17, C17’), 41.86 (C13, C13’) 39.03 (C14, C14’), 33.97 (C15, C15’), 20.92 (C10, 
C10’) 
IR: υ (cm-1), 2912, 1717 (C=O), 1488 (C-C, Ar), 1437, 1280, 1255, 1201, 1175, 1159, 
1123, 1107, 1054, 1019 
HRMS (EI, 70eV) Calculated for [M+H]+, C44H43Br79Br79N2O8+, requires: 885.1386, 
found 885.1427. Calculated for [M+H]+, C44H43Br79Br81N2O8+, requires: 887.1366, 
found 887.1541, m.p. = 233-235 °C, [α]D = -213° c = (0.10, CHCl3, 589 nm, 20 °C) 
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1,3-bis(1S,5R,13R,14S,17R)-8-bromo-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl benzene-
1,3-dicarboxylate, (144);  
 
 
 
Following representative procedure 1, 1-bromocodeine (75) (0.247 g, 0.65 mmol), 
DMAP (0.089 g, 0.72 mmol, 1.1 Eq), DCM (8 mL) and isophthaloyl dichloride (0.067 
g, 0.33 mmol, 0.5 Eq) gave, after purification by column chromatography (SiO2 10% 
MeOH/DCM, 1% NH4OH) followed by recrystallisation in CHCl3:Hexane, 144 as a 
white solid in 75% yield (0.218 g, 0.25 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ, 8.62 (s, 1H, (H23)), 8.21 (dd, J = 7.6, 2.0 Hz, 2H, 
(H21, H21’)), 7.46 (t, J = 7.6 Hz, 1H, (H22)), 6.78 (s, 2H, (H2)), 5.75-5.73 (m, 2H, 
(H7, H7’)), 5.47-5.43 (m, 2H, (H8, H8’)) 5.39-5.35 (m, 2H, (H6, H6’)), 5.16 (d, J = 6.0 
Hz, 2H, (H5, H5’)), 3.59 (s, 6H, (H18, H18’)) 3.41-3.39 (m, 2H, (H9, H9’)), 2.87 (d, J 
= 18.8 Hz, 2H, (H10, H10’)), 2.77-2.76 (m, 2H, (H14, H14)), 2.56 (dd, J = 12.0, 4.8 Hz 
2H, (H16, H16’)), 2.41 (s, 6H, (H17, H17’)), 2.26 (ddd, J = 12.0, 12.0, 3.6 Hz, 2H, 
(H16, H16’)), 2.14 (dd, J = 18.8, 6.4 Hz, 2H, (H10, H10’)), 2.03 (ddd, J = 12.4, 12.4, 
4.8 Hz, 2H, (H15, H15’)), 1.82 (d, J = 12.4 Hz, 2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ, 164.09 (C19, C19’), 145.16 (C4, C4’), 142.14 (C3, 
C3’), 133.30 (C21, C21’), 131.03 (C12, C12’), 130.24 (C23), 129.28 (C20, C20’), 
128.40 (C8, C8’), 127.62 (C7, C7’), 127.38 (C22), 125.28 (C11, C11’), 116.03 (C2, 
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C2’), 111.57 (C1, C1’), 86.96 (C5, C5’), 67.49 (C6, C6’), 58.05 (C9, C9’), 55.74 (C18, 
C18’), 45.47 (C16, C16’), 42.00 (C17, C17’), 41.98 (C13, C13’), 39.25 (C14, C14’), 
34.17 (C15, C15’), 20.85 (C10, C10’) 
IR: υ (cm-1), 2909, 1723 (C=O), 1487 (C-C, Ar), 1435, 1281, 1252, 1230, 1201, 1175, 
1158, 1115, 1080, 1051, 1017  
HRMS (EI, 70eV) Calculated for [M+H]+, C44H43Br79Br79N2O8+, requires: 885.1386, 
found 885.1407. Calculated for [M+H]+, C44H43Br79Br81N2O8+, requires: 887.1366, 
found 887.1531, m.p. = 227-229 °C, [α]D = -168° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
1,2-bis(1S,5R,13R,14S,17R)-8-bromo-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl benzene-
1,2-dicarboxylate, (145); 
 
 
 
Following representative procedure 1, 1-bromocodeine (75) (0.200 g, 0.53 mmol), 
DMAP (0.071 g, 0.58 mmol, 1.1 Eq), DCM (8 mL) and phthaloyl dichloride (0.038 
mL, 0.27 mmol, 0.5 Eq) gave, after purification by column chromatography (SiO2 10% 
MeOH/DCM, 1% NH4OH) followed by recrystallisation in CHCl3:Hexane, 145 as a 
white solid in 71% yield (0.170 g, 0.19 mmol).  
 
1H NMR, (CDCl3, 600 MHz) δ, 7.85-7.83 (m, 2H, (H21, H21’)), 7.50-7.48 (m, 2H, 
(H22, H22’)), 6.79 (s, 2H, (H2, H2’)), 5.72-5.71 (m, 2H, (H7, H7’)), 5.36-5.33 (m, 4H, 
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(H8, H8’, H6, H6’)), 5.17 (d, J = 6.6 Hz, 2H, (H5, H5’)), 3.68 (s, 6H, (H18, H18’)) 
3.49 (s, 2H, (H9, H9’)), 2.91 (s, 2H, (H14, H14’)), 2.86 (d, J = 19.8 Hz, 2H, (H10, 
H10’)), 2.68 (s, 2H, (H16, H16’)), 2.49 (s, 6H, (H17, H17’)), 2.38-2.34 (m, 2H, (H16, 
H16’)), 2.24-2.19 (m, 4H, (H10, H10’, H15’,H15’)), 1.85 (d, J = 12.6 Hz, 2H, (H15, 
H15’)) 
13C NMR, (CDCl3, 150 MHz) δ, 166.72 (C19, C19’), 146.38 (C4, C4’), 143.32 (C3, 
C3’), 131.79 (C20, 20’), 131.75 (C12, C12’), 131.12 (C22, C22’), 129.51 (C21, C21’), 
129.19 (C7, C7’), 129.14 (C8, C8’), 128.47 (C11, C11’), 117.10 (C2, C2’), 112.58 (C1, 
C1’), 88.12 (C5, C5’), 68.91 (C6, C6’), 59.33 (C9, C9’), 56.76 (C18, C18’), 46.63 
(C16, C16’), 42.87 (C13, C13’), 42.75 (C17, C17’), 39.60 (C14, C14’), 34.69 (C15, 
C15’), 22.19 (C10, C10’) 
IR: υ (cm-1), 2898, 1718 (C=O), 1489 (C-C, Ar), 1438, 1268, 1256, 1201, 1177, 1124, 
1101, 1083, 1054, 1032  
HRMS (EI, 70eV) Calculated for [M+H]+, C44H43Br79Br79N2O8+, requires: 885.1386, 
found 885.1367. Calculated for [M+H]+, C44H43Br79Br81N2O8+, requires: 887.1366, 
found 887.1376, m.p. = 240-242 °C, [α]D = -219° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
(1S,5R,13R,14S,17R)-8-bromo-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl 2-(2-
{[(1S,5R,13R,14S,17R)-8-bromo-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl]oxy}-2-
oxoethoxy)acetate, (146); 
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Following representative procedure 1, 1-bromocodeine (75) (0.259 g, 0.69 mmol), 
DMAP (0.093 g, 0.76 mmol, 1.1 Eq), DCM (8 mL) and diglycolyl dichloride (0.042 
mL, 0.35 mmol, 0.5 Eq) gave, after purification by column chromatography (SiO2 10% 
MeOH/DCM, 1% NH4OH) followed by recrystallisation in CHCl3:Hexane, 146 as a 
white solid in 39% yield (0.114 g, 0.13 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ 6.79 (s, 2H, (H2, H2’)), 5.60-5.57 (m, 2H, (H7, H7’)), 
5.40-5.36 (m, 2H, (H8, H8’)), 5.21-5.18 (m, 2H, (H6, H6’)), 5.05 (dd, J = 6.8, 0.8 Hz, 
2H, (H5, H5’)), 4.34 (d, J = 5.2 Hz, 4H, (H20, H20’)), 3.73 (s, 6H, (H18, H18’)) 3.37 
(s, 2H, (H9, H9’)), 2.84 (d, J = 19.2 Hz, 2H, (H10, H10’)), 2.73-2.72 (m, 2H, (H14, 
H14’)), 2.55 (d, J = 9.6 Hz, 2H, (H16, H16’)), 2.40 (s, 6H, (H17, H17’)), 2.25 (ddd, J = 
12.4, 12.4, 3.2 Hz, 2H, (H16, H16’)), 2.11 (dd, J = 19.2, 6.0 Hz 2H, (H10, H10’)), 2.00 
(ddd, J = 12.4, 12.4, 4.0 Hz, 2H, (H15, H15’)), 1.79 (dd, J = 12.4, 1.6 Hz, 2H, (H15, 
H15’)) 
13C NMR, (CDCl3, 100 MHz) δ, 169.53 (C19, C19’), 146.06 (C4, C4’), 143.11 (C3, 
C3’), 131.89 (C12, C12’), 129.63 (C8, C8’), 128.17 (C7, C7’), 126.38 (C11, C11’), 
116.41 (C2, C2’), 112.60 (C1, C1’), 87.83 (C5, C5’), 68.28 (C6, C6’), 68.05 (C20, 
C20’), 59.00 (C9, C9’), 56.58 (C18, C18’), 46.44 (C16, C16’), 43.05 (C17, C17’), 
43.03 (C13, C13’) 40.31 (C14, C14’), 35.24 (C15, C15’), 21.82 (C10, C10’) 
IR: υ (cm-1), 2927, 1753 (C=O), 1735, 1486 (C-C, Ar), 1431, 1273, 1251, 1203, 1157, 
1143, 1109, 1051, 1030, 1019  
HRMS (EI, 70eV) Calculated for [M+H]+, C44H43Br79Br79N2O8+, requires: 853.1335, 
found 853.1331. Calculated for [M+H]+, C44H43Br79Br81N2O8+, requires: 855.1315, 
found 855.1323, m.p. = 210-212 °C, [α]D = -199° c = (0.10, CHCl3, 589 nm, 20 °C) 
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(1S,5R,13R,14S,17R)-8-bromo-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl benzoate, 
(147); 
 
 
Following representative procedure 1, 1-bromocodeine (75) (0.181 g, 0.48 mmol), 
DMAP (0.065 g, 0.53 mmol, 1.1 Eq), DCM (8 mL) and benzoyl chloride (0.056 mL, 
0.48 mmol, 1 Eq) gave, after purification by column chromatography (SiO2 10% 
MeOH/DCM, 1% NH4OH) followed by recrystallisation in CHCl3:Hexane, 147 as a 
white solid in 89% yield (0.205 g, 0.43 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ 7.98 (dd, J = 8.0, 0.8 Hz, 2H, (H21)), 7.50 (t, J = 8.0 
Hz, 1H, (H23)), 7.36 (t, J = 8.0 Hz, 2H, (H22)) 6.80 (s, 1H, (H2)), 5.77-5.73 (m, 1H, 
(H7)), 5.43-5.39 (m, 1H, (H8)), 5.37-5.34 (m, 1H, (H6)), 5.18 (d, J = 6.4 Hz, 1H, (H5)), 
3.60 (s, 4H, (H18, H9)), 2.95 (s, 1H, (H14)), 2.88 (d, J = 19.2 Hz, 1H, (H10)), 2.79 (dd, 
J = 12.0, 4.0 Hz, 1H, (H16)), 2.53 (s, 3H, (H17)), 2.40 (ddd, J = 12.0, 12.0, 4.0 Hz, 1H, 
(H16)), 2.30 (dd, J = 19.2, 6.0 Hz, 1H, (H10)), 2.16 (ddd, J = 12.8, 12.8, 4.8 Hz, 1H, 
(H15)), 1.86 (dd, J = 12.8, 1.6 Hz, 1H, (H15)) 
13C NMR, (CDCl3, 100 MHz) δ, 165.92 (C19), 146.25 (C4), 143.41 (C3), 133.21 
(C23), 131.55 (C12), 129.91 (C21), 129.70 (C20), 129.46 (C7), 128.32 (C22), 128.19 
(C8), 125.01 (C11), 117.37 (C2), 112.66 (C1), 87.91 (C5), 67.83 (C6), 59.30 (C9), 
56.79 (C18), 46.63 (C16), 42.52 (C13), 42.45 (C17), 39.25 (C14), 34.26 (C15), 22.28 
(C10) 
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IR: υ (cm-1), 2929, 1714 (C=O), 1487 (C-C, Ar), 1436, 1280, 1264, 1201, 1173, 1158, 
1117, 1107, 1058, 1028 
HRMS (EI, 70eV) Calculated for [M+H]+, C25H25Br79NO4+, requires: 482.0967, found 
482.0967, m.p. = 161-163 °C, [α]D = -228° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
2,6-bis(1S,5R,13R,14S,17R)-8-bromo-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl pyridine-
2,6-dicarboxylate, (148); 
 
 
 
Following representative procedure 1, 1-bromocodeine (75) (0.458 g, 1.21 mmol), 
DMAP (0.162 g, 1.33 mmol, 1.1 Eq), DCM (10 mL) and 2,6-pyridinedicarbonyl 
dichloride (0.123 g, 0.61 mmol, 0.5 Eq) gave, after purification by column 
chromatography (SiO2 10% MeOH/DCM, 1% NH4OH) followed by recrystallisation in 
CHCl3:Hexane, 148 as a white solid in 51% yield (0.274 g, 0.31 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ, 8.23 (d, J = 8.0 Hz, 2H, (H21, H21’)), 7.93 (t, J = 8.0 
Hz, 1H, (H22), 6.79 (s, 2H, (H2, H2’)) 5.82-5.78 (m, 2H, (H7, H7’)), 5.44-5.41 (m, 4H, 
(H8, H8’, H6, H6’)), 5.22 (d, J = 6.4 Hz, 2H, (H5, H5’)), 3.63 (s, 6H, (H18, H18’)) 
3.51-3.50 (m, 2H, (H9, H9’)), 2.90-2.85 (m, 4H, (H10, H10’, H14, H14’)), 2.68 (dd, J 
= 12.0, 4.0 Hz, 2H, (H16, H16’)), 2.48 (s, 6H, (H17, H17’)), 2.35 (ddd, J = 12.0, 12.0, 
3.2 Hz, 2H, (H16, H16’)), 2.23 (dd, J = 19.2, 6.4 Hz, (H10, H10’)) 2.15 (ddd, J = 12.4, 
12.4, 3.2 Hz, 2H, (H15, H15’)), 1.88 (dd, J = 12.4, 1.6 Hz, 2H, (H15, H15’)) 
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13C NMR, (CDCl3, 100 MHz) δ, 163.59 (C19, C19’), 148.34 (C20, C20’), 146.26 (C4, 
C4’), 143.28 (C3, C3’), 137.98 (C22), 131.77 (C12, C12’), 128.94 (C8, C8’), 128.70 
(C7, C7’), 128.31 (C21, C21’), 125.72 (C11, C11’), 117.33 (C2, C2’), 112.71 (C1, 
C1’), 87.81 (C5, C5’), 69.28 (C6, C6’), 59.24 (C9, C9’), 56.91 (C18, C18’), 46.58 
(C16, C16’), 42.88 (C13, C13’), 42.77 (C17, C17’), 39.72 (C14, C14’), 34.72 (C15, 
C15’), 22.13 (C10, C10’) 
IR: υ (cm-1), 2910, 1746 (C=O), 1721, 1486 (C-C, Ar), 1435, 1281, 1235, 1202, 1174, 
1143, 1114, 1051, 1017  
HRMS (EI, 70eV) Calculated for [M+H]+, C44H43Br79Br79N2O8+, requires: 886.1339, 
found 886.1354. Calculated for [M+H]+, C44H43Br79Br81N2O8+, requires: 888.1318, 
found 888.1494, m.p. = 182-183 °C, [α]D = -196° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
1,4-bis(1S,5R,13R,14S,17R)-8-iodo-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl benzene-
1,4-dicarboxylate, (149); 
  
 
 
Following representative procedure 1, 1-iodocodeine (142) (0.438 g, 1.03 mmol), 
DMAP (0.138 g, 1.13 mmol, 1.1 Eq), DCM (8 mL) and terephthaloyl dichloride, (0.106 
g, 0.52 mmol, 0.5 Eq) gave, after purification by column chromatography (SiO2 10% 
MeOH/DCM, 1% NH4OH) followed by recrystallisation in acetone, 149 as an off white 
solid in 76% yield (0.386 g, 0.39 mmol).  
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1H NMR, (CDCl3, 400 MHz) δ, 8.05 (s, 4H, (H21, H21’)) 7.02 (s, 2H, (H2, H2’)), 5.77-
5.73 (m, 2H, (H7, H7’)), 5.46-5.44 (m, 2H, (H8, H8’)), 5.39-5.37 (m, 2H, (H6, H6’)), 
5.16 (d, J = 6.8 Hz, 2H, (H5, H5’)), 3.61 (s, 6H, (H18, H18’)) 3.54-3.52 (m, 2H, (H9, 
H9’)), 2.87 (s, 2H, (H14, H14’)), 2.78 (d, J = 18.8 Hz, 2H, (H10, H10’)), 2.70 (dd, J = 
12.0, 3.6 Hz, 2H, (H16, H16’)), 2.49 (s, 6H, (H17, H17’)), 2.32 (ddd, J = 12.0, 12.0, 3.6 
Hz, 2H, (H16, H16’)), 2.18-2.09 (m, 4H (H10, H10’, H15, H15’)), 1.84 (d, J = 11.6 Hz, 
2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ, 165.18 (C19, C19’), 147.15 (C4, C4’), 143.64 (C3, 
C3’), 133.76 (C20, C20’), 131.47 (C12, C12’), 129.77 (C21, C21’), 129.22 (C11, 
C11’), 128.93 (C7, C7’) 128.89 (C8, C8’), 123.13 (C2, C2’), 87.59 (C5, C5’), 86.49 
(C1, C1’), 68.28 (C6, C6’), 59.77 (C9, C9’), 56.74 (C18, C18’), 46.58 (C16, C16’), 
42.86 (C13, C13’), 42.70 (C17, C17’) 39.65 (C14, C14’), 34.63 (C15, C15’), 26.55 
(C10, C10’) 
IR: υ (cm-1), 2909, 1714 (C=O), 1481 (C-C, Ar), 1436, 1279, 1252, 1200, 1173, 1157, 
1121, 1053, 1019 
HRMS (EI, 70eV) Calculated for [M+H]+, C44H43I2N2O8+, requires: 981.1109, found 
981.1118, m.p. = 222-223 °C, [α]D = -206° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
1,3-bis(1S,5R,13R,14S,17R)-8-iodo-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl benzene-
1,3-dicarboxylate, (150); 
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Following representative procedure 1, 1-iodocodeine (142) (0.449 g, 1.05 mmol), 
DMAP (0.142 g, 1.16 mmol, 1.1 Eq), DCM (8 mL) and isophthaloyl dichloride (0.108 
g, 0.53 mmol, 0.5 Eq) gave, after purification by column chromatography (SiO2 10% 
MeOH/DCM, 1% NH4OH) followed by recrystallisation in CHCl3:Hexane, 150 as an 
off white solid in 79% yield (0.410 g, 0.42 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ, 8.56 (s, 1H, (H23)), 8.17 (dd, J = 8.0, 2.0 Hz, 2H, 
(H21, H21’)), 7.45 (t, J = 8.0 Hz, 1H, (H22)), 7.02 (s, 2H, (H2, H2’)), 5.81-5.77 (m, 
2H, (H7, H7’)), 5.46-5.42 (m, 2H, (H8, H8’)) 5.39-5.36 (m, 2H, (H6, H6’)), 5.19 (d, J = 
6.8 Hz, 2H, (H5, H5’)), 3.78-3.75 (m, 2H, (H9, H9’)) 3.56 (s, 6H, (H18, H18’)), 3.14 
(s, 2H, (H14, H14’)), 2.94 (dd, J = 12.4, 3.6 Hz, 2H, (H16, H16’)), 2.79 (d, J = 19.2 Hz, 
2H, (H10, H10’)), 2.63 (s, 6H, (H17, H17’) ), 2.49 (ddd, J = 12.4, 12.4, 3.6 Hz, 2H, 
(H16, H16’), 2.36-2.27 (m, 4H, (H10, H10’, H15, H15’)), 1.90 (dd, J = 13.6, 2.0 Hz, 
2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ, 164.95 (C19, C19’), 147.18 (C4, C4’), 144.03 (C3, 
C3’), 134.39 (C21, C21’), 131.27 (C23), 130.80 (C12, C12’), 130.11 (C20, C20’), 
129.75 (C7, C7’), 128.48 (C22), 127.59 (C11, C11’), 127.48 (C8, C8’), 123.53 (C2, 
C2’), 87.17 (C5, C5’), 86.43 (C1, C1’), 67.84 (C6, C6’), 60.38 (C9, C9’), 56.73 (C18, 
C18’), 47.01 (C16, C16’), 42.31 (C17, C17’), 42.27 (C13, C13’), 38.63 (C14, C14’), 
33.63 (C15, C15’), 26.98 (C10, C10’) 
IR: υ (cm-1), 2929, 1717 (C=O), 1481 (C-C, Ar), 1431, 1278, 1232, 1200, 1173, 1157, 
1115, 1096, 1050, 1017 
HRMS (EI, 70eV) Calculated for [M+H]+, C44H43I2N2O8+, requires: 981.1109, found 
981.1109, m.p. = 215-216 °C, [α]D = -132° c = (0.10, CHCl3, 589 nm, 20 °C) 
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(1S,5R,13R,14S,17R)-8-bromo-14-{[4-({[(1S,5R,13R,14S,17R)-8-bromo-10-
methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-
7,9,11(18),15-tetraen-14-yl]oxy}methyl)phenyl]methoxy}-10-methoxy-4-methyl-12-
oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraene, (151): 
 
 
 
Following representative procedure 2, 1-bromocodeine (75) (0.400 g, 1.06 mmol), 
KOH (0.714 g, 12.72 mmol, 12 Eq), THF (10 mL), KI (0.035 g, 0.21 mmol, 0.2 Eq) 
and 1,4-bis(bromomethyl)benzene (0.140 g, 0.53 mmol, 0.5 Eq) gave, after purification 
by column chromatography (SiO2 10% MeOH/DCM, 1% NH4OH), 151 as an off white 
solid in 53% yield (0.239 g, 0.28 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ, 7.33 (s, 4H, (H21, H21’))  6.76 (s, 2H, (H2, H2’)), 
5.72-5.68 (m, 2H, (H7, H7’)), 5.25-5.22 (m, 2H, (H8, H8’)), 4.93 (dd, J = 6.0, 1.2 Hz, 
2H, (H5, H5’)), 4.76 (d, J = 12.0 Hz, 2H, (H19, H19’)), 4.57 (d, J = 12.0 Hz, 2H, (H19, 
H19’)), 3.90-3.87 (m, 2H, (H6, H6’)), 3.76 (s, 6H, (H18, H18’)), 3.36-3.34 (m, 2H, 
(H9, H9’)), 2.82 (d, J = 18.8 Hz, 2H, (H10, H10’)), 2.59-2.58 (m, 2H, (H14, H14’) 2.38 
(dd, J = 12.0, 4.0 Hz, 2H, (H16, H16’)), 2.39 (s, 6H, (H17, H17’)), 2.29 (ddd, J = 12.0, 
12.0, 3.6 Hz 2H, (H16, H16’)), 2.13 (dd, J = 18.8, 6.4 Hz, 2H, (H10, H10’)), 1.96 (ddd, 
J = 12.4, 12.4, 4.8 Hz, 2H, (H15, H15’)), 1.81 (dd, J = 12.4, 1.6 Hz, 2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ, 146.98 (C4, C4’), 143.11 (C3, C3’), 137.56 (C20, 
C20’), 132.11 (C12, C12’), 131.22 (C7, C7’), 128.37 (C8, C8’) 128.00 (C21, C21’), 
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126.15 (C11, C11’), 116.20 (C2, C2’) 112.12 (C1, C1’), 88.87 (C5, C5’), 72.76 (C6, 
C6’), 70.57 (C19, C19’), 58.93 (C9, C9’) 56.58 (C18, C18’), 46.33 (C16, C16’), 43.73 
(C13, C13’), 43.04 (C17, C17’), 40.60 (C14, C14’), 35.67 (C15, C15’), 22.11 (C10, 
C10’) 
IR: υ (cm-1), 2907, 1487 (C-C, Ar), 1435, 1280, 1254, 1202, 1175, 1156, 1120, 1085, 
1052, 1018  
HRMS (EI, 70eV) Calculated for [M+H]+, C44H47Br79Br79N2O6+, requires: 857.1801, 
found 857.1800. Calculated for [M+H]+, C44H47Br79Br81N2O6+, requires: 859.1780, 
found 859.1800, m.p. = 131-133 °C, [α]D = -220° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
(1S,5R,13R,14S,17R)-8-bromo-14-{[3-({[(1S,5R,13R,14S,17R)-8-bromo-10-
methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-
7,9,11(18),15-tetraen-14-yl]oxy}methyl)phenyl]methoxy}-10-methoxy-4-methyl-12-
oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraene, (152);  
 
 
 
Following representative procedure 2, 1-bromocodeine (75) (0.400 g, 1.06 mmol), 
KOH (0.714 g, 12.72 mmol, 12 Eq), THF (10 mL), KI (0.035 g, 0.21 mmol, 0.2 Eq) 
and 1,4-bis(bromomethyl)benzene (0.140 g, 0.53 mmol, 0.5 Eq) gave, after purification 
by column chromatography (SiO2 10% MeOH/DCM, 1% NH4OH), 152 as in an off 
white solid in 59% yield (0.270 g, 0.31 mmol). 
 
1H NMR, (CDCl3, 400 MHz) δ, 7.36 (s, 1H, (H23)), 7.29-7.25 (m, 3H, (H22, H21, 
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H21’)), 6.76 (s, 2H, (H2, H2’)), 5.72-5.68 (m, 2H, (H7, H7’)), 5.25-5.22 (m, 2H, (H8, 
H8’)), 4.93 (dd, J = 6.0, 0.8 Hz, 2H, (H5, H5’)), 4.77 (d, J = 12.0 Hz, 2H (H19, H19’)), 
4.58 (d, J = 12.0 Hz, 2H (H19, H19’)), 3.91-3.87 (m, 2H, (H6, H6’)), 3.74 (s, 6H, (H18, 
H18’)) 3.34-3.32 (m, 2H, (H9, H9’)), 2.82 (d, J = 19.2 Hz, 2H, (H10, H10’)), 2.58-2.55 
(m, 2H, (H14, H14’)), 2.51 (dd, J = 12.0, 4.0 Hz, 2H, (H16, H16’)), 2.37 (s, 6H, (H17, 
H17’)), 2.28 (ddd, J = 12.0, 12.0, 3.6 Hz, 2H (H16, H16’)), 2.11 (dd, J = 19.2, 6.0 Hz, 
2H, (H10, H10’)), 1.94 (ddd, J = 12.8, 12.8, 5.2 Hz, 2H, (H15, H15’)), 1.80 (dd, J = 
12.8, 1.2 Hz, 2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ, 146.99 (C4, C4’), 143.09 (C3, C3’), 138.24 (C20, 
C20’), 132.15 (C12, C12’), 131.17 (C7, C7’), 128.57 (C22), 128.47 (C8, C8’), 127.24 
(C21, C21’), 127.21 (C23), 126.25 (C21, C21’), 116.22 (C2, C2’) 112.11 (C1, C1’), 
89.88 (C5, C5’), 72.92 (C6, C6’), 70.69 (C19, C19’), 58.90 (C9, C9’) 56.59 (C18, 
C18’), 46.31 (C16, C16’), 43.77 (C13, C13’), 43.08 (C17, C17’), 40.69 (C14, C14’), 
35.75 (C15, C15’), 22.07 (C10, C10’) 
IR: υ (cm-1), 2930, 1487 (C-C, Ar), 1435, 1280, 1254, 1202, 1175, 1156, 1120, 1083, 
1052, 1017 
HRMS (EI, 70eV) Calculated for [M+H]+, C44H47Br79Br79N2O6+, requires: 857.1801, 
found 857.1808. Calculated for [M+H]+, C44H47Br79Br81N2O6+, requires: 859.1780, 
found 859.1792, m.p. = 110-111 °C, [α]D = -163° c = (0.10, CHCl3, 589 nm, 20 °C) 
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(1S,5R,13R,14S,17R)-8-iodo-14-{[4-({[(1S,5R,13R,14S,17R)-8-iodo-10-methoxy-4-
methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-
14-yl]oxy}methyl)phenyl]methoxy}-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraene, (153); 
 
 
 
Following representative procedure 2, 1-iodocodeine (142) (0.601 g, 1.41 mmol), KOH 
(0.949 g, 16.92 mmol, 12 Eq), THF (10 mL), KI (0.046 g, 0.28 mmol, 0.2 Eq) and 1,4-
bis(bromomethyl)benzene (0.187 g, 0.71 mmol, 0.5 Eq) gave, after purification by 
column chromatography (SiO2 10% MeOH/DCM, 1% NH4OH), 153 as an off white 
solid in 60% yield (0.403 g, 0.42 mmol).  
  
1H NMR, (CDCl3, 400 MHz) δ, 7.33 (s, 4H, (H21, H21’))  6.98 (s, 2H, (H2, H2’)), 
5.71-5.69 (m, 2H, (H7, H7’)), 5.25-5.21 (m, 2H, (H8, H8’)), 4.91 (dd, J = 6.0, 0.8 Hz, 
2H, (H5, H5’)), 4.75 (d, J = 12.0 Hz, 2H, (H19, H19’)), 4.57 (d, J = 12.0 Hz, 2H, (H19, 
H19’)), 3.91-3.87 (m, 2H, (H6, H6’)), 3.75 (s, 6H, (H18, H18’)), 3.36-3.34 (m, 2H, 
(H9, H9’)), 2.72 (d, J = 18.8 Hz, 2H, (H10, H10’)), 2.58-2.52 (m, 4H, (H14, H14’, 
H16, H16’)), 2.39 (s, 6H, (H17, H17’)), 2.27 (ddd, J = 12.4, 12.4, 3.6 Hz 2H, (H16, 
H16’)), 2.04 (dd, J = 18.8, 6.4 Hz, 2H, (H10, H10’)), 1.96 (ddd, J = 12.4, 12.4, 4.8 Hz, 
2H, (H15, H15’)), 1.79 (dd, J = 12.4, 1.6 Hz, 2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ, 148.02 (C4, C4’), 143.45 (C3, C3’), 137.55 (C20, 
C20’), 131.86 (C12, C12’), 131.29 (C7, C7’), 129.71 (C11, C11’) 128.31 (C8, C8’), 
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128.00 (C21, C21’) 122.21 (C2, C2’) 89.70 (C5, C5’), 85.86 (C1, C1’), 72.73 (C6, 
C6’), 70.59 (C19, C19’), 59.55 (C9, C9’) 56.60 (C18, C18’), 46.35 (C16, C16’), 43.88 
(C13, C13’), 43.04 (C17, C17’), 40.59 (C14, C14’), 35.62 (C15, C15’), 26.62 (C10, 
C10’) 
IR: υ (cm-1), 2930, 1481 (C-C, Ar), 1433, 1279, 1252, 1201, 1175, 1157, 1120, 1086, 
1051, 1018 
HRMS (EI, 70eV) Calculated for [M+H]+, C44H47I2N2O6+, requires: 953.1523, found 
953.1536, m.p. = 140-141 °C, [α]D = -210° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
(13R,14S)-8-iodo-14-{[3-({[(1R,5S,13S,14R)-8-iodo-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-
yl]oxy}methyl)phenyl]methoxy}-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene, (154);  
 
 
 
Following representative procedure 2, 1-iodocodeine (142) (0.731 g, 1.72 mmol), KOH 
(1.158 g, 20.64 mmol, 12 Eq), THF (10 mL), KI (0.056 g, 0.34 mmol, 0.2 Eq) and 1,3-
bis(bromomethyl)benzene (0.227 g, 0.86 mmol, 0.5 Eq) gave, after purification by 
column chromatography (SiO2 10% MeOH/DCM, 1% NH4OH), 154 as an off white 
solid in 45% yield (0.369 g, 0.39 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ, 7.36 (s, 1H, (H23)), 7.30-7.28 (m, 3H, (H22, H21, 
H21’)), 6.98 (s, 2H, (H2, H2’)), 5.74-5.70 (m, 2H, (H7, H7’)), 5.25-5.21 (m, 2H, (H8, 
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H8’)), 4.93 (dd, J = 6.4, 0.8 Hz, 2H, (H5, H5’)), 4.77 (d, J = 12.0 Hz, 2H (H19, H19’)), 
4.58 (d, J = 12.0 Hz, 2H (H19, H19’)), 3.91-3.89 (m, 2H, (H6, H6’)), 3.75 (s, 6H, (H18, 
H18’)) 3.44-3.42 (m, 2H, (H9, H9’)), 2.73 (d, J = 18.8 Hz, 2H, (H10, H10’)), 2.68 (s, 
2H, (H14, H14’)), 2.62 (dd, J = 12.0, 4.0 Hz, 2H, (H16, H16’)), 2.45 (s, 6H, (H17, 
H17’)), 2.33 (ddd, J = 12.0, 12.0, 3.6 Hz, 2H (H16, H16’)), 2.13-2.00 (m, 4H, (H10, 
H10’, H15, H15’)), 1.83 (dd, J = 12.8, 1.6 Hz, 2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ, 148.05 (C4, C4’), 143.56 (C3, C3’), 138.18 (C20, 
C20’), 131.65 (C12, C12’), 131.52 (C7, C7’), 129.21 (C11, C11’), 128.61 (C8, C8’), 
127.91 (C22), 127.29 (C21, C21’), 127.23 (C23), 122.40 (C2, C2’) 89.58 (C5, C5’), 
85.82 (C1, C1’), 72.73 (C6, C6’), 70.77 (C19, C19’), 59.71 (C9, C9’) 56.62 (C18, 
C18’), 46.45 (C16, C16’), 43.70 (C13, C13’), 42.88 (C17, C17’), 40.24 (C14, C14’), 
35.29 (C15, C15’), 26.74 (C10, C10’) 
IR: υ (cm-1), 2929, 1481 (C-C, Ar), 1433, 1278, 1253, 1201, 1175, 1156, 1120, 1083, 
1051, 1018 
HRMS (EI, 70eV) Calculated for [M+H]+, C44H47I2N2O6+, requires: 953.1523, found 
953.1539, m.p. = 74-75 °C, [α]D = -170° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
6.4 Palladium Coupled Codeine Derivatives 
 
Representative Procedure 4 
A flask was charged with the appropriate opioid, imidazole, t-butyldimethylsilyl 
chloride and anhydrous DMF and stirred under a nitrogen atmosphere at RT for 20 h. 
The reaction mixture was diluted with DCM, washed with distilled water (3 x 10 mL), 
dried over anhydrous Na2SO4 and concentrated in vacuo before purification. 
 
Representative Procedure 5 
A flask was charged with the appropriate opioid, palladium acetate, phosphine ligand, 
anhydrous DMF, anhydrous NEt3 and appropriate alkene and stirred under a nitrogen 
atmosphere at 100 °C for 24 h. After cooling the mixture was diluted with diethyl ether, 
filtered and concentrated in vacuo before purification. 
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Representative Procedure 6 
A flask was charged with the appropriate TBDMS protected opioid, TBAF (1 M 
solution in THF) and THF and stirred for at RT for 24 h. THF was removed from the 
reaction mixture via rotary evaporation and contents redissolved in DCM. The resulting 
mixture was washed with distilled water (3 x 10 mL), dried over Na2SO4 and 
concentrated in vacuo before purification. 
 
(1S,5R,13R,14S,17R)-14-[(tert-butyldimethylsilyl)oxy]-10-methoxy-4-methyl-12-
oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraene, (160); 
 
 
 
Following representative procedure 4, codeine (2) (0.301 g, 1.01 mmol), imidazole 
(0.082 g, 1.21 mmol, 1.2 Eq), t-butyldimethylsilyl chloride (0.183 g, 1.21 mmol, 1.2 
Eq) and anhydrous DMF (2 mL), gave, after purification by column chromatography 
(SiO2 10% MeOH/DCM) followed by recrystallisation in EtOH, 160 as a white solid in 
87% yield (0.365 g, 0.88 mmol).  
 
1H NMR data in agreement with literature101 
1H NMR, (CDCl3, 400 MHz) δ, 6.60 (d, J = 8.2 Hz, 1H, (H2, H2’)), 6.46 (d, J = 8.2 Hz, 
1H, (H1, H1’)), 5.65-5.62 (m, 1H, (H7)), 5.13-5.09 (m, 1H, (H8)), 4.69 (d, J = 6.4 Hz, 
1H, (H5)), 4.24-4.20 (m, 1H, (H6)), 3.90-3.87 (m, 1H, (H9)), 3.78 (s, 3H, (H18)), 3.37 
(m, 1H, (H14)), 3.16 (dd, J = 12.4, 4.0 Hz, 1H, (H16)), 2.70 (J = 18.8 Hz, 1H, (H10)), 
2.85-2.70 (m, 5H, (H17, H16, H10)), 2.53 (ddd, J = 13.6, 13.6, 4.8 Hz, 1H, (H15)), 
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1.92 (dd, J = 13.6, 2.8 Hz, 1H, (H15), 0.82 (s, 9H, (H21)), 0.05 (s, 3H, (H19)), 0.02 (s, 
3H, (H19)),  
13C NMR, (CDCl3, 100 MHz) δ, 147.76 (C4), 142.98 (C3), 135.94 (C7), 129.18 (C12), 
124.24 (C8), 122.58 (C11), 119.24 (C1), 115.98 (C2), 90.97 (C5), 67.45 (C6), 60.57 
(C9), 57.21 (C18), 47.26 (C16), 41.72 (C13), 41.59 (C17), 37.63 (C14), 32.84 (C15), 
25.81 (C20), 21.92 (C10), 18.29 (C21), -4.59 (C19), -4.86 (C19) 
 
(1S,5R,13R,14S,17R)-8-bromo-14-[(tert-butyldimethylsilyl)oxy]-10-methoxy-4-
methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraene, 
(158); 
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Following representative procedure 4, 1-bromocodeine (75) (0.784 g, 2.07 mmol), 
imidazole (0.169 g, 2.48 mmol, 1.2 Eq), t-butyldimethylsilyl chloride (0.374 g, 2.48 
mmol, 1.2 Eq) and anhydrous DMF (2 mL) gave, after purification by column 
chromatography (SiO2 10% MeOH/DCM) followed by recrystallisation in 
CHCl3:Hexane, 158 as a white solid in 89% yield (0.905 g, 1.84 mmol).  
 
1H and 13C NMR data in agreement with literature74 
1H NMR, (CDCl3, 400 MHz) δ, 6.76 (s, 1H, (H2)), 5.60-5.58 (m, 1H, (H7)), 5.20-5.16 
(m, 1H, (H8)), 4.64 (dd, J = 6.4, 1.2 Hz, 1H, (H5)), 4.20-4.16 (m, 1H, (H6)), 3.77 (s, 
3H, (H18)), 3.33-3.31 (m, 1H, (H9)), 2.82 (J = 18.8 Hz, 1H, (H10)), 2.57 (s, 1H, 
(H14)), 2.51 (dd, J = 12.0, 4.0 Hz, 1H, (H16)), 2.38 (s, 3H, (H17)), 2.27 (ddd, J = 12.4, 
12.4, 3.6 Hz, 1H, (H16)), 2.10 (dd, J = 18.8, 6.4 Hz 1H, (H10)), 1.94 (ddd, J = 12.4, 
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12.4, 5.2 Hz, 1H, (H15)), 1.77 (dd, J = 12.4, 1.6 Hz, 1H, (H15)), 0.85 (s, 9H, (H21), 
0.06 (s, 3H, (H19)), 0.05 (s, 3H, (H19)) 
13C NMR, (CDCl3, 100 MHz) δ, 146.28 (C4), 141.92 (C3), 133.18 (C7), 131.52 (C8), 
126.68 (C12), 125.54 (C11), 116.26 (C1), 110.83 (C2), 91.44 (C5), 67.27 (C6), 57.86 
(C9), 56.07 (C18), 45.27 (C16), 42.73 (C17), 42.11 (C13), 39.72 (C14), 34.85 (C15), 
24.85 (C20), 21.07 (C10), 17.35 (C21), -5.59 (C19), -5.78 (C19) 
 
(1S,5R,13R,14S,17R)-8-iodo-14-[(tert-butyldimethylsilyl)oxy]-10-methoxy-4-
methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraene, 
(159); 
 
 
 
Following representative procedure 4, 1-iodocodeine (142) (0.477 g, 1.12 mmol), 
imidazole (0.091 g, 1.34 mmol, 1.2 Eq), t-butyldimethylsilyl chloride (0.202 g, 1.34 
mmol, 1.2 Eq) and anhydrous DMF (2 mL) gave, after purification by column 
chromatography (SiO2 10% MeOH/DCM) followed by recrystallisation in 
CHCl3:Hexane, 159 as a white solid in 86% yield (0.520 g, 0.96 mmol). 
 
1H NMR data in agreement with literature99 
1H NMR, (CDCl3, 400 MHz) δ, 7.00 (s, 1H, (H2)), 5.64-5.61 (m, 1H, (H7)), 5.16-5.12 
(m, 1H, (H8)), 4.67 (dd, J = 6.4, 0.8 Hz, 1H, (H5)), 4.22-4.18 (m, 1H, (H6)), 3.77 (s, 
3H, (H18)), 3.65-3.63 (m, 1H, (H9)), 2.91-2.86 (m, 2H, (H14, H16)), 2.73 (d, J = 19.2 
Hz, (H10)), 2.60 (s, 3H, (H17)), 2.49 (ddd, J = 12.4, 12.4, 3.6 Hz, 1H, (H16)), 2.30-
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2.18 (m, 2H, (H10, H15)), 1.84 (dd, J = 13.2, 2.0 Hz, 1H, (H15)), 0.84 (s, 9H, (H21)), 
0.06 (s, 3H, (H19)), 0.04 (s, 3H, (H19)) 
13C NMR, (CDCl3, 100 MHz) δ, 148.33 (C4), 143.80 (C3), 135.37 (C7), 131.35 (C8), 
127.82 (C12), 125.67 (C11), 123.94 (C2), 91.58 (C5), 85.48 (C1), 67.66 (C6), 60.22 
(C9), 57.16 (C18), 46.71 (C16), 43.01 (C17), 42.37 (C13), 39.04 (C14), 34.27 (C15), 
27.17 (C20), 25.84 (C10), 18.33 (C21), -4.57 (C19), -4.80 (C19) 
 
Methyl (2E)-3-[(1S,5R,13R,14S,17R)-14-[(tert-butyldimethylsilyl)oxy]-10-methoxy-
4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-
tetraen-8-yl]prop-2-enoate, (161); 
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Following representative procedure 5, 159 (0.505 g, 0.94 mmol, 1 Eq), palladium 
acetate (0.011 g, 5 mol%), triphenylphosphine (0.049 g, 20 mol%), DMF (1 mL), NEt3 
(0.46 mL, 3.29 mmol, 3.5 Eq) and methyl acrylate (0.34 mL, 3.76 mmol, 4 Eq) gave, 
after purification by column chromatography (SiO2 10% MeOH/DCM) followed by 
recrystallisation in EtOH, 161 as white solid in 85% yield (0.399 g, 0.80 mmol).  
 
1H and 13C NMR data in agreement with literature74 
1H NMR, (CDCl3, 400 MHz) δ, 7.74 (d, J = 16.0 Hz, 1H, (H22)), 6.89 (s, 1H, (H2)), 
6.14 (d, J = 16.0 Hz, 1H, (H23)), 5.62-5.58 (m, 1H, (H7)), 5.21-5.18 (m, 1H, (H8)), 
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4.69 (dd, J = 6.0, 1.2 Hz, 1H, (H5)), 4.23-4.19 (m, 1H, (H6)), 3.80 (s, 3H, (H18)), 3.73 
(s, 3H, (H25)) 3.36-3.34 (m, 1H, (H9)), 3.06 (d, J = 18.8 Hz, 1H, (H10)), 2.61-2.60 (m, 
1H, (H14), 2.53 (dd, J = 12.0, 4.0 Hz, 1H, (H16)), 2.40 (s, 3H, (H17)), 2.32-2.25 (m, 
2H, (H16, H10)), 1.97 (ddd, J = 12.8, 12.8, 5.2 Hz, 1H, (H15)), 1.77 (dd, J = 12.8, 1.6 
Hz, 1H, (H15)), 0.86 (s, 9H, (H21)), 0.07 (s, 3H, (H19)), 0.05 (s, 3H, (H19)) 
13C NMR, (CDCl3, 100 MHz) δ, 167.98 (C24), 150.43 (C4), 142.61 (C3), 141.04 
(C22), 134.15 (C7), 131.67 (C8), 127.92 (C23), 127.87 (C12), 124.30 (C11), 115.09 
(C1), 112.21 (C2), 93.00 (C5), 68.38 (C6), 58.61 (C9), 56.83 (C18), 51.61 (C25), 46.26 
(C16), 43.28 (C13) 43.17 (C17), 40.53 (C14), 35.84 (C15), 25.98 (C21), 19.35 (C10), 
18.37 (C20), -4.57 (C19), -4.77 (C19) 
 
Methyl (2E)-3-[(1S,5R,13R,14S,17R)-14-hydroxy-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-8-yl]prop-2-
enoate, (140); 
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Following representative procedure 5, 159 (0.631 g, 1.17 mmol, 1 Eq), palladium 
acetate (0.013 g, 5 mol%), triphenylphosphine (0.061 g, 20 mol%), DMF (1 mL), NEt3 
(0.568 mL, 4.10 mmol, 3.5 Eq) and methyl acrylate (0.419 mL, 4.68 mmol, 4 Eq) gave, 
after treatment with TBAF (1 M solution in THF, 2.34 mL, 2.34 mmol, 2 Eq) in THF (5 
mL) according to representative procedure 6 and purification by column 
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chromatography (SiO2 10% MeOH/DCM, 1% NH4OH) followed by recrystallisation in 
CHCl3:Hexane, 140 as a white solid in 63% yield (0.283 g, 0.74 mmol).  
 
1H and 13C NMR data in agreement with literature74 
1H NMR, (CDCl3, 400 MHz) δ, 7.73 (d, J = 15.6 Hz, 1H, (H22)), 6.88 (s, 1H, (H2)), 
6.17 (d, J = 15.6 Hz, 1H, (H23)), 5.67-5.63 (m, 1H, (H7)), 5.23-5.20 (m, 1H, (H8)), 
4.87 (dd, J = 6.4, 1.2 Hz, 1H, (H5)), 4.14 (s, 1H, (H6)), 3.78 (s, 3H, (H18)), 3.73 (s, 3H, 
(H25)) 3.39-3.38 (m, 1H, (H9)), 3.08 (d, J = 18.8 Hz, 1H, (H10)), 2.68 (s, 1H, (H14), 
2.57 (dd, J = 12.0, 4.4 Hz, 1H, (H16)), 2.41 (s, 3H, (H17)), 2.34-2.26 (m, 2H, (H16, 
H10)), 2.05 (ddd, J = 12.8, 12.8, 4.8 Hz, 1H, (H15)), 1.79 (dd, J = 12.8, 1.6 Hz, 1H, 
(H15)) 
13C NMR, (CDCl3, 100 MHz) δ, 167.80 (C21), 148.91 (C4), 142.80 (C3), 140.75 
(C19), 133.67 (C7), 131.52 (C12), 128.12 (C8), 127.63 (C1), 125.20 (C11), 115.84 
(C20), 110.47 (C2), 92.19 (C5), 66.54 (C6), 58.62 (C9), 56.15 (C18), 51.73 (C22), 
46.24 (C16), 43.10 (C17) 42.96 (C13), 40.19 (C14), 35.55 (C15), 19.36 (C10) 
 
(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-8-[(E)-2-phenylethenyl]-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-ol, (155); 
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Following representative procedure 5, 159 (0.410 g, 0.76 mmol, 1 Eq), palladium 
acetate (0.009 g, 5 mol%), triphenylphosphine (0.040 g, 20 mol%), DMF (1 mL), NEt3 
(0.369 mL, 2.66 mmol, 3.5 Eq) and styrene (0.348 mL, 3.04 mmol, 4 Eq) gave, after 
treatment with TBAF (1 M solution in THF, 1.52 mL, 1.52 mmol, 2 Eq) in THF (5 mL) 
according to representative procedure 6 and purification by column chromatography 
(SiO2 10% MeOH/DCM, 1% NH4OH) followed by recrystallisation in CHCl3:Hexane, 
155 as an off white solid in 62% yield (0.188 g, 0.47 mmol).  
 
1H and 13C NMR data in agreement with literature74 
1H NMR, (CDCl3, 400 MHz) δ, 7.44-7.43 (m, 2H, (H22)), 7.31-7.28 (m, 2H, (H23)), 
7.24.7.23 (m, 1H, (H24)), 7.05 (d, J = 16.0 Hz, 1H, (H19)), 6.95 (s, 1H, (H2)), 6.85 (d, 
J = 16.0 Hz, 1H, (H20)), 5.73-5.71 (m, 1H, (H7)), 5.22-5.20 (m, 1H, (H8)), 4.90 (d, J = 
6.0 Hz, 1H, (H5)), 4.19-4.17 (m, 1H, (H6)), 3.85 (s, 3H, (H18)), 3.74 (s, 1H, (H9)), 
3.10 (d, J = 18.8 Hz, 1H, (H10)), 3.06 (s, 1H, (H14)), 2.93 (d, J = 14.4 Hz, 1H, (H16)), 
2.66-2.56 (m, 5H, (H17, H16, H10)), 2.34 (ddd, J = 12.4, 12.4, 3.6 Hz, 1H, (H15)), 
1.91 (d, J = 12.4 Hz, 1H, (H15)) 
13C NMR, (CDCl3, 100 MHz) δ, 146.54 (C4), 142.83 (C3), 137.57 (C21), 133.91 (C7), 
130.82 (C12), 128.74 (C23), 128.59 (C1), 128.19 (C8), 127.54 (C20), 126.68 (C24), 
126.38 (C22), 124.51 (C19), 124.27 (C11), 109.31 (C2), 91.51 (C5), 66.35 (C6), 59.07 
(C9), 56.30 (C18), 46.49 (C16), 42.83 (C17), 42.81 (C13), 39.70 (C14), 35.11 (C15), 
19.72 (C10) 
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(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-8-(2-phenylethynyl)-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-ol, (156); 
 
 
 
Following representative procedure 5, 159 (0.523 g, 0.97 mmol), palladium acetate 
(0.011 g, 5 mol%), triphenylphosphine (0.051 g, 20 mol%), DMF (1 mL), NEt3 (0.471 
mL, 3.40 mmol, 3.5 Eq) and tributyl(phenylethynyl)tin (0.407 mL, 1.16 mmol, 1.2 Eq) 
gave, after treatment with TBAF (1 M solution in THF, 1.94 mL, 1.94 mmol, 2 Eq) in 
THF (5 mL) according to representative procedure 6 and purification by column 
chromatography (SiO2 10% MeOH/DCM, 1% NH4OH) followed by recrystallisation in 
CHCl3:Hexane, 156 as an off white solid in 48% yield (0.192 g, 0.48 mmol).  
 
1H and 13C NMR data in agreement with literature74 
1H NMR, (CDCl3, 400 MHz) δ, 7.45-7.43 (m, 2H, (H22), 7.29-7.23 (m, 3H, (H23, 
H24)), 6.80 (s, 1H, (H2)), 5.63-5.61 (m, 1H, (H7)), 5.22-5.18 (m, (H8)), 4.85 (dd, J = 
6.4, 0.8 Hz, 1H, (H5)), 4.14-4.10 (m, 1H, (H6)), 3.74 (s, 3H, (H18)), 3.39-3.37 (m, 1H, 
(H9)), 3.05 (d, J = 19.2 Hz, 1H, (H10)), 2.66-2.64 (m, 1H, (H14)), 2.57 (dd, J = 12.0, 
4.0 Hz, 1H, (H16)), 2.40 (s, 3H, (H17)), 2.37-2.30 (m, 2H, (H16, H10)), 2.03 (ddd J = 
12.0, 12.0, 4.8 Hz, 1H, (H15)), 1.79 (d, J = 12.0 Hz, 1H, (H15))  
13C NMR, (CDCl3, 100 MHz) δ, 147.42 (C4), 142.15 (C3), 133.52 (C7), 131.41 (C22), 
131.23 (C12), 129.65 (C21), 128.42 (C23), 128.18 (C24), 128.14 (C8), 123.47 (C11), 
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115.84 (C2), 113.79 (C1), 92.50 (C20), 92.17 (C5), 87.42 (C19), 66.64 (C6), 58.73 
(C9), 56.18 (C18), 46.24 (C16), 43.09 (C13), 42.99 (C17), 40.39 (C14), 35.41 (C15), 
20.42 (C10) 
 
(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-8-phenyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-ol, (157); 
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A flask was charged with 159 (0.674 g, 1.25 mmol), palladium acetate (0.014 g, 5 
mol%), triphenylphosphine (0.066 g, 20 mol%), DMF (1 mL), Na2CO3 (0.464 g, 4.38 
mmol, 3.5 Eq) and phenylboronic acid (0.305 g, 2.50 mmol, 2 Eq) and stirred under a 
nitrogen atmosphere at 100 °C for 20 h. After cooling the mixture was diluted with 
diethyl ether (5 mL), filtered and concentrated in vacuo. Following representative 
procedure 6, TBAF (1 M solution in THF, 2.50 mL, 2.5 mmol, 2 Eq) in THF (5 mL) 
gave, after purification by column chromatography (SiO2 10% MeOH/DCM, 1% 
NH4OH) followed by recrystallisation in CHCl3:Hexane, 157 as an off white solid in 
80% yield (0.375 g, 1.00 mmol).  
 
1H and 13C NMR data in agreement with literature74 
1H NMR, (CDCl3, 400 MHz) δ, 7.37-7.26 (m, 5H, (H20, H21, H22), 6.57 (s, 1H, (H2)), 
5.72-5.69 (m, 1H, (H7)), 5.21-5.17 (m, 1H, (H8)), 4.88 (dd, J = 6.4, 0.8 Hz, 1H, (H5)), 
4.17-4.15 (m, 1H, (H6)), 3.79 (s, 3H, (H18)), 3.33 (s, 1H, (H9)), 2.98 (d, J = 19.2 Hz, 
1H, (H10)), 2.75-2.70 (m, 2H, (H14, H16)), 2.56-2.51 (m, 1H, (H16)), 2.42 (s, 3H, 
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(H17)), 2.12-2.09 (m, 2H, (H10, H15)), 1.90 (dd, J = 12.8, 1.6 Hz, 1H, (H15))  
13C NMR, (CDCl3, 100 MHz) δ, 145.81 (C4), 142.06 (C3), 140.62 (C19), 134.16 
(C12), 133.69 (C7), 131.13 (C11), 129.17 (C20), 128.39 (C21), 127.99 (C8), 126.93 
(C22), 123.96 (C1), 114.12 (C2), 91.44 (C5), 66.46 (C6), 59.02 (C9), 56.24 (C18), 
46.64 (C16), 43.22 (C13), 43.07 (C17), 40.15 (C14), 35.54 (C15), 20.42 (C10) 
 
(1S,5R,13R,14S,17R)-14-[(tert-butyldimethylsilyl)oxy]-10-methoxy-4-methyl-8-
[(E)-2-(pyridin-4-yl)ethenyl]-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-
7,9,11(18),15-tetraene, (164); 
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Following representative procedure 5, 159 (0.537 g, 1.00 mmol, palladium acetate 
(0.011 g, 5 mol%), triphenylphosphine (0.052 g, 20 mol%), DMF (1 mL), NEt3 (0.49 
mL, 3.5 mmol, 3.5 Eq) and 4-vinylpyridine (0.431 mL, 4.00 mmol, 4 Eq) gave, after 
purification by column chromatography (SiO2 10% MeOH/DCM) followed by 
recrystallisation in CHCl3:Hexane, 164 as an orange solid in 92% yield (0.475 g, 0.92 
mmol). 
 
1H NMR, (CDCl3, 400 MHz) δ, 8.47-8.45 (m, 2H, (H26)), 7.30 (d, J = 16.0 Hz, 1H, 
(H22)), 7.26-7.24 (m, 2H, (H25)), 6.92 (s, 1H, (H2)), 6.70 (d, J = 16.0 Hz, 1H, (H23)), 
5.61-5.58 (m, 1H, (H7)), 5.22-5.18 (m, 1H, (H8)), 4.67 (dd, J = 6.4, 1.2 Hz, 1H, (H5)), 
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4.22-4.19 (m, 1H, (H6)), 3.84 (s, 3H, (H18)), 3.37-3.35 (m, 1H, (H9)), 3.04 (d, J = 18.8 
Hz, 1H, (H10)), 2.61 (s, 1H, (H14)), 2.53 (dd, J = 12.0, 4.0 Hz, 1H, (H16)), 2.41 (s, 3H, 
(H17)), 2.37-2.27 (m, 2H, (H16, H10), 1.97 (ddd, J = 12.4, 12.4, 4.8 Hz, 1H, (H15)), 
1.79 (dd, J = 12.4, 1.6 Hz, 1H, (H15)), 0.92 (s, 9H, (H21)), 0.13 (s, 3H, (H19)), 0.11 (s, 
3H, (H19)) 
13C NMR, (CDCl3, 100 MHz) δ, 150.11 (C26), 149.07 (C24), 145.21 (C4), 142.63 
(C3), 134.19 (C7), 131.65 (C12), 129.27 (C22), 127.83 (C8), 126.27 (C11), 126.18 
(C1), 124.28 (C23), 120.64 (C25), 111.59 (C2), 92.75 (C5), 68.42 (C6), 58.77 (C9), 
57.13 (C18), 46.37 (C16), 43.37 (C13), 43.21 (C17), 40.55 (C14), 35.84 (C15), 25.88 
(C21), 19.45 (C10), 18.37 (C20), -4.54 (C19), -4.74 (C19) 
IR: υ (cm-1), 2928, 2854, 1589, 1325, 1252, 1201, 1174, 1129, 1117, 1101, 1084 
HRMS (EI, 70eV) Calculated for [M+H]+, C31H41N2O3Si+, requires: 517.2886, found 
517.2869, m.p. = 220-221 °C, [α]D = -72° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-8-[(E)-2-(pyridin-4-yl)ethenyl]-12-oxa-
4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-ol, (162); 
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Following representative procedure 5, 159 (0.508 g, 0.94 mmol), palladium acetate 
(0.011 g, 5 mol%), triphenylphosphine (0.049 g, 20 mol%), DMF (1 mL), NEt3 (0.456 
mL, 3.29 mmol, 3.5 Eq) and 4-vinylpyridine (0.405 mL, 3.76 mmol, 4 Eq) gave, after 
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treatment with TBAF (1 M solution in THF, 1.88 mL, 1.88 mmol, 2 Eq) in THF (5 mL) 
according to representative procedure 6 and purification by column chromatography 
(SiO2 10% MeOH/DCM, 1% NH4OH) followed by recrystallisation in CHCl3:Hexane, 
162 as an off white solid in 79% yield (0.298 g, 0.74 mmol). 
 
1H NMR, (CDCl3, 400 MHz) δ, 8.48-8.46 (m, 2H, (H23)), 7.31 (d, J = 16.0 Hz, 1H, 
(H19)), 7.28-7.26 (m, 2H, (H22)), 6.92 (s, 1H, (H2)), 6.72 (d, J = 16.0 Hz, 1H, (H20)) 
5.68-5.66 (m, 1H, (H7)), 5.25-5.21 (m, 1H, (H8)), 4.86 (dd, J = 6.4, 1.2 Hz, 1H, (H5)), 
4.15-4.12 (m, 1H, (H6)), 3.83 (s, 3H, (H18)), 3.39-3.37 (m, 1H, (H9)), 3.05 (d, J = 18.8 
Hz, 1H, (H10)), 2.99 (s, 1H (OH)), 2.65-2.64 (m, 1H, (H14)), 2.56 (dd, J = 12.0, 4.0 
Hz, 1H, (H16)), 2.41 (s, 3H, (H17)), 2.37-2.27 (m, 2H, (H16, H10), 2.02 (ddd, J = 12.4, 
12.4, 5.2 Hz, 1H, (H15)), 1.81 (dd, J = 12.4, 1.6 Hz, 1H, (H15))  
13C NMR, (CDCl3, 100 MHz) δ, 150.10 (C23), 147.60 (C4), 145.06 (C21), 142.78 
(C3), 133.66 (C7), 131.50 (C12), 129.15 (C19), 128.19 (C8), 127.13 (C1), 126.04 
(C11), 124.83 (C20), 120.71 (C22), 109.62 (C2), 92.00 (C5), 66.54 (C6), 58.69 (C9), 
56.32 (C18), 46.29 (C16), 43.16 (C17), 43.10 (C13), 40.30 (C14), 35.65 (C15), 19.40 
(C10) 
IR: υ (cm-1), 2932, 2901, 1589, 1488, 1443, 1354, 1319, 1173, 1116, 1063 
HRMS (EI, 70eV) Calculated for [M+H]+, C25H27N2O3+, requires: 403.2016, found 
403.2008, m.p. = 224-225 °C, [α]D = -27° c = (0.10, CHCl3, 589 nm, 20 °C) 
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(1S,5R,13R,14S,17R)-14-[(tert-butyldimethylsilyl)oxy]-10-methoxy-4-methyl-8-
[(E)-2-(pyridin-2-yl)ethenyl]-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-
7,9,11(18),15-tetraene, (163); 
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Following representative procedure 5, 159 (0.540 g, 1.00 mmol), palladium acetate 
(0.011 g, 5 mol%), triphenylphosphine (0.052 g, 20 mol%), DMF (1 mL), NEt3 (0.49 
mL, 3.5 mmol, 3.5 Eq) and 2-vinylpyridine (0.431 mL, 4.00 mmol, 4 Eq) gave, after 
purification by column chromatography (SiO2 10% MeOH/DCM) followed by 
recrystallisation in CHCl3:Hexane, 163 as an orange solid in 81% yield (0.419 g, 0.81 
mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ, 8.50-8.49 (m, 1H, (H28)), 7.65 (d, J = 16.0 Hz, 1H 
(H22)), 7.55 (ddd, J = 7.6, 7.6, 1.6 Hz, 1H (H26)), 7.25 (d, J = 8.0 Hz, 1H, (H25)), 
7.05-7.02 (m, 1H, (H27)), 6.98 (s, 1H, (H2)), 6.86 (d, J = 16.0 Hz, 1H, (H23)), 5.61-
5.58 (m, 1H, (H7)), 5.20-5.16 (m, 1H, (H8)), 4.67 (dd, J = 6.0, 0.8 Hz, 1H, (H5)), 4.22-
4.19 (m, 1H, (H6)), 3.83 (s, 3H, (H18)), 3.42-3.39 (m, 1H, (H9)), 3.12 (d, J = 18.8 Hz, 
1H, (H10)), 2.69 (s, 1H, (H14)), 2.58 (dd, J = 12.0, 4.0 Hz, 1H, (H16)), 2.44 (s, 3H, 
(H17)), 2.42-2.35 (m, 2H, (H16, H10)), 2.03 (ddd, J = 12.0, 12.0, 4.8 Hz 1H, (H15)), 
1.81 (d, J = 12.0 Hz, 1H, (H15)), 0.85 (s, 9H, (H21)), 0.07 (s, 3H, (H19)), 0.05 (s, 3H, 
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(H19))   
13C NMR, (CDCl3, 100 MHz) δ, 156.00 (C24), 149.61 (C28), 148.72 (C4), 142.62 
(C3), 136.53 (C26), 134.26 (C7), 131.21 (C12), 128.69 (C22), 127.53 (C8), 126.82 
(C11), 126.36 (C23), 125.83 (C1), 122.07 (C25), 121.68 (C27), 111.44 (C2), 92.58 
(C5), 68.41 (C6), 59.01 (C9), 56.98 (C18), 46.49 (C16), 43.25 (C13), 43.12 (C17), 
40.35 (C14), 35.64 (C15), 25.90 (C21), 19.76 (C10), 18.37 (C20), -4.55 (C19), -4.75 
(C19) 
IR: υ (cm-1), 2929, 2854, 1585, 1471, 1436, 1316, 1251, 1121 
HRMS (EI, 70eV) Calculated for [M+H]+, C31H41N2O3Si+, requires: 517.2881, found 
517.2886, m.p. = 102-104 °C, [α]D = -76° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-8-[(E)-2-(pyridin-2-yl)ethenyl]-12-oxa-
4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-ol, (165); 
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Following representative procedure 5, 159 (0.506 g, 0.94 mmol), palladium acetate 
(0.011 g, 5 mol%), triphenylphosphine (0.049 g, 20 mol%), DMF (1 mL), NEt3 (0.456 
mL, 3.29 mmol, 3.5 Eq) and 2-vinylpyridine (0.405 mL, 3.76 mmol, 4 Eq) gave, after 
treatment with TBAF (1 M solution in THF, 1.88 mL, 1.88 mmol, 2 Eq) in THF (5 mL) 
according to representative procedure 6 and purification by column chromatography 
Experimental 
——————————————————————————————————————— 
 
 
228 
——————————————————————————————————————— 
 
(SiO2 10% MeOH/DCM, 1% NH4OH) followed by recrystallisation in CHCl3:Hexane, 
165 as an off white solid in 64% yield (0.241 g, 0.60 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ, 8.53-8.51 (m, 1H, (H25)), 7.67 (d, J = 16.0 Hz, 1H 
(H19)), 7.59 (ddd, J = 7.6, 7.6, 1.6 Hz, 1H, (H23)), 7.29 (d, J = 7.6 Hz, 1H, (H22)), 
7.09-7.05 (m, 1H, (H24)), 7.00 (s, 1H, (H2)), 6.91 (d, J = 16.0 Hz, 1H, (H20)), 5.68-
5.65 (m, 1H, (H7)), 5.24-5.20 (m, 1H, (H8)), 4.87 (dd, J = 6.4, 1.2 Hz, 1H, (H5)), 4.15-
4.13 (m, 1H, (H6)), 3.83 (s, 3H, (H18)), 3.43-3.40 (m, 1H, (H9)), 3.14 (d, J = 18.8 Hz, 
1H, (H10)), 2.70-2.68 (m, 1H, (H14)), 2.60 (dd, J = 12.0, 4.0 Hz, 1H, (H16)), 2.44 (s, 
3H, (H17)), 2.42-2.33 (m, 2H, (H16, H10)), 2.06 (ddd, J = 12.8, 12.8, 5.2 Hz 1H, 
(H15)), 1.83 (dd, J = 12.8, 1.6 Hz, 1H, (H15))  
13C NMR, (CDCl3, 100 MHz) δ, 155.82 (C21), 149.67 (C25), 147.19 (C4), 142.73 
(C3), 136.61 (C23), 133.65 (C7), 131.16 (C12), 128.57 (C19), 128.04 (C8), 127.69 
(C1), 126.88 (C20), 125.89 (11), 122.07 (C22), 121.88 (C24), 109.50 (C2), 91.82 (C5), 
66.49 (C6), 58.85 (C9), 56.21 (C18), 46.37 (C16), 43.09 (C17), 43.00 (C13), 40.20 
(C14), 35.56 (C15), 19.62 (C10) 
IR: υ (cm-1), 2932, 1584, 1493, 1468, 1445, 1318, 1120, 1089, 1066 
HRMS (EI, 70eV) Calculated for [M+H]+, C25H27N2O3+, requires: 403.2022, found 
403.2006, m.p. = 105-106 °C, [α]D = -31° c = (0.10, CHCl3, 589 nm, 20 °C) 
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6.5 Palladium Coupled “Linked” Codeine Derivatives 
 
1,4-bis(1S,5R,13R,14S,17R)-10-methoxy-8-[(1E)-3-methoxy-3-oxoprop-1-en-1-yl]-
4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-
tetraen-14-yl benzene-1,4-dicarboxylate, (141); 
 
 
 
Following representative procedure 1, 140 (0.314 g, 0.82 mmol), DMAP (0.110 g, 0.90 
mmol, 1.1 Eq), DCM (8 mL) and terephthaloyl dichloride, (0.083 g, 0.41 mmol, 0.5 Eq) 
gave, after purification by column chromatography (SiO2 10% MeOH/DCM, 1% 
NH4OH) followed by recrystallisation in acetone, 141 as a white solid in 65% yield 
(0.238 g, 0.27 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ, 8.07 (s, 4H, (H21, H21’)), 7.76 (d, J = 16.0 Hz, 2H, 
(H22, H22’)), 6.91 (s, 2H, (H2, H2’)), 6.18 (d, J = 16.0 Hz, 2H, (H23, H23’)), 5.75-
5.72 (m, 2H, (H7, H7’)), 5.48-5.44 (m, 2H, (H8, H8’)), 5.41-5.38 (m, 2H, (H6, H6’)), 
5.20 (d, J = 6.8 Hz, 2H, (H5, H5’)), 3.73 (s, 6H, (H25, H25’)), 3.67 (s, 6H, (H18, 
H18’)), 3.42-3.40 (m, 2H, (H9, H9’)), 3.10 (d, J = 18.8 Hz, 2H, (H10, H10’)), 2.78 (s, 
2H, (H14, H14’)), 2.56 (dd, J = 12.0, 3.6 Hz, 2H, (H16, H16’)), 2.41 (s, 6H, (H17, 
H17’)), 2.35-2.23 (m, 4H, (H10, H10’, H16, H16’)), 2.04 (ddd, J = 12.4, 12.4, 4.8 Hz, 
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2H, (H15, H15’)), 1.82 (d, J = 11.2 Hz, 2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ(ppm), 167.84 (C24, C24’), 165.21 (C19, C19’), 149.14 
(C4, C4’), 142.77 (C3, C3’), 140.82 (C22, C22’), 133.80 (C20, C20’), 131.29 (C12, 
C12’), 129.80 (C8, C8’), 129.78 (C21, C21’), 128.44 (C7, C7’), 127.69 (C11, C11’), 
125.04 (C1, C1’), 115.73 (C23, C23’), 111.87 (C2, C2’), 88.55 (C5, C5’), 68.73 (C6, 
C6’), 58.78 (C9, C9’), 56.53 (C18, C18’), 51.68 (C25, C25’), 46.47 (C16, C16’), 43.14 
(C17, C17), 42.67 (C13, C13’), 40.23 (C14, C14’), 35.30 (C15, C15’), 19.16 (C10, 
C10’) 
IR: υ (cm-1), 2939, 1710 (C=O), 1496 (C-C, Ar), 1438, 1267, 1169, 1161, 1120, 1103, 
1047, 1018 
HRMS (EI, 70eV) Calculated for [M+H]+, C52H53N2O12+, requires: 897.3599, found 
897.3622, m.p. = 221-223 °C, [α]D = -307° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
1,4-bis(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-8-[(E)-2-phenylethenyl]-12-oxa-
4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl benzene-
1,4-dicarboxylate, (166); 
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Route A;  
Following representative procedure 1, 155 (0.280 g, 0.70 mmol), DMAP (0.094 g, 0.77 
mmol, 1.1 Eq), DCM (8 mL) and terephthaloyl dichloride, (0.071 g, 0.35 mmol, 0.5 Eq) 
gave, after purification by column chromatography (SiO2 10% MeOH/DCM, 1% 
NH4OH) followed by recrystallisation in acetone, 166 as an off white solid in 56% 
yield (0.183 g, 0.20 mmol).  
 
Route B;  
Following representative procedure 5, 149 (0.317 g, 0.32 mmol), palladium acetate 
(0.007 g, 10 mol%), triphenylphosphine (0.034 g, 40 mol%), DMF (1 mL), NEt3 (0.311 
mL, 2.24 mmol, 7 Eq) and styrene (0.293 mL, 2.56 mmol, 8 Eq) gave, after purification 
by column chromatography (SiO2 10% MeOH/DCM, 1% NH4OH) followed by 
recrystallisation in acetone, 166 as an off white solid in 42% yield (0.126 g, 0.14 
mmol). 
 
1H NMR, (CDCl3, 400 MHz) δ(ppm), 8.08 (s, 4H, (H21, H21’)) 7.44-7.42 (m, 4H, 
(H25, H25’)), 7.30-7.26 (m, 4H, (H26, H26’)), 7.19-7.17 (m, 2H, (H27, H27’)), 7.11 (d, 
J = 16.4 Hz, 2H, (H22, H22’)), 6.94 (s, 2H, (H2, H2’)), 6.84 (d, J = 16.4 Hz, 2H, (H23, 
H23’)), 5.75-5.73 (m, 2H, (H7, H7’)), 5.48-5.45 (m, 2H, (H8, H8’)), 5.40-5.38 (m, 2H, 
(H6, H6’)), 5.17 (d, J = 6.8 Hz, 2H, (H5, H5’)), 3.70 (s, 6H, (H18, H18’)), 3.41-3.40 
(m, 2H, (H9, H9’)), 3.07 (d, J = 18.8 Hz, 2H, (H10, H10’)), 2.78 (s, 2H, (H14, H14’)), 
2.57 (dd, J = 12.0 Hz, 4.0 Hz 2H, (H16, H16’)) 2.42 (s, 6H, (H17, H17’)), 2.37-2.29 
(m, 4H, (H16, H16’, H10, H10’)), 2.04-2.00 (m, 2H, (H15, H15’)), 1.84 (d, J = 12.4 
Hz, 2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ(ppm), 165.34 (C19, C19’), 146.82 (C4, C4’), 142.70 
(C3, C3’), 137.78 (C24, C24’), 133.89 (C20, C20’), 130.91 (C12, C12’), 129.81 (C21, 
C21’), 129.78 (C8, C8’), 128.73 (C26, C26’), 128.43 (C7, C7’), 128.24 (C1, C1’), 
127.85 (C23, C23’), 127.42 (C27, C27’), 126.37 (C25, C25’), 125.05 (C11, C11’), 
124.72 (C22, C22’), 110.58 (C2, C2’), 88.07 (C5, C5’), 68.77 (C6, C6’), 59.05 (C9, 
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C9’), 56.73 (C18, C18’), 46.67 (C16, C16’), 43.14 (C17, C17’), 42.70 (C13, C13’), 
40.25 (C14, C14), 35.30 (C15, C15’), 19.28 (C10, C10’) 
IR: υ (cm-1), 2909, 1713 (C=O), 1498 (C-C, Ar), 1444, 1267, 1121, 1104, 1050, 1018 
HRMS (EI, 70eV) Calculated for [M+H]+, C60H57N2O8H+, requires: 933.4115, found 
933.4141, m.p. = 217-219 °C, [α]D = -161° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
1,4-bis(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-8-[(E)-2-(pyridin-4-yl)ethenyl]-
12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl 
benzene-1,4-dicarboxylate, (167); 
 
  
 
Route A; 
Following representative procedure 1, 164 (0.297 g, 0.74 mmol), DMAP (0.099 g, 0.81 
mmol, 1.1 Eq), DCM (8 mL) and terephthaloyl dichloride, (0.075 g, 0.37 mmol, 0.5 Eq) 
gave, after purification by column chromatography (SiO2 10% MeOH/DCM, 1% 
NH4OH) followed by recrystallisation in acetone, 167 as an off white solid in 57% 
yield (0.197 g, 0.21 mmol).  
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Route B;  
Following representative procedure 5, 149 (0.301 g, 0.31 mmol), palladium acetate 
(0.007 g, 10 mol%), triphenylphosphine (0.033 g, 40 mol%), DMF (1 mL), NEt3 (0.301 
mL, 2.17 mmol, 7 Eq) and 4-vinylpyridine (0.267 mL, 2.48 mmol, 8 Eq) gave, after 
purification by column chromatography (SiO2 10% MeOH/DCM, 1% NH4OH) 
followed by recrystallisation in acetone, 167 as an off white solid in 49% yield (0.143 
g, 0.15 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ(ppm), 8.49-8.48 (m, 4H, (H26, H26’)), 8.08 (s, 4H, 
(H21, H21’)), 7.33 (d, J = 16.0 Hz, 2H, (H22, H22’)), 7.29-7.28 (m, 4H, (H25, H25’)), 
6.95 (s, 2H, (H2, H2’)), 6.75 (d, J = 16.0 Hz, 2H, (H23, H23’)), 5.77-5.73 (m, 2H, (H7, 
H7’)), 5.50-5.46 (m, 2H, (H8, H8’)), 5.42-5.39 (m, 2H, (H6, H6’)), 5.20 (d, J = 6.4 Hz, 
2H, (H5, H5’)), 3.70 (s, 6H, (H18, H18’)), 3.48-3.45 (m, 2H, (H9, H9’)), 3.09 (d, J = 
18.4 Hz, 2H, (H10, H10’)), 2.83-2.81 (s, 2H, (H14, H14’)), 2.61 (dd, J = 12.0, 4.0 Hz 
2H, (H16, H16’)) 2.45 (s, 6H, (H17, H17’)), 2.41-2.30 (m, 4H, (H16, H16’, H10, 
H10’)), 2.07 (ddd, J = 12.0, 12.0, 4.8 Hz 2H, (H15, H15’)),  1.88 (d, J = 12.0 Hz, 2H, 
(H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ(ppm), 165.26 (C19, C19’), 150.06 (C26, C26’), 147.76 
(C4, C4’), 145.11 (C24, C24’), 142.83 (C3, C3’), 133.83 (C20, C20’), 131.12 (C12, 
C12’), 129.79 (C21, C21’), 129.65 (C8, C8’), 129.08 (C22, C22’), 128.52 (C7, C7’), 
127.05 (C11, C11’), 125.74 (C1, C1’), 124.86 (C23, C23’), 120.74 (C25, C25’), 111.08 
(C2, C2’),  88.21 (C5, C5’), 68.69 (C6, C6’), 58.90 (C9, C9’), 56.73 (C18, C18’), 46.55 
(C16, C16’), 43.02 (C17, C17’), 42.63 (C13, C13’), 40.01 (C14, C14’), 35.11 (C15, 
C15’), 19.31 (C10, C10’) 
IR: υ (cm-1), 2937, 1709 (C=O), 1589, 1489 (C-C, Ar), 1439, 1267, 1120, 1104, 1050, 
1016 
HRMS (EI, 70eV) Calculated for [M+H]+, C58H55N4O8+, requires: 935.4020, found 
935.4038, m.p. = 264-266 °C, [α]D = -112° c = (0.10, CHCl3, 589 nm, 20 °C) 
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1,4-bis(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-8-[(E)-2-(pyridin-2-yl)ethenyl]-
12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl 
benzene-1,4-dicarboxylate, (168); 
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Route A; 
Following representative procedure 1, 165 (0.298 g, 0.74 mmol), DMAP (0.099 g, 0.81 
mmol, 1.1 Eq), DCM (8 mL) and terephthaloyl dichloride, (0.075 g, 0.37 mmol, 0.5 Eq) 
gave, after purification by column chromatography (SiO2 10% MeOH/DCM, 1% 
NH4OH) followed by recrystallisation in acetone, 168 as an off white solid in 49% 
yield (0.169 g, 0.18 mmol).  
 
Route B;  
Following representative procedure 5, 149 (0.307 g, 0.31 mmol), palladium acetate 
(0.007 g, 10 mol%), triphenylphosphine (0.033 g, 40 mol%), DMF (1 mL), NEt3 (0.301 
mL, 2.17 mmol, 7 Eq) and 4-vinylpyridine (0.267 mL, 2.48 mmol, 8 Eq) gave, after 
purification by column chromatography (SiO2 10% MeOH/DCM, 1% NH4OH) 
followed by recrystallisation in acetone, 168 as an off white solid in 44% yield (0.127 
g, 0.14 mmol).  
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1H NMR, (CDCl3, 400 MHz) δ, 8.53-8.52 (m, 2H, (H28, H28’)), 8.09 (s, 4H, (H21, 
H21’)), 7.69, (d, J = 16.0 Hz, 2H (H22, H22’)), 7.59 (ddd, J = 7.6, 7.6, 1.6 Hz, 2H 
(H26, H26’)), 7.29 (d, J = 8.0 Hz, 2H, (H25, H25’)), 7.08-7.05 (m, 2H, (H27, H27’)), 
7.01 (s, 2H, (H2, H2’)), 6.91 (d, J = 16.0 Hz, 2H (H23, H23’)), 5.76-5.73 (m, 2H, (H7, 
H7’)), 5.48-5.45 (m, 2H, (H8, H8’)), 5.42-5.39 (m, 2H, (H6, H6’)), 5.19 (d, J = 6.8 Hz, 
2H, (H5, H5’)), 3.71 (s, 6H, (H18, H18’)) 3.46-3.44 (m, 2H, (H9, H9’)), 3.17 (d, J = 
18.8 Hz, 2H, (H10, H10’)), 2.83 (s, 2H, (H14, H14’)), 2.60 (dd, J = 12.0, 4.0 Hz, 2H, 
(H16, H16’)), 2.45 (s, 6H, (H17, H17’)), 2.40-2.31 (m, 4H, (H16, H16’, H10, H10’)), 
2.08 (ddd, J = 12.4, 12.4, 4.8 Hz, 2H, (H15, H15’)), 1.86 (d, J = 11.6 Hz, 2H, (H15, 
H15’)) 
13C NMR, (CDCl3, 100 MHz) δ, 165.32 (C19, C19’), 155.87 (C24, C24’), 149.67 (C28, 
C28’), 147.46 (C4, C4’), 142.72 (C3, C3’), 136.62 (C26, C26’), 133.85 (C20, C20’), 
130.90 (C12, C12’), 129.81 (C21, C21’), 129.74 (C8, C8’), 128.59 (C22, C22’), 128.42 
(C7, C7’), 127.49 (C11, C11’), 126.75 (C23, C23’), 125.93 (C1, C1’), 122.16 (C25, 
C25’), 121.84 (C27, C27’), 110.79 (C2, C2’), 88.22 (C5, C5’), 68.80 (C6, C6’), 58.99 
(C9, C9’), 56.59 (C18, C18’)), 46.61 (C16, C16’), 43.13 (C17, C17’), 42.70 (C13, 
C13’), 40.22 (C14, C14’), 35.27 (C15, C15’), 19.42 (C10, C10’) 
IR: υ (cm-1), 2907, 1717 (C=O), 1584, 1485 (C-C, Ar), 1469, 1443, 1248, 1120, 1102, 
1049, 1018 
HRMS (EI, 70eV) Calculated for [M+H]+, C58H55N4O8+, requires: 935.4020, found 
935.4033, m.p. = 192-194 °C, [α]D = -140° c = (0.10, CHCl3, 589 nm, 20 °C) 
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1,4-bis(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-8-(2-phenylethynyl)-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl benzene-
1,4-dicarboxylate, (169); 
 
 
 
Following representative procedure 1, 156 (0.140 g, 0.35 mmol), DMAP (0.048 g, 0.39 
mmol, 1.1 Eq), DCM (6 mL) and terephthaloyl dichloride, (0.037 g, 0.18 mmol, 0.5 Eq) 
gave, after purification by column chromatography (SiO2 10% MeOH/DCM, 1% 
NH4OH) followed by recrystallisation in acetone, 169 as an off white solid in 53% 
yield (0.089 g, 0.10 mmol).  
 
1H NMR Data, (CDCl3, 400 MHz) δ, 8.06 (s, 4H, (H21, H21’)), 7.47-7.44 (m, 4H, 
(H25, H25’)), 7.27-7.24 (m, 6H, (H26, H26’, H27, H27’)), 6.81 (s, 2H, (H2, H2’)), 
5.72-5.68 (m, 2H, (H7, H7’)), 5.47-5.43 (m, 2H, (H8, H8’)), 5.41-5.38 (m, 2H, (H6, 
H6’)), 5.17 (d, J = 6.4 Hz, 2H, (H5, H5’)), 3.66 (s, 6H, (H18, H18’)) 3.39-3.37 (m, 2H, 
(H9, H9’)), 3.09 (d, J = 18.8 Hz, 2H, (H10, H10’)), 2.76-2.75 (m, 2H, (H14, H14’)), 
2.54 (dd, J = 12.0, 4.0 Hz, 2H, (H16, H16’)), 2.40 (s, 6H, (H17, H17’)), 2.37-2.27 
(H16, H16’, H10, H10’)) 2.02 (ddd, J = 12.4, 12.4, 4.8 Hz, 2H, (H15, H15’)), 1.82 (d, J 
= 11.2 Hz, 2H, (H15, H15’)) 
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13C NMR, (CDCl3, 100 MHz) δ(ppm), 165.30 (C19, C19’), 147.59 (C4, C4’), 142.24 
(C3, C3’), 133.87 (C20, C20’), 131.44 (C25, C25’), 131.00 (C12, C12’), 129.96 (C8, 
C8’), 129.80 (C21, C21’), 129.75 (C24, C24’), 128.39 (C26, C26’), 128.23 (C27, 
C27’), 128.06 (C7, C7’), 123.62 (C11, C11’), 117.11 (C2, C2’), 113.68 (C1, C1’), 
92.31 (C23, C23’), 88.42 (C5, C5’), 87.52 (C22, C22’), 68.82 (C6, C6’), 58.97 (C9, 
C9’), 56.57 (C18, C18’), 46.53 (C16, C16’), 43.15 (C17, C17’), 42.85 (C13, C13’), 
40.62 (C14, C14’), 35.33 (C15, C15’), 20.21 (C10, C10’) 
IR: υ (cm-1), 2908, 2204 (C≡C) 1712 (C=O), 1500 (C-C, Ar), 1440, 1267, 1248, 1204, 
1120, 1104, 1050, 1019 
HRMS (EI, 70eV) Calculated for [M+H]+, C60H53N2O8+, requires: 929.3802, found 
929.3829, m.p. = 236-238 °C, [α]D = -281° c = (0.10, CHCl3, 589 nm, 20 °C) 
 
1,4-bis(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-8-phenyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl benzene-
1,4-dicarboxylate, (170); 
 
 
 
Following representative procedure 1, 157 (0.462 g, 1.23 mmol), DMAP (0.165 g, 1.35 
mmol, 1.1 Eq), DCM (8 mL) and terephthaloyl dichloride, (0.126 g, 0.62 mmol, 0.5 Eq) 
gave, after purification by column chromatography (SiO2 10% MeOH/DCM, 1% 
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NH4OH) followed by recrystallisation in acetone, 170 as an off white solid in 61% 
yield (0.332 g, 0.38 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ, 8.11 (s, 4H, (H21, H21’)), 7.37-7.24 (m, 10H, (H23, 
H23’, H24, H24’, H25, H25’)), 6.57 (s, 2H, (H2, H2’)), 5.79-5.77 (m, (H7, H7’)), 5.46-
5.40 (m, 4H, (H8, H8’, H6, H6’)), 5.19 (d, J = 7.2 Hz, 2H, (H5, H5’)), 3.67 (s, 6H, 
(H18, H18’)) 3.33-3.31 (m, 2H, (H9, H9’)), 3.00 (d, J = 18.4 Hz, 2H, (H10, H10’)), 
2.81 (s, 2H, (H14, H14’)), 2.66 (dd, J = 12.0, 4.0 Hz, 2H, (H16, H16’)), 2.46 (ddd, J = 
12.0, 12.0, 3.2 Hz, 2H, (H16, H16’)), 2.39 (s, 6H, (H17, H17’)), 2.16-2.06 (m, 4H, 
(H10, H10’, H15, H15’)), 1.90 (dd, J = 12.8, 2.0 Hz, 2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ(ppm), 165.37 (C19, C19’), 146.03 (C4, C4’), 142.13 
(C3, C3’), 140.65 (C22, C22’), 133.91 (C20, C20’), 133.85 (C12, C12’), 130.73 (C11, 
C11’), 129.84 (C21, C21’), 129.63 (C8, C8’), 129.14 (C23, C23’), 128.57 (C7, C7’), 
128.37 (C24, C24’), 126.86 (C25, C25’), 123.81 (C1, C1’), 115.53 (C2, C2’),  87.89 
(C5, C5’), 68.85 (C6, C6’), 59.23 (C9, C9’), 56.67 (C18, C18’), 46.90 (C16, C16’), 
43.05 (C17, C17’), 42.91 (C13, C13’), 40.03 (C14, C14’)), 35.16 (C15, C15’), 20.29 
(C10, C10’) 
IR: υ (cm-1), 2929, 1715 (C=O), 1484 (C-C, Ar), 1448, 1339, 1265, 1242, 1149, 1123, 
1104, 1051, 1018 
HRMS (EI, 70eV) Calculated for [M+H]+, C56H53N2O8+, requires: 881.3802, found 
881.3809, m.p. = 218-220 °C, [α]D = -279° c = (0.10, CHCl3, 589 nm, 20 °C) 
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1,3-bis(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-8-phenyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl benzene-
1,3-dicarboxylate, (171); 
 
 
 
Following representative procedure 1, 157 (0.512 g, 1.36 mmol), DMAP (0.183 g, 1.50 
mmol, 1.1 Eq), DCM (8 mL) and terephthaloyl dichloride, (0.138 g, 0.68 mmol, 0.5 Eq) 
gave, after purification by column chromatography (SiO2 10% MeOH/DCM, 1% 
NH4OH) followed by recrystallisation in CHCl3:Hexane, 171 as an off white solid in 
39% yield (0.236 g, 0.27 mmol).  
 
1H NMR, (CDCl3, 400 MHz) δ, 8.69-8.68 (m, 1H, (H23)), 8.25 (dd, J = 8.0, 2.0 Hz, 
2H, (H21, H21’)), 7.48 (t, J = 8.0 Hz, 1H, (H22)), 7.36-7.24 (m, 10H, (H25, H25’, H26, 
H26’, H27, H27’)), 6.57 (s, 2H, (H2)), 5.82-5.78 (m, 2H, (H7, H7’)), 5.43-5.40 (m, 4H, 
(H8, H8’, H6, H6’)), 5.19 (d, J = 6.4 Hz, 2H, (H5, H5’)), 3.64 (s, 6H, (H18, H18’)) 
3.36-3.34 (m, 2H, (H9, H9’)), 2.98 (d, J = 18.8 Hz, 2H, (H10, H10’)), 2.87 (s, 2H, 
(H14, H14)), 2.69 (dd, J = 12.0, 4.0 Hz 2H, (H16, H16’)), 2.48 (ddd, J = 12.0, 12.0, 3.6 
Hz, 2H, (H16, H16’)), 2.41 (s, 6H, (H17, H17’)), 2.20-2.10 (m, 4H, (H10, H10’, H15, 
H15’)), 1.90 (dd, J = 12.4, 1.6 Hz, 2H, (H15, H15’)) 
13C NMR, (CDCl3, 100 MHz) δ(ppm), 165.25 (C19, C19’), 146.07 (C4, C4’), 142.21 
(C3, C3’), 140.61 (C24, C24’), 134.42 (C21, C21’), 133.85 (C20, C20’), 131.32 (C23), 
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130.58 (C12, C12’), 130.38 (C11, C11’), 129.24 (C8, C8’) 129.14 (C26, C26’), 128.84 
(C7, C7’), 128.47 (C22, C22’), 128.37 (C25, C25’), 126.86 (C27, C27’), 123.45 (C1, 
C1’), 115.68 (C2, C2’), 87.80 (C5, C5’), 68.77 (C6, C6’), 59.35 (C9, C9’), 56.68 (C18, 
C18’), 46.98 (C16, C16’), 42.95 (C17, C17’), 42.79 (C13, C13’), 39.82 (C14, C14’)), 
34.96 (C15, C15’), 20.37 (C10, C10’) 
IR: υ (cm-1), 2930, 1721 (C=O), 1480 (C-C, Ar), 1446, 1230, 1142, 1049, 1018 
HRMS (EI, 70eV) Calculated for [M+H]+, C56H53N2O8+, requires: 881.3802, found 
881.3824, m.p. = 152-154 °C, [α]D = -223° c = (0.10, CHCl3, 589 nm, 20 °C) 
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Appendix A 
 
A.1 X-ray crystal data of 126 
 
1,3-bis(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl benzene-
1,3-dicarboxylate, (126); 
 
Fig A.1 ORTEP diagram of 126 with atom labels 
 
Formula C44H44N2O8 
Space Group P 21 
Cell Lengths (Å) a 8.7535(4) b 12.4059(5) c 16.6518(7) 
Cell Angles (°) α 90 β 100 γ 90 
Cell Volume (Å3) 1780.83 
Z, Z’ Z: 2 Z': 0 
R-Factor (%) 3.3 
Table A.1 X-ray crystal data for 126 
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Number Atom1 Atom2 Length (Å) 
1 C1 H1 0.949(2) 
2 C1 C2 1.405(2) 
3 C1 C11 1.394(2) 
4 C2 H2 0.951(2) 
5 C2 C3 1.405(3) 
6 C3 C4 1.387(2) 
7 C3 O1 1.365(2) 
8 C4 O2 1.381(2) 
9 C4 C12 1.373(2) 
10 O2 C5 1.465(2) 
11 C5 H5 1.000(2) 
12 C5 C6 1.544(2) 
13 C5 C13 1.548(2) 
14 C6 H6 1.001(2) 
15 C6 C7 1.505(2) 
16 C6 O3 1.445(2) 
17 C7 H7 0.950(2) 
18 C7 C8 1.322(2) 
19 C8 H8 0.950(2) 
20 C8 C14 1.506(2) 
21 C9 H9 1.000(2) 
22 C9 C10 1.555(3) 
23 C9 C14 1.537(3) 
24 C9 N1 1.474(2) 
25 C10 H10A 0.990(2) 
26 C10 H10B 0.990(2) 
27 C10 C11 1.517(2) 
28 C11 C12 1.381(2) 
29 C12 C13 1.494(2) 
30 C13 C14 1.551(2) 
31 C13 C15 1.538(2) 
32 C14 H14 1.000(2) 
33 C15 H15A 0.991(2) 
34 C15 H15B 0.991(2) 
35 C15 C16 1.517(3) 
36 C16 H16A 0.990(2) 
37 C16 H16B 0.990(2) 
38 C16 N1 1.459(2) 
39 N1 C17 1.447(3) 
40 C17 H17A 0.980(2) 
41 C17 H17B 0.980(2) 
42 C17 H17C 0.980(3) 
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43 O1 C18 1.423(2) 
44 C18 H18A 0.981(2) 
45 C18 H18B 0.980(2) 
46 C18 H18C 0.980(2) 
47 O3 C19 1.347(2) 
48 C19 O4 1.206(2) 
49 C19 C20 1.490(2) 
50 C20 C21 1.393(2) 
51 C20 C25 1.392(2) 
52 C21 H21 0.949(2) 
53 C21 C22 1.392(3) 
54 C22 H22 0.950(2) 
55 C22 C23 1.388(3) 
56 C23 H23 0.950(2) 
57 C23 C24 1.393(2) 
58 C24 C25 1.389(2) 
59 C24 C26 1.490(2) 
60 C25 H25 0.950(1) 
61 C1' H1' 0.950(2) 
62 C1' C2' 1.386(3) 
63 C1' C11' 1.398(2) 
64 C2' H2' 0.950(2) 
65 C2' C3' 1.408(2) 
66 C3' C4' 1.393(2) 
67 C3' O1' 1.368(2) 
68 C4' O2' 1.382(2) 
69 C4' C12' 1.374(2) 
70 O2' C5' 1.463(2) 
71 C5' H5' 1.000(2) 
72 C5' C6' 1.564(2) 
73 C5' C13' 1.544(2) 
74 C6' H6' 1.000(2) 
75 C6' C7' 1.491(2) 
76 C6' O3' 1.455(2) 
77 C7' H7' 0.951(2) 
78 C7' C8' 1.328(2) 
79 C8' H8' 0.950(2) 
80 C8' C14' 1.500(2) 
81 C9' H9' 1.000(2) 
82 C9' C10' 1.552(2) 
83 C9' C14' 1.547(2) 
84 C9' N1' 1.476(2) 
85 C10' H10C 0.990(2) 
86 C10' H10D 0.990(2) 
87 C10' C11' 1.508(2) 
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88 C11' C12' 1.384(2) 
89 C12' C13' 1.507(2) 
90 C13' C14' 1.537(2) 
91 C13' C15' 1.534(2) 
92 C14' H14' 1.001(1) 
93 C15' H15C 0.991(2) 
94 C15' H15D 0.990(2) 
95 C15' C16' 1.521(3) 
96 C16' H16C 0.991(2) 
97 C16' H16D 0.990(2) 
98 C16' N1' 1.469(2) 
99 N1' C17' 1.462(2) 
100 C17' H17D 0.980(2) 
101 C17' H17E 0.980(2) 
102 C17' H17F 0.980(2) 
103 O1' C18' 1.432(2) 
104 C18' H18D 0.980(2) 
105 C18' H18E 0.980(2) 
106 C18' H18F 0.980(2) 
107 O3' C26 1.346(2) 
108 C26 O5 1.201(2) 
Table A.2 Bond length data for 126 
 
Number Atom1 Atom2 Atom3 Angle (°) 
1 H1 C1 C2 119.3(2) 
2 H1 C1 C11 119.3(2) 
3 C2 C1 C11 121.5(2) 
4 C1 C2 H2 119.4(2) 
5 C1 C2 C3 121.3(2) 
6 H2 C2 C3 119.3(2) 
7 C2 C3 C4 116.1(2) 
8 C2 C3 O1 126.2(2) 
9 C4 C3 O1 117.6(1) 
10 C3 C4 O2 126.0(1) 
11 C3 C4 C12 121.3(1) 
12 O2 C4 C12 112.6(1) 
13 C4 O2 C5 106.7(1) 
14 O2 C5 H5 109.0(1) 
15 O2 C5 C6 111.6(1) 
16 O2 C5 C13 106.7(1) 
17 H5 C5 C6 109.0(1) 
18 H5 C5 C13 109.0(1) 
19 C6 C5 C13 111.4(1) 
20 C5 C6 H6 107.8(1) 
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21 C5 C6 C7 114.3(1) 
22 C5 C6 O3 112.3(1) 
23 H6 C6 C7 107.7(1) 
24 H6 C6 O3 107.8(1) 
25 C7 C6 O3 106.6(1) 
26 C6 C7 H7 119.9(2) 
27 C6 C7 C8 120.2(1) 
28 H7 C7 C8 119.9(2) 
29 C7 C8 H8 120.1(2) 
30 C7 C8 C14 119.7(1) 
31 H8 C8 C14 120.2(2) 
32 H9 C9 C10 107.3(2) 
33 H9 C9 C14 107.2(2) 
34 H9 C9 N1 107.3(2) 
35 C10 C9 C14 112.7(1) 
36 C10 C9 N1 115.8(2) 
37 C14 C9 N1 106.2(1) 
38 C9 C10 H10A 108.4(2) 
39 C9 C10 H10B 108.3(2) 
40 C9 C10 C11 115.5(2) 
41 H10A C10 H10B 107.5(2) 
42 H10A C10 C11 108.3(2) 
43 H10B C10 C11 108.4(2) 
44 C1 C11 C10 126.5(2) 
45 C1 C11 C12 115.6(2) 
46 C10 C11 C12 117.6(1) 
47 C4 C12 C11 123.4(2) 
48 C4 C12 C13 109.8(1) 
49 C11 C12 C13 126.6(1) 
50 C5 C13 C12 100.5(1) 
51 C5 C13 C14 116.8(1) 
52 C5 C13 C15 111.2(1) 
53 C12 C13 C14 106.8(1) 
54 C12 C13 C15 111.2(1) 
55 C14 C13 C15 109.9(1) 
56 C8 C14 C9 115.2(1) 
57 C8 C14 C13 109.1(1) 
58 C8 C14 H14 108.6(1) 
59 C9 C14 C13 106.5(1) 
60 C9 C14 H14 108.6(2) 
61 C13 C14 H14 108.6(1) 
62 C13 C15 H15A 109.2(1) 
63 C13 C15 H15B 109.2(1) 
64 C13 C15 C16 112.2(1) 
65 H15A C15 H15B 107.9(2) 
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66 H15A C15 C16 109.1(1) 
67 H15B C15 C16 109.2(1) 
68 C15 C16 H16A 109.4(2) 
69 C15 C16 H16B 109.4(2) 
70 C15 C16 N1 111.1(1) 
71 H16A C16 H16B 108.0(2) 
72 H16A C16 N1 109.4(2) 
73 H16B C16 N1 109.4(2) 
74 C9 N1 C16 112.5(1) 
75 C9 N1 C17 113.5(2) 
76 C16 N1 C17 111.3(2) 
77 N1 C17 H17A 109.5(2) 
78 N1 C17 H17B 109.5(2) 
79 N1 C17 H17C 109.4(2) 
80 H17A C17 H17B 109.5(2) 
81 H17A C17 H17C 109.5(2) 
82 H17B C17 H17C 109.5(2) 
83 C3 O1 C18 116.8(1) 
84 O1 C18 H18A 109.5(2) 
85 O1 C18 H18B 109.5(2) 
86 O1 C18 H18C 109.4(2) 
87 H18A C18 H18B 109.5(2) 
88 H18A C18 H18C 109.5(2) 
89 H18B C18 H18C 109.5(2) 
90 C6 O3 C19 116.5(1) 
91 O3 C19 O4 123.5(2) 
92 O3 C19 C20 111.9(1) 
93 O4 C19 C20 124.5(2) 
94 C19 C20 C21 122.4(1) 
95 C19 C20 C25 117.6(1) 
96 C21 C20 C25 119.8(2) 
97 C20 C21 H21 120.2(2) 
98 C20 C21 C22 119.7(2) 
99 H21 C21 C22 120.2(2) 
100 C21 C22 H22 119.6(2) 
101 C21 C22 C23 120.6(2) 
102 H22 C22 C23 119.7(2) 
103 C22 C23 H23 120.2(2) 
104 C22 C23 C24 119.5(2) 
105 H23 C23 C24 120.3(2) 
106 C23 C24 C25 120.2(2) 
107 C23 C24 C26 123.3(1) 
108 C25 C24 C26 116.5(1) 
109 C20 C25 C24 120.1(2) 
110 C20 C25 H25 119.9(2) 
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111 C24 C25 H25 119.9(2) 
112 H1' C1' C2' 119.1(2) 
113 H1' C1' C11' 119.2(2) 
114 C2' C1' C11' 121.7(2) 
115 C1' C2' H2' 119.0(2) 
116 C1' C2' C3' 121.9(2) 
117 H2' C2' C3' 119.1(2) 
118 C2' C3' C4' 116.0(1) 
119 C2' C3' O1' 125.5(1) 
120 C4' C3' O1' 118.4(1) 
121 C3' C4' O2' 126.9(1) 
122 C3' C4' C12' 121.0(1) 
123 O2' C4' C12' 111.9(1) 
124 C4' O2' C5' 104.8(1) 
125 O2' C5' H5' 109.8(1) 
126 O2' C5' C6' 109.3(1) 
127 O2' C5' C13' 104.9(1) 
128 H5' C5' C6' 109.8(1) 
129 H5' C5' C13' 109.9(1) 
130 C6' C5' C13' 113.1(1) 
131 C5' C6' H6' 107.8(1) 
132 C5' C6' C7' 116.3(1) 
133 C5' C6' O3' 110.1(1) 
134 H6' C6' C7' 107.7(1) 
135 H6' C6' O3' 107.8(1) 
136 C7' C6' O3' 106.8(1) 
137 C6' C7' H7' 118.1(2) 
138 C6' C7' C8' 123.8(1) 
139 H7' C7' C8' 118.1(2) 
140 C7' C8' H8' 118.9(2) 
141 C7' C8' C14' 122.0(1) 
142 H8' C8' C14' 119.0(2) 
143 H9' C9' C10' 107.0(1) 
144 H9' C9' C14' 106.9(1) 
145 H9' C9' N1' 107.0(1) 
146 C10' C9' C14' 112.4(1) 
147 C10' C9' N1' 115.4(1) 
148 C14' C9' N1' 107.7(1) 
149 C9' C10' H10C 108.7(1) 
150 C9' C10' H10D 108.6(1) 
151 C9' C10' C11' 114.7(1) 
152 H10C C10' H10D 107.6(2) 
153 H10C C10' C11' 108.5(1) 
154 H10D C10' C11' 108.6(1) 
155 C1' C11' C10' 126.3(1) 
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156 C1' C11' C12' 115.4(1) 
157 C10' C11' C12' 118.1(1) 
158 C4' C12' C11' 123.8(1) 
159 C4' C12' C13' 109.0(1) 
160 C11' C12' C13' 126.8(1) 
161 C5' C13' C12' 98.8(1) 
162 C5' C13' C14' 118.0(1) 
163 C5' C13' C15' 111.6(1) 
164 C12' C13' C14' 108.1(1) 
165 C12' C13' C15' 112.0(1) 
166 C14' C13' C15' 108.0(1) 
167 C8' C14' C9' 113.2(1) 
168 C8' C14' C13' 110.8(1) 
169 C8' C14' H14' 108.6(1) 
170 C9' C14' C13' 106.6(1) 
171 C9' C14' H14' 108.8(1) 
172 C13' C14' H14' 108.7(1) 
173 C13' C15' H15C 109.5(1) 
174 C13' C15' H15D 109.4(1) 
175 C13' C15' C16' 110.8(1) 
176 H15C C15' H15D 108.1(2) 
177 H15C C15' C16' 109.4(2) 
178 H15D C15' C16' 109.6(2) 
179 C15' C16' H16C 109.3(2) 
180 C15' C16' H16D 109.3(2) 
181 C15' C16' N1' 111.7(1) 
182 H16C C16' H16D 107.9(2) 
183 H16C C16' N1' 109.3(1) 
184 H16D C16' N1' 109.3(1) 
185 C9' N1' C16' 113.9(1) 
186 C9' N1' C17' 112.6(1) 
187 C16' N1' C17' 109.4(1) 
188 N1' C17' H17D 109.5(2) 
189 N1' C17' H17E 109.4(2) 
190 N1' C17' H17F 109.5(2) 
191 H17D C17' H17E 109.5(2) 
192 H17D C17' H17F 109.5(2) 
193 H17E C17' H17F 109.4(2) 
194 C3' O1' C18' 115.9(1) 
195 O1' C18' H18D 109.5(2) 
196 O1' C18' H18E 109.5(2) 
197 O1' C18' H18F 109.4(2) 
198 H18D C18' H18E 109.4(2) 
199 H18D C18' H18F 109.5(2) 
200 H18E C18' H18F 109.5(2) 
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201 C6' O3' C26 114.1(1) 
202 C24 C26 O3' 112.4(1) 
203 C24 C26 O5 124.0(1) 
Table A.3 Bond angle data for 126 
 
Number Atom1 Atom2 Atom3 Atom4 Torsion (°) 
1 H1 C1 C2 H2 -3.8(3) 
2 H1 C1 C2 C3 176.2(2) 
3 C11 C1 C2 H2 176.2(2) 
4 C11 C1 C2 C3 -3.9(3) 
5 H1 C1 C11 C10 -6.5(3) 
6 H1 C1 C11 C12 180.0(2) 
7 C2 C1 C11 C10 173.6(2) 
8 C2 C1 C11 C12 0.0(2) 
9 C1 C2 C3 C4 0.7(2) 
10 C1 C2 C3 O1 -178.1(2) 
11 H2 C2 C3 C4 -179.3(2) 
12 H2 C2 C3 O1 1.9(3) 
13 C2 C3 C4 O2 -172.6(1) 
14 C2 C3 C4 C12 6.2(2) 
15 O1 C3 C4 O2 6.3(2) 
16 O1 C3 C4 C12 -174.9(1) 
17 C2 C3 O1 C18 5.7(2) 
18 C4 C3 O1 C18 -173.1(2) 
19 C3 C4 O2 C5 172.5(2) 
20 C12 C4 O2 C5 -6.4(2) 
21 C3 C4 C12 C11 -10.7(3) 
22 C3 C4 C12 C13 174.5(1) 
23 O2 C4 C12 C11 168.3(1) 
24 O2 C4 C12 C13 -6.6(2) 
25 C4 O2 C5 H5 133.7(1) 
26 C4 O2 C5 C6 -105.7(1) 
27 C4 O2 C5 C13 16.1(2) 
28 O2 C5 C6 H6 -152.9(1) 
29 O2 C5 C6 C7 87.4(2) 
30 O2 C5 C6 O3 -34.3(2) 
31 H5 C5 C6 H6 -32.4(2) 
32 H5 C5 C6 C7 -152.1(1) 
33 H5 C5 C6 O3 86.2(2) 
34 C13 C5 C6 H6 88.0(2) 
35 C13 C5 C6 C7 -31.8(2) 
36 C13 C5 C6 O3 -153.4(1) 
37 O2 C5 C13 C12 -18.8(1) 
38 O2 C5 C13 C14 -133.8(1) 
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39 O2 C5 C13 C15 99.0(1) 
40 H5 C5 C13 C12 -136.4(1) 
41 H5 C5 C13 C14 108.6(2) 
42 H5 C5 C13 C15 -18.6(2) 
43 C6 C5 C13 C12 103.2(1) 
44 C6 C5 C13 C14 -11.8(2) 
45 C6 C5 C13 C15 -139.0(1) 
46 C5 C6 C7 H7 -137.3(2) 
47 C5 C6 C7 C8 42.7(2) 
48 H6 C6 C7 H7 102.9(2) 
49 H6 C6 C7 C8 -77.1(2) 
50 O3 C6 C7 H7 -12.6(2) 
51 O3 C6 C7 C8 167.4(1) 
52 C5 C6 O3 C19 -76.8(2) 
53 H6 C6 O3 C19 41.8(2) 
54 C7 C6 O3 C19 157.2(1) 
55 C6 C7 C8 H8 176.8(2) 
56 C6 C7 C8 C14 -3.2(2) 
57 H7 C7 C8 H8 -3.2(3) 
58 H7 C7 C8 C14 176.8(2) 
59 C7 C8 C14 C9 -160.6(2) 
60 C7 C8 C14 C13 -40.9(2) 
61 C7 C8 C14 H14 77.4(2) 
62 H8 C8 C14 C9 19.4(2) 
63 H8 C8 C14 C13 139.1(2) 
64 H8 C8 C14 H14 -102.6(2) 
65 H9 C9 C10 H10A -88.6(2) 
66 H9 C9 C10 H10B 27.8(2) 
67 H9 C9 C10 C11 149.7(2) 
68 C14 C9 C10 H10A 153.7(2) 
69 C14 C9 C10 H10B -89.9(2) 
70 C14 C9 C10 C11 31.9(2) 
71 N1 C9 C10 H10A 31.1(2) 
72 N1 C9 C10 H10B 147.5(2) 
73 N1 C9 C10 C11 -90.7(2) 
74 H9 C9 C14 C8 -58.2(2) 
75 H9 C9 C14 C13 -179.3(1) 
76 H9 C9 C14 H14 63.9(2) 
77 C10 C9 C14 C8 59.6(2) 
78 C10 C9 C14 C13 -61.6(2) 
79 C10 C9 C14 H14 -178.4(1) 
80 N1 C9 C14 C8 -172.6(1) 
81 N1 C9 C14 C13 66.2(2) 
82 N1 C9 C14 H14 -50.6(2) 
83 H9 C9 N1 C16 178.5(1) 
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84 H9 C9 N1 C17 51.0(2) 
85 C10 C9 N1 C16 58.8(2) 
86 C10 C9 N1 C17 -68.7(2) 
87 C14 C9 N1 C16 -67.2(2) 
88 C14 C9 N1 C17 165.4(2) 
89 C9 C10 C11 C1 -176.7(2) 
90 C9 C10 C11 C12 -3.3(2) 
91 H10A C10 C11 C1 61.5(2) 
92 H10A C10 C11 C12 -125.1(2) 
93 H10B C10 C11 C1 -54.9(2) 
94 H10B C10 C11 C12 118.5(2) 
95 C1 C11 C12 C4 7.2(2) 
96 C1 C11 C12 C13 -178.9(2) 
97 C10 C11 C12 C4 -167.0(2) 
98 C10 C11 C12 C13 7.0(2) 
99 C4 C12 C13 C5 15.5(2) 
100 C4 C12 C13 C14 137.8(1) 
101 C4 C12 C13 C15 -102.4(2) 
102 C11 C12 C13 C5 -159.2(2) 
103 C11 C12 C13 C14 -36.9(2) 
104 C11 C12 C13 C15 83.0(2) 
105 C5 C13 C14 C8 47.5(2) 
106 C5 C13 C14 C9 172.4(1) 
107 C5 C13 C14 H14 -70.8(2) 
108 C12 C13 C14 C8 -64.0(2) 
109 C12 C13 C14 C9 61.0(2) 
110 C12 C13 C14 H14 177.8(1) 
111 C15 C13 C14 C8 175.3(1) 
112 C15 C13 C14 C9 -59.7(2) 
113 C15 C13 C14 H14 57.1(2) 
114 C5 C13 C15 H15A -56.6(2) 
115 C5 C13 C15 H15B 61.1(2) 
116 C5 C13 C15 C16 -177.8(1) 
117 C12 C13 C15 H15A 54.5(2) 
118 C12 C13 C15 H15B 172.3(1) 
119 C12 C13 C15 C16 -66.6(2) 
120 C14 C13 C15 H15A 172.5(1) 
121 C14 C13 C15 H15B -69.7(2) 
122 C14 C13 C15 C16 51.4(2) 
123 C13 C15 C16 H16A 71.9(2) 
124 C13 C15 C16 H16B -170.0(1) 
125 C13 C15 C16 N1 -49.1(2) 
126 H15A C15 C16 H16A -49.3(2) 
127 H15A C15 C16 H16B 68.9(2) 
128 H15A C15 C16 N1 -170.2(1) 
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129 H15B C15 C16 H16A -167.0(2) 
130 H15B C15 C16 H16B -48.9(2) 
131 H15B C15 C16 N1 72.0(2) 
132 C15 C16 N1 C9 58.0(2) 
133 C15 C16 N1 C17 -173.4(2) 
134 H16A C16 N1 C9 -62.9(2) 
135 H16A C16 N1 C17 65.7(2) 
136 H16B C16 N1 C9 178.9(2) 
137 H16B C16 N1 C17 -52.5(2) 
138 C9 N1 C17 H17A -48.2(2) 
139 C9 N1 C17 H17B -168.2(2) 
140 C9 N1 C17 H17C 71.8(2) 
141 C16 N1 C17 H17A -176.3(2) 
142 C16 N1 C17 H17B 63.7(2) 
143 C16 N1 C17 H17C -56.3(2) 
144 C3 O1 C18 H18A -59.5(2) 
145 C3 O1 C18 H18B -179.5(2) 
146 C3 O1 C18 H18C 60.5(2) 
147 C6 O3 C19 O4 2.9(2) 
148 C6 O3 C19 C20 -174.4(1) 
149 O3 C19 C20 C21 11.8(2) 
150 O3 C19 C20 C25 -171.9(1) 
151 O4 C19 C20 C21 -165.5(2) 
152 O4 C19 C20 C25 10.8(3) 
153 C19 C20 C21 H21 -5.4(3) 
154 C19 C20 C21 C22 174.6(2) 
155 C25 C20 C21 H21 178.4(2) 
156 C25 C20 C21 C22 -1.6(3) 
157 C19 C20 C25 C24 -177.0(2) 
158 C19 C20 C25 H25 3.0(2) 
159 C21 C20 C25 C24 -0.7(2) 
160 C21 C20 C25 H25 179.4(2) 
161 C20 C21 C22 H22 -178.1(2) 
162 C20 C21 C22 C23 1.9(3) 
163 H21 C21 C22 H22 1.9(3) 
164 H21 C21 C22 C23 -178.1(2) 
165 C21 C22 C23 H23 179.9(2) 
166 C21 C22 C23 C24 -0.0(3) 
167 H22 C22 C23 H23 -0.0(3) 
168 H22 C22 C23 C24 180.0(2) 
169 C22 C23 C24 C25 -2.3(3) 
170 C22 C23 C24 C26 177.2(2) 
171 H23 C23 C24 C25 177.8(2) 
172 H23 C23 C24 C26 -2.8(3) 
173 C23 C24 C25 C20 2.6(2) 
Appendix 
——————————————————————————————————————— 
 
 
259 
——————————————————————————————————————— 
 
174 C23 C24 C25 H25 -177.4(2) 
175 C26 C24 C25 C20 -176.9(1) 
176 C26 C24 C25 H25 3.1(2) 
177 C23 C24 C26 O3' -2.7(2) 
178 C23 C24 C26 O5 178.6(2) 
179 C25 C24 C26 O3' 176.8(1) 
180 C25 C24 C26 O5 -2.0(2) 
181 H1' C1' C2' H2' -0.8(3) 
182 H1' C1' C2' C3' 179.2(2) 
183 C11' C1' C2' H2' 179.2(2) 
184 C11' C1' C2' C3' -0.8(3) 
185 H1' C1' C11' C10' -10.0(3) 
186 H1' C1' C11' C12' 176.5(2) 
187 C2' C1' C11' C10' 170.0(2) 
188 C2' C1' C11' C12' -3.6(2) 
189 C1' C2' C3' C4' 3.5(2) 
190 C1' C2' C3' O1' -174.6(2) 
191 H2' C2' C3' C4' -176.5(2) 
192 H2' C2' C3' O1' 5.4(3) 
193 C2' C3' C4' O2' -176.4(1) 
194 C2' C3' C4' C12' -1.7(2) 
195 O1' C3' C4' O2' 1.8(2) 
196 O1' C3' C4' C12' 176.5(1) 
197 C2' C3' O1' C18' 18.6(2) 
198 C4' C3' O1' C18' -159.5(1) 
199 C3' C4' O2' C5' 155.7(2) 
200 C12' C4' O2' C5' -19.4(2) 
201 C3' C4' C12' C11' -2.9(2) 
202 C3' C4' C12' C13' -176.5(1) 
203 O2' C4' C12' C11' 172.6(1) 
204 O2' C4' C12' C13' -1.1(2) 
205 C4' O2' C5' H5' 149.4(1) 
206 C4' O2' C5' C6' -90.1(1) 
207 C4' O2' C5' C13' 31.4(1) 
208 O2' C5' C6' H6' -128.9(1) 
209 O2' C5' C6' C7' 110.1(1) 
210 O2' C5' C6' O3' -11.5(2) 
211 H5' C5' C6' H6' -8.4(2) 
212 H5' C5' C6' C7' -129.4(1) 
213 H5' C5' C6' O3' 109.0(1) 
214 C13' C5' C6' H6' 114.7(1) 
215 C13' C5' C6' C7' -6.3(2) 
216 C13' C5' C6' O3' -127.9(1) 
217 O2' C5' C13' C12' -30.4(1) 
218 O2' C5' C13' C14' -146.5(1) 
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219 O2' C5' C13' C15' 87.7(1) 
220 H5' C5' C13' C12' -148.4(1) 
221 H5' C5' C13' C14' 95.5(2) 
222 H5' C5' C13' C15' -30.3(2) 
223 C6' C5' C13' C12' 88.6(1) 
224 C6' C5' C13' C14' -27.5(2) 
225 C6' C5' C13' C15' -153.4(1) 
226 C5' C6' C7' H7' -155.2(1) 
227 C5' C6' C7' C8' 24.8(2) 
228 H6' C6' C7' H7' 83.7(2) 
229 H6' C6' C7' C8' -96.3(2) 
230 O3' C6' C7' H7' -31.8(2) 
231 O3' C6' C7' C8' 148.2(2) 
232 C5' C6' O3' C26 -66.8(2) 
233 H6' C6' O3' C26 50.6(2) 
234 C7' C6' O3' C26 166.1(1) 
235 C6' C7' C8' H8' 173.5(2) 
236 C6' C7' C8' C14' -6.5(3) 
237 H7' C7' C8' H8' -6.5(3) 
238 H7' C7' C8' C14' 173.5(1) 
239 C7' C8' C14' C9' -147.4(2) 
240 C7' C8' C14' C13' -27.7(2) 
241 C7' C8' C14' H14' 91.6(2) 
242 H8' C8' C14' C9' 32.6(2) 
243 H8' C8' C14' C13' 152.3(2) 
244 H8' C8' C14' H14' -88.3(2) 
245 H9' C9' C10' H10C -83.8(2) 
246 H9' C9' C10' H10D 33.0(2) 
247 H9' C9' C10' C11' 154.6(1) 
248 C14' C9' C10' H10C 159.2(1) 
249 C14' C9' C10' H10D -84.1(2) 
250 C14' C9' C10' C11' 37.6(2) 
251 N1' C9' C10' H10C 35.1(2) 
252 N1' C9' C10' H10D 151.9(1) 
253 N1' C9' C10' C11' -86.5(2) 
254 H9' C9' C14' C8' -58.7(2) 
255 H9' C9' C14' C13' 179.2(1) 
256 H9' C9' C14' H14' 62.2(2) 
257 C10' C9' C14' C8' 58.4(2) 
258 C10' C9' C14' C13' -63.7(2) 
259 C10' C9' C14' H14' 179.3(1) 
260 N1' C9' C14' C8' -173.4(1) 
261 N1' C9' C14' C13' 64.5(2) 
262 N1' C9' C14' H14' -52.5(2) 
263 H9' C9' N1' C16' -174.7(1) 
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264 H9' C9' N1' C17' 60.0(2) 
265 C10' C9' N1' C16' 66.4(2) 
266 C10' C9' N1' C17' -58.9(2) 
267 C14' C9' N1' C16' -60.1(2) 
268 C14' C9' N1' C17' 174.7(1) 
269 C9' C10' C11' C1' 179.8(2) 
270 C9' C10' C11' C12' -6.8(2) 
271 H10C C10' C11' C1' 58.1(2) 
272 H10C C10' C11' C12' -128.5(2) 
273 H10D C10' C11' C1' -58.5(2) 
274 H10D C10' C11' C12' 114.9(2) 
275 C1' C11' C12' C4' 5.4(2) 
276 C1' C11' C12' C13' 177.9(1) 
277 C10' C11' C12' C4' -168.7(1) 
278 C10' C11' C12' C13' 3.8(2) 
279 C4' C12' C13' C5' 19.6(2) 
280 C4' C12' C13' C14' 143.0(1) 
281 C4' C12' C13' C15' -98.1(2) 
282 C11' C12' C13' C5' -153.8(2) 
283 C11' C12' C13' C14' -30.4(2) 
284 C11' C12' C13' C15' 88.5(2) 
285 C5' C13' C14' C8' 44.4(2) 
286 C5' C13' C14' C9' 168.0(1) 
287 C5' C13' C14' H14' -74.9(2) 
288 C12' C13' C14' C8' -66.5(2) 
289 C12' C13' C14' C9' 57.1(2) 
290 C12' C13' C14' H14' 174.1(1) 
291 C15' C13' C14' C8' 172.0(1) 
292 C15' C13' C14' C9' -64.4(2) 
293 C15' C13' C14' H14' 52.7(2) 
294 C5' C13' C15' H15C -49.8(2) 
295 C5' C13' C15' H15D 68.5(2) 
296 C5' C13' C15' C16' -170.6(1) 
297 C12' C13' C15' H15C 60.0(2) 
298 C12' C13' C15' H15D 178.3(1) 
299 C12' C13' C15' C16' -60.8(2) 
300 C14' C13' C15' H15C 179.0(1) 
301 C14' C13' C15' H15D -62.7(2) 
302 C14' C13' C15' C16' 58.2(2) 
303 C13' C15' C16' H16C 69.4(2) 
304 C13' C15' C16' H16D -172.8(1) 
305 C13' C15' C16' N1' -51.7(2) 
306 H15C C15' C16' H16C -51.5(2) 
307 H15C C15' C16' H16D 66.3(2) 
308 H15C C15' C16' N1' -172.6(1) 
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309 H15D C15' C16' H16C -169.8(2) 
310 H15D C15' C16' H16D -52.0(2) 
311 H15D C15' C16' N1' 69.1(2) 
312 C15' C16' N1' C9' 53.7(2) 
313 C15' C16' N1' C17' -179.4(1) 
314 H16C C16' N1' C9' -67.4(2) 
315 H16C C16' N1' C17' 59.5(2) 
316 H16D C16' N1' C9' 174.7(1) 
317 H16D C16' N1' C17' -58.4(2) 
318 C9' N1' C17' H17D 74.9(2) 
319 C9' N1' C17' H17E -45.2(2) 
320 C9' N1' C17' H17F -165.1(1) 
321 C16' N1' C17' H17D -52.8(2) 
322 C16' N1' C17' H17E -172.8(1) 
323 C16' N1' C17' H17F 67.2(2) 
324 C3' O1' C18' H18D -69.3(2) 
325 C3' O1' C18' H18E 170.8(1) 
326 C3' O1' C18' H18F 50.8(2) 
327 C6' O3' C26 C24 170.6(1) 
328 C6' O3' C26 O5 -10.6(2) 
Table A.4 Torsion Angle data for 126 
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A.2 X-ray crystal data of 127 
 
1,2-bis(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-
azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-yl benzene-
1,2-dicarboxylate, (127); 
 
Fig A.2 ORTEP diagram of 127 with atom labels 
 
Formula C44H44N2O8 
Space Group P 21 21 21 
Cell Lengths (Å) a 7.5800(2) b 8.2045(2) c 56.9797(18) 
Cell Angles (°) α 90 β 90 γ 90 
Cell Volume (Å3) 3543.57 
Z, Z’ Z: 4 Z': 0 
R-Factor (%) 4.19 
Table A.5 X-ray crystal data for 127 
 
Number Atom1 Atom2 Length (Å) 
1 C1 H1 0.948(2) 
2 C1 C2 1.378(2) 
3 C1 C11 1.405(3) 
4 C2 H2 0.950(2) 
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5 C2 C3 1.401(3) 
6 C3 C4 1.394(3) 
7 C3 O1 1.375(2) 
8 C4 O2 1.383(3) 
9 C4 C12 1.373(2) 
10 O2 C5 1.464(3) 
11 C5 H5 1.000(2) 
12 C5 C6 1.537(3) 
13 C5 C13 1.558(2) 
14 C6 H6 1.000(2) 
15 C6 C7 1.509(2) 
16 C6 O3 1.450(2) 
17 C7 H7 0.950(2) 
18 C7 C8 1.315(2) 
19 C8 H8 0.950(2) 
20 C8 C14 1.505(2) 
21 C9 H9 0.999(2) 
22 C9 C10 1.555(3) 
23 C9 C14 1.542(3) 
24 C9 N1 1.469(2) 
25 C10 H10A 0.988(2) 
26 C10 H10B 0.990(2) 
27 C10 C11 1.509(2) 
28 C11 C12 1.382(2) 
29 C12 C13 1.510(3) 
30 C13 C14 1.545(2) 
31 C13 C15 1.534(2) 
32 C14 H14 0.999(2) 
33 C15 H15A 0.990(2) 
34 C15 H15B 0.990(2) 
35 C15 C16 1.520(2) 
36 C16 H16A 0.988(2) 
37 C16 H16B 0.990(2) 
38 C16 N1 1.468(2) 
39 N1 C17 1.461(2) 
40 C17 H17A 0.983(2) 
41 C17 H17B 0.981(2) 
42 C17 H17C 0.980(2) 
43 O1 C18 1.441(2) 
44 C18 H18A 0.979(2) 
45 C18 H18B 0.981(3) 
46 C18 H18C 0.979(3) 
47 O3 C19 1.340(2) 
48 C19 O4 1.203(2) 
49 C19 C20 1.496(2) 
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50 C20 C21 1.392(2) 
51 C20 C25 1.397(2) 
52 C21 H21 0.951(2) 
53 C21 C22 1.385(2) 
54 C22 H22 0.950(2) 
55 C22 C23 1.384(2) 
56 C23 H23 0.950(2) 
57 C23 C24 1.386(2) 
58 C24 H24 0.949(2) 
59 C24 C25 1.383(2) 
60 C25 C26 1.490(2) 
61 C1' H1' 0.949(2) 
62 C1' C2' 1.381(2) 
63 C1' C11' 1.405(3) 
64 C2' H2' 0.951(2) 
65 C2' C3' 1.401(3) 
66 C3' C4' 1.386(3) 
67 C3' O1' 1.379(2) 
68 C4' O2' 1.388(3) 
69 C4' C12' 1.374(2) 
70 O2' C5' 1.461(3) 
71 C5' H5' 1.001(2) 
72 C5' C6' 1.536(3) 
73 C5' C13' 1.553(2) 
74 C6' H6' 1.001(2) 
75 C6' C7' 1.499(2) 
76 C6' O3' 1.455(2) 
77 C7' H7' 0.950(2) 
78 C7' C8' 1.322(2) 
79 C8' H8' 0.950(2) 
80 C8' C14' 1.504(2) 
81 C9' H9' 0.999(2) 
82 C9' C10' 1.558(3) 
83 C9' C14' 1.536(3) 
84 C9' N2' 1.478(2) 
85 C10' H10C 0.991(2) 
86 C10' H10D 0.990(2) 
87 C10' C11' 1.512(2) 
88 C11' C12' 1.380(3) 
89 C12' C13' 1.510(3) 
90 C13' C14' 1.544(3) 
91 C13' C15' 1.535(2) 
92 C14' H14' 1.000(2) 
93 C15' H15C 0.991(2) 
94 C15' H15D 0.989(2) 
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95 C15' C16' 1.516(2) 
96 C16' H16C 0.991(2) 
97 C16' H16D 0.990(2) 
98 C16' N2' 1.468(2) 
99 N2' C17' 1.466(3) 
100 C17' H17D 0.981(2) 
101 C17' H17E 0.981(3) 
102 C17' H17F 0.980(2) 
103 O1' C18' 1.434(4) 
104 C18' H18D 0.979(3) 
105 C18' H18E 0.979(3) 
106 C18' H18F 0.980(3) 
107 O3' C26 1.344(2) 
108 C26 O5 1.207(2) 
Table A.6 Bond length data for 127 
 
Number Atom1 Atom2 Atom3 Angle (°) 
1 H1 C1 C2 119.7(2) 
2 H1 C1 C11 119.5(2) 
3 C2 C1 C11 120.8(2) 
4 C1 C2 H2 118.9(2) 
5 C1 C2 C3 122.2(2) 
6 H2 C2 C3 118.9(2) 
7 C2 C3 C4 116.4(2) 
8 C2 C3 O1 117.8(2) 
9 C4 C3 O1 125.8(2) 
10 C3 C4 O2 126.7(2) 
11 C3 C4 C12 120.7(2) 
12 O2 C4 C12 112.4(2) 
13 C4 O2 C5 106.9(1) 
14 O2 C5 H5 109.1(2) 
15 O2 C5 C6 111.9(1) 
16 O2 C5 C13 106.7(1) 
17 H5 C5 C6 109.0(2) 
18 H5 C5 C13 109.0(2) 
19 C6 C5 C13 111.1(1) 
20 C5 C6 H6 107.3(2) 
21 C5 C6 C7 114.3(1) 
22 C5 C6 O3 114.1(1) 
23 H6 C6 C7 107.3(2) 
24 H6 C6 O3 107.3(2) 
25 C7 C6 O3 106.1(1) 
26 C6 C7 H7 120.0(2) 
27 C6 C7 C8 120.0(2) 
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28 H7 C7 C8 120.0(2) 
29 C7 C8 H8 120.1(2) 
30 C7 C8 C14 119.8(2) 
31 H8 C8 C14 120.1(2) 
32 H9 C9 C10 106.6(2) 
33 H9 C9 C14 106.8(2) 
34 H9 C9 N1 106.7(2) 
35 C10 C9 C14 112.9(1) 
36 C10 C9 N1 115.6(1) 
37 C14 C9 N1 107.7(1) 
38 C9 C10 H10A 108.5(2) 
39 C9 C10 H10B 108.7(2) 
40 C9 C10 C11 114.5(1) 
41 H10A C10 H10B 107.5(2) 
42 H10A C10 C11 108.8(2) 
43 H10B C10 C11 108.6(2) 
44 C1 C11 C10 124.7(2) 
45 C1 C11 C12 116.2(2) 
46 C10 C11 C12 118.7(2) 
47 C4 C12 C11 123.1(2) 
48 C4 C12 C13 110.0(2) 
49 C11 C12 C13 126.2(2) 
50 C5 C13 C12 99.8(1) 
51 C5 C13 C14 116.7(1) 
52 C5 C13 C15 111.9(1) 
53 C12 C13 C14 106.4(1) 
54 C12 C13 C15 112.9(1) 
55 C14 C13 C15 108.9(1) 
56 C8 C14 C9 114.2(1) 
57 C8 C14 C13 109.3(1) 
58 C8 C14 H14 109.0(2) 
59 C9 C14 C13 106.4(1) 
60 C9 C14 H14 108.9(2) 
61 C13 C14 H14 108.9(2) 
62 C13 C15 H15A 109.2(2) 
63 C13 C15 H15B 109.2(2) 
64 C13 C15 C16 112.1(1) 
65 H15A C15 H15B 107.9(2) 
66 H15A C15 C16 109.2(2) 
67 H15B C15 C16 109.2(2) 
68 C15 C16 H16A 109.4(2) 
69 C15 C16 H16B 109.4(2) 
70 C15 C16 N1 111.0(1) 
71 H16A C16 H16B 108.1(2) 
72 H16A C16 N1 109.4(2) 
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73 H16B C16 N1 109.5(2) 
74 C9 N1 C16 112.5(1) 
75 C9 N1 C17 113.0(1) 
76 C16 N1 C17 110.4(1) 
77 N1 C17 H17A 109.5(2) 
78 N1 C17 H17B 109.4(2) 
79 N1 C17 H17C 109.5(2) 
80 H17A C17 H17B 109.5(2) 
81 H17A C17 H17C 109.4(2) 
82 H17B C17 H17C 109.5(2) 
83 C3 O1 C18 115.4(2) 
84 O1 C18 H18A 109.5(2) 
85 O1 C18 H18B 109.4(2) 
86 O1 C18 H18C 109.5(2) 
87 H18A C18 H18B 109.6(2) 
88 H18A C18 H18C 109.3(2) 
89 H18B C18 H18C 109.5(2) 
90 C6 O3 C19 117.8(1) 
91 O3 C19 O4 125.3(2) 
92 O3 C19 C20 109.9(1) 
93 O4 C19 C20 124.8(2) 
94 C19 C20 C21 118.6(2) 
95 C19 C20 C25 121.9(2) 
96 C21 C20 C25 119.4(2) 
97 C20 C21 H21 119.9(2) 
98 C20 C21 C22 120.2(2) 
99 H21 C21 C22 119.9(2) 
100 C21 C22 H22 120.0(2) 
101 C21 C22 C23 120.1(2) 
102 H22 C22 C23 119.9(2) 
103 C22 C23 H23 120.0(2) 
104 C22 C23 C24 120.1(2) 
105 H23 C23 C24 119.9(2) 
106 C23 C24 H24 119.9(2) 
107 C23 C24 C25 120.1(2) 
108 H24 C24 C25 119.9(2) 
109 C20 C25 C24 120.1(2) 
110 C20 C25 C26 123.0(2) 
111 C24 C25 C26 116.9(2) 
112 H1' C1' C2' 119.8(2) 
113 H1' C1' C11' 119.5(2) 
114 C2' C1' C11' 120.7(2) 
115 C1' C2' H2' 119.0(2) 
116 C1' C2' C3' 122.0(2) 
117 H2' C2' C3' 119.1(2) 
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118 C2' C3' C4' 116.8(2) 
119 C2' C3' O1' 117.4(2) 
120 C4' C3' O1' 125.6(2) 
121 C3' C4' O2' 127.3(2) 
122 C3' C4' C12' 120.3(2) 
123 O2' C4' C12' 112.3(2) 
124 C4' O2' C5' 107.3(1) 
125 O2' C5' H5' 109.5(2) 
126 O2' C5' C6' 112.0(1) 
127 O2' C5' C13' 106.9(1) 
128 H5' C5' C6' 109.2(2) 
129 H5' C5' C13' 109.4(2) 
130 C6' C5' C13' 109.7(1) 
131 C5' C6' H6' 107.3(2) 
132 C5' C6' C7' 113.8(2) 
133 C5' C6' O3' 114.0(1) 
134 H6' C6' C7' 107.2(2) 
135 H6' C6' O3' 107.2(2) 
136 C7' C6' O3' 106.9(1) 
137 C6' C7' H7' 120.8(2) 
138 C6' C7' C8' 118.4(2) 
139 H7' C7' C8' 120.8(2) 
140 C7' C8' H8' 120.6(2) 
141 C7' C8' C14' 118.9(2) 
142 H8' C8' C14' 120.6(2) 
143 H9' C9' C10' 106.9(2) 
144 H9' C9' C14' 107.1(2) 
145 H9' C9' N2' 107.0(2) 
146 C10' C9' C14' 112.6(1) 
147 C10' C9' N2' 115.0(1) 
148 C14' C9' N2' 107.8(1) 
149 C9' C10' H10C 108.8(2) 
150 C9' C10' H10D 108.8(2) 
151 C9' C10' C11' 114.2(1) 
152 H10C C10' H10D 107.6(2) 
153 H10C C10' C11' 108.6(2) 
154 H10D C10' C11' 108.6(2) 
155 C1' C11' C10' 124.1(2) 
156 C1' C11' C12' 116.1(2) 
157 C10' C11' C12' 119.4(2) 
158 C4' C12' C11' 123.3(2) 
159 C4' C12' C13' 110.0(2) 
160 C11' C12' C13' 125.6(2) 
161 C5' C13' C12' 100.4(1) 
162 C5' C13' C14' 116.3(1) 
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163 C5' C13' C15' 111.4(1) 
164 C12' C13' C14' 106.3(1) 
165 C12' C13' C15' 113.3(1) 
166 C14' C13' C15' 109.0(1) 
167 C8' C14' C9' 113.8(1) 
168 C8' C14' C13' 109.2(1) 
169 C8' C14' H14' 109.0(2) 
170 C9' C14' C13' 106.9(1) 
171 C9' C14' H14' 108.9(2) 
172 C13' C14' H14' 109.0(2) 
173 C13' C15' H15C 109.3(2) 
174 C13' C15' H15D 109.3(2) 
175 C13' C15' C16' 111.6(1) 
176 H15C C15' H15D 108.0(2) 
177 H15C C15' C16' 109.3(2) 
178 H15D C15' C16' 109.3(2) 
179 C15' C16' H16C 109.4(2) 
180 C15' C16' H16D 109.4(2) 
181 C15' C16' N2' 111.3(1) 
182 H16C C16' H16D 107.9(2) 
183 H16C C16' N2' 109.4(2) 
184 H16D C16' N2' 109.4(2) 
185 C9' N2' C16' 112.6(1) 
186 C9' N2' C17' 112.0(2) 
187 C16' N2' C17' 110.3(2) 
188 N2' C17' H17D 109.5(2) 
189 N2' C17' H17E 109.4(2) 
190 N2' C17' H17F 109.5(2) 
191 H17D C17' H17E 109.6(2) 
192 H17D C17' H17F 109.4(2) 
193 H17E C17' H17F 109.5(2) 
194 C3' O1' C18' 115.8(2) 
195 O1' C18' H18D 109.5(3) 
196 O1' C18' H18E 109.5(3) 
197 O1' C18' H18F 109.5(3) 
198 H18D C18' H18E 109.4(3) 
199 H18D C18' H18F 109.4(3) 
200 H18E C18' H18F 109.5(3) 
201 C6' O3' C26 116.7(2) 
202 C25 C26 O3' 111.5(2) 
203 C25 C26 O5 124.3(2) 
204 O3' C26 O5 124.2(2) 
Table A.7 Bond angle data for 127 
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Number Atom1 Atom2 Atom3 Atom4 Torsion (°) 
1 H1 C1 C2 H2 -4.3(3) 
2 H1 C1 C2 C3 175.8(2) 
3 C11 C1 C2 H2 175.8(2) 
4 C11 C1 C2 C3 -4.1(3) 
5 H1 C1 C11 C10 -6.7(3) 
6 H1 C1 C11 C12 -178.9(2) 
7 C2 C1 C11 C10 173.2(2) 
8 C2 C1 C11 C12 1.0(3) 
9 C1 C2 C3 C4 0.6(3) 
10 C1 C2 C3 O1 -177.2(2) 
11 H2 C2 C3 C4 -179.3(2) 
12 H2 C2 C3 O1 2.9(3) 
13 C2 C3 C4 O2 -169.3(2) 
14 C2 C3 C4 C12 5.9(3) 
15 O1 C3 C4 O2 8.3(3) 
16 O1 C3 C4 C12 -176.5(2) 
17 C2 C3 O1 C18 -148.0(2) 
18 C4 C3 O1 C18 34.4(3) 
19 C3 C4 O2 C5 166.7(2) 
20 C12 C4 O2 C5 -8.8(2) 
21 C3 C4 C12 C11 -9.4(3) 
22 C3 C4 C12 C13 179.2(2) 
23 O2 C4 C12 C11 166.5(2) 
24 O2 C4 C12 C13 -4.9(2) 
25 C4 O2 C5 H5 136.0(2) 
26 C4 O2 C5 C6 -103.3(2) 
27 C4 O2 C5 C13 18.4(2) 
28 O2 C5 C6 H6 -154.3(2) 
29 O2 C5 C6 C7 86.9(2) 
30 O2 C5 C6 O3 -35.5(2) 
31 H5 C5 C6 H6 -33.6(2) 
32 H5 C5 C6 C7 -152.4(2) 
33 H5 C5 C6 O3 85.2(2) 
34 C13 C5 C6 H6 86.6(2) 
35 C13 C5 C6 C7 -32.2(2) 
36 C13 C5 C6 O3 -154.6(1) 
37 O2 C5 C13 C12 -19.9(2) 
38 O2 C5 C13 C14 -133.9(2) 
39 O2 C5 C13 C15 99.8(2) 
40 H5 C5 C13 C12 -137.5(2) 
41 H5 C5 C13 C14 108.5(2) 
42 H5 C5 C13 C15 -17.8(2) 
43 C6 C5 C13 C12 102.3(2) 
44 C6 C5 C13 C14 -11.7(2) 
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45 C6 C5 C13 C15 -138.0(2) 
46 C5 C6 C7 H7 -136.1(2) 
47 C5 C6 C7 C8 44.0(2) 
48 H6 C6 C7 H7 105.0(2) 
49 H6 C6 C7 C8 -74.9(2) 
50 O3 C6 C7 H7 -9.5(2) 
51 O3 C6 C7 C8 170.6(2) 
52 C5 C6 O3 C19 -77.4(2) 
53 H6 C6 O3 C19 41.4(2) 
54 C7 C6 O3 C19 155.9(2) 
55 C6 C7 C8 H8 175.4(2) 
56 C6 C7 C8 C14 -4.6(3) 
57 H7 C7 C8 H8 -4.5(3) 
58 H7 C7 C8 C14 175.5(2) 
59 C7 C8 C14 C9 -159.0(2) 
60 C7 C8 C14 C13 -40.0(2) 
61 C7 C8 C14 H14 78.9(2) 
62 H8 C8 C14 C9 21.0(3) 
63 H8 C8 C14 C13 140.0(2) 
64 H8 C8 C14 H14 -101.1(2) 
65 H9 C9 C10 H10A -89.4(2) 
66 H9 C9 C10 H10B 27.2(2) 
67 H9 C9 C10 C11 148.9(2) 
68 C14 C9 C10 H10A 153.6(2) 
69 C14 C9 C10 H10B -89.7(2) 
70 C14 C9 C10 C11 31.9(2) 
71 N1 C9 C10 H10A 29.0(2) 
72 N1 C9 C10 H10B 145.6(2) 
73 N1 C9 C10 C11 -92.7(2) 
74 H9 C9 C14 C8 -59.4(2) 
75 H9 C9 C14 C13 180.0(1) 
76 H9 C9 C14 H14 62.7(2) 
77 C10 C9 C14 C8 57.4(2) 
78 C10 C9 C14 C13 -63.2(2) 
79 C10 C9 C14 H14 179.6(1) 
80 N1 C9 C14 C8 -173.7(1) 
81 N1 C9 C14 C13 65.7(2) 
82 N1 C9 C14 H14 -51.6(2) 
83 H9 C9 N1 C16 -178.8(1) 
84 H9 C9 N1 C17 55.5(2) 
85 C10 C9 N1 C16 62.9(2) 
86 C10 C9 N1 C17 -62.8(2) 
87 C14 C9 N1 C16 -64.4(2) 
88 C14 C9 N1 C17 169.8(1) 
89 C9 C10 C11 C1 -172.9(2) 
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90 C9 C10 C11 C12 -0.9(2) 
91 H10A C10 C11 C1 65.5(2) 
92 H10A C10 C11 C12 -122.5(2) 
93 H10B C10 C11 C1 -51.2(2) 
94 H10B C10 C11 C12 120.8(2) 
95 C1 C11 C12 C4 5.7(3) 
96 C1 C11 C12 C13 175.6(2) 
97 C10 C11 C12 C4 -167.0(2) 
98 C10 C11 C12 C13 3.0(3) 
99 C4 C12 C13 C5 15.2(2) 
100 C4 C12 C13 C14 136.9(2) 
101 C4 C12 C13 C15 -103.7(2) 
102 C11 C12 C13 C5 -155.9(2) 
103 C11 C12 C13 C14 -34.2(2) 
104 C11 C12 C13 C15 85.2(2) 
105 C5 C13 C14 C8 47.3(2) 
106 C5 C13 C14 C9 171.1(1) 
107 C5 C13 C14 H14 -71.7(2) 
108 C12 C13 C14 C8 -62.9(2) 
109 C12 C13 C14 C9 60.8(2) 
110 C12 C13 C14 H14 178.1(2) 
111 C15 C13 C14 C8 175.1(1) 
112 C15 C13 C14 C9 -61.1(2) 
113 C15 C13 C14 H14 56.1(2) 
114 C5 C13 C15 H15A -53.8(2) 
115 C5 C13 C15 H15B 64.0(2) 
116 C5 C13 C15 C16 -174.9(1) 
117 C12 C13 C15 H15A 57.9(2) 
118 C12 C13 C15 H15B 175.6(2) 
119 C12 C13 C15 C16 -63.3(2) 
120 C14 C13 C15 H15A 175.8(1) 
121 C14 C13 C15 H15B -66.5(2) 
122 C14 C13 C15 C16 54.6(2) 
123 C13 C15 C16 H16A 70.0(2) 
124 C13 C15 C16 H16B -171.8(2) 
125 C13 C15 C16 N1 -50.8(2) 
126 H15A C15 C16 H16A -51.1(2) 
127 H15A C15 C16 H16B 67.1(2) 
128 H15A C15 C16 N1 -171.9(2) 
129 H15B C15 C16 H16A -168.9(2) 
130 H15B C15 C16 H16B -50.6(2) 
131 H15B C15 C16 N1 70.3(2) 
132 C15 C16 N1 C9 56.2(2) 
133 C15 C16 N1 C17 -176.6(1) 
134 H16A C16 N1 C9 -64.6(2) 
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135 H16A C16 N1 C17 62.5(2) 
136 H16B C16 N1 C9 177.1(2) 
137 H16B C16 N1 C17 -55.7(2) 
138 C9 N1 C17 H17A 67.4(2) 
139 C9 N1 C17 H17B -52.6(2) 
140 C9 N1 C17 H17C -172.6(2) 
141 C16 N1 C17 H17A -59.4(2) 
142 C16 N1 C17 H17B -179.5(2) 
143 C16 N1 C17 H17C 60.5(2) 
144 C3 O1 C18 H18A -77.2(2) 
145 C3 O1 C18 H18B 162.8(2) 
146 C3 O1 C18 H18C 42.7(3) 
147 C6 O3 C19 O4 16.4(3) 
148 C6 O3 C19 C20 -164.5(1) 
149 O3 C19 C20 C21 -133.3(2) 
150 O3 C19 C20 C25 43.3(2) 
151 O4 C19 C20 C21 45.8(3) 
152 O4 C19 C20 C25 -137.6(2) 
153 C19 C20 C21 H21 -4.9(3) 
154 C19 C20 C21 C22 174.9(2) 
155 C25 C20 C21 H21 178.4(2) 
156 C25 C20 C21 C22 -1.7(3) 
157 C19 C20 C25 C24 -173.2(2) 
158 C19 C20 C25 C26 10.2(3) 
159 C21 C20 C25 C24 3.3(3) 
160 C21 C20 C25 C26 -173.2(2) 
161 C20 C21 C22 H22 178.4(2) 
162 C20 C21 C22 C23 -1.5(3) 
163 H21 C21 C22 H22 -1.7(3) 
164 H21 C21 C22 C23 178.4(2) 
165 C21 C22 C23 H23 -176.8(2) 
166 C21 C22 C23 C24 3.1(3) 
167 H22 C22 C23 H23 3.3(3) 
168 H22 C22 C23 C24 -176.8(2) 
169 C22 C23 C24 H24 178.5(2) 
170 C22 C23 C24 C25 -1.5(3) 
171 H23 C23 C24 H24 -1.6(3) 
172 H23 C23 C24 C25 178.4(2) 
173 C23 C24 C25 C20 -1.8(3) 
174 C23 C24 C25 C26 175.0(2) 
175 H24 C24 C25 C20 178.3(2) 
176 H24 C24 C25 C26 -5.0(3) 
177 C20 C25 C26 O3' 43.2(2) 
178 C20 C25 C26 O5 -139.7(2) 
179 C24 C25 C26 O3' -133.5(2) 
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180 C24 C25 C26 O5 43.7(3) 
181 H1' C1' C2' H2' -4.3(3) 
182 H1' C1' C2' C3' 175.8(2) 
183 C11' C1' C2' H2' 175.8(2) 
184 C11' C1' C2' C3' -4.1(3) 
185 H1' C1' C11' C10' -7.7(3) 
186 H1' C1' C11' C12' 179.9(2) 
187 C2' C1' C11' C10' 172.2(2) 
188 C2' C1' C11' C12' -0.3(3) 
189 C1' C2' C3' C4' 0.9(3) 
190 C1' C2' C3' O1' -175.2(2) 
191 H2' C2' C3' C4' -179.0(2) 
192 H2' C2' C3' O1' 4.9(3) 
193 C2' C3' C4' O2' -168.4(2) 
194 C2' C3' C4' C12' 6.6(3) 
195 O1' C3' C4' O2' 7.2(3) 
196 O1' C3' C4' C12' -177.7(2) 
197 C2' C3' O1' C18' -151.2(2) 
198 C4' C3' O1' C18' 33.2(3) 
199 C3' C4' O2' C5' 167.9(2) 
200 C12' C4' O2' C5' -7.5(2) 
201 C3' C4' C12' C11' -11.5(3) 
202 C3' C4' C12' C13' 179.9(2) 
203 O2' C4' C12' C11' 164.2(2) 
204 O2' C4' C12' C13' -4.3(2) 
205 C4' O2' C5' H5' 134.2(2) 
206 C4' O2' C5' C6' -104.4(2) 
207 C4' O2' C5' C13' 15.8(2) 
208 O2' C5' C6' H6' -160.5(2) 
209 O2' C5' C6' C7' 81.0(2) 
210 O2' C5' C6' O3' -42.1(2) 
211 H5' C5' C6' H6' -39.1(2) 
212 H5' C5' C6' C7' -157.5(2) 
213 H5' C5' C6' O3' 79.4(2) 
214 C13' C5' C6' H6' 80.9(2) 
215 C13' C5' C6' C7' -37.6(2) 
216 C13' C5' C6' O3' -160.7(1) 
217 O2' C5' C13' C12' -17.2(2) 
218 O2' C5' C13' C14' -131.3(2) 
219 O2' C5' C13' C15' 103.1(2) 
220 H5' C5' C13' C12' -135.7(2) 
221 H5' C5' C13' C14' 110.2(2) 
222 H5' C5' C13' C15' -15.4(2) 
223 C6' C5' C13' C12' 104.5(2) 
224 C6' C5' C13' C14' -9.6(2) 
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225 C6' C5' C13' C15' -135.2(2) 
226 C5' C6' C7' H7' -130.5(2) 
227 C5' C6' C7' C8' 49.5(2) 
228 H6' C6' C7' H7' 111.1(2) 
229 H6' C6' C7' C8' -69.0(2) 
230 O3' C6' C7' H7' -3.6(2) 
231 O3' C6' C7' C8' 176.3(2) 
232 C5' C6' O3' C26 -75.1(2) 
233 H6' C6' O3' C26 43.4(2) 
234 C7' C6' O3' C26 158.1(2) 
235 C6' C7' C8' H8' 173.8(2) 
236 C6' C7' C8' C14' -6.3(3) 
237 H7' C7' C8' H8' -6.3(3) 
238 H7' C7' C8' C14' 173.6(2) 
239 C7' C8' C14' C9' -160.7(2) 
240 C7' C8' C14' C13' -41.4(2) 
241 C7' C8' C14' H14' 77.5(2) 
242 H8' C8' C14' C9' 19.2(3) 
243 H8' C8' C14' C13' 138.6(2) 
244 H8' C8' C14' H14' -102.5(2) 
245 H9' C9' C10' H10C -89.9(2) 
246 H9' C9' C10' H10D 27.0(2) 
247 H9' C9' C10' C11' 148.5(2) 
248 C14' C9' C10' H10C 152.7(2) 
249 C14' C9' C10' H10D -90.4(2) 
250 C14' C9' C10' C11' 31.1(2) 
251 N2' C9' C10' H10C 28.7(2) 
252 N2' C9' C10' H10D 145.6(2) 
253 N2' C9' C10' C11' -92.8(2) 
254 H9' C9' C14' C8' -59.9(2) 
255 H9' C9' C14' C13' 179.4(1) 
256 H9' C9' C14' H14' 61.9(2) 
257 C10' C9' C14' C8' 57.3(2) 
258 C10' C9' C14' C13' -63.3(2) 
259 C10' C9' C14' H14' 179.1(1) 
260 N2' C9' C14' C8' -174.8(1) 
261 N2' C9' C14' C13' 64.6(2) 
262 N2' C9' C14' H14' -53.0(2) 
263 H9' C9' N2' C16' -178.2(1) 
264 H9' C9' N2' C17' 56.7(2) 
265 C10' C9' N2' C16' 63.1(2) 
266 C10' C9' N2' C17' -61.9(2) 
267 C14' C9' N2' C16' -63.3(2) 
268 C14' C9' N2' C17' 171.6(2) 
269 C9' C10' C11' C1' -172.0(2) 
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270 C9' C10' C11' C12' 0.2(2) 
271 H10C C10' C11' C1' 66.3(2) 
272 H10C C10' C11' C12' -121.5(2) 
273 H10D C10' C11' C1' -50.4(2) 
274 H10D C10' C11' C12' 121.8(2) 
275 C1' C11' C12' C4' 8.0(3) 
276 C1' C11' C12' C13' 174.8(2) 
277 C10' C11' C12' C4' -164.8(2) 
278 C10' C11' C12' C13' 1.9(3) 
279 C4' C12' C13' C5' 13.2(2) 
280 C4' C12' C13' C14' 134.7(2) 
281 C4' C12' C13' C15' -105.7(2) 
282 C11' C12' C13' C5' -155.1(2) 
283 C11' C12' C13' C14' -33.6(2) 
284 C11' C12' C13' C15' 86.1(2) 
285 C5' C13' C14' C8' 48.5(2) 
286 C5' C13' C14' C9' 172.1(1) 
287 C5' C13' C14' H14' -70.4(2) 
288 C12' C13' C14' C8' -62.2(2) 
289 C12' C13' C14' C9' 61.4(2) 
290 C12' C13' C14' H14' 178.9(2) 
291 C15' C13' C14' C8' 175.3(1) 
292 C15' C13' C14' C9' -61.1(2) 
293 C15' C13' C14' H14' 56.4(2) 
294 C5' C13' C15' H15C -54.4(2) 
295 C5' C13' C15' H15D 63.6(2) 
296 C5' C13' C15' C16' -175.4(1) 
297 C12' C13' C15' H15C 57.9(2) 
298 C12' C13' C15' H15D 175.9(2) 
299 C12' C13' C15' C16' -63.1(2) 
300 C14' C13' C15' H15C 176.0(1) 
301 C14' C13' C15' H15D -66.0(2) 
302 C14' C13' C15' C16' 55.1(2) 
303 C13' C15' C16' H16C 69.4(2) 
304 C13' C15' C16' H16D -172.7(2) 
305 C13' C15' C16' N2' -51.6(2) 
306 H15C C15' C16' H16C -51.6(2) 
307 H15C C15' C16' H16D 66.4(2) 
308 H15C C15' C16' N2' -172.6(2) 
309 H15D C15' C16' H16C -169.6(2) 
310 H15D C15' C16' H16D -51.6(2) 
311 H15D C15' C16' N2' 69.4(2) 
312 C15' C16' N2' C9' 56.4(2) 
313 C15' C16' N2' C17' -177.7(2) 
314 H16C C16' N2' C9' -64.6(2) 
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315 H16C C16' N2' C17' 61.4(2) 
316 H16D C16' N2' C9' 177.3(1) 
317 H16D C16' N2' C17' -56.7(2) 
318 C9' N2' C17' H17D 69.0(2) 
319 C9' N2' C17' H17E -51.1(2) 
320 C9' N2' C17' H17F -171.1(2) 
321 C16' N2' C17' H17D -57.2(2) 
322 C16' N2' C17' H17E -177.4(2) 
323 C16' N2' C17' H17F 62.6(2) 
324 C3' O1' C18' H18D -77.4(3) 
325 C3' O1' C18' H18E 162.7(2) 
326 C3' O1' C18' H18F 42.6(3) 
327 C6' O3' C26 C25 -172.0(1) 
328 C6' O3' C26 O5 10.9(3) 
Table A.8 Torsion Angle data for 127 
 
A.3 X-ray crystal data of 162 
 
(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-8-[(E)-2-(pyridin-4-yl)ethenyl]-12-oxa-
4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18),15-tetraen-14-ol, (162); 
 
Fig A.3 ORTEP diagram of 162 with atom labels 
 
 
 
Appendix 
——————————————————————————————————————— 
 
 
279 
——————————————————————————————————————— 
 
 
Formula C25H26N2O3 
Space Group P 21 
Cell Lengths (Å) a 7.0000(6) b 7.4627(7) c 19.2449(17) 
Cell Angles (°) α 90 β 98.251(5) γ 90 
Cell Volume (Å3) 994.926 
Z, Z’ Z: 2 Z': 0 
R-Factor (%) 3.17 
Table A.9 X-ray crystal data for 162 
 
Number Atom1 Atom2 Length (Å) 
1 O1 C3 1.361(2) 
2 O1 C18 1.436(2) 
3 O2 C4 1.376(2) 
4 O2 C5 1.479(2) 
5 O3 H3 0.840(1) 
6 O3 C6 1.419(2) 
7 N1 C9 1.468(2) 
8 N1 C16 1.462(2) 
9 N1 C17 1.461(2) 
10 N2 C23 1.335(2) 
11 N2 C25 1.347(2) 
12 C1 C2 1.412(2) 
13 C1 C11 1.415(2) 
14 C1 C19 1.465(2) 
15 C2 H2 0.951(2) 
16 C2 C3 1.394(2) 
17 C3 C4 1.391(2) 
18 C4 C12 1.369(2) 
19 C5 H5 1.000(1) 
20 C5 C6 1.538(2) 
21 C5 C13 1.536(2) 
22 C6 H6 1.000(2) 
23 C6 C7 1.512(2) 
24 C7 H7 0.950(1) 
25 C7 C8 1.323(2) 
26 C8 H8 0.951(1) 
27 C8 C14 1.503(2) 
28 C9 H9 1.000(1) 
29 C9 C10 1.561(2) 
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30 C9 C14 1.537(2) 
31 C10 H10A 0.990(2) 
32 C10 H10B 0.990(1) 
33 C10 C11 1.515(2) 
34 C11 C12 1.381(2) 
35 C12 C13 1.507(2) 
36 C13 C14 1.548(2) 
37 C13 C15 1.531(2) 
38 C14 H14 0.999(2) 
39 C15 H15A 0.990(1) 
40 C15 H15B 0.991(2) 
41 C15 C16 1.521(2) 
42 C16 H16A 0.991(2) 
43 C16 H16B 0.990(1) 
44 C17 H17A 0.980(2) 
45 C17 H17B 0.979(2) 
46 C17 H17C 0.980(2) 
47 C18 H18A 0.980(2) 
48 C18 H18B 0.980(2) 
49 C18 H18C 0.980(2) 
50 C19 H19 0.950(1) 
51 C19 C20 1.340(2) 
52 C20 H20 0.950(1) 
53 C20 C21 1.463(2) 
54 C21 C22 1.394(2) 
55 C21 C24 1.399(2) 
56 C22 H22 0.950(2) 
57 C22 C23 1.378(3) 
58 C23 H23 0.950(2) 
59 C24 H24 0.950(2) 
60 C24 C25 1.378(2) 
61 C25 H25 0.950(2) 
Table A.10 Bond length data for 162 
 
Number Atom1 Atom2 Atom3 Angle (°) 
1 C3 O1 C18 117.1(1) 
2 C4 O2 C5 106.4(1) 
3 H3 O3 C6 109.5(1) 
4 C9 N1 C16 112.7(1) 
5 C9 N1 C17 113.1(1) 
6 C16 N1 C17 110.4(1) 
7 C23 N2 C25 115.2(2) 
8 C2 C1 C11 119.5(1) 
9 C2 C1 C19 121.6(1) 
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10 C11 C1 C19 118.9(1) 
11 C1 C2 H2 119.0(1) 
12 C1 C2 C3 121.9(1) 
13 H2 C2 C3 119.0(1) 
14 O1 C3 C2 126.8(1) 
15 O1 C3 C4 116.2(1) 
16 C2 C3 C4 117.0(1) 
17 O2 C4 C3 125.6(1) 
18 O2 C4 C12 112.8(1) 
19 C3 C4 C12 121.4(1) 
20 O2 C5 H5 109.4(1) 
21 O2 C5 C6 108.2(1) 
22 O2 C5 C13 106.2(1) 
23 H5 C5 C6 109.4(1) 
24 H5 C5 C13 109.4(1) 
25 C6 C5 C13 114.1(1) 
26 O3 C6 C5 110.4(1) 
27 O3 C6 H6 106.6(1) 
28 O3 C6 C7 113.0(1) 
29 C5 C6 H6 106.5(1) 
30 C5 C6 C7 113.2(1) 
31 H6 C6 C7 106.5(1) 
32 C6 C7 H7 119.7(1) 
33 C6 C7 C8 120.5(1) 
34 H7 C7 C8 119.8(1) 
35 C7 C8 H8 119.5(1) 
36 C7 C8 C14 121.0(1) 
37 H8 C8 C14 119.5(1) 
38 N1 C9 H9 106.9(1) 
39 N1 C9 C10 114.9(1) 
40 N1 C9 C14 107.9(1) 
41 H9 C9 C10 106.9(1) 
42 H9 C9 C14 106.8(1) 
43 C10 C9 C14 113.0(1) 
44 C9 C10 H10A 108.5(1) 
45 C9 C10 H10B 108.6(1) 
46 C9 C10 C11 114.8(1) 
47 H10A C10 H10B 107.5(1) 
48 H10A C10 C11 108.5(1) 
49 H10B C10 C11 108.6(1) 
50 C1 C11 C10 124.8(1) 
51 C1 C11 C12 117.0(1) 
52 C10 C11 C12 117.8(1) 
53 C4 C12 C11 122.9(1) 
54 C4 C12 C13 109.5(1) 
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55 C11 C12 C13 127.0(1) 
56 C5 C13 C12 100.7(1) 
57 C5 C13 C14 116.0(1) 
58 C5 C13 C15 112.1(1) 
59 C12 C13 C14 106.6(1) 
60 C12 C13 C15 112.4(1) 
61 C14 C13 C15 108.8(1) 
62 C8 C14 C9 114.6(1) 
63 C8 C14 C13 109.0(1) 
64 C8 C14 H14 108.9(1) 
65 C9 C14 C13 106.3(1) 
66 C9 C14 H14 108.9(1) 
67 C13 C14 H14 109.0(1) 
68 C13 C15 H15A 109.2(1) 
69 C13 C15 H15B 109.2(1) 
70 C13 C15 C16 112.0(1) 
71 H15A C15 H15B 107.9(1) 
72 H15A C15 C16 109.2(1) 
73 H15B C15 C16 109.2(1) 
74 N1 C16 C15 110.8(1) 
75 N1 C16 H16A 109.4(1) 
76 N1 C16 H16B 109.5(1) 
77 C15 C16 H16A 109.5(1) 
78 C15 C16 H16B 109.5(1) 
79 H16A C16 H16B 108.0(1) 
80 N1 C17 H17A 109.5(2) 
81 N1 C17 H17B 109.5(2) 
82 N1 C17 H17C 109.5(2) 
83 H17A C17 H17B 109.4(2) 
84 H17A C17 H17C 109.5(2) 
85 H17B C17 H17C 109.4(2) 
86 O1 C18 H18A 109.5(1) 
87 O1 C18 H18B 109.5(1) 
88 O1 C18 H18C 109.4(1) 
89 H18A C18 H18B 109.5(2) 
90 H18A C18 H18C 109.5(2) 
91 H18B C18 H18C 109.5(2) 
92 C1 C19 H19 116.1(1) 
93 C1 C19 C20 127.9(1) 
94 H19 C19 C20 116.0(1) 
95 C19 C20 H20 117.5(1) 
96 C19 C20 C21 125.0(1) 
97 H20 C20 C21 117.5(1) 
98 C20 C21 C22 120.4(1) 
99 C20 C21 C24 124.0(1) 
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100 C22 C21 C24 115.6(1) 
101 C21 C22 H22 119.9(2) 
102 C21 C22 C23 120.2(2) 
103 H22 C22 C23 119.9(2) 
104 N2 C23 C22 124.6(2) 
105 N2 C23 H23 117.6(2) 
106 C22 C23 H23 117.7(2) 
107 C21 C24 H24 120.0(2) 
108 C21 C24 C25 120.1(2) 
109 H24 C24 C25 120.0(2) 
110 N2 C25 C24 124.2(2) 
111 N2 C25 H25 117.9(2) 
112 C24 C25 H25 117.9(2) 
Table A.11 Bond angle data for 162 
 
Number Atom1 Atom2 Atom3 Atom4 Torsion 
1 C18 O1 C3 C2 2.1(2) 
2 C18 O1 C3 C4 -175.0(1) 
3 C3 O1 C18 H18A 60.2(2) 
4 C3 O1 C18 H18B -59.8(2) 
5 C3 O1 C18 H18C -179.8(1) 
6 C5 O2 C4 C3 164.1(1) 
7 C5 O2 C4 C12 -10.4(2) 
8 C4 O2 C5 H5 137.5(1) 
9 C4 O2 C5 C6 -103.4(1) 
10 C4 O2 C5 C13 19.5(1) 
11 H3 O3 C6 C5 32.8(2) 
12 H3 O3 C6 H6 148.2(1) 
13 H3 O3 C6 C7 -95.2(1) 
14 C16 N1 C9 H9 -179.0(1) 
15 C16 N1 C9 C10 62.6(2) 
16 C16 N1 C9 C14 -64.4(2) 
17 C17 N1 C9 H9 54.9(2) 
18 C17 N1 C9 C10 -63.5(2) 
19 C17 N1 C9 C14 169.5(1) 
20 C9 N1 C16 C15 56.5(2) 
21 C9 N1 C16 H16A -64.4(2) 
22 C9 N1 C16 H16B 177.4(1) 
23 C17 N1 C16 C15 -176.0(1) 
24 C17 N1 C16 H16A 63.1(2) 
25 C17 N1 C16 H16B -55.1(2) 
26 C9 N1 C17 H17A -171.9(1) 
27 C9 N1 C17 H17B 68.2(2) 
28 C9 N1 C17 H17C -51.8(2) 
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29 C16 N1 C17 H17A 60.9(2) 
30 C16 N1 C17 H17B -59.1(2) 
31 C16 N1 C17 H17C -179.0(1) 
32 C25 N2 C23 C22 -0.8(3) 
33 C25 N2 C23 H23 179.2(2) 
34 C23 N2 C25 C24 1.0(3) 
35 C23 N2 C25 H25 -179.0(2) 
36 C11 C1 C2 H2 178.7(1) 
37 C11 C1 C2 C3 -1.4(2) 
38 C19 C1 C2 H2 -1.4(2) 
39 C19 C1 C2 C3 178.6(1) 
40 C2 C1 C11 C10 168.7(1) 
41 C2 C1 C11 C12 -3.4(2) 
42 C19 C1 C11 C10 -11.2(2) 
43 C19 C1 C11 C12 176.6(1) 
44 C2 C1 C19 H19 -161.9(1) 
45 C2 C1 C19 C20 18.0(2) 
46 C11 C1 C19 H19 18.0(2) 
47 C11 C1 C19 C20 -162.0(2) 
48 C1 C2 C3 O1 -174.7(1) 
49 C1 C2 C3 C4 2.3(2) 
50 H2 C2 C3 O1 5.3(2) 
51 H2 C2 C3 C4 -177.7(1) 
52 O1 C3 C4 O2 4.9(2) 
53 O1 C3 C4 C12 178.9(1) 
54 C2 C3 C4 O2 -172.5(1) 
55 C2 C3 C4 C12 1.6(2) 
56 O2 C4 C12 C11 168.0(1) 
57 O2 C4 C12 C13 -3.4(2) 
58 C3 C4 C12 C11 -6.7(2) 
59 C3 C4 C12 C13 -178.1(1) 
60 O2 C5 C6 O3 -36.6(2) 
61 O2 C5 C6 H6 -152.0(1) 
62 O2 C5 C6 C7 91.2(1) 
63 H5 C5 C6 O3 82.5(1) 
64 H5 C5 C6 H6 -32.8(2) 
65 H5 C5 C6 C7 -149.6(1) 
66 C13 C5 C6 O3 -154.6(1) 
67 C13 C5 C6 H6 90.1(1) 
68 C13 C5 C6 C7 -26.7(2) 
69 O2 C5 C13 C12 -20.3(1) 
70 O2 C5 C13 C14 -134.8(1) 
71 O2 C5 C13 C15 99.4(1) 
72 H5 C5 C13 C12 -138.2(1) 
73 H5 C5 C13 C14 107.3(1) 
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74 H5 C5 C13 C15 -18.5(2) 
75 C6 C5 C13 C12 98.8(1) 
76 C6 C5 C13 C14 -15.7(2) 
77 C6 C5 C13 C15 -141.5(1) 
78 O3 C6 C7 H7 -13.5(2) 
79 O3 C6 C7 C8 166.6(1) 
80 C5 C6 C7 H7 -140.0(1) 
81 C5 C6 C7 C8 40.1(2) 
82 H6 C6 C7 H7 103.2(2) 
83 H6 C6 C7 C8 -76.7(2) 
84 C6 C7 C8 H8 174.6(1) 
85 C6 C7 C8 C14 -5.4(2) 
86 H7 C7 C8 H8 -5.3(2) 
87 H7 C7 C8 C14 174.7(1) 
88 C7 C8 C14 C9 -157.1(1) 
89 C7 C8 C14 C13 -38.1(2) 
90 C7 C8 C14 H14 80.7(2) 
91 H8 C8 C14 C9 22.9(2) 
92 H8 C8 C14 C13 141.9(1) 
93 H8 C8 C14 H14 -99.4(2) 
94 N1 C9 C10 H10A 30.1(2) 
95 N1 C9 C10 H10B 146.7(1) 
96 N1 C9 C10 C11 -91.5(2) 
97 H9 C9 C10 H10A -88.3(2) 
98 H9 C9 C10 H10B 28.3(2) 
99 H9 C9 C10 C11 150.1(1) 
100 C14 C9 C10 H10A 154.5(1) 
101 C14 C9 C10 H10B -88.9(2) 
102 C14 C9 C10 C11 32.8(2) 
103 N1 C9 C14 C8 -174.3(1) 
104 N1 C9 C14 C13 65.3(1) 
105 N1 C9 C14 H14 -52.0(2) 
106 H9 C9 C14 C8 -59.7(2) 
107 H9 C9 C14 C13 179.9(1) 
108 H9 C9 C14 H14 62.6(2) 
109 C10 C9 C14 C8 57.6(2) 
110 C10 C9 C14 C13 -62.9(1) 
111 C10 C9 C14 H14 179.8(1) 
112 C9 C10 C11 C1 -174.6(1) 
113 C9 C10 C11 C12 -2.5(2) 
114 H10A C10 C11 C1 63.8(2) 
115 H10A C10 C11 C12 -124.2(1) 
116 H10B C10 C11 C1 -52.8(2) 
117 H10B C10 C11 C12 119.2(1) 
118 C1 C11 C12 C4 7.5(2) 
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119 C1 C11 C12 C13 177.3(1) 
120 C10 C11 C12 C4 -165.2(1) 
121 C10 C11 C12 C13 4.6(2) 
122 C4 C12 C13 C5 14.8(1) 
123 C4 C12 C13 C14 136.2(1) 
124 C4 C12 C13 C15 -104.7(1) 
125 C11 C12 C13 C5 -156.2(1) 
126 C11 C12 C13 C14 -34.7(2) 
127 C11 C12 C13 C15 84.3(2) 
128 C5 C13 C14 C8 47.5(2) 
129 C5 C13 C14 C9 171.5(1) 
130 C5 C13 C14 H14 -71.2(2) 
131 C12 C13 C14 C8 -63.6(1) 
132 C12 C13 C14 C9 60.4(1) 
133 C12 C13 C14 H14 177.7(1) 
134 C15 C13 C14 C8 175.0(1) 
135 C15 C13 C14 C9 -61.0(1) 
136 C15 C13 C14 H14 56.3(2) 
137 C5 C13 C15 H15A -54.3(2) 
138 C5 C13 C15 H15B 63.5(2) 
139 C5 C13 C15 C16 -175.4(1) 
140 C12 C13 C15 H15A 58.3(2) 
141 C12 C13 C15 H15B 176.1(1) 
142 C12 C13 C15 C16 -62.8(2) 
143 C14 C13 C15 H15A 176.1(1) 
144 C14 C13 C15 H15B -66.1(2) 
145 C14 C13 C15 C16 54.9(2) 
146 C13 C15 C16 N1 -51.3(2) 
147 C13 C15 C16 H16A 69.5(2) 
148 C13 C15 C16 H16B -172.2(1) 
149 H15A C15 C16 N1 -172.5(1) 
150 H15A C15 C16 H16A -51.7(2) 
151 H15A C15 C16 H16B 66.6(2) 
152 H15B C15 C16 N1 69.8(2) 
153 H15B C15 C16 H16A -169.4(1) 
154 H15B C15 C16 H16B -51.1(2) 
155 C1 C19 C20 H20 -4.2(3) 
156 C1 C19 C20 C21 175.8(1) 
157 H19 C19 C20 H20 175.8(1) 
158 H19 C19 C20 C21 -4.3(2) 
159 C19 C20 C21 C22 -174.2(2) 
160 C19 C20 C21 C24 4.4(2) 
161 H20 C20 C21 C22 5.7(2) 
162 H20 C20 C21 C24 -175.6(1) 
163 C20 C21 C22 H22 -1.5(3) 
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164 C20 C21 C22 C23 178.5(2) 
165 C24 C21 C22 H22 179.7(2) 
166 C24 C21 C22 C23 -0.3(3) 
167 C20 C21 C24 H24 1.7(3) 
168 C20 C21 C24 C25 -178.2(2) 
169 C22 C21 C24 H24 -179.5(2) 
170 C22 C21 C24 C25 0.5(2) 
171 C21 C22 C23 N2 0.4(3) 
172 C21 C22 C23 H23 -179.6(2) 
173 H22 C22 C23 N2 -179.5(2) 
174 H22 C22 C23 H23 0.5(3) 
175 C21 C24 C25 N2 -0.9(3) 
176 C21 C24 C25 H25 179.1(2) 
177 H24 C24 C25 N2 179.1(2) 
178 H24 C24 C25 H25 -0.9(3) 
Table A.12 Torsion angle data for 162 
 
 
 
 
 
 
